

GenCore version 5.1.7  
Copyright (c) 1993.- 2006 Bioceleration Ltd.

# OM protein - protein search, using sw model

Run on: March 10, 2006, 19:52:00 ; Search time 106.537 Seconds  
(without alignments)  
1187.771 Million cell updates/sec

Title: US-10-781-181-3  
Perfect score: 1540  
Sequence: 1 MSLMVERCGEILLFENPDQN.....GTWDFDIFLPLDRLTNGNSLV 288

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_21.\*

- 1: Geneseqp1980s.\*
- 2: Geneseqp1990s.\*
- 3: Geneseqp2000s.\*
- 4: Geneseqp2001s.\*
- 5: Geneseqp2002s.\*
- 6: Geneseqp2003as.\*
- 7: Geneseqp2003bs.\*
- 8: Geneseqp2004s.\*
- 9: Geneseqp2005s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1540	100.0	288	3	AA93568 Amino aci
2	1430	92.9	268	3	AA93593 Amino aci
3	1430	92.9	450	3	AA93569 Amino aci
4	1430	92.9	450	4	AAU08675 Human pho
5	1430	92.9	450	4	AA978915 Human typ
6	1430	92.9	450	8	ADP79549 Human pho
7	1376	89.4	446	3	AA93567 Amino aci
8	1356	88.1	445	3	AA93573 Amino aci
9	1356	88.1	446	3	AA93574 Amino aci
10	1356	88.1	451	3	AA93575 Amino aci
11	1337	86.8	437	3	AA93572 Amino aci
12	1280	83.1	320	4	AA93504 Human sho
13	1280	83.1	320	8	ADJ58906 Human cyc
14	1280	83.1	502	5	ABD09005 Human pho
15	1280	83.1	502	8	ADJ58904 Human cyc
16	1262	81.9	502	4	AA93503 Human lon
17	1259.5	81.8	413	3	AA93571 Amino aci
18	1145	74.4	391	4	AAU08676 Human pho
19	980	63.6	335	9	ADJ50214 Human PDE
20	980	63.6	335	9	ADZ46770 Human PDE
21	913	59.3	456	5	AAE24530 Mouse PDE
22	907	58.9	424	5	AAU79727 Human cyc
23	907	58.9	432	4	AAU16967 Human nov
24	907	58.9	482	5	AAE24531 Human PDE

25	907	58.9	482	8	ADO40842 Human pho
26	907	58.9	482	8	ADR46207 Human pho
27	907	58.9	482	9	ADY18092 PRO polyp
28	907	58.9	498	2	AAW00094 CAMP phos
29	907	58.9	498	2	AA949808 Human gli
30	907	58.9	498	3	AA920619 pTM22 hum
31	907	58.9	498	3	ADR66097 Human pro
32	907	58.9	498	8	ADR66439 Human pro
33	906	58.8	456	8	ADO21910 Human CAM
34	906	58.8	456	9	ADY18172 PRO polyp
35	898	58.3	426	5	AAE24528 Mouse PDE
36	892	57.9	426	5	AAE24529 Rat PDE7
37	892	57.9	428	5	AAE24533 Rat PDE7a
38	891	57.9	426	5	AAE24527 Human PDE
39	891	57.9	446	5	AAE24532 Human PDE
40	890	57.8	441	8	ABM83121 Human dia
41	890	57.8	468	8	ABM83120 Human dia
42	807	52.4	424	5	AAU79713 Human pho
43	788	51.2	270	8	ADH61297 INTSIG pr
44	788	51.2	425	8	ABM83119 Human dia
45	772	50.1	437	8	ABM83118 Human dia

## ALIGNMENTS

RESULT 1  
AA93568  
ID AA93568 standard; protein; 288 AA.  
XX  
AC AA93568;  
XX  
DT 25-SEP-2000 (first entry)  
XX  
DE Amino acid sequence of a human phosphodiesterase enzyme.  
XX  
KW Phosphodiesterase; PDE-XIV; human; enzyme.  
XX  
OS Homo sapiens.  
XX  
PN EP1018559-A1.  
XX  
PD 12-JUL-2000.  
XX  
PF 09-NOV-1999; 99EP-00308902.  
XX  
PR 23-DEC-1998; 98GB-00028603.  
PR 17-SEP-1999; 99GB-00022123.  
XX  
XX (PFIZ ) PFIZER LTD.  
XX (PFIZ ) PFIZER INC.  
Fidock M;  
XX  
WFI; 2000-433274/38.  
DR N-PSDB; AAA46650.  
XX  
XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes, useful for preventing diagnosing and treating diseases associated with inappropriate PDE-XIV expression and/or activity.  
XX  
XX Disclosure; Page 42-44; 104pp; English.  
XX  
XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The phosphodiesterase polynucleotide and polypeptide may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate PDE-XIV expression. For example, the polynucleotide be administered to treat diseases by rectifying mutations or deletions in a patient's genome that affect the activity of PDE-XIV. They may also be used to study the expression and function of PDE-XIV polypeptides and their role in metabolism. The PDE-XIV polypeptides may be used as antigens in the production of antibodies against PDE-XIV and in assays to identify modulators (agonists and antagonists) of PDE-XIV expression and

CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
 CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
 CC gene and/or expression product may be used in the preparation of a  
 CC composition for the treatment of a disorder associated with inappropriate  
 CC PDE-XIV expression and/or activity and to screen for agents that can  
 CC modulate PDE-XIV expression and/or activity. The anti-PDE-XIV antibodies  
 CC may also be used as diagnostic agents for detecting the presence of PDE-  
 CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay  
 CC (ELISA))  
 XX  
 SQ Sequence 288 AA;

Query Match 100.0%; Score 1540; DB 3; Length 288;  
 Best Local Similarity 100.0%; Pred. No. 9.1e-162;  
 Matches 288; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDRLRGQTGVRAERGSYPFIDRLINSTYS 60  
 Db 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDRLRGQTGVRAERGSYPFIDRLINSTYS 60  
 Qy 61 GEIGTKKKVKRLLSFORYPHARLLRGIIPQAPLHLLDEDLGQARHMLSKVGMWDFDIF 120  
 Db 61 GEIGTKKKVKRLLSFORYPHARLLRGIIPQAPLHLLDEDLGQARHMLSKVGMWDFDIF 120  
 Qy 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
 Db 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
 Qy 181 VTQAMHCYLKEPKLASPLTDLIMLGLLAAAHVDHPGVNQPFLIKTNHHLANLYQNMS 240  
 Db 181 VTQAMHCYLKEPKLASPLTDLIMLGLLAAAHVDHPGVNQPFLIKTNHHLANLYQNMS 240  
 Qy 241 VLENHHWRSTIGMLRESRLAHLPKEMTGTWDFDIFLFDRLTNGNSLV 288  
 Db 241 VLENHHWRSTIGMLRESRLAHLPKEMTGTWDFDIFLFDRLTNGNSLV 288

## RESULT 2

AA93593  
 ID AA93593 standard; protein; 268 AA.  
 XX  
 AC AA93593;  
 DT 25-SEP-2000 (first entry)  
 XX  
 DE Amino acid sequence of a human phosphodiesterase enzyme.  
 XX  
 KW Phosphodiesterase; PDE-XIV; enzyme.

XX Homo sapiens.  
 XX EP1018559-A1.  
 XX 12-JUL-2000.  
 XX 09-NOV-1999; 99EP-00308902.  
 XX 23-DEC-1998; 98GB-00028603.  
 PR 17-SEP-1999; 99GB-00022123.  
 XX (PFIZ ) PFIZER LTD.  
 PA (PFIZ ) PFIZER INC.  
 XX Fidoack M;  
 XX WPI; 2000-433274/38.  
 DR  
 XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,  
 PT useful for preventing diagnosing and treating diseases associated with  
 PT inappropriate PDE-XIV expression and/or activity.  
 XX  
 PS Disclosure; Page 87-88; 104pp; English.  
 XX

CC The present sequence represents a phosphodiesterase (PDE) enzyme. The  
 CC phosphodiesterase polynucleotide and polypeptide may be used in the  
 CC prevention, treatment and diagnosis of diseases associated with  
 CC inappropriate PDE-XIV expression. For example, the polynucleotide be  
 CC administered to treat diseases by rectifying mutations or deletions in a  
 CC patient's genome that affect the activity of PDE-XIV. They may also be  
 CC used to study the expression and function of PDE-XIV polypeptides and  
 CC their role in metabolism. The PDE-XIV polypeptides may be used as  
 CC antigens in the production of antibodies against PDE-XIV and in assays to  
 CC identify modulators (agonists and antagonists) of PDE-XIV expression and  
 CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
 CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
 CC gene and/or expression product may be used in the preparation of a  
 CC composition for the treatment of a disorder associated with inappropriate  
 CC PDE-XIV expression and/or activity and to screen for agents that can  
 CC modulate PDE-XIV expression and/or activity. The anti-PDE-XIV antibodies  
 CC may also be used as diagnostic agents for detecting the presence of PDE-  
 CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay  
 CC (ELISA))  
 XX  
 SQ Sequence 268 AA;

Query Match 92.9%; Score 1430; DB 3; Length 268;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-149;  
 Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDRLRGQTGVRAERGSYPFIDRLINSTYS 60  
 Db 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDRLRGQTGVRAERGSYPFIDRLINSTYS 60  
 Qy 61 GEIGTKKKVKRLLSFORYPHARLLRGIIPQAPLHLLDEDLGQARHMLSKVGMWDFDIF 120  
 Db 61 GEIGTKKKVKRLLSFORYPHARLLRGIIPQAPLHLLDEDLGQARHMLSKVGMWDFDIF 120  
 Qy 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
 Db 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
 Qy 181 VTQAMHCYLKEPKLASPLTDLIMLGLLAAAHVDHPGVNQPFLIKTNHHLANLYQNMS 240  
 Db 181 VTQAMHCYLKEPKLASPLTDLIMLGLLAAAHVDHPGVNQPFLIKTNHHLANLYQNMS 240  
 Qy 241 VLENHHWRSTIGMLRESRLAHLPKEMT 268  
 Db 241 VLENHHWRSTIGMLRESRLAHLPKEMT 268

## RESULT 3

AA93569  
 ID AA93569 standard; protein; 450 AA.  
 XX  
 AC AA93569;  
 DT 25-SEP-2000 (first entry)  
 XX  
 DE Amino acid sequence of a human phosphodiesterase enzyme.  
 XX  
 KW Phosphodiesterase; PDE-XIV; human; enzyme.

XX Homo sapiens.  
 XX EP1018559-A1.  
 XX 12-JUL-2000.  
 XX 09-NOV-1999; 99EP-00308902.  
 PR 23-DEC-1998; 98GB-00028603.  
 PR 17-SEP-1999; 99GB-00022123.  
 XX (PFIZ ) PFIZER LTD.  
 PA (PFIZ ) PFIZER INC.  
 XX

PI Fidock M;  
XX WPI; 2000-433274/38.  
DR N-PSDB; AAA46651.  
XX  
XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,  
PT useful for preventing diagnosing and treating diseases associated with  
PT inappropriate PDE-XIV expression and/or activity.  
XX  
XX  
PS Disclosure; Page 45-47; 104pp; English.  
XX  
XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The  
CC phosphodiesterase polynucleotide and polypeptide may be used in the  
CC prevention, treatment and diagnosis of diseases associated with  
CC inappropriate PDE-XIV expression. For example, the polynucleotide be  
CC administered to treat diseases by rectifying mutations or deletions in a  
CC patient's genome that affect the activity of PDE-XIV. They may also be  
CC used to study the expression and function of PDE-XIV polypeptides and  
CC their role in metabolism. The PDE-XIV polypeptides may be used as  
CC antigens in the production of antibodies against PDE-XIV and in assays to  
CC identify modulators (agonists and antagonists) of PDE-XIV expression and  
CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
CC gene and/or expression product may be used in the preparation of a  
CC composition for the treatment of a disorder associated with inappropriate  
CC PDE-XIV expression and/or activity and to screen for agents that can  
CC modulate PDE-XIV expression and/or activity. The anti-PDE-XIV antibodies  
CC may also be used as diagnostic agents for detecting the presence of PDE-  
CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay  
CC (ELISA))  
XX  
SQ Sequence 450 AA;  
Query Match 92.9%; Score 1430; DB 3; Length 450;  
Best Local Similarity 100.0%; Pred. No. 2.8e-149;  
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLRGQTGVRAERGSYPFIDFRLINSTYS 60  
DB 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLRGQTGVRAERGSYPFIDFRLINSTYS 60  
QY 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPHLHLLDEYLGQARHMLSKVGWDPDIF 120  
DB 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPHLHLLDEYLGQARHMLSKVGWDPDIF 120  
QY 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRLFLVMQVEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRLFLVMQVEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLIMGLLAAAHDVDHPGVNQPFLLIKTNHLLANLYQNM 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLIMGLLAAAHDVDHPGVNQPFLLIKTNHLLANLYQNM 240  
QY 241 VLENHWRSTIGMLRESRLAHLPKEMT 268  
DB 241 VLENHWRSTIGMLRESRLAHLPKEMT 268  
RESULT 4  
AAU08675  
ID AAU08675 standard; protein; 450 AA.  
XX  
XX AAU08675;  
AC  
XX  
XX 18-DEC-2001 (first entry)  
DT  
XX Human phosphodiesterase type 7B #1.  
XX  
XX Human; phosphodiesterase type 7B; cardiovascular disease; asthma;  
KW allergy; inflammatory disease; immune-related disorder; cardiovascular;  
KW antiasthmatic; antiallergic; immunosuppressive; antiinflammatory.  
XX  
OS Homo sapiens.

XX  
PN WO200162940-A2.  
XX  
XX 30-AUG-2001.  
XX  
XX 20-FEB-2001; 2001WO-EP001858.  
XX  
XX 21-FEB-2000; 2000EP-00103655.  
XX  
XX (MERE ) MERCK PATENT GMBH.  
XX  
XX Kluxen F, Hentsch B;  
PI  
XX WPI; 2001-570636/64.  
DR N-PSDB; AAS13248.  
XX  
XX Phosphodiesterase 7B proteins and nucleic acids, useful for preventing,  
PT diagnosing and treating, e.g. asthma, inflammation and allergies.  
XX  
XX Claim 1; Page 36-37; 40pp; English.  
XX  
XX The invention relates to a novel human Phosphodiesterase type 7B  
CC polypeptide and the nucleic acid that encodes it. The protein and nucleic  
CC acid may be used in the prevention, diagnosis and treatment of diseases  
CC associated with inappropriate phosphodiesterase 7B (P7B) expression. For  
CC example, The protein and nucleic acid may be used to treat disorders  
CC associated with decreased expression by rectifying mutations or deletions  
CC in a patient's genome that affect the activity of P7B by expressing  
CC inactive proteins or to supplement the patients own production of P7B.  
CC The nucleic acids may be used to produce P7B polypeptides, by inserting  
CC the nucleic acids into a host cell and culturing the cell to express the  
CC protein. The nucleic acid and its complements may also be used as DNA  
CC probes in diagnostic assays to detect and quantitate the presence of  
CC similar nucleic acids in samples, and therefore which patients may be in  
CC need of restorative therapy. The P7B polypeptides may also be used as  
CC antigens in the production of antibodies against P7B and in assays to  
CC identify modulators of its expression and activity. The anti-P7B  
CC antibodies and antagonists may also be used to down regulate expression  
CC and activity. The anti-P7B antibodies may also be used as diagnostic  
CC agents for detecting the presence of P7B in samples (e.g. by enzyme  
CC linked immunosorbent assay (ELISA)). Disorders that may be prevented,  
CC diagnosed and/or treated by the above methods include, for example  
CC cardiovascular disease, asthma, allergy, inflammation, and immune-related  
CC disorders. The present sequence represents a human phosphodiesterase 7B  
XX  
SQ Sequence 450 AA;  
Query Match 92.9%; Score 1430; DB 4; Length 450;  
Best Local Similarity 100.0%; Pred. No. 2.8e-149;  
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLRGQTGVRAERGSYPFIDFRLINSTYS 60  
DB 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLRGQTGVRAERGSYPFIDFRLINSTYS 60  
QY 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPHLHLLDEYLGQARHMLSKVGWDPDIF 120  
DB 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPHLHLLDEYLGQARHMLSKVGWDPDIF 120  
QY 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRLFLVMQVEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRLFLVMQVEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLIMGLLAAAHDVDHPGVNQPFLLIKTNHLLANLYQNM 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLIMGLLAAAHDVDHPGVNQPFLLIKTNHLLANLYQNM 240  
QY 241 VLENHWRSTIGMLRESRLAHLPKEMT 268  
DB 241 VLENHWRSTIGMLRESRLAHLPKEMT 268  
RESULT 5

AAG78915  
ID AAG78915 standard; protein; 450 AA.  
AC AAG78915;  
XX  
XX  
DT 19-DEC-2001 (first entry)  
XX  
DE Human type 7B phosphodiesterase, PDE7B.  
XX  
XX Human; type 7B phosphodiesterase; PDE7B; enzyme.  
XX  
XX Homo sapiens.  
OS  
XX  
XX JP2001238680-A.  
PN  
XX  
XX 04-SEP-2001.  
PD  
XX  
XX 03-MAR-2000; 2000JP-00058159.  
PF  
XX  
XX 03-MAR-2000; 2000JP-00058159.  
PR  
XX  
XX (TANA ) TANABE SEIYAKU CO.  
PA  
XX  
XX WPI; 2001-610057/70.  
DR  
XX  
XX N-PSDB; AA170009.  
DR

XX New phosphodiesterase for use in the development of inhibitors of high selectivity and drugs of low side effect.  
PT  
XX  
XX Claim 2; Page 12-14; 18pp; Japanese.  
PS  
XX  
XX The present sequence is the protein sequence for human type 7B phosphodiesterase (PDE7B). The enzyme PDE7B can be used in the development of inhibitors of high selectivity and drugs of low side effects  
CC  
XX

XX Sequence 450 AA;  
SQ  
Query Match 92.9%; Score 1430; DB 4; Length 450;  
Best Local Similarity 100.0%; Pred. No. 2.8e-149;  
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYPPFIDFRLINSTTYS 60  
DB 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYPPFIDFRLINSTTYS 60  
QY 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGWDFDIF 120  
DB 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGWDFDIF 120  
QY 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268

RESULT 6  
ADP79549  
ID ADP79549 standard; protein; 450 AA.  
XX  
XX ADP79549;  
AC  
XX  
XX 04-NOV-2004 (first entry)  
DT  
XX  
XX Human phosphodiesterase 7B nucleotide sequence.  
DE  
XX

KW Human; phosphodiesterase 7B; PDE7b; cardiovascular-gen.; CNS-Gen.;  
KW gynaecological; haemostatic; respiratory-Gen.; cytostatic; gene therapy;  
KW enzyme.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO2004044196-A1.  
PN  
XX  
XX 27-MAY-2004.  
PD  
XX  
XX 05-NOV-2003; 2003WO-EP012342.  
PF  
XX  
XX 13-NOV-2002; 2002EP-00025502.  
PR  
XX  
XX (FARB ) BAYER HEALTHCARE AG.  
PA  
XX  
XX Golz S, Brueggemeier U, Summer H;  
PI  
XX  
XX WPI; 2004-440631/41.  
DR  
XX  
XX N-PSDB; ADP79548.  
DR

XX Screening for therapeutic agents, useful in treating cardiovascular, reproduction, urological, hematological, respiratory system or cancer diseases, comprises contacting a test compound with a phosphodiesterase 7b.  
PT  
XX  
XX Disclosure; SEQ ID NO 2; 128pp; English.  
PS  
XX

XX The present sequence is that of human phosphodiesterase 7b (PDE7b), an enzyme regulating intracellular levels of cAMP and cGMP. The invention relates to novel disease associations of PDE7b polynucleotides and CC polypeptides. It also relates to novel methods of screening for CC therapeutic agents for the treatment of cardiovascular diseases, CC disorders of the peripheral and central nervous system, reproduction CC diseases, urological diseases, haematological diseases, disorders of the CC respiratory system and cancer. PDE7b polynucleotides, polypeptides and CC regulators or modulators of PDE7b activity (e.g. an RNA molecule, CC antisense oligonucleotide, polypeptide, antibody or ribozyme) can be used CC in the treatment or diagnosis of these diseases and disorders.  
XX

SQ Sequence 450 AA;

Query Match 92.9%; Score 1430; DB 8; Length 450;  
Best Local Similarity 100.0%; Pred. No. 2.8e-149;  
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYPPFIDFRLINSTTYS 60  
DB 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYPPFIDFRLINSTTYS 60  
QY 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGWDFDIF 120  
DB 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGWDFDIF 120  
QY 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268

RESULT 7  
AAY93567  
ID AAY93567 standard; protein; 446 AA.  
XX  
XX AAY93567;  
XX



DT 25-SEP-2000 (first entry)  
DE Amino acid sequence of a murine phosphodiesterase enzyme.  
XX Phosphodiesterase; PDE-XIV; murine; enzyme.  
XX Mus sp.  
XX EPI018559-A1.  
XX 12-JUL-2000.  
XX 09-NOV-1999; 99EP-00308902.  
XX 23-DEC-1998; 98GB-00028603.  
XX 17-SEP-1999; 99GB-00022123.  
XX (PFIZ ) PFIZER LTD.  
XX (PFIZ ) PFIZER INC.  
XX Fido M;  
XX WPI; 2000-433274/38.  
XX N-PSDB; AAA46649.  
XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,  
PT useful for preventing diagnosing and treating diseases associated with  
PT inappropriate PDE-XIV expression and/or activity.  
XX Disclosure; Page 39-41; 104pp; English.  
XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The  
CC phosphodiesterase polynucleotide and polypeptide may be used in the  
CC prevention, treatment and diagnosis of diseases associated with  
CC inappropriate PDE-XIV expression. For example, the polynucleotide be  
CC administered to treat diseases by rectifying mutations or deletions in a  
CC patient's genome that affect the activity of PDE-XIV. They may also be  
CC used to study the expression and function of PDE-XIV polypeptides and  
CC their role in metabolism. The PDE-XIV polypeptides may be used as  
CC antigens in the production of antibodies against PDE-XIV and in assays to  
CC identify modulators (agonists and antagonists) of PDE-XIV expression and  
CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
CC gene and/or expression product may be used in the preparation of a  
CC composition for the treatment of a disorder associated with inappropriate  
CC PDE-XIV expression and/or activity and to screen for agents that can  
CC modulate PDE-XIV expression and/or activity. The anti-PDE-XIV antibodies  
CC may also be used as diagnostic agents for detecting the presence of PDE-  
CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbent assay  
XX (ELISA))  
SQ Sequence 446 AA;  
Query Match 89.4%; Score 1376; DB 3; Length 446;  
Best Local Similarity 95.1%; Pred. No. 2.7e-143;  
Matches 255; Conservative 8; Mismatches 5; Indels 0; Gaps 0;  
QY 1 MSLMVERCEIIPENPDQNAKVCMLGDIRLQGTGVAERGSYPFIDRLINNTYS 60  
DB 1 MSLMVERCEIIPENPDQNAKVCMLGDIRLQGTGVAERGSYPFIDRLINNTYS 60  
QY 61 GEIGTKKKVRLLSFQRYFHASRLRGIIIPQAPLHLLDELDYLGQARHLSKVGWDPDIF 120  
DB 61 GEIGTKKKVRLLSFQRYFHASRLRGIIIPQAPLHLLDELDYLGQARHLSKVGWDPDIF 120  
QY 121 LFDRLTNGNSLVTLCHLFTNTHGLIHFFKLDMTVLRFLVMQVQDHYHSQNPYHNAVAAD 180  
DB 121 LFDRLTNGNSLVTLCHLFTNTHGLIHFFKLDMTVLRFLVMQVQDHYHSQNPYHNAVAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLIMGLLAAAHVDHPGVNQPPLIKTNHHLANLYQNM 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLIMGLLAAAHVDHPGVNQPPLIKTNHHLANLYQNM 240

QY 241 VLENHWRSTIGMLRESRLLAHLPKEMT 268  
DB 241 VLENHWRSTIGMLRESRLLAHLPKEMT 268  
RESULT 8  
AAAY93573  
ID AAY93573 standard; protein; 445 AA.  
XX AC AAY93573;  
XX 25-SEP-2000 (first entry)  
XX Amino acid sequence of a phosphodiesterase enzyme.  
XX Phosphodiesterase; PDE-XIV; enzyme.  
XX Synthetic.  
XX Key Location/Qualifiers  
FT Misc-difference 12 /label= Val, Ile  
FT Misc-difference 16 /label= Ser, Asn  
FT Misc-difference 18 /label= Glu, Asp  
FT Misc-difference 20..21 /label= Ser, Val, Asn, Ala  
FT /note= "these residues are a peptide comprising at least  
FT two or more of the above residues"  
FT Misc-difference 30 /label= Val, Ile  
FT Misc-difference 39 /label= Pro, Arg  
FT Misc-difference 56 /label= Asn, Ser  
FT Misc-difference 59 /label= His, Tyr  
FT Misc-difference 114 /label= Thr, Met  
FT Misc-difference 141 /label= Ser, Thr  
FT Misc-difference 168..169 /label= Gly, His, Ser, Gln  
FT /note= "these residues are a peptide comprising at least  
FT two or more of the above residues"  
FT Misc-difference 307..308 /label= Asp, Ala, Asn, Val  
FT /note= "these residues are a peptide comprising at least  
FT two or more of the above residues"  
FT Misc-difference 350 /label= Glu, Asp  
FT Misc-difference 379 /label= Ser, Thr  
FT Misc-difference 391 /label= His, Arg  
FT Misc-difference 404 /label= Gly, Ser  
FT Misc-difference 418..419 /label= Pro, Arg, Ser, Asn  
FT /note= "these residues are a peptide comprising at least  
FT two or more of the above residues"  
FT Misc-difference 423 /label= Ser, Arg  
FT Misc-difference 423 /label= Ser, Arg  
FT Misc-difference 427..428 /label= Ser, Gly, Pro, Asp, His, Gln  
FT /note= "these residues are a peptide comprising at least  
FT two or more of the above residues"  
FT Misc-difference 430 /label= His, Leu  
FT Misc-difference 433..434 /label= Gln, Gly, Thr, Pro, Ala  
FT

/note= "these residues are a peptide comprising at least two or more of the above residues"

436..437

/label= Ser, Glu, Thr, Leu

/note= "these residues are a peptide comprising at least two or more of the above residues"

440

/note= "optionally absent"

443..444

/label= Asp, Ser, Ala, Thr

/note= "these residues are a peptide comprising at least two or more of the above residues"

EPI018559-A1.

12-JUL-2000.

09-NOV-1999; 99EP-00308902.

23-DEC-1998; 98GB-00028603.

17-SEP-1999; 99GB-00022123.

(PFIZ ) PFIZER LTD.

(PFIZ ) PFIZER INC.

Fidock M;

WPI; 2000-433274/38.

Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes, useful for preventing diagnosing and treating diseases associated with inappropriate PDE-XIV expression and/or activity.

Disclosure; Page 64-66; 104pp; English.

The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The enzyme sequence is derived from a formula of the invention. The phosphodiesterase polynucleotide and polypeptide may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate PDE-XIV expression. For example, the polynucleotide be administered to treat diseases by rectifying mutations or deletions in a patient's genome that affect the activity of PDE-XIV. They may also be used to study the expression and function of PDE-XIV polypeptides and their role in metabolism. The PDE-XIV polypeptides may be used as antigens in the production of antibodies against PDE-XIV and in assays to identify modulators (agonists and antagonists) of PDE-XIV expression and activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV gene and/or expression product may be used in the preparation of a composition for the treatment of a disorder associated with inappropriate PDE-XIV expression and/or activity and to screen for agents that can modulate PDE-XIV expression and or activity. The anti-PDE-XIV antibodies may also be used as diagnostic agents for detecting the presence of PDE-XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay (ELISA))

SQ Sequence 445 AA;

Query Match 88.1%; Score 1356; DB 3; Length 445;

Best Local Similarity 95.1%; Pred. No. 4.5e-141;

Matches 255; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

1 MSCLMVERCGEIIIPENDONAKVCMLGDIRLRGQTGVRAERGSYPFIDRLNNTTYS 60

1 MSCLMVERCGEXLPEAPXPKXKVCMLGDIRLRGQTGVRAERGSYPFIDRLNNTTYS 60

61 GEIGTKKKVKRLLSFQRYFHASRLLRGIIPQAPLHLLDELDYLQARHMLSKVGWDFDIF 120

61 GEIGTKKKVKRLLSFQRYFHASRLLRGIIPQAPLHLLDELDYLQARHMLSKVGWDFDIF 120

121 LFDRLTNGNSLVTLCHLFWNTHGLIIHFHFKLDMVTLHRLFMVQEDYHSQNPYHNAVAAD 180

121 LFDRLTNGNSLVTLCHLFWNTHGLIIHFHFKLDMVTLHRLFMVQEDYHSQNPYHNAVAAD 180

QY 181 VTQAMCYLKEPKLASFLTPDLIMGLLAAAHDVDPGVNQPFLLIKTNHHLANLYQMS 240

Db 181 VTQAMCYLKEPKLASFLTPDLIMGLLAAAHDVDPGVNQPFLLIKTNHHLANLYQMS 240

QY 241 VLENHWRSTIGMLRESRLLAHLPKEMT 268

Db 241 VLENHWRSTIGMLRESRLLAHLPKEMT 268

RESULT 9

AA93574

ID AAY93574 standard; protein; 446 AA.

XX AAY93574;

XX 25-SEP-2000 (first entry)

XX Amino acid sequence of a phosphodiesterase enzyme.

DE Phosphodiesterase; PDE-XIV; enzyme.

XX Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 12 /label= Val, Ile

FT Misc-difference 16 /label= Ser, Asn

FT Misc-difference 18 /label= Glu, Asp

FT Misc-difference 20 /label= Ser, Val, Asn, Ala

FT Misc-difference 21 /label= Ser, Val, Asn, Ala

FT Misc-difference 30 /label= Val, Ile

FT Misc-difference 39 /label= Pro, Arg

FT Misc-difference 56 /label= Asn, Ser

FT Misc-difference 59 /label= His, Tyr

FT Misc-difference 114 /label= Thr, Met

FT Misc-difference 141 /label= Ser, Thr

FT Misc-difference 168 /label= Gly, His, Ser, Gln

FT Misc-difference 169 /label= Gly, His, Ser, Gln

FT Misc-difference 307 /label= Asp, Ala, Asn, Val

FT Misc-difference 308 /label= Asp, Ala, Asn, Val

FT Misc-difference 350 /label= Glu, Asp

FT Misc-difference 379 /label= Ser, Thr

FT Misc-difference 391 /label= His, Arg

FT Misc-difference 404 /label= Gly, Ser

FT Misc-difference 418 /label= Pro, Arg, Ser, Asn

FT Misc-difference 419 /label= Pro, Arg, Ser, Asn

FT Misc-difference 423 /label= Ser, Arg

FT Misc-difference 430 /label= His, Leu

FT Misc-difference 433 /label= Gln, Gly, Thr, Pro, Ala





PD 12-JUL-2000.  
 PF 09-NOV-1999; 99EP-00308902.  
 PR 23-DEC-1998; 98GB-00028603.  
 PR 17-SEP-1999; 99GB-00022123.  
 PA (PFIZ ) PFIZER LTD.  
 PA (PFIZ ) PFIZER INC.  
 XX Fidoack M;  
 XX WPI; 2000-433274/38.  
 XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,  
 PT useful for preventing diagnosing and treating diseases associated with  
 PT inappropriate PDE-XIV expression and/or activity.  
 XX  
 XX Disclosure; Page 58-60; 104pp; English.  
 XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The  
 CC enzyme sequence is derived from a formula of the invention. The  
 CC phosphodiesterase polynucleotide and polypeptide may be used in the  
 CC prevention, treatment and diagnosis of diseases associated with  
 CC inappropriate PDE-XIV expression. For example, the polynucleotide be  
 CC administered to treat diseases by rectifying mutations or deletions in a  
 CC patient's genome that affect the activity of PDE-XIV. They may also be  
 CC used to study the expression and function of PDE-XIV polypeptides and  
 CC their role in metabolism. The PDE-XIV polypeptides may be used as  
 CC antigens in the production of antibodies against PDE-XIV and in assays to  
 CC identify modulators (agonists and antagonists) of PDE-XIV expression and  
 CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
 CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
 CC gene and/or expression product may be used in the preparation of a  
 CC composition for the treatment of a disorder associated with inappropriate  
 CC PDE-XIV expression and/or activity and to screen for agents that can  
 CC modulate PDE-XIV expression and/or activity. The anti-PDE-XIV antibodies  
 CC may also be used as diagnostic agents for detecting the presence of PDE-  
 CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay  
 CC (ELISA))  
 XX  
 SQ Sequence 437 AA;  
 Query Match 86.8%; Score 1337; DB 3; Length 437;  
 Best Local Similarity 95.1%; Pred. No. 5.7e-139;  
 Matches 255; Conservative 0; Mismatches 11; Indels 2; Gaps 2;  
 QY 1 MSCLMVERCGEILFENPDONAKVCMLGDIRLRCGTGVAERRGSGYPFIDFRLNSTTYS 60  
 DB 1 MSCLMVERCGEXLFEXPXQ-KKVCMLGDXRLRGCTGVAERRGSGYPFIDFRLNXTTXS 59  
 QY 61 GEIGTKKKVRLLSFQRYFHASRLLRGIIPOAPLHLLDEYLGQARHMLSKVGWDFDIF 120  
 DB 60 GEIGTKKKVRLLSFQRYFHASRLLRGIIPOAPLHLLDEYLGQARHMLSKVGWDFDIF 119  
 QY 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRFLVMVQEDYHSQNPYHNAHAAD 180  
 DB 120 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRFLVMVQEDYHX-NPYHNAHAAD 178  
 QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPPFLIKTNHHLANLYQNS 240  
 DB 179 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPPFLIKTNHHLANLYQNS 238  
 QY 241 VLENHWRSTIGMLRESRLLAHLPKEMT 268  
 DB 239 VLENHWRSTIGMLRESRLLAHLPKEMT 266  
 RESULT 12  
 AAB36504  
 ID AAB36504 standard; protein; 320 AA.  
 XX  
 AC AAB36504;

XX 06-MAR-2001 (first entry)  
 DT Human short phosphodiesterase protein SEQ ID NO:3.  
 DE  
 XX Human; long phosphodiesterase; short phosphodiesterase; diagnosis;  
 KW cyclic nucleotide phosphodiesterase; nootropic; cardiac; hypotensive;  
 KW nephrotropic; antidepressant; antiinflammatory; immunosuppressive;  
 KW antifertility; antiasthmatic; vasotropic; gene therapy; dementia;  
 KW annesia; congestive heart failure; thrombosis; pulmonary hypertension;  
 KW glomerulonephritis; bipolar depression; bronchial asthma; salt retention;  
 KW atopic disease; autoimmune encephalomyelitis; organ transplantation;  
 KW nephrotic syndrome; erectile dysfunction.  
 XX Homo sapiens.  
 OS  
 XX US6146876-A.  
 PN  
 XX 14-NOV-2000.  
 PD  
 XX 11-JUN-1999; 99US-00330970.  
 PF  
 XX 26-MAR-1999; 99US-00277423.  
 PR  
 XX (MILL-) MILLENNIUM PHARM INC.  
 PA  
 XX Kapeller-Libermann R, White D, Robision KE;  
 PI  
 XX WPI; 2001-023577/03.  
 XX N-PSDB; AAC87949.  
 DR  
 XX Polynucleotide encoding novel cyclic nucleotide phosphodiesterase useful  
 XX for treating disorders related with to protein e.g. dementia,  
 PT hypertension, glomerulonephritis, and organ transplantation.  
 PT  
 XX Claim 3; Fig 6; 42pp; English.  
 PS  
 XX The present sequence represents the human short phosphodiesterase which  
 CC is a cyclic nucleotide phosphodiesterase (I). (I) can have nootropic,  
 CC cardiac, hypotensive, nephrotropic, antidepressant, antiinflammatory,  
 CC immunosuppressive, antifertility, antiasthmatic and vasotropic  
 CC activities, and can be used in gene therapy. (I) can be used for treating  
 CC various disorders associated or mediated by (I), such as dementia,  
 CC annesia, congestive heart failure, thrombosis, pulmonary hypertension,  
 CC glomerulonephritis, bipolar depression, bronchial asthma, atopic  
 CC diseases, autoimmune encephalomyelitis, organ transplantation, salt  
 CC retention in nephrotic syndrome and erectile dysfunction  
 CC  
 SQ Sequence 320 AA;  
 Query Match 83.1%; Score 1280; DB 4; Length 320;  
 Best Local Similarity 100.0%; Pred. No. 7.7e-133;  
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 28 GDIRLRCGTGVAERRGSGYPFIDFRLNSTTYSGEIGTKKKVRLLSFQRYFHASRLRG 87  
 DB 80 GDIRLRCGTGVAERRGSGYPFIDFRLNSTTYSGEIGTKKKVRLLSFQRYFHASRLRG 139  
 QY 88 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147  
 DB 140 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199  
 QY 148 FKLDWVTLHRFLVMVQEDYHSQNPYHNAHAADVTQAMHCYLKEPKLASFLTPDLMGL 207  
 DB 200 FKLDWVTLHRFLVMVQEDYHSQNPYHNAHAADVTQAMHCYLKEPKLASFLTPDLMGL 259  
 QY 208 LAAAHDVDHPGVNQPPFLIKTNHHLANLYQNSVLENHWRSTIGMLRESRLLAHLPKEM 267  
 DB 260 LAAAHDVDHPGVNQPPFLIKTNHHLANLYQNSVLENHWRSTIGMLRESRLLAHLPKEM 319  
 QY 268 T 268  
 DB 320 T 320

```
RESULT 13
ADJ58906
ID ADJ58906 standard; protein; 320 AA.
XX
AC ADJ58906;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human cyclic nucleotide phosphodiesterase protein #2.
XX
KW 27875; 22025; 27420; 17906; 16319; 55092; 10218; cancer;
KW cellular proliferation; cellular differentiation; immune disorder;
KW cardiovascular disorder; endothelial cell disorder;
KW haematopoietic disorder; blood vessel disorder; brain disorder; pain;
KW metabolic disorder; liver disorder; platelet disorder; gene therapy;
KW human; cyclic; enzyme.
XX
OS Homo sapiens.
XX
PN US2004006016-A1.
XX
PD 08-JAN-2004.
XX
PF 11-MAR-2003; 2003US-00386414.
XX
PR 11-JUN-1999; 99US-00330970.
XX
PR 25-OCT-1999; 99US-00426282.
XX
PR 16-MAY-2000; 2000US-00571689.
XX
PR 22-SEP-2000; 2000US-00668266.
XX
PR 28-NOV-2000; 2000US-00724599.
XX
PR 07-DEC-2000; 2000US-0254037P.
XX
PR 10-APR-2001; 2001US-00833082.
XX
PR 16-MAY-2001; 2001US-00860193.
XX
PR 31-OCT-2001; 2001US-0335044P.
XX
PR 06-DEC-2001; 2001US-00010943.
XX
PR 29-OCT-2002; 2002US-00283023.
XX
PA (WILL-) MILLENNIUM PHARM INC.
XX
PI Kapeller-Libermann R, White D, Robison KE, Macbeth KJ, Carroll JM;
PI Cook WJ, Meyers RE, Chun M, Williamson MJ;
XX
XX WPI; 2004-081738/08.
XX
DR N-PSDB; ADJ58905.
XX
XX New isolated 27875, 22025, 27420, 17906, 16319, 55092, or 10218 nucleic
XX acid molecules, useful for diagnosing or treating cancer, pain, or
XX immune, endothelial cell, hematopoietic, blood vessel, brain, metabolic
XX and liver disorders.
XX
PS Claim 4; SEQ ID NO 6; 245pp; English.
XX
CC The present invention relates to an isolated 27875, 22025, 27420, 17906,
CC 16319, 55092, or 10218 nucleic acid molecule. The invention is useful for
CC diagnosing or treating cancer or aberrant cellular proliferation and/or
CC differentiation, immune disorders, heart disorders, cardiovascular
CC disorders including endothelial cell disorders, haematopoietic disorders,
CC blood vessel disorders, brain disorders, pain and metabolic disorders,
CC liver disorders and platelet disorders. The invention is also useful in
CC gene therapy. The present sequence is human cyclic nucleotide
CC phosphodiesterase.
XX
SQ Sequence 320 AA;
Query Match 83.1%; Score 1280; DB 8; Length 320;
Best Local Similarity 100.0%; Pred. No. 7.7e-133;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 28 GDIRLGGQTGVARRGSGYPFIDRLNLTSTYSGEITGKKVKRLLSFQRYFHASLLRG 87
DB 80 GDIRLGGQTGVARRGSGYPFIDRLNLTSTYSGEITGKKVKRLLSFQRYFHASLLRG 139
```

```
QY 88 IIPQAPLHLLDEYLGQARHMLSKVGWDFDI FLFRLTNGNSLVTLCHLFNTHGLIHH 147
DB 140 IIPQAPLHLLDEYLGQARHMLSKVGWDFDI FLFRLTNGNSLVTLCHLFNTHGLIHH 199
QY 148 FKLDVMTLHRLFLVMQEDYHSQNPYHNAHAADVTQAMHCYLKPKLASFLTPLDIMLGL 207
DB 200 FKLDVMTLHRLFLVMQEDYHSQNPYHNAHAADVTQAMHCYLKPKLASFLTPLDIMLGL 259
QY 208 LAAAADVDHPGVNQPFLLKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 267
DB 260 LAAAADVDHPGVNQPFLLKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 319
QY 268 T 268
DB 320 T 320

RESULT 14
AB09005
ID AB09005 standard; protein; 502 AA.
XX
AC AB09005;
XX
DT 23-MAY-2002 (first entry)
XX
DE Human phosphodiesterase-1.
XX
KW HPDE; human phosphodiesterase; cyclic nucleotide phosphodiesterase;
KW antiinflammatory; neuroprotective; cytostatic; antianaemic;
KW immunosuppressive; HIV; cardiovascular disorder; mental disorder;
KW gene therapy; transgene; enzyme.
XX
OS Homo sapiens.
XX
PN WO200198471-A2.
XX
PD 27-DEC-2001.
XX
PF 21-JUN-2001; 2001WO-US020140.
XX
PR 22-JUN-2000; 2000US-0213741P.
XX
PR 14-JUL-2000; 2000US-0218234P.
XX
PR 16-OCT-2000; 2000US-0241100P.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Thornton M, Ding L, Patterson C, Yao MG, Tribouley CM, Lal P;
PI Hafalia AJA, Baughn MR, Ramkumar J, Lu Y, Walia NK;
XX
XX WPI; 2002-147799/19.
XX
DR N-PSDB; ABA99136.
XX
PT Novel human phosphodiesterase polypeptides and polynucleotides for
PT diagnosing, preventing and treating eye, neurological, cardiovascular,
PT cell proliferative and autoimmune/inflammatory disorders.
XX
PS Claim 1; Page 97-98; 105pp; English.
XX
CC This invention relates to isolated human phosphodiesterase polypeptides
CC (HPDE 1-4), which are antiinflammatory, neuroprotective, cytostatic,
CC antianaemic, immunosuppressive and anti-HIV in their action. The
CC polypeptides are useful for screening a compound for effectiveness as an
CC agonist or antagonist of the protein. The identified agonist, antagonist
CC and protein are useful for treating a disease or condition associated
CC with decreased or overexpression of functional HPDE in a patient. The
CC proteins are useful in preparing polyclonal or monoclonal antibodies by
CC hybridoma technology. They are also useful in the treatment and
CC prevention of eye, neurological, cardiovascular, cell proliferative and
CC autoimmune and inflammatory disorders, metabolic disorders and mental
CC disorders. The polynucleotides are useful for creating humanised animals
CC or transgenic animals to model human disease and to detect and quantify
CC gene expression in biopsied tissues in which expression of HPDE is
```

CC correlated with disease. HPDE, its fragments and antibodies specific for  
CC HPDE are useful as elements on a microarray which is useful to monitor or  
CC measure protein-protein interactions, drug-target interactions and gene  
CC expression profiles. This sequence represents HPDE-1

XX SQ Sequence 502 AA;

Query Match 83.1%; Score 1280; DB 5; Length 502;  
Best Local Similarity 100.0%; Pred. No. 1.5e-132;  
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDILRGQTGVRAERGSYPFIDFRLNLSNTTYSGEIGTKKKVKKLLSFQRYFHASRLRG 87  
Db 80 GDILRGQTGVRAERGSYPFIDFRLNLSNTTYSGEIGTKKKVKKLLSFQRYFHASRLRG 139  
Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHH 199  
Qy 148 FKLDVMTLHRLVWQEDYHSQNPYHNAVHAADVQAMHCYLKPKLASFLTPDIDIMGL 207  
Db 200 FKLDVMTLHRLVWQEDYHSQNPYHNAVHAADVQAMHCYLKPKLASFLTPDIDIMGL 259  
Qy 208 LAAAHADVHPGVNQPFILKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAHADVHPGVNQPFILKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 319

Qy 268 T 268

Db 320 T 320

RESULT 15

ADJ58904  
ID ADJ58904 standard; protein; 502 AA.

XX AC ADJ58904;

XX DT 06-MAY-2004 (first entry)

XX DE Human cyclic nucleotide phosphodiesterase protein #1.

XX KW 27875; 22025; 27420; 17906; 16319; 55092; 10218; cancer;  
KW cellular proliferation; cellular differentiation; immune disorder;  
KW cardiovascular disorder; endothelial cell disorder;  
KW haematopoietic disorder; blood vessel disorder; brain disorder; pain;  
KW metabolic disorder; liver disorder; platelet disorder; gene therapy;  
KW human; cyclic; enzyme.

XX OS Homo sapiens.

XX PN US2004006016-A1.

XX PD 08-JAN-2004.

XX PF 11-MAR-2003; 2003US-00386414.

XX PR 11-JUN-1999; 99US-00330970.

XX PR 25-OCT-1999; 99US-00426282.

XX PR 16-MAY-2000; 2000US-00571689.

XX PR 22-SEP-2000; 2000US-00668266.

XX PR 08-NOV-2000; 2000US-00724599.

XX PR 07-DEC-2000; 2000US-0254037P.

XX PR 10-APR-2001; 2001US-00833082.

XX PR 16-MAY-2001; 2001US-00860193.

XX PR 31-OCT-2001; 2001US-0335044P.

XX PR 06-DEC-2001; 2001US-00010943.

XX PR 29-OCT-2002; 2002US-00283023.

XX PA (MILL-) MILLENNIUM PHARM INC.

XX PI Kapeller-Libermann R, White D, Robison KE, Macbeth KJ, Carroll JM;

PI Cook WJ, Meyers RE, Chun M, Williamson MJ;

XX

DR WPI; 2004-081738/08.

XX N-PSDB; ADJ58903.

XX New isolated 27875, 22025, 27420, 17906, 16319, 55092, or 10218 nucleic  
PT acid molecules, useful for diagnosing or treating cancer, pain, or  
PT immune, endothelial cell, hematopoietic, blood vessel, brain, metabolic  
PT and liver disorders.

XX PS Claim 4; SEQ ID NO 4; 245pp; English.

XX The present invention relates to an isolated 27875, 22025, 27420, 17906,  
CC 16319, 55092, or 10218 nucleic acid molecule. The invention is useful for  
CC diagnosing or treating cancer or aberrant cellular proliferation and/or  
CC differentiation, immune disorders, heart disorders, cardiovascular  
CC disorders including endothelial cell disorders, haematopoietic disorders,  
CC blood vessel disorders, brain disorders, pain and metabolic disorders,  
CC liver disorders and platelet disorders. The invention is also useful in  
CC gene therapy. The present sequence is human cyclic nucleotide  
CC phosphodiesterase.

XX SQ Sequence 502 AA;

Query Match 83.1%; Score 1280; DB 8; Length 502;

Best Local Similarity 100.0%; Pred. No. 1.5e-132;

Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDILRGQTGVRAERGSYPFIDFRLNLSNTTYSGEIGTKKKVKKLLSFQRYFHASRLRG 87

Db 80 GDILRGQTGVRAERGSYPFIDFRLNLSNTTYSGEIGTKKKVKKLLSFQRYFHASRLRG 139

Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHH 147

Db 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHH 199

Qy 148 FKLDVMTLHRLVWQEDYHSQNPYHNAVHAADVQAMHCYLKPKLASFLTPDIDIMGL 207

Db 200 FKLDVMTLHRLVWQEDYHSQNPYHNAVHAADVQAMHCYLKPKLASFLTPDIDIMGL 259

Qy 208 LAAAHADVHPGVNQPFILKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 267

Db 260 LAAAHADVHPGVNQPFILKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 319

Qy 268 T 268

Db 320 T 320

Search completed: March 10, 2006, 19:56:51

Job time : 109.537 secs

**this Page Blank (uspio)**



GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 19:57:15 ; Search time 19.9024 Seconds  
(without alignments)  
1392.313 Million cell updates/sec

Title: US-10-781-181-3

Perfect score: 1540

Sequence: 1 MSCLMVERCGEILFENPDQN.....GTWDFDIFLFDRLTNGSLV 288

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: pir1.\*

2: pir2.\*

3: pir3.\*

4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1430	92.9	450	2 JC7266	3',5'-cyclic-AMP nucle
2	907	58.9	498	2 A47286	3',5'-cyclic-AMP p
3	331.5	21.5	584	2 B53109	3',5'-cyclic-nucle
4	331.5	21.5	672	2 161259	3',5'-cyclic-nucle
5	330.5	21.5	673	2 161358	3',5'-cyclic-nucle
6	320.5	20.8	886	2 A54442	3',5'-cyclic-nucle
7	317.5	20.6	562	2 159143	cAMP phosphodiesterase
8	317.5	20.6	564	2 A40949	cyclic-AMP phospho
9	316.5	20.6	610	2 167946	3',5'-cyclic-nucle
10	316.5	20.6	844	2 153865	phosphodiesterase
11	314.5	20.4	564	2 JC1519	3',5'-cyclic-nucle
12	314.5	20.4	736	2 161354	phosphodiesterase
13	305	19.8	712	2 S71626	3',5'-cyclic-nucle
14	301.5	19.6	323	2 S55348	3',5'-cyclic-nucle
15	296.5	19.3	534	1 A44162	3',5'-cyclic-nucle
16	296.5	19.3	535	1 A46378	3',5'-cyclic-nucle
17	295.5	19.2	535	1 A44161	3',5'-cyclic-nucle
18	295	19.2	536	2 167945	3',5'-cyclic-nucle
19	291	18.9	519	2 T14783	hypothetical prote
20	285	18.5	713	2 JW0088	3',5'-cyclic-nucle
21	282.5	18.3	536	1 JC6129	3',5'-cyclic-nucle
22	281	18.2	549	2 T16769	hypothetical prote
23	279	18.1	664	2 T24459	hypothetical prote
24	278	18.1	530	1 A45334	3',5'-cyclic-nucle
25	269.5	17.5	659	2 JC0293	3',5'-cyclic-nucle
26	269.5	17.5	885	2 JC7858	3',5'-cyclic-nucle
27	268	17.4	777	2 S65543	3',5'-cyclic-nucle
28	263	17.1	768	2 T10796	3',5'-cyclic-nucle
29	258	16.8	491	2 A40283	3',5'-cyclic-nucle

30 246 16.0 267 2 B33904  
31 228.5 14.8 1054 2 T30901  
32 223.5 14.5 875 2 A48719  
33 223.5 14.5 875 1 JW0106  
34 216.5 14.1 259 2 T20399  
35 204 13.2 1108 2 A48508  
36 198.5 12.9 1112 2 S70522  
37 186 12.1 928 1 JC2486  
38 185 12.0 921 1 A40981  
39 180.5 11.7 853 2 A36617  
40 176.5 11.5 854 2 A42828  
41 176.5 11.5 856 1 A47451  
42 176 11.4 858 2 JC4520  
43 176 11.4 1141 2 A44093  
44 175.5 11.4 800 2 S13032  
45 175.5 11.4 856 2 S30762

#### ALIGNMENTS

##### RESULT 1

JC7266

N;Alternate names: cAMP-specific phosphodiesterase (EC 3.1.4.17) 7B - human

C;Species: Homo sapiens (man)

C;Date: 18-Aug-2000 #sequence\_revision 18-Aug-2000 #text\_change 09-Jul-2004

C;Accession: JC7266

R;Sasaki, T.; Kotera, J.; Yuasa, K.; Omori, K.

Biochem. Biophys. Res. Commun. 271, 575-583, 2000

A;Title: Identification of human PDE7B, a cAMP-specific phosphodiesterase.

A;Reference number: JC7266

A;Accession: JC7266

A;Molecule type: mRNA

A;Residues: 1-450 <SAS>

A;Cross-references: UNIPROT:Q9NP56; UNIPARC:UPI00000339FF; DDBJ:AB038040

A;Experimental source: caudate nucleus

C;Genetics:

A;Gene: pde7B

A;Map position: 6q23-24

C;Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'

C;Keywords: phosphoric diester hydrolase

Query Match 92.9%; Score 1430; DB 2; Length 450;

Best Local Similarity 100.0%; Pred. No. 8.2e-121;

Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLGRGQTGVRAERGSYPFIDFRLNLTYS 60

Db 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLGRGQTGVRAERGSYPFIDFRLNLTYS 60

Qy 61 GEITGKKVKRLLSFQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGWDFDIF 120

Db 61 GEITGKKVKRLLSFQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGWDFDIF 120

Qy 121 LFDRLTNGSLVTLCHLNFTHGLIHFFKLDVMVTLHRFLVMVQEDYHSQNPYHNAHAAD 180

Db 121 LFDRLTNGSLVTLCHLNFTHGLIHFFKLDVMVTLHRFLVMVQEDYHSQNPYHNAHAAD 180

Qy 181 VTQAMHCYLKEPKLASFLPLDLMGLLAAAHDVDPGVNQPFLIKTNHHLANLYQNM 240

Db 181 VTQAMHCYLKEPKLASFLPLDLMGLLAAAHDVDPGVNQPFLIKTNHHLANLYQNM 240

Qy 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268

Db 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268

RESULT 2

A47286

3',5'-cyclic-AMP phosphodiesterase (EC 3.1.4.-) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 03-May-1994 #sequence\_revision 03-May-1994 #text\_change 03-Nov-2000







Db 118 AOELENSK---WGLNIFCVSEYAGRSLSICIMYTIQERDLLKKFHIPVDTWMMYMLTL 174  
Qy 163 QEDYHSQNPYHVAADVTQAMHCYKLPKASFLTPDLIMGLLAAAHVDVHPGVNQ 222  
Db 175 EDHYHADVAYHNSLHAADVLQSTHVLATPALDAVFTDLLEILAAAFAAAIHVDVHPGVSN 234  
Qy 223 PFLIKTHHLANLYONMSVLENHHRSTIGMLRE 256  
Db 235 QFLINTSELALMYNDSVLENHHLAVGFKLQE 268

RESULT 10  
153865  
phosphodiesterase - rat  
C;Species: Rattus norvegicus (Norway rat)  
C;Date: 29-May-1998 #sequence\_revision 29-May-1998 #text\_change 09-Jul-2004  
C;Accession: J53865  
R;Bolger, G.B.; Rodgers, L.K.; Riggs, M.  
Gene 149, 237-244, 1994  
A;Title: Differential CNS expression of alternative mRNA isoforms of the mammalian genes  
A;Reference number: I53865; MUID:95047482; PMID:7958996  
A;Accession: I53865  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: mRNA  
A;Residues: 1-844 <RES>  
A;Cross-references: UNIPROT:P54748; UNIPARC:UPI0000127BF5; GB:L27057; NID:G3334904; PIDN:  
F;418-646/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 20.6%; Score 316.5; DB 2; Length 844;  
Best Local Similarity 33.2%; Pred. No. 2.9e-20;  
Matches 71; Conservative 32; Mismatches 86; Indels 25; Gaps 2;

Qy 43 RGSYPFDPLRLNSTYSGBIGTKKVKRLLSFORYPHASRLRLGRIIPQAPLHLLDBDYL 102  
Db 314 RQSPQMSQITGLKVLVHTGSLNTN-----VPRFGVKTQDQDL 351

Qy 103 GOARHMLSKVGMDFDIFLDRLTNGNSLVTLCHLNFTHHFKLDMVTLHRLVMV 162  
Db 352 AOELENSK---WGLNIFCVSEYAGRSLSICIMYTIQERDLLKKFHIPVDTWMMYMLTL 408

Qy 163 QEDYHSQNPYHVAADVTQAMHCYKLPKASFLTPDLIMGLLAAAHVDVHPGVNQ 222  
Db 409 EDHYHADVAYHNSLHAADVLQSTHVLATPALDAVFTDLLEILAAAFAAAIHVDVHPGVSN 468

Qy 223 PFLIKTHHLANLYONMSVLENHHRSTIGMLRE 256  
Db 469 QFLINTSELALMYNDSVLENHHLAVGFKLQE 502

RESULT 11  
JC1519  
3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17), cAMP-specific (clone HBP106) -  
C;Species: Homo sapiens (man)  
C;Date: 14-Jul-1994 #sequence\_revision 14-Jul-1994 #text\_change 09-Jul-2004  
C;Accession: JC1519; A45500; I61359  
R;Obernolte, R.; Bhakta, S.; Alvarez, R.; Bach, C.; Zuppan, P.; Mulkins, M.; Jarnagin, K.  
Gene 129, 239-247, 1993  
A;Title: The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a  
A;Reference number: JC1519; MUID:93314968; PMID:8392015  
A;Accession: JC1519  
A;Molecule type: mRNA  
A;Residues: 1-564 <OBE>  
A;Cross-references: UNIPROT:Q13945; UNIPARC:UPI000014C5AB; GB:L12686  
A;Experimental source: lymphocyte  
A;Note: only partial nucleotide sequence is given  
R;McLaughlin, M.M.; Cielesinski, L.B.; Burman, M.; Torphy, T.J.; Livi, G.P.;  
J. Biol. Chem. 268, 6470-6476, 1993  
A;Title: A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain.  
f mRNA.  
A;Reference number: A45500; MUID:93203241; PMID:8394210  
A;Accession: A45500  
A;Molecule type: mRNA  
A;Residues: 1-564 <MCL>

A;Cross-references: UNIPARC:UPI000014C5AB; GB:M97515; NID:G2923387; PIDN:AAA36426.1; PID:  
A;Experimental source: frontal cortex  
A;Note: sequence extracted from NCBI backbone (NCBIN:127929, NCBIP:127930)  
R;Bolger, G.; Michaeli, T.; Martins, T.; St. John, T.; Steiner, B.; Rodgers, L.; Riggs, M.  
Mol. Cell. Biol. 13, 6558-6571, 1993  
A;Title: A family of human phosphodiesterases homologous to the dunce learning and memory  
A;Reference number: A54442; MUID:94019330; PMID:8413254  
A;Accession: I61359  
A;Status: preliminary; nucleic acid sequence not shown; translated from GB/EMBL/DBJ  
A;Molecule type: mRNA  
A;Residues: 1-564 <RES>  
A;Cross-references: UNIPARC:UPI000014C5AB; GB:L20971; NID:G347131; PIDN:AAA03593.1; PID:  
C;Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'-  
C;Keywords: phosphoric diester hydrolase  
F;233-461/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 20.4%; Score 314.5; DB 2; Length 564;  
Best Local Similarity 33.6%; Pred. No. 2.6e-20;  
Matches 71; Conservative 44; Mismatches 87; Indels 9; Gaps 3;

Qy 66 KKKVKRLLS-----FQRYFHASRLRLGRIIPQAPLHLLDEDYLGQARHMLSKVGMDFDIFL 121  
Db 126 KKKKQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNK---WGLNIFN 182

Qy 122 FDLRTNGNSLVTLCHLNFTHHFKLDMVTLHRLVMVQEDYHSQNPYHVAADV 181  
Db 183 VAGYSHNRPLTCIMYAIQERDLTKFRISSTDTFTYMTLEDHYHSDVAYHNSLHAADV 242

Qy 182 TQAMHCYKLPKASFLTPDLIMGLLAAAHVDVHPGVNQPLIKTHHLANLYONMSV 241  
Db 243 AQSTHVLSTPALDAVFTDLLEILAAAFAAAIHVDVHPGVSNQFLINTSELALMYNDSV 302

Qy 242 LENHWRSTIGMLRESR--LLAHLPKEMTGT 270  
Db 303 LENHHLAVGFKLQERHCDIFMNLTKKQRT 333

RESULT 12  
I61354  
phosphodiesterase - human  
C;Species: Homo sapiens (man)  
C;Date: 06-Sep-1996 #sequence\_revision 06-Sep-1996 #text\_change 09-Jul-2004  
C;Accession: I61354  
R;Bolger, G.; Michaeli, T.; Martins, T.; St. John, T.; Steiner, B.; Rodgers, L.; Riggs, M.  
Mol. Cell. Biol. 13, 6558-6571, 1993  
A;Title: A family of human phosphodiesterases homologous to the dunce learning and memory  
A;Reference number: A54442; MUID:94019330; PMID:8413254  
A;Accession: I61354  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: mRNA  
A;Residues: 1-736 <RES>  
A;Cross-references: UNIPROT:Q07343; UNIPARC:UPI0000127BF6; GB:L20966; NID:G347121; PIDN:  
C;Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'-  
F;405-633/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 20.4%; Score 314.5; DB 2; Length 736;  
Best Local Similarity 33.6%; Pred. No. 3.6e-20;  
Matches 71; Conservative 44; Mismatches 87; Indels 9; Gaps 3;

Qy 66 KKKVKRLLS-----FQRYFHASRLRLGRIIPQAPLHLLDEDYLGQARHMLSKVGMDFDIFL 121  
Db 298 KKKKQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNK---WGLNIFN 354

Qy 122 FDLRTNGNSLVTLCHLNFTHHFKLDMVTLHRLVMVQEDYHSQNPYHVAADV 181  
Db 355 VAGYSHNRPLTCIMYAIQERDLTKFRISSTDTFTYMTLEDHYHSDVAYHNSLHAADV 414

Qy 182 TQAMHCYKLPKASFLTPDLIMGLLAAAHVDVHPGVNQPLIKTHHLANLYONMSV 241  
Db 415 AQSTHVLSTPALDAVFTDLLEILAAAFAAAIHVDVHPGVSNQFLINTSELALMYNDSV 474

Qy 242 LENHWRSTIGMLRESR--LLAHLPKEMTGT 270  
Db 303 LENHHLAVGFKLQERHCDIFMNLTKKQRT 333

Db 475 LENHHLAVGFKLLQBEHCDFMNLTKKQRT 505

RESULT 13

S71626

3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17), cAMP-specific - human

N;Alternate names: 3',5'-cyclic AMP phosphodiesterase

C;Species: Homo sapiens (man)

C;Date: 27-Nov-1997 #sequence\_revision 12-Dec-1997 #text\_change 09-Jul-2004

C;Accession: S71626; 161356

R;Engels, P.; Sullivan, M.; Mueller, T.; Luebbert, H.

FEBS Lett. 358, 305-310, 1995

A;Title: Molecular cloning and functional expression in yeast of a human cAMP-specific p

A;Reference number: S71626; MUID:95145731; PMID:7843419

A;Accession: S71626

A;Molecule type: DNA

A;Residues: 1-712 <ENG>

A;Cross-references: UNIPROT:Q08493; UNIPARC:UPI0000163B31; EMBL:Z46632; NID:G727222; PID

A;Experimental source: substantia nigra

R;Bolger, G.; Michaeli, T.; Martins, T.; St. John, T.; Steiner, B.; Rodgers, L.; Riggs,

Mol. Cell. Biol. 13, 6558-6571, 1993

A;Title: A family of human phosphodiesterases homologous to the dunce learning and memoz

A;Reference number: A54442; MUID:94019330; PMID:8413254

A;Accession: I61356

A;Status: preliminary;

A;Molecule type: mRNA

A;Residues: 462-712 <RES>

A;Cross-references: UNIPARC:UPI000016AE86; GB:I20968; NID:G347125; PIDN:AAA03591.1; PID:

C;Genetics:

A;Gene: HSPDE4C1

C;Function:

A;Description: cAMP hydrolysis; converts cAMP to non-cyclic AMP

A;Pathway: cyclic nucleotide metabolism

A;Note: expressed in various tissues but not in cells of the immune system

C;Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'

C;Keywords: phosphoric diester hydrolase

F;387-615/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 19.8%; Score 305; DB 2; Length 712;

Best Local Similarity 28.8%; Pred. No. 2.5e-19;

Matches 76; Conservative 44; Mismatches 107; Indels 40; Gaps 5;

QY 11 EILFEPDQNAKVCMLGDIRLGGQGVRAERGSYPFDIFRLN-----STTYSG-- 61

Db 204 KLAETLDELDCDQLETLQTRHSVGENASNKFK-----RLNRELTHLSTSGNQ 257

QY 62 -----ETGTYK-----KVRLLSFQRYFHASRLLRGIIPQAPLHLDE 99

Db 258 VSEYISRTFLDQOTEVELPKVTAEEAPQPMRSIRISGLHGLCHSASLSSATVPREGVQTDQE 317

QY 100 DYLGQARHLSKVGWDFDIFLFDRLTNGNSLVTLCHLFTNTHGLIHHFKLDWTLHREL 159

Db 318 EQAKE---LEDNKNWGLDVKVADVSGNRPPLTAIIFSIQERDLTKTFQIPADTLATYL 374

QY 160 VMVQEDYHSONPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIMLGLLAAAHAHDVDFHG 219

Db 375 LMLEGHYHANVAHNSLHAADVAQSTHVLATPALEAVFTDLEILALFASAIHDVDFHG 434

QY 220 VNQPFLLKTNHHLANLYQNMSVLENH 246

Db 435 VSNQFLINTNSDVALMYNDASVLENH 461

RESULT 14

S55348

3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17) HSPDE4A7 - human

N;Alternate names: 3',5'-cyclic AMP phosphodiesterase

C;Species: Homo sapiens (man)

C;Date: 23-Aug-1995 #sequence\_revision 03-Nov-1995 #text\_change 09-Jul-2004

C;Accession: S55348

R;Horton, Y.M.; Sullivan, M.; Houslay, M.D.

Biochem. J. 308, 683-691, 1995

A;Title: Molecular cloning of a novel splice variant of human type IV(A) (PDE-IV(A)) cyd

A;Reference number: S55348; MUID:95290008; PMID:7772058

A;Accession: S55348

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-323 <HOR>

A;Cross-references: UNIPROT:P27815; UNIPARC:UPI000002A6D0; EMBL:U18088; NID:G604376; PID:

C;Keywords: phosphoric diester hydrolase

F;98-312/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 19.6%; Score 301.5; DB 2; Length 323;

Best Local Similarity 37.3%; Pred. No. 1.8e-19;

Matches 66; Conservative 32; Mismatches 72; Indels 7; Gaps 4;

QY 83 RLILRGII--POAPLHLLDEYLGQARHM--LSKVGWMDFDIFLFDRLTNGNSLVTLCHLF 139

Db 10 KLGNVLQGP--PYRLTSS---GLRLHQELENKWLGNIFCVSDYAGGSLTCIMTMIF 65

QY 140 NTHGLIHHFKLDWTLHRLVWVQEDYHSONPYHNAVHAADVTQAMHCYLKEPKLASFLT 199

Db 66 QERDLKKFRIIPVDITWVTYMLTLEDHYHADVAHNSLHAADVLQSTHVLATPALDAVFT 125

QY 200 PLDIMLGLLAAAHAHDVDFHGVPQPFLLKTNHHLANLYQNMSVLENHHRSTIGMLRE 256

Db 126 DLEILALFAAAIHDVDHFGVSNQFLINTNSLSEALMYNDESVLNHHHLAVGFKLLQE 182

RESULT 15

A44162

3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17) 1B, calmodulin-dependent, 63K sp

N;Alternate names: 63K calmodulin-stimulated phosphodiesterase, brain; CAM-PDE1B1

C;Species: Bos primigenius taurus (cattle)

C;Date: 20-Aug-1999 #sequence\_revision 20-Aug-1999 #text\_change 09-Jul-2004

C;Accession: A44162; B40283

R;Bentley, J.K.; Kadlecek, A.; Sherbert, C.H.; Seger, D.; Sonnenburg, W.K.; Charbonneau,

J. Biol. Chem. 267, 18676-18682, 1992

A;Title: Molecular cloning of cDNA encoding a "63"-kDa calmodulin-stimulated phosphodiester

A;Reference number: A44162; MUID:92406781; PMID:1326531

A;Accession: A44162

A;Molecule type: mRNA

A;Residues: 1-534 <BEN>

A;Cross-references: UNIPROT:Q01061; UNIPARC:UPI0000127BEB; GB:M94867; NID:G162782; PIDN:

A;Experimental source: brain

R;Novack, J.P.; Charbonneau, H.; Bentley, J.K.; Walsh, K.A.; Beavo, J.A.

Biochemistry 30, 7940-7947, 1991

A;Title: Sequence comparison of the 63-, 61-, and 59-kDa calmodulin-dependent cyclic nuc

A;Reference number: A40283; MUID:91329366; PMID:1651112

A;Accession: B40283

A;Molecule type: protein

A;Residues: 29-45,'IP', 48,'R', 50-52,'IS', 55-85;196-215;277,'D', 279,'T', 281-287,'T', 289-2;

A;Cross-references: UNIPARC:UPI0000144B58; UNIPARC:UPI000017288B; UNIPARC:UPI000017288C;

A;Experimental source: brain

C;Comment: This enzyme is a useful target for inducing the death of leukemic cells, and t

C;Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'

C;Keywords: alternative splicing; calmodulin binding; cGMP binding; phosphoric diester h

F;220-437/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNPD>

Query Match 19.3%; Score 296.5; DB 1; Length 534;

Best Local Similarity 37.9%; Pred. No. 1e-18;

Matches 61; Conservative 30; Mismatches 67; Indels 3; Gaps 2;

QY 109 LSKVGWMDFDIFLFDRLTNGNSLVTLCHLFTNTHGLIHHFKLDWTLHRLVWVQEDYHS 168

Db 156 LKNVDLMCFDVSFLNRAADDHALRTIVFELLTRHNLISRFKIPVTFMLTFDLDALEYGYK 215

QY 169 -QNYPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIMLGLLAAAHAHDVDFHGVPQPFLLK 227

Db 216 YKNPYHNLHAADVTQTVHCFLLRTGMVHCLSEIVLAIIFAAAIDHYEHTGTTSFHIQ 275

QY 228 TNHHLANLYQNMSVLENHHRSTIGMLR--ESRLLAHLPE 266

Db 276 TKSECAILYNDRSVLENHHSIVFRMMQDDEMNIFINLTKD 316

Search completed: March 10, 2006, 20:03:02  
Job time : 22.9024 secs

---

This Page Blank (uspto)



GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 19:52:25 ; Search time 120.195 Seconds  
(without alignments)  
1690.519 Million cell updates/sec

Title: US-10-781-181-3  
Perfect score: 1540  
Sequence: 1 MSCLMVERCGEILFENPDQN.....GTWDFDIFLDRLTNGNSLV 288

Scoring table:  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt 05.80.\*

1: uniprot\_sprot.\*

2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1430	92.9	450	1	PDE7B_HUMAN
2	1430	92.9	450	2	Q5VWY9_HUMAN
3	1376	89.4	446	1	PDE7B_MOUSE
4	1376	89.4	446	2	Q8CB82_MOUSE
5	1367	88.8	446	2	Q8VIE4_RAT
6	1350.5	87.7	459	2	Q8VIE2_RAT
7	1280	83.1	586	2	Q4LE81_HUMAN
8	999.5	64.9	456	2	Q4RR95_TETNG
9	953	61.9	359	2	Q8VIE3_RAT
10	914	59.4	482	2	Q6P5G2_MOUSE
11	913	59.3	456	1	PDE7A_MOUSE
12	907	58.9	424	2	Q96T72_HUMAN
13	907	58.9	482	1	PDE7A_HUMAN
14	906	58.8	456	2	Q5R5B5_PONPY
15	892	57.9	426	1	PDE7A_RAT
16	775	50.3	381	2	Q505M0_XENLA
17	711	46.2	199	2	Q4VX30_HUMAN
18	595	38.6	324	2	Q4R6T4_WACPA
19	475	30.8	305	2	Q7PNE5_ANOGA
20	409	26.6	162	2	Q86V65_HUMAN
21	331.5	21.5	747	1	PDE4D_MOUSE
22	331.5	21.5	803	1	PDE4D_RAT
23	330.5	21.5	809	1	PDE4D_HUMAN
24	325.5	21.1	682	2	Q5XGT5_XENLA
25	320.5	20.8	563	2	Q5ZKR6_CHICK
26	320.5	20.8	647	2	Q8IV47_HUMAN
27	320.5	20.8	825	2	Q9H3H2_HUMAN
28	320.5	20.8	860	2	Q5DM53_HUMAN
29	320.5	20.8	864	2	Q6PMT2_HUMAN
30	320.5	20.8	886	1	PDE4A_HUMAN
31	319.5	20.7	1051	2	Q4SML2_TETNG

32	318.5	20.7	721	2	Q9OXI7_MOUSE
33	317.5	20.6	383	2	Q8QB2_MOUSE
34	317.5	20.6	503	2	Q6IQI6_MOUSE
35	317.5	20.6	542	2	Q91VY2_MOUSE
36	317.5	20.6	659	2	Q8VD81_RAT
37	317.5	20.6	721	1	PDE4B_RAT
38	317.5	20.6	721	2	Q8VBU5_MOUSE
39	317.5	20.6	722	2	Q5RKL0_RAT
40	317.5	20.6	736	2	Q8VD82_RAT
41	317.5	20.6	867	2	Q4RL51_TETNG
42	316.5	20.6	771	2	Q9EQR7_RAT
43	316.5	20.6	844	1	PDE4A_RAT
44	314.5	20.4	518	2	Q43850_HUMAN
45	314.5	20.4	564	2	Q5T3Z8_HUMAN

#### ALIGNMENTS

RESULT 1  
ID PDE7B\_HUMAN STANDARD; PRT; 450 AA.  
AC Q9NP56,  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 10-MAY-2005 (Rel. 47, Last annotation update)  
DE CAMP-specific 3',5'-cyclic phosphodiesterase 7B (EC 3.1.4.17).  
GN Name=PDE7B;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Brain;  
RX MEDLINE=20275458; PubMed=10814504; DOI=10.1006/bbrc.2000.2661;  
RA Sasaki T., Kotera J., Yuasa K., Omori K.;  
RT "Identification of human PDE7B, a CAMP-specific phosphodiesterase.";  
RL Biochem. Biophys. Res. Commun. 271:575-583(2000).  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Fetal brain,  
RX MEDLINE=20329226; PubMed=10872825; DOI=10.1006/bbrc.2000.2743;  
RA Gardner C.E., Robas N.M., Cawkill D., Fidock M.D.;  
RT "Cloning and characterisation of the human and mouse PDE7B, a novel  
CAMP-specific nucleotide phosphodiesterase.";  
RL Biochem. Biophys. Res. Commun. 272:186-192(2000).  
RN [3]  
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].  
RC TISSUE=Brain;  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
Klausner R.D., Collins F.S., Wagner L.H., Shenmen C.M., Schuler G.D.,  
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,  
Bohak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
Fahey J., Helton E., Kettman M., Maman A.C., Rodriguez S., Sanchez A.,  
Whiting M., Maman A., Young A.C., Shevchenko Y., Bouffard G.G.,  
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
Butterfield Y.S.N., Krzywinski M.I., Skalka U., Small D.E.,  
Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
CC -!- FUNCTION: May be involved in the control of CAMP-mediated neural

activity and cAMP metabolism in the brain.  
-1- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O = adenosine 5'-phosphate.  
-1- COFACTOR: Divalent cations (By similarity).  
-1- ENZYME REGULATION: Inhibited by dipyrdimole, IBMX and SCH51866. Insensitive to zaprinast, rolipram, and milrinone.  
-1- PATHWAY: Cyclic nucleotide metabolism.  
-1- TISSUE SPECIFICITY: Highly expressed in brain. Also expressed in heart, liver, skeletal muscle and pancreas.  
-1- DOMAIN: Composed of a C-terminal catalytic domain containing two putative divalent metal sites and an N-terminal regulatory domain.  
-1- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase family.  
-----  
This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.  
-----  
DR EMBL; AB038040; BAA96537.1; -; mRNA.  
DR EMBL; AJ251860; CAB92441.1; -; mRNA.  
DR EMBL; BC075082; AAH75082.1; -; mRNA.  
DR EMBL; BC075083; AAH75083.1; -; mRNA.  
DR PIR; JCT266; JCT266.  
DR PDB; 1LXW; Model; A=104-433.  
DR Ensembl; ENSG00000171408; Homo sapiens.  
DR HGNC; HGNC:8792; PDE7B.  
DR MIM; 604645; -.  
DR GO; GO:0004115; F: cAMP-specific phosphodiesterase activity; TAS.  
DR GO; GO:0007165; P: signal transduction; TAS.  
DR GO; GO:0007268; P: synaptic transmission; TAS.  
DR InterPro; IPR002073; PDEase.  
DR Pfam; PF00233; PDEase\_I; 1.  
DR PRINTS; PR00387; PDIESTERASE1.  
DR PROSITE; PS00126; PDEASE\_I; 1.  
KW 3D-structure; cAMP; Hydrolyase.  
FT REGION 172 410 Catalytic (By similarity).  
SQ SEQUENCE 450 AA; 51835 MW; EC142BF3E28D0028 CRC64;

Query Match 92.9%; Score 1430; DB 1; Length 450;  
Best Local Similarity 100.0%; Pred. No. 5.8e-122;  
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MSCLMVERGCEILFENPDQNAKVCMLGDIRLGRGTGVAERGSYPFIDFRLNLTYS 60  
DB 1 MSCLMVERGCEILFENPDQNAKVCMLGDIRLGRGTGVAERGSYPFIDFRLNLTYS 60  
QY 61 GEIGTKKKVKRLLSFORYPHASRLLRGIIPQAPLHLLDELDYLQARHMLSKVGMWDFDIF 120  
DB 61 GEIGTKKKVKRLLSFORYPHASRLLRGIIPQAPLHLLDELDYLQARHMLSKVGMWDFDIF 120  
QY 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMTLHRFLVMQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMTLHRFLVMQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268

RESULT 2  
QSVY9 HUMAN  
ID QSVY9.HUMAN PRELIMINARY; PRT; 450 AA.  
AC QSVY9.  
DT 01-FEB-2005 (TrEMBLrel. 29, Created)  
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)  
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)  
DE OTTHUMP0000017267.

Names=PDE7B; ORFNames=RP11-472E5.2-001;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RA Thomas D.;  
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RA Williams S.;  
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RA Cobley V.;  
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AL360178; CAH73075.1; -; Genomic DNA.  
DR EMBL; AL138828; CAI95287.1; -; Genomic DNA.  
DR EMBL; AL133319; CAH73332.1; -; Genomic DNA.  
DR EMBL; AL133319; CAH73075.1; JOINED; Genomic DNA.  
DR EMBL; AL138828; CAH73075.1; JOINED; Genomic DNA.  
DR EMBL; AL138828; CAH73332.1; JOINED; Genomic DNA.  
DR EMBL; AL133319; CAI95287.1; JOINED; Genomic DNA.  
DR EMBL; AL360178; CAH73332.1; JOINED; Genomic DNA.  
DR EMBL; AL360178; CAI95287.1; JOINED; Genomic DNA.  
DR Ensembl; ENSG00000171408; Homo sapiens.  
DR GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase a. . .; IEA.  
DR GO; GO:0003824; F: catalytic activity; IEA.  
DR GO; GO:0007165; P: signal transduction; IEA.  
DR InterPro; IPR003607; Met\_phos\_hydro.  
DR InterPro; IPR002073; PDEase.  
DR Pfam; PF00233; PDEase\_I; 1.  
DR PRINTS; PR00387; PDIESTERASE1.  
DR SMART; SM00471; HDC; 1.  
DR PROSITE; PS00126; PDEASE\_I; 1.  
SQ SEQUENCE 450 AA; 51835 MW; EC142BF3E28D0028 CRC64;  
Query Match 92.9%; Score 1430; DB 2; Length 450;  
Best Local Similarity 100.0%; Pred. No. 5.8e-122;  
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MSCLMVERGCEILFENPDQNAKVCMLGDIRLGRGTGVAERGSYPFIDFRLNLTYS 60  
DB 1 MSCLMVERGCEILFENPDQNAKVCMLGDIRLGRGTGVAERGSYPFIDFRLNLTYS 60  
QY 61 GEIGTKKKVKRLLSFORYPHASRLLRGIIPQAPLHLLDELDYLQARHMLSKVGMWDFDIF 120  
DB 61 GEIGTKKKVKRLLSFORYPHASRLLRGIIPQAPLHLLDELDYLQARHMLSKVGMWDFDIF 120  
QY 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMTLHRFLVMQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMTLHRFLVMQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268

RESULT 3  
PDE7B MOUSE  
ID PDE7B.MOUSE STANDARD; PRT; 446 AA.  
AC Q9OXQ1.  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 10-MAY-2005 (Rel. 47, Last annotation update)  
DE cAMP-specific 3',5'-cyclic phosphodiesterase 7B (EC 3.1.4.17).  
GN Name=Pde7b;

OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
 OC Muridae; Murinae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RN NUCLEOTIDE SEQUENCE.  
 RX MEDLINE=20087273; PubMed=10618442; DOI=10.1073/pnas.97.1.472;  
 RA Hecman J.M., Soderling S.H., Glavas N.A., Beavo J.A.;  
 RT "Cloning and characterization of PDE7B, a cAMP-specific  
 phosphodiesterase.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 97:472-476(2000).  
 RN [2]  
 RN NUCLEOTIDE SEQUENCE.  
 RC STRAIN=C57BL/6J;  
 RX MEDLINE=20329226; PubMed=10872825; DOI=10.1006/bbrc.2000.2743;  
 RA Gardner C.E., Robas N.M., Cawkill D., Fido M.D.;  
 RT "Cloning and characterization of the human and mouse PDE7B, a novel  
 cAMP-specific nucleotide phosphodiesterase.";  
 RL Biochem. Biophys. Res. Commun. 272:186-192(2000).  
 CC -1- FUNCTION: May be involved in the control of cAMP-mediated neural  
 activity and cAMP metabolism in the brain.  
 CC -1- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O =  
 adenosine 5'-phosphate.  
 CC -1- COFACTOR: Divalent cations (By similarity).  
 CC -1- ENZYME REGULATION: Inhibited by dipyradimole, IBMX and SCH51866.  
 CC -1- INSENSITIVE TO zaprinast, rolipram, and milrinone.  
 CC -1- PATHWAY: Cyclic nucleotide metabolism.  
 CC -1- TISSUE SPECIFICITY: Highly expressed in brain.  
 CC -1- DOMAIN: Composed of a C-terminal catalytic domain containing two  
 putative divalent metal sites and an N-terminal regulatory domain.  
 CC -1- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase  
 family.  
 CC -----  
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use as long as its content is in no way modified and this statement is not  
 removed.  
 CC -----  
 CC ENBL; AF190639; AAF25195.1; -; mRNA.  
 DR ENBL; AJ251859; CAB92550.1; -; mRNA.  
 DR HSP; Q08499; IOYN.  
 DR Ensemble; ENSMUSG00000019980; Mus musculus.  
 DR MGI; MGI:1352752; Pde7b.  
 DR GO; GO:0004115; F:cAMP-specific phosphodiesterase activity; IDA.  
 DR InterPro; IPR02073; PDEase.  
 DR Pfam; PF00233; PDEase\_I; 1.  
 DR PRINTS; PRO0387; PDIESTERASE1.  
 DR PROSITE; PS00126; PDEASE\_I; 1.  
 KW cAMP; Hydrolase.  
 FT REGION 172 410 Catalytic (By similarity).  
 SQ SEQUENCE 446 AA; 51337 MW; 7C052664B693A5A8 CRC64;  
 Query Match 89.4%; Score 1376; DB 1; Length 446;  
 Best Local Similarity 95.1%; Pred. No. 5e-117;  
 Matches 255; Conservative 8; Mismatches 5; Indels 0; Gaps 0;  
 Qy 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVAERGSYPFIDFRLNNTYS 60  
 Db 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVAERGSYPFIDFRLNNTYS 60  
 Qy 61 GEIGTKKKVRLLSFQRYFHASRLRGTIIQAPLHLLDELYLQARHLSKVGWDPDIF 120  
 Db 61 GEIGTKKKVRLLSFQRYFHASRLRGTIIQAPLHLLDELYLQARHLSKVGWDPDIF 120  
 Qy 121 LFORLTNGSLVTLCHLFWNTHGLIHHFKLDMVTLHRLFLVWQSDYHSQPNVNAHAAD 180  
 Db 121 LFORLTNGSLVTLCHLFWNTHGLIHHFKLDMVTLHRLFLVWQSDYHSQPNVNAHAAD 180  
 Qy 181 VTQAMHCYLPKEPKLASELTPLDIMGILAAAHVDHPGVNQPPLIKTNHHLNLYQMS 240  
 Db 181 VTQAMHCYLPKEPKLASELTPLDIMGILAAAHVDHPGVNQPPLIKTNHHLNLYQMS 240

Qy 241 VLENHWRSTIGMLRBSRLLAHLPKEMT 268  
 Db 241 VLENHWRSTIGMLRBSRLLAHLPKEMT 268  
 RESULT 4  
 Q8CBS2 MOUSE  
 ID Q8CBS2\_MOUSE PRELIMINARY; PRT; 446 AA.  
 AC Q8CBS2;  
 DT 01-MAR-2003 (T-EMBLrel. 23, Created)  
 DT 01-MAR-2003 (T-EMBLrel. 23, Last sequence update)  
 DT 01-MAR-2004 (T-EMBLrel. 26, Last annotation update)  
 DE Mus musculus adult male urinary bladder cDNA, RIKEN full-length  
 DE enriched library, clone:9530027016 product:phosphodiesterase 7B, full  
 DE insert sequence.  
 GN Name=Pde7b;  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
 OC Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RN NUCLEOTIDE SEQUENCE.  
 RC STRAIN=C57BL/6J; TISSUE=Urinary bladder;  
 RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;  
 RA Carninci P., Hayashizaki Y.;  
 RT "High-efficiency full-length cDNA cloning.";  
 RL Meth. Enzymol. 303:19-44(1999).  
 RN [2]  
 RN NUCLEOTIDE SEQUENCE.  
 RC STRAIN=C57BL/6J; TISSUE=Urinary bladder;  
 RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;  
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 RA Aizawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
 RA Azawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamana K.I.,  
 RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 RA Schimpl L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,  
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-P.,  
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,  
 RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohseki S.,  
 RA Hayashizaki Y.;  
 RT "Functional annotation of a full-length mouse cDNA collection.";  
 RL Nature 409:685-690(2001).  
 RN [3]  
 RN NUCLEOTIDE SEQUENCE.  
 RC STRAIN=C57BL/6J; TISSUE=Urinary bladder;  
 RA The FANTOM Consortium,  
 RA the RIKEN Genome Exploration Research Group Phase I & II Team;  
 RT "Analysis of the mouse transcriptome based on functional annotation of  
 RT 60,770 full-length cDNAs.";  
 RL Nature 420:563-573(2002).  
 RN [4]  
 RN NUCLEOTIDE SEQUENCE.  
 RC STRAIN=C57BL/6J; TISSUE=Urinary bladder;  
 RX MEDLINE=20493374; PubMed=11042159; DOI=10.1101/gr.145100;  
 RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,  
 RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;  
 RT "Normalization and subtraction of cap-trapper-selected cDNAs to  
 RT prepare full-length cDNA libraries for rapid discovery of new genes.";  
 RL Genome Res. 10:1617-1630(2000).  
 RN [5]  
 RN NUCLEOTIDE SEQUENCE.  
 RC STRAIN=C57BL/6J; TISSUE=Urinary bladder;

RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;  
RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,  
RA Konno H., Akiyama J., Nishi K., Kitsuana T., Tashiro H., Itoh M.,  
RA Sumi N., Iehi Y., Nakamura S., Hazama M., Nishine T., Harada A.,  
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,  
RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,  
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,  
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.,  
RT "RIKEN integrated sequence analysis (RISA) system-384-format  
RL sequencing pipeline with 384 multicapillary sequencer.",  
RL Genome Res. 10:1757-1771(2000).  
RN [6]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=C57BL/6J; TISSUE=Urinary bladder;  
RA Adachi J., Aizawa K., Akimura T., Arakawa T., Bono H., Carninci P.,  
RA Fukuda S., Furuno M., Hanagaki T., Hara A., Hashizume W.,  
RA Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,  
RA Hori F., Imotani K., Iehi Y., Itoh M., Kagawa I., Kasukawa T.,  
RA Katoh H., Kawai J., Kojima Y., Kondo S., Konno H., Kouda M., Koya S.,  
RA Kurihara C., Matsuyama T., Miyazaki A., Murata M., Nakamura M.,  
RA Nishi K., Nomura K., Numazaki R., Ohno M., Ohsato N., Okazaki Y.,  
RA Saito K., Saitoh H., Sakai C., Sakai K., Sakazume N., Sano H.,  
RA Sasaki D., Shibata K., Shinagawa A., Shiraki T., Sogabe Y., Tegami M.,  
RA Tagawa A., Takahashi F., Takaku-Akahira S., Takeda Y., Tanaka T.,  
RA Tomaru A., Toya T., Yasunishi A., Muramatsu M., Hayashizaki Y.,  
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AK035385; BAC29052.1; -; mRNA.  
DR HSSP: Q08499; IOYN.  
DR MGI: MGI:1352752; Pde7b.  
DR GO: GO:0004115; F: CAMP-specific phosphodiesterase activity; IDA.  
DR InterPro: IPR003607; Met\_phos\_hydro.  
DR Pfam: PF00233; PDEase.  
DR PRINTS: PR00387; PDIESTERASE1.  
DR SMART: SM00471; HDc; 1.  
DR PROSITE: PS00126; PDEASE\_I; UNKNOWN\_1.  
SQ SEQUENCE 446 AA; 51307 MW; 7C002364B396A5A8 CRC64;  
Query Match 89.4%; Score 1376; DB 2; Length 446;  
Best Local Similarity 95.1%; Pred. No. 5e-117; Indels 0; Gaps 0;  
Matches 255; Conservative 8; Mismatches 5;  
QY 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERGSYPFIDFRLNNTTYS 60  
DB 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERGSYPFIDFRLNNTTYS 60  
QY 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPLHLLDEDLGQARHMLSKVGWDFDIF 120  
DB 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPLHLLDEDLGQARHMLSKVGWDFDIF 120  
QY 121 LFDRLTNGNSLVTLCHLNFTHGLIHFFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLNFTHGLIHFFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLIMLGLLAAAHDVDHPGVNQPFLLKTNHHLANLYQNMS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLIMLGLLAAAHDVDHPGVNQPFLLKTNHHLANLYQNMS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
QY 121 LFDRLTNGNSLVTLCHLNFTHGLIHFFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLNFTHGLIHFFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLIMLGLLAAAHDVDHPGVNQPFLLKTNHHLANLYQNMS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLIMLGLLAAAHDVDHPGVNQPFLLKTNHHLANLYQNMS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
RESULT 5  
QY Q8VIE4\_RAT PRELIMINARY; PRT; 446 AA.  
ID Q8VIE4\_RAT PRELIMINARY; PRT; 459 AA.  
AC Q8VIE2;  
DT 01-MAR-2002 (TrEMBLrel. 20, Created)  
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE Cyclic nucleotide phosphodiesterase 784 (EC 3.1.4.17).  
GN Names=Pde7b; Synonyms=RNPDE7B;  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Skeletal muscle;  
RA Sasaki T., Kotera J., Omori K.;  
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AB057411; BAB79639.1; -; mRNA.  
DR HSSP: Q08499; IOYN.  
DR Ensemble: ENSRNOG00000013436; Rattus norvegicus.  
DR RGD: 621016; Pde7b.

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Brain;  
RA Sasaki T., Kotera J., Omori K.;  
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AB057409; BAB79637.1; -; mRNA.  
DR HSSP: Q08499; IOYN.  
DR Ensemble: ENSRNOG00000013436; Rattus norvegicus.  
DR RGD: 621016; Pde7b.  
DR GO: GO:0004114; F:3', 5'-cyclic-nucleotide phosphodiesterase a. . .; IEA.  
DR GO: GO:0016787; F: hydrolase activity; IEA.  
DR GO: GO:0007165; P: signal transduction; IEA.  
DR InterPro: IPR003607; Met\_phos\_hydro.  
DR Pfam: PF00233; PDEase.  
DR PRINTS: PR00387; PDIESTERASE1.  
DR SMART: SM00471; HDc; 1.  
DR PROSITE: PS00126; PDEASE\_I; UNKNOWN\_1.  
KW Hydrolase.  
SQ SEQUENCE 446 AA; 51475 MW; 01567BDABC905D19 CRC64;  
Query Match 88.8%; Score 1367; DB 2; Length 446;  
Best Local Similarity 94.0%; Pred. No. 3.3e-116; Indels 0; Gaps 0;  
Matches 252; Conservative 10; Mismatches 6;  
QY 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERGSYPFIDFRLNNTTYS 60  
DB 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERGSYPFIDFRLNNTTYS 60  
QY 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPLHLLDEDLGQARHMLSKVGWDFDIF 120  
DB 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPLHLLDEDLGQARHMLSKVGWDFDIF 120  
QY 121 LFDRLTNGNSLVTLCHLNFTHGLIHFFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLNFTHGLIHFFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLIMLGLLAAAHDVDHPGVNQPFLLKTNHHLANLYQNMS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLIMLGLLAAAHDVDHPGVNQPFLLKTNHHLANLYQNMS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268  
RESULT 6  
QY Q8VIE2\_RAT PRELIMINARY; PRT; 459 AA.  
ID Q8VIE2\_RAT PRELIMINARY; PRT; 459 AA.  
AC Q8VIE2;  
DT 01-MAR-2002 (TrEMBLrel. 20, Created)  
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE Cyclic nucleotide phosphodiesterase 784 (EC 3.1.4.17).  
GN Names=Pde7b; Synonyms=RNPDE7B;  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Skeletal muscle;  
RA Sasaki T., Kotera J., Omori K.;  
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AB057411; BAB79639.1; -; mRNA.  
DR HSSP: Q08499; IOYN.  
DR Ensemble: ENSRNOG00000013436; Rattus norvegicus.  
DR RGD: 621016; Pde7b.

DR GO: 0004114; F:3',5'-cyclic-nucleotide phosphodiesterase a...; IEA.  
 DR GO: 0016787; F:hydrolase activity; IEA.  
 DR GO: 0007185; P:signal transduction; IEA.  
 DR InterPro: IPR003607; Met\_phos\_hydro.  
 DR Pfam: PF00233; PDEase.  
 DR PRINTS: PR00387; PDESTERASE1.  
 DR SMART: SM00471; HDC; 1.  
 DR PROSITE: PS00126; PDEASE\_I; UNKNOWN\_1.  
 KW Hydrolase.  
 SQ SEQUENCE 459 AA; 52680 MW; A3F26E95C7FC00A5 CRC64;  
 Query Match 87.7%; Score 1350.5; DB 2; Length 459;  
 Best Local Similarity 89.7%; Pred. No. 1.1e-114;  
 Matches 252; Conservative 10; Mismatches 6; Indels 13; Gaps 1;  
 QY 1 MSCLVRCGGEILFENPDQNAKVCML-----GDRLRGQTGVRAERRGSGYP 47  
 DB 1 MSCLVRCGGEILFENPDQNAKVCMLAASPPPLPMAGQGVRLRGQTGVRAERRGSGYP 60  
 QY 48 FIDRLNLTYSYGEIGTKKKVRLLSFQRYFHASRLRLGIIPOAPHLHLLDEDYLGQARH 107  
 DB 61 FIDRLNLTYSYGEIGTKKKVRLLSFQRYFHASRLRLGIIPOAPHLHLLDEDYLGQARH 120  
 QY 108 MLSKVGWMDPDIPLFDRLTNGNSLVTLCHLFTNTHLHNLQNSVLENNHWRSTIGMLRESRLLAHLPKEM 167  
 DB 121 MLSKVGWMDPDIPLFDRLTNGNSLVTLCHLFTNTHLHNLQNSVLENNHWRSTIGMLRESRLLAHLPKEM 180  
 QY 168 SQNPYHNAHAADVTOAMHCYLKEPKLASFLTPDIDIMGLAAAHVDHDPGVNQPFLLK 227  
 DB 181 GNPYHNAHAADVTOAMHCYLKEPKLASFLTPDIDIMGLAAAHVDHDPGVNQPFLLK 240  
 QY 228 TNHHLANLYQNSVLENNHWRSTIGMLRESRLLAHLPKEM 268  
 DB 241 TNHHLANLYQNSVLENNHWRSTIGMLRESRLLAHLPKEM 281  
 RESULT 7  
 Q4LE81 HUMAN PRELIMINARY; PRT; 596 AA.  
 AC Q4LE81;  
 DT 13-SEP-2005 (TrEMBLrel. 31, Created)  
 DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)  
 DE PDE7B variant protein (Fragment).  
 GN Name=PDE7B variant protein;  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
 OC Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE.  
 RC TISSUE=Brain;  
 RA Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,  
 RA Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;  
 RT "Preparation of a set of expression-ready clones of mammalian long  
 RT cDNAs encoding large proteins by the ORF trap cloning method.";  
 RL Submitted (MAR-2005) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AB209990; BAB06072.1; -, mRNA.  
 FT NON\_TER 1  
 SQ SEQUENCE 596 AA; 66230 MW; P96F4F0549A9F8D CRC64;  
 Query Match 83.1%; Score 1280; DB 2; Length 586;  
 Best Local Similarity 100.0%; Pred. No. 4.2e-108;  
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 28 GDRLRGQTGVRAERRGSGYPIDRLNLTYSYGEIGTKKKVRLLSFQRYFHASRLRLG 87  
 DB 164 GDRLRGQTGVRAERRGSGYPIDRLNLTYSYGEIGTKKKVRLLSFQRYFHASRLRLG 223  
 QY 88 IIPQAPHLHLLDEDYLGQARHLSKVGWMDPDIPLFDRLTNGNSLVTLCHLFTNTHLHNLQNSVLENNHWRSTIGMLRESRLLAHLPKEM 147

DB 224 IIPQAPHLHLLDEDYLGQARHLSKVGWMDPDIPLFDRLTNGNSLVTLCHLFTNTHLHNLQNSVLENNHWRSTIGMLRESRLLAHLPKEM 283  
 QY 148 FKLDVMTLHRLFLVWQEDYHSQNPYHNAHAADVTOAMHCYLKEPKLASFLTPDIDIMGL 207  
 DB 284 FKLDVMTLHRLFLVWQEDYHSQNPYHNAHAADVTOAMHCYLKEPKLASFLTPDIDIMGL 343  
 QY 208 LAAAADHDVDPGVNQPFLLKTNHHLANLYQNSVLENNHWRSTIGMLRESRLLAHLPKEM 267  
 DB 344 LAAAADHDVDPGVNQPFLLKTNHHLANLYQNSVLENNHWRSTIGMLRESRLLAHLPKEM 403  
 QY 268 T 268  
 DB 404 T 404  
 RESULT 8  
 Q4RR95 TETNG PRELIMINARY; PRT; 456 AA.  
 AC Q4RR95;  
 DT 13-SEP-2005 (TrEMBLrel. 31, Created)  
 DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)  
 DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)  
 DE Chromosome 14 SCAF15003, whole genome shotgun sequence.  
 DE (Fragment).  
 GN ORFNames=GSTENG0030267001;  
 OS Tetraodon nigroviridis (Green puffer).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorphi; Acanthopterygii; Percomorpha; Tetraodontiformes;  
 OC Tetraodontidae; Tetraodontidae; Tetraodon.  
 OX NCBI\_TaxID=99883;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE.  
 RA Jaillon O., Aury J.M., Brunet F., Petit J.L., Stange-Thomann N.,  
 RA Mauceli E., Bounneau L., Fischer C., Ozouf-Costaz C., Bernot A.,  
 RA Nicaud S., Jaffe D., Fisher S., Lutfalla G., Dossat C., Segurens B.,  
 RA Dasilva C., Salanoubat M., Levy M., Boudet N., Castellano S.,  
 RA Anhouard V., Jubin C., Castelli V., Katinka M., Vacherie B.,  
 RA Biemont C., Skalli Z., Cattolico L., Poulain J., De Bernardis V.,  
 RA Parraud C., Duprat S., Brottier P., Coutanceau J.P., Gouzy J.,  
 RA Carra G., Lardier G., Chapple C., McKernan K.J., McSwan P., Bosak S.,  
 RA Kellis M., Volff J.N., Guigo R., Zody M.C., Mesirov J.,  
 RA Lindblad-Toh K., Birren B., Nusbaum C., Kahn D., Robinson-Rechavi M.,  
 RA Laudet V., Schachter V., Quetier F., Saurin W., Scarpelli C.,  
 RA Wincker P., Lander E.S., Weissenbach J., Roest Crolius H.;  
 RT "Genome duplication in the teleost fish Tetraodon nigroviridis reveals  
 RT the early vertebrate proto-karyotype.";  
 RL Nature 431:946-957(2004).  
 RN [2]  
 RP NUCLEOTIDE SEQUENCE.  
 RG Genoscope; Whitehead Institute Centre for Genome Research;  
 RL Submitted (FEB-2004) to the EMBL/GenBank/DBJ databases.  
 CC -!- CAUTION: The sequence shown here is derived from an  
 CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is  
 CC preliminary data.  
 DR EMBL; CAAB01015003; CAG09087.1; -, Genomic\_DNA.  
 FT NON\_TER 1  
 FT NON\_TER 456  
 SQ SEQUENCE 456 AA; 52118 MW; 60B4805381D70669 CRC64;  
 Query Match 64.9%; Score 999.5; DB 2; Length 456;  
 Best Local Similarity 67.0%; Pred. No. 1.3e-82;  
 Matches 195; Conservative 32; Mismatches 35; Indels 29; Gaps 6;  
 QY 7 ERCEGILFENPDQNAKVCML-----GDRLRGQTGVRAERRGSGYP 47  
 DB 1 QRCGAVLTISPEQNAVQVRLMDRHDVDRNRPKHIPAAISAECKLSTGHAGVLLVERRGSGYP 60  
 QY 48 FIDRLNLTYSYGEIGTKKKVRLLSFQRYFHASRLRLGIIPOAPHLHLLDEDYLG 103  
 DB 61 LIDLQVLKSSQGEVAGSGTRKVRQLSFQRYCHASRLRLGLVPHAPLSHLDDGVLG 120  
 QY 104 QARHLSKVGWMDPDIPLFDRLTNGNSLVTLCHLFTNTHLHNLQNSVLENNHWRSTIGMLRESRLLAHLPKEM 163

```

Db 121 QAAHMLSKVGTWTFDIFLFDRLTNGSLVTLNCHLFNVYGLVHHFQLDWMVKLHFLGKVVQ 180
Qy 164 EDYHSQNPYHNAVAADVQAMHCYLPKPKLASFLTPDLMGLLAAAHADVDPHGVNQP 223
Db 181 EDYHSQNPYHNAVAADVQAMHCYLPKPKLASFLTPDLMGLLAAAHADVDPHGVNQP 240
Qy 224 FLIKTNHLLANLY-----QNMVLENHWRSTTGMRESRLLAHLPKEMT 268
Db 241 FLIKTRHLLASLYQHVSQVNTSVLESHHWRSTVGMRESGLSLHLPADM 291

```

## RESULT 9

```

ID Q8VIE3 RAT PRELIMINARY; PRT; 359 AA.
AC Q8VIE3;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Cyclic nucleotide phosphodiesterase 7B3 (EC 3.1.4.17).
GN Name=Pde7b; Synonym=RNPD7B;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Testis;
RA Sasaki T., Kotera J., Omori K.;
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB057410; BAB79638.1; -; mRNA.
DR HSSP; Q08499; IOYN.
DR RGD; 621016; Pde7b.
DR GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase a. . .; IEA.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR GO; GO:0007165; P:signal transduction; IEA.
DR InterPro; IPR003607; Met_phos_hydro.
DR InterPro; IPR002073; PDEase.
DR Pfam; PF00233; PDEase_I; 1.
DR PRINTS; PR00387; PD1ESTERASE1.
DR SMART; SM00471; HDC; 1.
DR PROSITE; PS00126; PDEASE_I; UNKNOWN_1.
KW Hydrolase.
SQ SEQUENCE 359 AA; 41456 MW; 0FF72792737CE48A CRC64;

```

```

Query Match 61.9%; Score 953; DB 2; Length 359;
Best Local Similarity 98.3%; Pred. No. 1.8e-78;
Matches 176; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 90 POAPLHLLDDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLNCHLNFTHGLIHHFK 149
Db 3 POAPLHLLDDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLNCHLNFTHGLIHHFK 62
Qy 150 LDMVTLHRLFLVMVQEDYHSQNPYHNAVAADVQAMHCYLPKPKLASFLTPDLMGLLA 209
Db 63 LDMVTLHRLFLVMVQEDYHGNPYHNAVAADVQAMHCYLPKPKLASFLTPDLMGLLA 122
Qy 210 AAADVDPHGVNQPFLIKTNHLLANLYQNMSVLENHWRSTIGMRESRLLAHLPKEMT 268
Db 123 AAADVDPHGVNQPFLIKTNHLLANLYQNMSVLENHWRSTIGMRESRLLAHLPKEMT 181

```

## RESULT 10

```

Q6P5G2 MOUSE
ID Q6P5G2_MOUSE PRELIMINARY; PRT; 482 AA.
AC Q6P5G2;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Pde7a protein.
GN Name=Pde7a;
OS Mus musculus (Mouse).

```

```

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C57BL/6; TISSUE=Brain;
RC MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C57BL/6; TISSUE=Brain;
RA Strausberg R.;
RL Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC062909; AAH62909.1; -; mRNA.
DR MGI; MGI:1202402; Pde7a.
DR GO; GO:0005615; C:extracellular space; TAS.
DR InterPro; IPR003607; Met_phos_hydro.
DR InterPro; IPR002073; PDEase.
DR Pfam; PF00233; PDEase_I; 1.
DR PRINTS; PR00387; PD1ESTERASE1.
DR SMART; SM00471; HDC; 1.
DR PROSITE; PS00126; PDEASE_I; UNKNOWN_1.
SQ SEQUENCE 482 AA; 55189 MW; F8460D84BFE7B65 CRC64;

```

```

Query Match 59.4%; Score 914; DB 2; Length 482;
Best Local Similarity 65.8%; Pred. No. 9.4e-75;
Matches 171; Conservative 36; Mismatches 53; Indels 0; Gaps 0;

Qy 7 ERCEILFENPDQNAKVCVCMGLDIRLQGTVRAERRGSYPFDIFRLNSTTYSGEIGTK 66
Db 46 QRRGALSYDSSDQATLYIRMLGDVVRVRAGPETERRGSHPIIDFRIFHSQSDIEASVSA 105
Qy 67 KVKRLLSQRFPHASRLRGRIPOAPLHLLDDEYLGQARHMLSKVGMWDFDIFLFDRLT 126
Db 106 RNIRLLSQRYLRSRVRFGATVCSLIDLDYNGQAKCMLEKVGNNWDFLFDRLT 165
Qy 127 NGSILVTLNCHLNFTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVAADVQAMH 186
Db 166 NGSILVTLNCHLNFTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVAADVQAMH 225
Qy 187 CYLKPKLASFLTPDLMGLLAAAHADVDPHGVNQPFLIKTNHLLANLYQNMSVLENH 246
Db 226 CYLKPKLASFLTPDLMGLLAAAHADVDPHGVNQPFLIKTNHLLANLYQNMSVLENH 285
Qy 247 WRSTIGMRESRLLAHLPKPE 266
Db 286 WRSVGLLRESGLFSLHPLP 305

```

## RESULT 11

```

PDE7A_MOUSE
ID PDE7A_MOUSE STANDARD; PRT; 456 AA.
AC P70453; Q9ERB3;

```



QY 127 NGNSLVTLCHLNFTHGLIHFKLDVTLHRLFMVQEDYHSQNPYHNAVHAADVTQAMH 186  
 DB 166 NGNSLVSLTFHFLSLHGLIEYFHLDMKRLRFLVMIQEDYHSQNPYHNAVHAADVTQAMH 225  
 QY 187 CYLKEPKLASFLTPDLTLMGLLAAAHDVHPGVNQPFLLKTNHLLANLYQNMVLENHH 246  
 DB 226 CYLKEPKLANSVTPWDILLSLIAAATHDLDPGVNQPFLLKTNHLLATLYKNTSVLENHH 285  
 QY 247 WRSTIGMLRESRLLAHLKPE 266  
 DB 286 WRSVGLRESGLFSLHPL 305

RESULT 13  
 PDE7A HUMAN STANDARD; PRT; 482 AA.  
 AC Q13946; Q15380; (Rel. 36, Created)  
 DT 15-JUL-1998 (Rel. 36, Last sequence update)  
 DT 15-JUL-1998 (Rel. 36, Last sequence update)  
 DT 10-MAY-2005 (Rel. 47, Last annotation update)  
 DE High-affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A  
 DE (EC 3.1.4.17) (HCP1) (TM22).  
 GN Name=PDE7A;  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
 OC Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE (ISOFORM PDE7A1).  
 RX MEDLINE=93286141; PubMed=8389765;  
 RA Michael T., Bloom T.J., Martins T., Loughney K., Ferguson K.,  
 RA Riggs M., Rodgers L., Beavo J.A., Wigler M.;  
 RT "Isolation and characterization of a previously undetected human cAMP  
 RT phosphodiesterase by complementation of cAMP phosphodiesterase-  
 RT deficient Saccharomyces cerevisiae.";  
 RL J. Biol. Chem. 268:12925-12932(1993).  
 RN [2]  
 RP NUCLEOTIDE SEQUENCE (ISOFORM PDE7A2).  
 RC TISSUE=Skeletal muscle;  
 RX MEDLINE=97341143; PubMed=9195912; DOI=10.1074/jbc.272.26.16152;  
 RA Han P., Zhu X., Michael T.;  
 RT "Alternative splicing of the high affinity cAMP-specific  
 RT phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart.";  
 RL J. Biol. Chem. 272:16152-16157(1997).  
 CC -1- FUNCTION: Plays a role in signal transduction by regulating the  
 CC intracellular concentration of cyclic nucleotides. This  
 CC phosphodiesterase is highly specific for cAMP and may have a role  
 CC in muscle signal transduction.  
 CC -1- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O =  
 CC adenosine 5'-phosphate.  
 CC -1- COFACTOR: Divalent cations.  
 CC -1- ENZYME REGULATION: Insensitive to all selective PDE inhibitors.  
 CC -1- PATHWAY: Cyclic nucleotide metabolism.  
 CC -1- SUBCELLULAR LOCATION: PDE7A1 (57 kDa) is located mostly to soluble  
 CC cellular fractions. PDE7A2 (50 kDa) is located to particulate  
 CC cellular fractions.  
 CC -1- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=2;  
 CC Name=PDE7A1;  
 CC IsoId=Q13946-1; Sequence=Displayed;  
 CC Name=PDE7A2;  
 CC IsoId=Q13946-2; Sequence=VSP\_004593;  
 CC -1- TISSUE SPECIFICITY: PDE7A1 is found at high levels in skeletal  
 CC muscle and at low levels in a variety of tissues including brain  
 CC and heart. It is expressed as well in two T-cell lines. PDE7A2 is  
 CC found abundantly in skeletal muscle and at low levels in heart.  
 CC -1- DEVELOPMENTAL STAGE: Developmentally regulated. PDE7A1 and PDE7A2  
 CC are found in several fetal tissues, expression is reduced  
 CC throughout development. It persists strongly only in adult  
 CC skeletal muscle.  
 CC -1- DOMAIN: Composed of a C-terminal catalytic domain containing two  
 CC putative divalent metal sites and an N-terminal regulatory domain.

CC -1- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase  
 CC family.  
 CC -----  
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use as long as its content is in no way modified and this statement is not  
 CC removed.  
 CC -----  
 CC ENBL; L12052; AAA35644.2; -; mRNA.  
 DR ENBL; U67932; AAB65772.1; -; mRNA.  
 DR HSSP; Q08499; IOYN.  
 DR HGNC; HGNC:8791; PDE7A.  
 DR MIM; 171885; -;  
 DR GO; GO:000267; C-cell fraction; NAS.  
 DR GO; GO:0004115; P-cAMP-specific phosphodiesterase activity; TAS.  
 DR GO; GO:0007165; P-signal transduction; NAS.  
 DR InterPro; IPR002073; PDEase.  
 DR Pfam; PF00233; PDEase I; 1.  
 DR PRINTS; PR00387; PDIESTERASE1.  
 DR PROSITE; PS00126; PDEASE\_1; 1.  
 KW Alternative splicing; cAMP; Hydrolase; Phosphorylation.  
 FT REGION 187 451  
 FT COMPBIAS 28 33 Poly-Ser.  
 FT MOD RES 84 84 Phosphoserine (Potential).  
 FT VARSPPLIC 1 46 MEVYQLPVLPLDRPVPQHVLSRRGALSFSSSSALFGCPNP  
 FT RQLSQ -> MGI TLWCLALVLKWTSK (in isoform  
 FT PDE7A2).  
 FT /FTID=VSP\_004593.  
 SQ SEQUENCE 482 AA; 55505 MW; 3B3C8F6E9154F88C CRC64;  
 Query Match 58.9%; Score 907; DB 1; Length 482;  
 Best Local Similarity 64.6%; Pred. No. 4.1e-74;  
 Matches 168; Conservative 39; Mismatches 53; Indels 0; Gaps 0;  
 QY 7 ERCEILFENPDQNAKVCMLGDIRLQGTGVRAERRGSPYDFLLNSTTYSGBIGTK 66  
 DB 46 QRRGALSYDSSDQALYIRMLGDVVRVRVRAGFESERRGSHPYIDFRIFHSQSIEVSVA 105  
 QY 67 KVKVRLLSFQRYFHASRLRGLIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLT 126  
 DB 106 RNIIRLLSFQRYLRSRFRFTAVNSNLILDDYNGQAKMLEKVGNNWDFDIFLDRLT 165  
 QY 127 NGNSLVTLCHLNFTHGLIHFKLDVTLHRLFMVQEDYHSQNPYHNAVHAADVTQAMH 186  
 DB 166 NGNSLVSLTFHFLSLHGLIEYFHLDMKRLRFLVMIQEDYHSQNPYHNAVHAADVTQAMH 225  
 QY 187 CYLKEPKLASFLTPDLTLMGLLAAAHDVHPGVNQPFLLKTNHLLANLYQNMVLENHH 246  
 DB 226 CYLKEPKLANSVTPWDILLSLIAAATHDLDPGVNQPFLLKTNHLLATLYKNTSVLENHH 285  
 QY 247 WRSTIGMLRESRLLAHLKPE 266  
 DB 286 WRSVGLRESGLFSLHPL 305

RESULT 14  
 QSR5B5\_PONPY PRELIMINARY; PRT; 456 AA.  
 AC QSR5B5;  
 DT 01-FEB-2005 (Tremblrel. 29, Created)  
 DT 01-FEB-2005 (Tremblrel. 29, Last sequence update)  
 DE Hypothetical protein DKFZp469E1731.  
 GN Name=DKFZp469E1731;  
 OS Pongo pygmaeus (Orangutan).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
 OC Pongo.  
 OX NCBI\_TaxID=9600;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE.  
 RC TISSUE=Kidney;



Search completed: March 10, 2006, 20:02:06  
Job time : 124.195 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 20:02:25 ; Search time 26.1463 Seconds  
(without alignments)  
910.666 Million cell updates/sec

Title: US-10-781-181-3  
Perfect score: 1540  
Sequence: 1 MSCLMVERCGEILFENPDQN.....GTWDFDIFLDRLTNGSLV 288

Scoring table:  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/iaa/5 COMB.pap:\*  
2: /cgn2\_6/ptodata/1/iaa/6 COMB.pap:\*  
3: /cgn2\_6/ptodata/1/iaa/H COMB.pap:\*  
4: /cgn2\_6/ptodata/1/iaa/PCTUS COMB.pap:\*  
5: /cgn2\_6/ptodata/1/iaa/RE COMB.pap:\*  
6: /cgn2\_6/ptodata/1/iaa/backfiles1.pap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1280	83.1	320	2	US-09-330-970-3
2	1280	83.1	502	2	US-09-330-970-1
3	1073	69.7	390	2	US-09-949-016-10020
4	907	58.9	498	1	US-07-688-352C-20
5	907	58.9	498	1	US-08-474-379C-20
6	907	58.9	498	2	US-09-146-249A-20
7	907	58.9	498	2	US-08-206-188B-20
8	331.5	21.5	517	2	US-09-602-735B-4
9	330.5	21.5	451	1	US-08-474-379C-61
10	330.5	21.5	451	2	US-09-146-249A-61
11	330.5	21.5	451	2	US-08-206-188B-61
12	330.5	21.5	518	2	US-09-602-735B-2
13	330.5	21.5	673	1	US-08-577-492-35
14	330.5	21.5	673	1	US-08-474-379C-63
15	330.5	21.5	673	2	US-09-146-249A-63
16	330.5	21.5	673	2	US-08-206-188B-63
17	330.5	21.5	673	2	US-09-079-630-35
18	323	21.0	302	4	PCT-US91-02714-21
19	323	21.0	398	1	US-08-474-379C-86
20	323	21.0	638	1	US-07-688-352C-22
21	323	21.0	734	2	US-09-146-249A-85
22	323	21.0	734	2	US-08-206-188B-85
23	320.5	20.8	686	1	US-08-942-521B-9
24	320.5	20.8	885	1	US-08-577-492-33
25	320.5	20.8	885	2	US-09-079-630-33
26	320.5	20.8	886	1	US-08-474-379C-65
27	320.5	20.8	886	2	US-09-146-249A-65

28 320.5 20.8 886 2 US-08-206-188B-65 Sequence 65, Appl  
29 320.5 20.8 901 2 US-09-917-254-93 Sequence 93, Appl  
30 318.5 20.7 721 2 US-09-983-754-2 Sequence 2, Appl  
31 317.5 20.6 562 1 US-07-688-352C-4 Sequence 4, Appl  
32 317.5 20.6 562 1 US-08-942-521B-8 Sequence 8, Appl  
33 317.5 20.6 562 1 US-08-474-379C-4 Sequence 4, Appl  
34 317.5 20.6 562 2 US-09-146-249A-4 Sequence 4, Appl  
35 317.5 20.6 562 2 US-08-206-188B-4 Sequence 4, Appl  
36 317.5 20.6 562 4 PCT-US91-02714-4 Sequence 4, Appl  
37 316.5 20.6 610 1 US-08-974-565C-9 Sequence 9, Appl  
38 316.5 20.6 610 2 US-09-255-748-9 Sequence 34, Appl  
39 314.5 20.4 564 1 US-08-577-492-34 Sequence 2, Appl  
40 314.5 20.4 564 1 US-08-942-521B-2 Sequence 2, Appl  
41 314.5 20.4 564 1 US-08-474-379C-59 Sequence 59, Appl  
42 314.5 20.4 564 2 US-09-146-249A-59 Sequence 59, Appl  
43 314.5 20.4 564 2 US-08-206-188B-59 Sequence 59, Appl  
44 314.5 20.4 564 2 US-09-192-702-2 Sequence 2, Appl  
45 314.5 20.4 564 2 US-09-079-630-34 Sequence 34, Appl

## ALIGNMENTS

RESULT 1  
US-09-330-970-3  
; Sequence 3, Application US/09330970  
; Patent No. 6146876  
; GENERAL INFORMATION:  
; APPLICANT: Robison, Keith E.  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: White, David  
; TITLE OF INVENTION: A No. 6146876el Human Cyclic Nucleotide  
; FILE OF INVENTION: Phosphodiesterase  
; FILE REFERENCE: 5800-28  
; CURRENT APPLICATION NUMBER: US/09/330,970  
; CURRENT FILING DATE: 1999-06-11  
; EARLIER APPLICATION NUMBER: 09/277,423  
; EARLIER FILING DATE: 1999-03-26  
; NUMBER OF SEQ ID NOS: 40  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 3  
; LENGTH: 320  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; US-09-330-970-3

Query Match 83.1%; Score 1280; DB 2; Length 320;  
Best Local Similarity 100.0%; Pred. No. 3.8e-140; Mismatches 0; Indels 0; Gaps 0;  
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 28 GDRLRGQTGVRAERGSYPFIDFRLNLTYSGEIGTKKKVKRLLSFQRYFHASRLLRG 87  
Db 80 GDRLRGQTGVRAERGSYPFIDFRLNLTYSGEIGTKKKVKRLLSFQRYFHASRLLRG 139  
Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLDRLTNGNSLVTLCHLFTNTHGLIHH 147  
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLDRLTNGNSLVTLCHLFTNTHGLIHH 199  
Qy 148 FKLDVMTLHRLFVNVQSDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPLDIMGL 207  
Db 200 FKLDVMTLHRLFVNVQSDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPLDIMGL 259  
Qy 208 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 319  
Qy 268 T 268  
Db 320 T 320  
RESULT 2  
US-09-330-970-1

```
; Sequence 1, Application US/09330970
; Patent No. 6146876
; GENERAL INFORMATION:
; APPLICANT: Robison, Keith E.
; APPLICANT: Kapeller-Libermann, Rosana
; APPLICANT: White, David
; TITLE OF INVENTION: A No. 6146876el Human Cyclic Nucleotide
; FILE REFERENCE: 5800-28
; CURRENT APPLICATION NUMBER: US/09/330,970
; CURRENT FILING DATE: 1999-06-11
; EARLIER APPLICATION NUMBER: 09/277,423
; EARLIER FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 502
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-330-970-1

Query Match      83.1%; Score 1280; DB 2; Length 502;
Best Local Similarity 100.0%; Pred. No. 7.4e-140;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDRLRGQTGVAERRGSGYPIDFRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87
Db 80 GDRLRGQTGVAERRGSGYPIDFRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139

Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHH 147
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHH 199

Qy 148 FKLDMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 207
Db 200 FKLDMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 259

Qy 208 LAAAHDVDHPGVNQPLIKTNHHLANLYQNMVLENHHWRSTIGMLRESLLAHLPKEM 267
Db 260 LAAAHDVDHPGVNQPLIKTNHHLANLYQNMVLENHHWRSTIGMLRESLLAHLPKEM 319

Qy 268 T 268
Db 320 T 320

RESULT 3
US-09-949-016-10020
; Sequence 10020, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10020
; LENGTH: 390
; TYPE: PRT
; ORGANISM: Human
US-09-949-016-10020

Query Match      69.7%; Score 1073; DB 2; Length 390;
Best Local Similarity 86.7%; Pred. No. 6.1e-116;

Qy 7 EFCGEILFENPDONAKVCVCMGLDIRLQGTGVAERRGSGYPIDFRLNLTSTYSGEIGTK 66
Db 62 QRRGAISYDSDQATLYIRMLGDRVRSRAGPESERRGSHPYIDFIRFHSQSIEVSVA 121
```

```
Matches 208; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

Qy 29 DIRLRGQTGVAERRGSGYPIDFRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG 88
Db 1 DIRLRGQTGVAERRGSGYPIDFRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG 60

Qy 89 IPOAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHH 148
Db 61 IPOAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTN----- 99

Qy 149 KLDMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 208
Db 100 -----VVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 148

Qy 209 AAAHDVDHPGVNQPLIKTNHHLANLYQNMVLENHHWRSTIGMLRESLLAHLPKEM 268
Db 149 AAAHDVDHPGVNQPLIKTNHHLANLYQNMVLENHHWRSTIGMLRESLLAHLPKEM 208

RESULT 4
US-07-688-352C-20
; Sequence 20, Application US/07688352C
; Patent No. 5527896
; GENERAL INFORMATION:
; APPLICANT: Wigler, Michael H.
; APPLICANT: Colicelli, John J.
; TITLE OF INVENTION: Cloning by Complementation and Related
; TITLE OF INVENTION: Processes
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; Bicknell
; STREET: Two First National Plaza, 20 South Clark
; STREET: Street
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/688,352C
; FILING DATE: 19910419
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/511,715
; FILING DATE: 20-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Borun, Michael F.
; REGISTRATION NUMBER: 25447
; REFERENCE/DOCKET NUMBER: 27805/30197
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 346-5750
; TELEFAX: (312) 984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 498 amino acids
; TYPE: AMINO ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
US-07-688-352C-20

Query Match      58.9%; Score 907; DB 1; Length 498;
Best Local Similarity 64.6%; Pred. No. 1.8e-96;
Matches 168; Conservative 39; Mismatches 53; Indels 0; Gaps 0;

Qy 7 EFCGEILFENPDONAKVCVCMGLDIRLQGTGVAERRGSGYPIDFRLNLTSTYSGEIGTK 66
Db 62 QRRGAISYDSDQATLYIRMLGDRVRSRAGPESERRGSHPYIDFIRFHSQSIEVSVA 121
```





```

; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/08/474,379C
; APPLICATION NUMBER: US/08/474,379C
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/511,715
; FILING DATE: 20-APR-1990
; APPLICATION NUMBER: US 08/206,188
; FILING DATE: 01-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/688,352
; FILING DATE: 19-APR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 27866/32771
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 451 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-474-379C-61

Query Match 21.5%; Score 330.5; DB 1; Length 451;
Best Local Similarity 37.8%; Pred. No. 1.8e-29;
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS----PQRYFHASRLRLGIIPQAPLHLLDEYLGQARHMLSKVGWDFDIPL 121
Db 234 KKKKRPMSQISGVKKLHSSSLTNSIPRGVKTQEDVLAK---LEDVKNKGLHVR 290

Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDMVTLHRLVWQEDYHSQNPYHNAHAAD 180
Db 291 IAEI-SGNRPLTVIMHTIFQERDLLTKFKIPVDLTLYLTMTLEDHYADVAYHNNIHAAD 349

Qy 181 VTQAMHCYKPEKPLASFLTPDLIMGLLAAAHAHDVDPHGYNQPLIKTNHHLNLYQNMS 240
Db 350 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQPLINTNSSELALMYNDSS 409

Qy 241 VLENHWRSTIGMLRE 256
Db 410 VLENHHLAVGFKLQ 425

RESULT 10
US-09-146-249A-61
; Sequence 61, Application US/09146249A
; Patent No. 6069240
; GENERAL INFORMATION:
; APPLICANT: Wigler, Michael H.
; APPLICANT: Colicelli, John J.
; TITLE OF INVENTION: Cloning by Complementation and Related
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/146,249A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/511,715
; FILING DATE: 20-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312-474-0448
; TELEEX: 25-3856
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 451 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-146-249A-61

Query Match 21.5%; Score 330.5; DB 2; Length 451;
Best Local Similarity 37.8%; Pred. No. 1.8e-29;
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS----PQRYFHASRLRLGIIPQAPLHLLDEYLGQARHMLSKVGWDFDIPL 121
Db 234 KKKKRPMSQISGVKKLHSSSLTNSIPRGVKTQEDVLAK---LEDVKNKGLHVR 290

Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDMVTLHRLVWQEDYHSQNPYHNAHAAD 180
Db 291 IAEI-SGNRPLTVIMHTIFQERDLLTKFKIPVDLTLYLTMTLEDHYADVAYHNNIHAAD 349

Qy 181 VTQAMHCYKPEKPLASFLTPDLIMGLLAAAHAHDVDPHGYNQPLIKTNHHLNLYQNMS 240
Db 350 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQPLINTNSSELALMYNDSS 409

Qy 241 VLENHWRSTIGMLRE 256
Db 410 VLENHHLAVGFKLQ 425

RESULT 11
US-08-206-188B-61
; Sequence 61, Application US/08206188B
; Patent No. 6100025
; GENERAL INFORMATION:
; APPLICANT: Wigler, Michael H.
; APPLICANT: Colicelli, John J.
; TITLE OF INVENTION: Cloning by Complementation and Related
; NUMBER OF SEQUENCES: 84
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/206,188B
; FILING DATE: 01-MAR-1994
```

[illegible]



QY 241 VLENHHRSTIGMLRE 256  
Db 394 VLENHHLAVGFKLLQE 409

RESULT 14  
US-08-474-379C-63  
; Sequence 63, Application US/08474379C  
; Patent No. 5977305  
; GENERAL INFORMATION:  
; APPLICANT: Wigler, Michael H.  
; APPLICANT: Colicelli, John J.  
; TITLE OF INVENTION: CLONING BY COMPLEMENTATION AND RELATED  
; TITLE OF INVENTION: PROCESSES  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 233 South Wacker Drive/6300 Sears Tower  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/474,379C  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/511,715  
; FILING DATE: 20-APR-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/206,188  
; FILING DATE: 01-MAR-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/688,352  
; FILING DATE: 19-APR-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clough, David W.  
; REGISTRATION NUMBER: 36,107  
; REFERENCE/DOCKET NUMBER: 27866/32771  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; INFORMATION FOR SEQ ID NO: 63:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 673 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-474-379C-63

Query Match 21.5%; Score 330.5; DB 1; Length 673;  
Best Local Similarity 37.8%; Pred. No. 3.3e-29;  
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

QY 66 KKKVKRLLS-----FQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSKVGWMDFDIFL 121  
Db 218 KKKKRPMSQISGVKKLMHSSSLTNSIPRFGVKTEQEDVLAKE---LEDVKNKGLHVR 274

QY 122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDVMTLHRLFMVQEDYHSQNPYHNAVHAAD 180  
Db 275 IAEI-SGNRPLTVIMHTIQRDLTKTKIPDVTLLTYLMTLEDHYADVAYHNNIHAAD 333

QY 181 VTQAMHCYLKEPKLASFLTDLIMGLLAAAHDVDPGVNQFPFLIKTNHHLANLYQNS 240  
Db 334 VQSTHVLSTPALEAVFTDLILAAIFASAIHDVDPGVSNQFLINTNSLALMYNDSS 393

QY 241 VLENHHRSTIGMLRE 256  
Db 394 VLENHHLAVGFKLLQE 409

Search completed: March 10, 2006, 20:04:13  
Job time : 27.1463 secs

Db 394 VLENHHLAVGFKLLQE 409

RESULT 15  
US-09-146-249A-63  
; Sequence 63, Application US/09146249A  
; Patent No. 6069240  
; GENERAL INFORMATION:  
; APPLICANT: Wigler, Michael H.  
; APPLICANT: Colicelli, John J.  
; TITLE OF INVENTION: Cloning by Complementation and Related  
; TITLE OF INVENTION: Processes  
; NUMBER OF SEQUENCES: 85  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/146,249A  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA: US 07/511,715  
; FILING DATE: 20-APR-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clough, David W.  
; REGISTRATION NUMBER: 36,107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 312/474-6300  
; TELEFAX: 312-474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 63:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 673 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-09-146-249A-63

Query Match 21.5%; Score 330.5; DB 2; Length 673;  
Best Local Similarity 37.8%; Pred. No. 3.3e-29;  
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

QY 66 KKKVKRLLS-----FQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSKVGWMDFDIFL 121  
Db 218 KKKKRPMSQISGVKKLMHSSSLTNSIPRFGVKTEQEDVLAKE---LEDVKNKGLHVR 274

QY 122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDVMTLHRLFMVQEDYHSQNPYHNAVHAAD 180  
Db 275 IAEI-SGNRPLTVIMHTIQRDLTKTKIPDVTLLTYLMTLEDHYADVAYHNNIHAAD 333

QY 181 VTQAMHCYLKEPKLASFLTDLIMGLLAAAHDVDPGVNQFPFLIKTNHHLANLYQNS 240  
Db 334 VQSTHVLSTPALEAVFTDLILAAIFASAIHDVDPGVSNQFLINTNSLALMYNDSS 393

QY 241 VLENHHRSTIGMLRE 256  
Db 394 VLENHHLAVGFKLLQE 409

Search completed: March 10, 2006, 20:04:13  
Job time : 27.1463 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

# OM protein - protein search, using sw model

Run on: March 10, 2006, 20:18:07 ; Search time 87.0244 Seconds  
(without alignments)  
1382.771 Million cell updates/sec

Title: US-10-781-181-3  
Perfect score: 1540  
Sequence: 1 MSCLMVERGCEILFENPDQN.....GTWDFDIFLDRLTNGNSLV 288

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications AA Main.\*  
1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/US11\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1540	100.0	288	4	US-10-781-181-3
2	1430	92.9	450	4	US-10-781-181-5
3	1430	92.9	450	5	US-10-284-268A-2
4	1376	89.4	446	4	US-10-781-181-1
5	1280	83.1	320	4	US-10-386-414-6
6	1280	83.1	502	4	US-10-273-517-1
7	1280	83.1	502	4	US-10-386-414-4
8	1280	83.1	502	4	US-10-311-104-1
9	1280	83.1	502	6	US-11-048-744-1
10	1280	83.1	502	6	US-10-048-068-1
11	1145	74.4	391	5	US-10-204-268A-4
12	980	63.6	335	5	US-10-771-833-23
13	980	63.6	335	5	US-10-886-949-23
14	907	58.9	424	5	US-10-380-437-6
15	907	58.9	424	5	US-10-380-437-53
16	907	58.9	432	3	US-09-764-898-208
17	898	58.3	426	3	US-09-966-781A-2
18	892	57.9	426	3	US-09-966-781A-3
19	891	57.9	426	3	US-09-966-781A-1
20	725	47.1	334	5	US-10-771-833-22
21	725	47.1	334	5	US-10-886-949-22
22	682	44.3	336	4	US-10-258-746-2
23	531	34.5	99	4	US-10-781-181-16
24	392	25.5	211	3	US-09-764-898-280
25	392	25.5	211	3	US-09-989-442-120
26	331.5	21.5	517	4	US-10-682-722-4
27	331.5	21.5	747	5	US-10-492-835-8

28	331.5	21.5	747	5	US-10-492-835-15	Sequence 15, Appl
29	331.5	21.5	747	5	US-10-492-835-27	Sequence 27, Appl
30	330.5	21.5	507	4	US-10-076-597-49	Sequence 49, Appl
31	330.5	21.5	507	4	US-10-067-514-10	Sequence 10, Appl
32	330.5	21.5	507	4	US-10-419-723-10	Sequence 10, Appl
33	330.5	21.5	507	4	US-10-255-120-10	Sequence 10, Appl
34	330.5	21.5	507	4	US-10-755-889-304	Sequence 304, App
35	330.5	21.5	507	5	US-10-868-397-10	Sequence 10, Appl
36	330.5	21.5	518	4	US-10-682-722-2	Sequence 2, Appli
37	330.5	21.5	585	4	US-10-067-514-9	Sequence 9, Appli
38	330.5	21.5	585	4	US-10-419-723-9	Sequence 9, Appli
39	330.5	21.5	585	4	US-10-255-120-9	Sequence 9, Appli
40	330.5	21.5	585	5	US-10-868-397-9	Sequence 9, Appli
41	330.5	21.5	664	5	US-10-735-973-2	Sequence 2, Appli
42	330.5	21.5	673	4	US-10-076-597-51	Sequence 51, Appli
43	330.5	21.5	673	4	US-10-067-514-6	Sequence 6, Appli
44	330.5	21.5	673	4	US-10-419-723-6	Sequence 6, Appli
45	330.5	21.5	673	4	US-10-255-120-6	Sequence 6, Appli

## ALIGNMENTS

### RESULT 1

US-10-781-181-3  
; Sequence 3, Application US/10781181  
; Publication No. US20040137508A1  
; GENERAL INFORMATION:  
; APPLICANT: Pfizer Inc.  
; APPLICANT: Fiddock, Mark David  
; TITLE OF INVENTION: Enzyme PDE xiv  
; FILE REFERENCE: PCI0315B  
; CURRENT APPLICATION NUMBER: US/10/781,181  
; CURRENT FILING DATE: 2004-02-18  
; PRIOR APPLICATION NUMBER: GB 9828603.2  
; PRIOR FILING DATE: 1998-12-23  
; PRIOR APPLICATION NUMBER: US 09/471,459  
; PRIOR FILING DATE: 1999-12-22  
; PRIOR APPLICATION NUMBER: GB 9922123.6  
; PRIOR FILING DATE: 1999-09-17  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 3  
; LENGTH: 288  
; TYPE: PRT  
; ORGANISM: Human  
US-10-781-181-3

Query Match		100.0%;	Score 1540;	DB 4;	Length 288;
Best Local Similarity		100.0%;	Pred. No. 3e-154;		
Matches 288;		Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	MSCLMVERGCEILFENPDQNAKVCVCMGDIRLRGQTVRAERGRSYPFIDPRLNSTTYS 60			
Db	1	MSCLMVERGCEILFENPDQNAKVCVCMGDIRLRGQTVRAERGRSYPFIDPRLNSTTYS 60			
Qy	61	GEIGTKKKVKRLSFRQYFHASRLRGITPQAPLHLLDELDYLQGAHMLSKVGMWDFDIF 120			
Db	61	GEIGTKKKVKRLSFRQYFHASRLRGITPQAPLHLLDELDYLQGAHMLSKVGMWDFDIF 120			
Qy	121	LPDRLTNGNSLVTLCHLNFTHGLIHFFKLDVMTLHRLFLVMQEDYHSQNPYHNAVAAD 180			
Db	121	LPDRLTNGNSLVTLCHLNFTHGLIHFFKLDVMTLHRLFLVMQEDYHSQNPYHNAVAAD 180			
Qy	181	VTQAMCHYLKEPKLASFLPLDLMGLLAAAADVDHPGVNQPFLLKTNHHLANLYQMS 240			
Db	181	VTQAMCHYLKEPKLASFLPLDLMGLLAAAADVDHPGVNQPFLLKTNHHLANLYQMS 240			
Qy	241	VLENHHRSTIGMLRESRLIAHLPKEMTGTWDFDIFLDRLTNGNSLV 288			
Db	241	VLENHHRSTIGMLRESRLIAHLPKEMTGTWDFDIFLDRLTNGNSLV 288			

```
RESULT 2
US-10-781-181-5
; Sequence 5, Application US/10781181
; Publication No. US20040137508A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Fidock, Mark David
; TITLE OF INVENTION: Enzyme PDE xiv
; FILE REFERENCE: PC10315B
; CURRENT APPLICATION NUMBER: US/10/781,181
; CURRENT FILING DATE: 2004-02-18
; PRIOR APPLICATION NUMBER: GB 9828603.2
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: US 09/471,459
; PRIOR FILING DATE: 1999-12-22
; PRIOR APPLICATION NUMBER: GB 9922123.6
; PRIOR FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Human
US-10-781-181-5

Query Match      92.9%; Score 1430; DB 4; Length 450;
Best Local Similarity 100.0%; Pred. No. 2.5e-142;
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERCGEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYFFIDFRLNLTYS 60
Db 1 MSCLMVERCGEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYFFIDFRLNLTYS 60
Qy 61 GEIGTKKKVKRLLSFORYPFASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGMWDFDIF 120
Db 61 GEIGTKKKVKRLLSFORYPFASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGMWDFDIF 120
Qy 121 LFDRLTNGNSLVTLCHLFNTHGLIHFFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180
Db 121 LFDRLTNGNSLVTLCHLFNTHGLIHFFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240
Db 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240
Qy 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268
Db 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268
```

```
RESULT 3
US-10-204-268A-2
; Sequence 2, Application US/10204268A
; Publication No. US20050058647A1
; GENERAL INFORMATION:
; APPLICANT: KLUXEN, FRANZ-WERNER
; APPLICANT: HENTSCH, BERND
; TITLE OF INVENTION: NEW PHOSPHODIESTERASE TYPE 7B
; FILE REFERENCE: MERCK-2484
; CURRENT APPLICATION NUMBER: US/10/204, 268A
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: PCT/EP01/01858
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: EP 00103655.7
; PRIOR FILING DATE: 2000-02-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-204-268A-2
```

```
Query Match      92.9%; Score 1430; DB 5; Length 450;
Best Local Similarity 100.0%; Pred. No. 2.5e-142;
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERCGEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYFFIDFRLNLTYS 60
Db 1 MSCLMVERCGEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYFFIDFRLNLTYS 60
Qy 61 GEIGTKKKVKRLLSFORYPFASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGMWDFDIF 120
Db 61 GEIGTKKKVKRLLSFORYPFASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGMWDFDIF 120
Qy 121 LFDRLTNGNSLVTLCHLFNTHGLIHFFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180
Db 121 LFDRLTNGNSLVTLCHLFNTHGLIHFFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240
Db 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240
Qy 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268
Db 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268

RESULT 4
US-10-781-181-1
; Sequence 1, Application US/10781181
; Publication No. US20040137508A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Fidock, Mark David
; TITLE OF INVENTION: Enzyme PDE xiv
; FILE REFERENCE: PC10315B
; CURRENT APPLICATION NUMBER: US/10/781,181
; CURRENT FILING DATE: 2004-02-18
; PRIOR APPLICATION NUMBER: GB 9828603.2
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: US 09/471,459
; PRIOR FILING DATE: 1999-12-22
; PRIOR APPLICATION NUMBER: GB 9922123.6
; PRIOR FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 446
; TYPE: PRT
; ORGANISM: Mouse
US-10-781-181-1

Query Match      89.4%; Score 1376; DB 4; Length 446;
Best Local Similarity 95.1%; Pred. No. 1.3e-136;
Matches 255; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Qy 1 MSCLMVERCGEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYFFIDFRLNLTYS 60
Db 1 MSCLMVERCGEILFENPDQNAKVCVCMGLDIRLGRGTGVAERRGSYFFIDFRLNLTYS 60
Qy 61 GEIGTKKKVKRLLSFORYPFASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGMWDFDIF 120
Db 61 GEIGTKKKVKRLLSFORYPFASRLRGIIPOAPLHLLDELDYLGOARHMLSKVGMWDFDIF 120
Qy 121 LFDRLTNGNSLVTLCHLFNTHGLIHFFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180
Db 121 LFDRLTNGNSLVTLCHLFNTHGLIHFFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240
Db 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHPGVNQPFLIKTNHHLANLYQNMS 240
Qy 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268
Db 241 VLENHHRSTIGMLRESRLLAHLPKEMT 268
```

RESULT 5  
US-10-386-414-6  
; Sequence 6, Application US/10386414  
; Publication No. US20040006016A1  
; GENERAL INFORMATION:  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: Robison, Keith E.  
; APPLICANT: White, David  
; APPLICANT: Williamson, Mark W.  
; APPLICANT: Cook, William James  
; APPLICANT: Meyers, Rachel E.  
; APPLICANT: MacBeth, Kyle J.  
; APPLICANT: Carroll, Joseph M.  
; APPLICANT: Chun, Miyoung  
; TITLE OF INVENTION: NOVEL 27875, 22025, 27420, 17906, 16319,  
; TITLE OF INVENTION: 55092 AND 10218 MOLECULES AND USES THEREFOR  
; FILE REFERENCE: MPI03-0210MNM  
; CURRENT APPLICATION NUMBER: US/10/386,414  
; CURRENT FILING DATE: 2003-03-11  
; PRIOR APPLICATION NUMBER: 09/426,282  
; PRIOR FILING DATE: 1999-10-25  
; PRIOR APPLICATION NUMBER: 09/668,266  
; PRIOR FILING DATE: 2000-09-22  
; PRIOR APPLICATION NUMBER: 09/330,970  
; PRIOR FILING DATE: 1999-06-11  
; PRIOR APPLICATION NUMBER: 09/724,599  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 09/860,193  
; PRIOR FILING DATE: 2001-05-16  
; PRIOR APPLICATION NUMBER: 10/283,023  
; PRIOR FILING DATE: 2002-10-29  
; PRIOR APPLICATION NUMBER: 60/335,044  
; PRIOR FILING DATE: 2001-10-31  
; PRIOR APPLICATION NUMBER: 10/010,943  
; PRIOR FILING DATE: 2001-12-06  
; PRIOR APPLICATION NUMBER: 60/254,037  
; PRIOR FILING DATE: 2000-12-07  
; PRIOR APPLICATION NUMBER: 09/833,082  
; PRIOR FILING DATE: 2001-04-10  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 6  
; LENGTH: 320  
; TYPE: PRT  
; ORGANISM: Homo Sapien  
US-10-386-414-6  
Query Match 83.1%; Score 1280; DB 4; Length 320;  
Best Local Similarity 100.0%; Pred. No. 1.2e-126;  
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 28 GDRLRGQTGVRAERRGSPFIDFRLNLSNTTSGEIGTKKKVKLLSFOFYFHASRLRG 87  
Db 80 GDRLRGQTGVRAERRGSPFIDFRLNLSNTTSGEIGTKKKVKLLSFOFYFHASRLRG 139  
Qy 88 IIPQAPHLHLDDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPHLHLDDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199  
Qy 148 FKLDVMTLHRLFLVMQEDYHSQNPYHNAHAAVDTQAMHCYLKEPKLASFLTPDLMGL 207  
Db 200 FKLDVMTLHRLFLVMQEDYHSQNPYHNAHAAVDTQAMHCYLKEPKLASFLTPDLMGL 259  
Qy 208 LAAAHDVDHPGVNQPFLLKTNHHLANLYQNMSVLENHHRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAHDVDHPGVNQPFLLKTNHHLANLYQNMSVLENHHRSTIGMLRESRLLAHLPKEM 319  
Qy 268 T 268  
Db 320 T 320

RESULT 6  
US-10-273-517-1  
; Sequence 1, Application US/10273517  
; Publication No. US20030143588A1  
; GENERAL INFORMATION:  
; APPLICANT: THORNTON, Michael B.; DING, Li  
; APPLICANT: ARVIZU, Chandra S.; YAO, Monique G.  
; APPLICANT: TRIBOULEY, Catherine M.; LAL, Preeti G.  
; APPLICANT: HAPALIA, April J. A.; BAUGHN, Mariah R.  
; APPLICANT: RAMKUMAR, Jayalaxmi; LU, Yan  
; APPLICANT: CHAWLA, Narinder K.  
; TITLE OF INVENTION: PHOSPHODIESTERASES  
; FILE REFERENCE: PI-0136 USA  
; CURRENT APPLICATION NUMBER: US/10/273,517  
; CURRENT FILING DATE: 2002-10-18  
; PRIOR APPLICATION NUMBER: 60/241,100  
; PRIOR FILING DATE: 2000-10-16  
; PRIOR APPLICATION NUMBER: 60/218,234  
; PRIOR FILING DATE: 2000-07-14  
; PRIOR APPLICATION NUMBER: US01/20140  
; PRIOR FILING DATE: 2001-06-21  
; PRIOR APPLICATION NUMBER: 60/213,741  
; PRIOR FILING DATE: 2000-06-22  
; NUMBER OF SEQ ID NOS: 8  
; SOFTWARE: PERL Program  
; SEQ ID NO 1  
; LENGTH: 502  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; NAME/KEY: misc feature  
; OTHER INFORMATION: Incyte ID No. US20030143588A1 7476201CD1  
US-10-273-517-1  
Query Match 83.1%; Score 1280; DB 4; Length 502;  
Best Local Similarity 100.0%; Pred. No. 2.3e-126;  
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 28 GDRLRGQTGVRAERRGSPFIDFRLNLSNTTSGEIGTKKKVKLLSFOFYFHASRLRG 87  
Db 80 GDRLRGQTGVRAERRGSPFIDFRLNLSNTTSGEIGTKKKVKLLSFOFYFHASRLRG 139  
Qy 88 IIPQAPHLHLDDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPHLHLDDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199  
Qy 148 FKLDVMTLHRLFLVMQEDYHSQNPYHNAHAAVDTQAMHCYLKEPKLASFLTPDLMGL 207  
Db 200 FKLDVMTLHRLFLVMQEDYHSQNPYHNAHAAVDTQAMHCYLKEPKLASFLTPDLMGL 259  
Qy 208 LAAAHDVDHPGVNQPFLLKTNHHLANLYQNMSVLENHHRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAHDVDHPGVNQPFLLKTNHHLANLYQNMSVLENHHRSTIGMLRESRLLAHLPKEM 319  
Qy 268 T 268  
Db 320 T 320

RESULT 7  
US-10-386-414-4  
; Sequence 4, Application US/10386414  
; Publication No. US20040006016A1  
; GENERAL INFORMATION:  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: Robison, Keith E.  
; APPLICANT: White, David  
; APPLICANT: Williamson, Mark W.  
; APPLICANT: Cook, William James  
; APPLICANT: Meyers, Rachel E.  
; APPLICANT: MacBeth, Kyle J.  
; APPLICANT: Carroll, Joseph M.

```
; APPLICANT: Chun, Miyoung
; TITLE OF INVENTION: NOVEL 27875, 22025, 27420, 17906, 16319,
; FILE REFERENCE: 55092 AND 10218 MOLECULES AND USES THEREFOR
; CURRENT APPLICATION NUMBER: US/10/386,414
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: 09/426,282
; PRIOR FILING DATE: 1999-10-25
; PRIOR APPLICATION NUMBER: 09/668,266
; PRIOR FILING DATE: 2000-09-22
; PRIOR APPLICATION NUMBER: 09/330,970
; PRIOR FILING DATE: 1999-06-11
; PRIOR APPLICATION NUMBER: 09/724,599
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 09/860,193
; PRIOR FILING DATE: 2001-05-16
; PRIOR APPLICATION NUMBER: 10/283,023
; PRIOR FILING DATE: 2002-10-29
; PRIOR APPLICATION NUMBER: 60/335,044
; PRIOR FILING DATE: 2001-10-31
; PRIOR APPLICATION NUMBER: 10/010,943
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: 60/254,037
; PRIOR FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: 09/833,082
; PRIOR FILING DATE: 2001-04-10
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 502
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-386-414-4

Query Match      83.1%; Score 1280; DB 4; Length 502;
Best Local Similarity 100.0%; Pred. No. 2.3e-126;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 GDRLRGQTGVRAERGSYPFDIFRLNLSNTTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87
DB 80 GDRLRGQTGVRAERGSYPFDIFRLNLSNTTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139

QY 88 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147
DB 140 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199

QY 148 FKLDVMTLHRLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIDMLGL 207
DB 200 FKLDVMTLHRLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIDMLGL 259

QY 208 LAAAAHDVDHPGVNQPFLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 267
DB 260 LAAAAHDVDHPGVNQPFLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 319

QY 268 T 268
DB 320 T 320

RESULT 8
US-10-311-104-1
; Sequence 1, Application US/10311104
; Publication No. US20040054138A1
; GENERAL INFORMATION:
; APPLICANT: INCYTE GENOMICS, INC.
; APPLICANT: THORNTON, Michael
; APPLICANT: DING, Li
; APPLICANT: ARIVZU Chandra S.
; APPLICANT: YAO, Monique G.
; APPLICANT: TRIBOULEY, Catherine M.
; APPLICANT: LAL, Preeti G.
; APPLICANT: HAFALIA, April J. A.
; APPLICANT: BAUGHN, Mariah R.

Query Match      83.1%; Score 1280; DB 4; Length 502;
Best Local Similarity 100.0%; Pred. No. 2.3e-126;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 GDRLRGQTGVRAERGSYPFDIFRLNLSNTTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87
DB 80 GDRLRGQTGVRAERGSYPFDIFRLNLSNTTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139

QY 88 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147
DB 140 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199

QY 148 FKLDVMTLHRLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIDMLGL 207
DB 200 FKLDVMTLHRLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIDMLGL 259

QY 208 LAAAAHDVDHPGVNQPFLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 267
DB 260 LAAAAHDVDHPGVNQPFLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 319

QY 268 T 268
DB 320 T 320

RESULT 9
US-11-048-744-1
; Sequence 1, Application US/11048744
; Publication No. US20050164275A1
; GENERAL INFORMATION:
; APPLICANT: THORNTON, Michael B.; DING, Li
; APPLICANT: ARIVZU, Chandra S.; YAO, Monique G.
; APPLICANT: TRIBOULEY, Catherine M.; LAL, Preeti G.
; APPLICANT: HAFALIA, April J. A.; BAUGHN, Mariah R.
; APPLICANT: RAMKUMAR, Jayalaxmi; LU, Yan
; APPLICANT: CHAWLA, Narinder K.
; TITLE OF INVENTION: PHOSPHODIESTERASES
; FILE REFERENCE: PI-0136 USA
; CURRENT APPLICATION NUMBER: US/11/048,744
; CURRENT FILING DATE: 2005-02-03
; PRIOR APPLICATION NUMBER: US/10/273,517
; PRIOR FILING DATE: 2002-10-18
; PRIOR APPLICATION NUMBER: 60/241,100
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/218,234
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US01/20140
```

```
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: 60/213,741
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PERL Program
; SEQ ID NO 1
; LENGTH: 502
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No: 7476201CD1
US-11-048-744-1

Query Match      83.1%; Score 1280; DB 6; Length 502;
Best Local Similarity 100.0%; Pred. No. 2.3e-126;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 GDIRLRGQTGVRAERRGSYPFIDFRLNLSNLTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87
   |||||
DB 80 GDIRLRGQTGVRAERRGSYPFIDFRLNLSNLTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139
   |||||
QY 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147
   |||||
DB 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199
   |||||
QY 148 FKLDMTVTLHRLFLVNVQEDYHSQNPYHNAVAADVTQAMHCYLKEPKLASFLTPDIDIMGL 207
   |||||
DB 200 FKLDMTVTLHRLFLVNVQEDYHSQNPYHNAVAADVTQAMHCYLKEPKLASFLTPDIDIMGL 259
   |||||
QY 208 LAAAAHDVDHGVNQPFLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 267
   |||||
DB 260 LAAAAHDVDHGVNQPFLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 319
   |||||
QY 268 T 268
DB 320 T 320

RESULT 11
US-10-204-268A-4
; Sequence 4, Application US/10204268A
; Publication No. US2005058647A1
; GENERAL INFORMATION:
; APPLICANT: KLUXEN, FRANZ-WERNER
; APPLICANT: HENTSCH, BERND
; TITLE OF INVENTION: NEW PHOSPHODIESTERASE TYPE 7B
; FILE REFERENCE: MERCK-2484
; CURRENT APPLICATION NUMBER: US/10/204,268A
; PRIOR FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: PCT/EP01/01858
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: EP 00103655.7
; PRIOR FILING DATE: 2000-02-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 391
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD RES
; LOCATION: (188)
; OTHER INFORMATION: Pro or His
; FEATURE:
; NAME/KEY: MOD RES
; LOCATION: (387)
; OTHER INFORMATION: Val, Ala, Asp, Glu or Gly
US-10-204-268A-4

Query Match      74.4%; Score 1145; DB 5; Length 391;
Best Local Similarity 99.5%; Pred. No. 3.2e-112;
Matches 216; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 52 RLNLSNLTYSGEIGTKKKVKRLLSFQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSK 111
   |||||
DB 10 RLNLSNLTYSGEIGTKKKVKRLLSFQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSK 69
   |||||
QY 112 VGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMTVTLHRLFLVNVQEDYHSQNP 171
   |||||
DB 70 VGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMTVTLHRLFLVNVQEDYHSQNP 129
   |||||
QY 172 YHNAVAADVTQAMHCYLKEPKLASFLTPDIDIMGLIAAAAHVDHGVNQPFLIKTNHH 231
   |||||
DB 130 YHNAVAADVTQAMHCYLKEPKLASFLTPDIDIMGLIAAAAHVDHGVNQPFLIKTNH 189
   |||||
QY 232 LANLYQNMVLENHHRSTIGMLRESRLLAHLPKEMT 268
```

```
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: 60/213,741
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PERL Program
; SEQ ID NO 1
; LENGTH: 502
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No: 7476201CD1
US-11-048-744-1

Query Match      83.1%; Score 1280; DB 6; Length 502;
Best Local Similarity 100.0%; Pred. No. 2.3e-126;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 GDIRLRGQTGVRAERRGSYPFIDFRLNLSNLTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87
   |||||
DB 80 GDIRLRGQTGVRAERRGSYPFIDFRLNLSNLTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139
   |||||
QY 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147
   |||||
DB 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199
   |||||
QY 148 FKLDMTVTLHRLFLVNVQEDYHSQNPYHNAVAADVTQAMHCYLKEPKLASFLTPDIDIMGL 207
   |||||
DB 200 FKLDMTVTLHRLFLVNVQEDYHSQNPYHNAVAADVTQAMHCYLKEPKLASFLTPDIDIMGL 259
   |||||
QY 208 LAAAAHDVDHGVNQPFLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 267
   |||||
DB 260 LAAAAHDVDHGVNQPFLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 319
   |||||
QY 268 T 268
DB 320 T 320

RESULT 10
US-11-048-068-1
; Sequence 1, Application US/11048068
; Publication No. US20050202478A1
; GENERAL INFORMATION:
; APPLICANT: INCYTE GENOMICS, INC.
; APPLICANT: THORNTON, Michael
; APPLICANT: DING, Li
; APPLICANT: PATTERSON, Chandra
; APPLICANT: YAO, Monique G.
; APPLICANT: TRIBOULEY, Catherine M.
; APPLICANT: LAL, Preeti
; APPLICANT: HAPALIA, April J. A.
; APPLICANT: BAUGHN, Mariah R.
; APPLICANT: RAMKUMAR, Jayalaxmi
; APPLICANT: LU, Yan
; APPLICANT: WALIA, Narinder K.
; TITLE OF INVENTION: PHOSPHODIESTERASES
; FILE REFERENCE: PI-0136 PCT
; CURRENT APPLICATION NUMBER: US/11/048,068
; CURRENT FILING DATE: 2005-02-02
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PERL Program
; SEQ ID NO 1
; LENGTH: 502
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No: 7476201CD1
US-11-048-068-1
```

```
Db 190 LANLYQNSVLENHHWRSTIGMLRESRLLAHLPKMT 226
|||||
RESULT 12
US-10-771-833-23
; Sequence 23, Application US/10771833
; Publication No. US20050048573A1
; GENERAL INFORMATION:
; APPLICANT: MILBURN, MICHAEL V.
; TITLE OF INVENTION: PDESA CRYSTAL STRUCTURE AND USES
; FILE REFERENCE: 039363-1106
; CURRENT APPLICATION NUMBER: US/10/771.833
; CURRENT FILING DATE: 2004-02-03
; PRIOR APPLICATION NUMBER: 60/485,627
; PRIOR FILING DATE: 2003-07-07
; PRIOR APPLICATION NUMBER: 60/444,734
; PRIOR FILING DATE: 2003-02-03
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 335
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-833-23

Query Match 63.6%; Score 980; DB 5; Length 335;
Best Local Similarity 100.0%; Pred. No. 7.9e-95;
Matches 182; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 87 GIIPQAPLHLLDELDYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLNFTHGLIH 146
Db 1 GIIPQAPLHLLDELDYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLNFTHGLIH 60
|||||
QY 147 HFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDMLG 206
Db 61 HFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDMLG 120
|||||
QY 207 LAAAAHVDVHPGVNPFLLKTNHHLANLYQNSVLENHHWRSTIGMLRESRLLAHLPK 266
Db 121 LAAAAHVDVHPGVNPFLLKTNHHLANLYQNSVLENHHWRSTIGMLRESRLLAHLPK 180
|||||
QY 267 MT 268
Db 181 MT 182
|||||

RESULT 14
US-10-380-437-6
; Sequence 6, Application US/10380437
; Publication No. US20050058998A1
; GENERAL INFORMATION:
; APPLICANT: Beavo, Joseph A
; APPLICANT: Seebek, Thomas
; APPLICANT: Soderling, Scott Haydn
; APPLICANT: Rascon, Ana
; APPLICANT: Zoraghi, Roya
; APPLICANT: Kunz, Stefan
; APPLICANT: Gong, Kewei
; APPLICANT: Glavas, Natalie
; TITLE OF INVENTION: NOVEL PDEs AND USES THEREOF
; FILE REFERENCE: 30429.3W001
; CURRENT APPLICATION NUMBER: US/10/380,437
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: 60/232,445
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 60/240,500
; PRIOR FILING DATE: 2000-10-12
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 424
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-380-437-6

Query Match 58.9%; Score 907; DB 5; Length 424;
Best Local Similarity 64.6%; Pred. No. 5.9e-87;
Matches 168; Conservative 39; Mismatches 53; Indels 0; Gaps 0;

QY 7 ERCGEILFENPDQNAKVCMLGDIRLGTQVRAERGSYPFIDFRLLNSTTYSGBIGTK 66
Db 46 QRRGALSVDSDQALYIRMLGDVVRVRAGFESERRGSHPYIDFRIFHSQSEIEVSVA 105
|||||
QY 67 KVKRLLSPQRYPHASRLRGIIPOAPLHLLDELDYLGQARHMLSKVGMWDFDIFLFDRLT 126
Db 106 RNIRLLSPQRYLRSSRFRGTAVSNSNLILDDYNGQAKCMLEKVGNNWDFDIFLFDRLT 165
|||||
QY 127 NGNSLVTLCHLNFTHGLIHFKLDMVTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMH 186
Db 166 NGNSLVTLCHLNFTHGLIHFKLDMVTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMH 225
|||||
QY 187 CYLKEPKLASFLTPDMLGLAAAAHVDVHPGVNPFLLKTNHHLANLYQNSVLENHH 246
Db 226 CYLKEPKLASFLTPDMLGLAAAAHVDVHPGVNPFLLKTNHHLANLYQNSVLENHH 285
|||||
QY 247 WRSTIGMLRESRLLAHLPK 266
Db 286 WRSVGLLRSGFLSHLPLE 305
|||||

Query Match 63.6%; Score 980; DB 5; Length 335;
US-10-886-949-23
; Sequence 23, Application US/10886949
; Publication No. US20050079548A1
; GENERAL INFORMATION:
; APPLICANT: DEAN R. ARTIS
; APPLICANT: BOLLAG, GIDRON
; APPLICANT: CARD, GRAHAM
; APPLICANT: MARTIN, FERNANDO
; APPLICANT: MILBURN, MICHAEL V.
; APPLICANT: ZHANG, KAM
; TITLE OF INVENTION: PDESA CRYSTAL STRUCTURE AND USES
; FILE REFERENCE: 039363-1108
; CURRENT APPLICATION NUMBER: US/10/886,949
; CURRENT FILING DATE: 2004-07-07
; PRIOR APPLICATION NUMBER: 60/485,627
; PRIOR FILING DATE: 2003-07-07
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 335
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-886-949-23
```



## RESULT 15

US-10-380-437-53  
; Sequence 53, Application US/10380437  
; Publication No. US20050058998A1  
; GENERAL INFORMATION:  
; APPLICANT: Beavo, Joseph A  
; APPLICANT: Seebeck, Thomas  
; APPLICANT: Soderling, Scott Haydn  
; APPLICANT: Rascon, Ana  
; APPLICANT: Zoraghi, Roya  
; APPLICANT: Kunz, Stefan  
; APPLICANT: Gong, Kewei  
; APPLICANT: Glavas, Natalie  
; TITLE OF INVENTION: NOVEL PDES AND USES THEREOF  
; FILE REFERENCE: 30429.3WO01  
; CURRENT APPLICATION NUMBER: US/10/380,437  
; CURRENT FILING DATE: 2003-03-12  
; PRIOR APPLICATION NUMBER: 60/232,445  
; PRIOR FILING DATE: 2000-09-12  
; PRIOR APPLICATION NUMBER: 60/240,500  
; PRIOR FILING DATE: 2000-10-12  
; NUMBER OF SEQ ID NOS: 61  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 53  
; LENGTH: 424  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-380-437-53

Query Match 58.9%; Score 907; DB 5; Length 424;  
Best Local Similarity 64.6%; Pred. No. 5.9e-87;  
Matches 168; Conservative 39; Mismatches 53; Indels 0; Gaps 0;

Qy	7	ERCEILFENPDONAKCVMGLDIRLGGTVRAERGSYPFIDFRLNSTTYSGEIGTK	66
Db	46	ORGAISYDSDQTALYIRMLGTVRVRSRAGFESERGSHPYIDFRIFHSQSIEVSVA	105
Qy	67	KKVKRLLSFORYPHASRLRLGIIPQAPLHLLDEDYLGQARHMLSKVGMWDFDIFLFDRLT	126
Db	106	RNIRRLLSFQYLRSSRRFFRGTAVSNSLNILDDDDYNGQAKCMLEKVGWNFDIFLFDRLT	165
Qy	127	NGNSLVTLCHLNFTHGLIHFKLDWVTLHRFLVMQEDYHSONPYHNAVHAADVTQAMH	186
Db	166	NGNSVSLTFLHFLSLHGLIEYFHLDMKLRFLVMIQEDYHSONPYHNAVHAADVTQAMH	225
Qy	187	CYLKEPKLASFLTPDLMGLAAAHVDVDPGVNQPFLIKTNHHLANLYONMSVLENHH	246
Db	226	CYLKEPKLANSVTPWDILLSLIAAATHDLOHPGVNQPFLLIKTNHLYLATLYKNTSVLENHH	285
Qy	247	WRSTIGMLRESRLLAHLPK	266
Db	286	WRSVGLLRRESGLFSLHPL	305

Search completed: March 10, 2006, 20:22:33  
Job time : 88.0244 secs

**This Page Blank (uspio)**

GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 20:19:01 ; Search time 11.3171 Seconds  
(without alignments)  
708.350 Million cell updates/sec

Title: US-10-781-181-3

Perfect score: 1540

Sequence: 1 MSLMVERGCEILLFENPDQN.....GTWDFDIFLFDRLTNGSLV 288

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 161667 seqs, 27834885 residues

Total number of hits satisfying chosen parameters: 161667

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA New:

1: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB pep:\*  
2: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB pep:\*  
3: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB pep:\*  
4: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB pep:\*  
5: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB pep:\*  
6: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB pep:\*  
7: /cgn2\_6/ptodata/2/pubpaa/US11\_NEW\_PUB pep:\*  
8: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1280	83.1	320	7	US-11-226-701-6
2	1280	83.1	502	7	US-11-226-701-4
3	331.5	21.5	747	6	US-10-492-835-8
4	331.5	21.5	747	6	US-10-492-835-15
5	331.5	21.5	747	6	US-10-492-835-27
6	330.5	21.5	507	7	US-11-091-018-10
7	330.5	21.5	585	7	US-11-091-018-9
8	330.5	21.5	673	7	US-11-091-018-6
9	330.5	21.5	687	7	US-11-091-018-8
10	330.5	21.5	745	7	US-11-091-018-4
11	330.5	21.5	748	6	US-10-492-835-12
12	330.5	21.5	748	6	US-10-492-835-28
13	330.5	21.5	809	7	US-11-091-018-2
14	314.5	20.4	736	7	US-11-169-041-207
15	303.5	19.7	398	7	US-11-123-893-11
16	302.5	19.6	349	7	US-11-123-893-13
17	296.5	19.3	357	7	US-11-123-893-12
18	261	16.9	769	7	US-11-072-512-2646
19	189	12.3	786	6	US-11-072-512-2944
20	185	12.0	941	6	US-10-501-035-343
21	176.5	11.5	854	6	US-10-511-657-4
22	98	6.4	968	6	US-10-501-035-219
23	84	5.5	635	7	US-11-096-568A-29628
24	84	5.5	710	7	US-11-096-568A-29627
25	82.5	5.4	418	7	US-11-109-156-2

26	81	5.3	394	7	US-11-096-568A-5451	Sequence 5451, Ap
27	81	5.3	852	6	US-10-467-657-5004	Sequence 5004, Ap
28	81	5.3	6738	6	US-10-522-232B-56	Sequence 56, Appl
29	80.5	5.2	376	7	US-11-098-686-10379	Sequence 10379, A
30	79	5.1	643	7	US-11-096-568A-27797	Sequence 27797, A
31	77.5	5.0	418	7	US-11-099-691-1	Sequence 1, Appli
32	76	4.9	281	6	US-10-467-657-988	Sequence 988, App
33	75.5	4.9	259	7	US-11-096-568A-5912	Sequence 5912, Ap
34	75.5	4.9	344	6	US-10-522-232B-61	Sequence 61, Appl
35	75.5	4.9	398	7	US-11-087-099-1516	Sequence 1516, Ap
36	75.5	4.9	398	7	US-11-087-099-4038	Sequence 4038, Ap
37	75.5	4.9	398	7	US-11-087-099-4756	Sequence 4756, Ap
38	75.5	4.9	398	7	US-11-087-099-8044	Sequence 8044, Ap
39	75.5	4.9	398	7	US-11-087-099-9817	Sequence 9817, Ap
40	75.5	4.9	1007	7	US-11-087-099-735	Sequence 735, App
41	74.5	4.8	276	7	US-11-096-568A-12387	Sequence 12387, A
42	74.5	4.8	295	7	US-11-096-568A-12386	Sequence 12386, A
43	74.5	4.8	380	7	US-11-096-568A-27808	Sequence 27808, A
44	73.5	4.8	443	7	US-11-087-099-7032	Sequence 7032, Ap
45	73.5	4.8	443	7	US-11-087-099-7719	Sequence 7719, Ap

#### ALIGNMENTS

#### RESULT 1

US-11-226-701-6  
; Sequence 6, Application US/11226701  
; Publication No. US2006009632A1  
; GENERAL INFORMATION:  
; APPLICANT: Millennium Pharmaceuticals, Inc.  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: Robison, Keith E.  
; APPLICANT: White, David  
; APPLICANT: Williamson, Mark W.  
; APPLICANT: Cook, William James  
; APPLICANT: Meyers, Rachel E.  
; APPLICANT: MacBeth, Kyle J.  
; APPLICANT: Carroll, Joseph M.  
; APPLICANT: Chun, Miyoung  
; TITLE OF INVENTION: NOVEL 27875, 22025, 27420, 17906, 16319,  
55092 AND 10218 MOLECULES AND USES THEREFOR  
; FILE REFERENCE: WP03-0210NMIM  
; CURRENT APPLICATION NUMBER: US/11/226,701  
; PRIOR FILING DATE: 2005-09-14  
; PRIOR FILING DATE: 2003-03-11  
; PRIOR FILING DATE: 1999-10-25  
; PRIOR FILING DATE: 2000-09-22  
; PRIOR FILING DATE: 2000-09-22  
; PRIOR FILING DATE: 1999-06-11  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR FILING DATE: 2001-05-16  
; PRIOR FILING DATE: 2001-05-16  
; PRIOR FILING DATE: 2000-05-16  
; PRIOR FILING DATE: 2002-10-29  
; PRIOR FILING DATE: 2002-10-29  
; PRIOR FILING DATE: 2001-10-31  
; PRIOR FILING DATE: 2001-10-31  
; PRIOR FILING DATE: 2001-12-06  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 6  
; LENGTH: 320  
; TYPE: PRT  
; ORGANISM: Homo Sapiens  
US-11-226-701-6

Query Match 83.1%; Score 1280; DB 7; Length 320;  
Best Local Similarity 100.0%; Pred. No. 1.3e-123;  
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDIRLRGQTGVRAERRGSGYFFIDFRLNLSNTTYSGEIGTKKKVKRLLSFGQYFHASRLLRG 87  
Db 80 GDIRLRGQTGVRAERRGSGYFFIDFRLNLSNTTYSGEIGTKKKVKRLLSFGQYFHASRLLRG 139

Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFRLTNGNSLVTLCHLFNTHGLIHH 199

Qy 148 FKLDVMTLHRLVLMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 207  
Db 200 FKLDVMTLHRLVLMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 259

Qy 208 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 319

Qy 268 T 268  
Db 320 T 320

RESULT 2  
US-11-226-701-4  
; Sequence 4, Application US/11226701  
; Publication No. US2006009632A1  
; GENERAL INFORMATION:  
; APPLICANT: Millennium Pharmaceuticals, Inc.  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: Robison, Keith E.  
; APPLICANT: White, David  
; APPLICANT: Williamson, Mark W.  
; APPLICANT: Cook, William James  
; APPLICANT: Meyers, Rachel E.  
; APPLICANT: MacBeth, Kyle J.  
; APPLICANT: Carroll, Joseph M.  
; APPLICANT: Chun, Miyoung  
; TITLE OF INVENTION: NOVEL 27875, 22025, 27420, 17906, 16319,  
; FILE REFERENCE: 55092 AND 10218 MOLECULES AND USES THEREFOR  
; CURRENT APPLICATION NUMBER: US/11/226,701  
; CURRENT FILING DATE: 2005-09-14  
; PRIOR APPLICATION NUMBER: US/10/386,414  
; PRIOR FILING DATE: 2003-03-11  
; PRIOR APPLICATION NUMBER: 09/426,282  
; PRIOR FILING DATE: 1999-10-25  
; PRIOR APPLICATION NUMBER: 09/668,266  
; PRIOR FILING DATE: 2000-09-22  
; PRIOR APPLICATION NUMBER: 09/330,970  
; PRIOR FILING DATE: 1999-06-11  
; PRIOR APPLICATION NUMBER: 09/724,599  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 09/860,193  
; PRIOR FILING DATE: 2001-05-16  
; PRIOR APPLICATION NUMBER: 09/571,689  
; PRIOR FILING DATE: 2000-05-16  
; PRIOR APPLICATION NUMBER: 10/283,023  
; PRIOR FILING DATE: 2002-10-29  
; PRIOR APPLICATION NUMBER: 60/335,044  
; PRIOR FILING DATE: 2001-10-31  
; PRIOR APPLICATION NUMBER: 10/010,943  
; PRIOR FILING DATE: 2001-12-06  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 502  
; TYPE: PRT  
; ORGANISM: Homo Sapiens

US-11-226-701-4  
Query Match 83.1%; Score 1280; DB 7; Length 502;  
Best Local Similarity 100.0%; Pred. No. 2.3e-123;  
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDIRLRGQTGVRAERRGSGYFFIDFRLNLSNTTYSGEIGTKKKVKRLLSFGQYFHASRLLRG 87  
Db 80 GDIRLRGQTGVRAERRGSGYFFIDFRLNLSNTTYSGEIGTKKKVKRLLSFGQYFHASRLLRG 139

Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFRLTNGNSLVTLCHLFNTHGLIHH 199

Qy 148 FKLDVMTLHRLVLMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 207  
Db 200 FKLDVMTLHRLVLMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 259

Qy 208 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 319

Qy 268 T 268  
Db 320 T 320

RESULT 3  
US-10-492-835-8  
; Sequence 8, Application US/10492835  
; Publication No. US20050289660A2  
; GENERAL INFORMATION:  
; APPLICANT: MEMORY PHARMACEUTICALS CORPORATION  
; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS  
; TITLE OF INVENTION: OF USE  
; FILE REFERENCE: MEMORY 4 WO  
; CURRENT APPLICATION NUMBER: US/10/492,835  
; CURRENT FILING DATE: 2004-04-15  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 8  
; LENGTH: 747  
; TYPE: PRT  
; ORGANISM: Rattus sp.  
US-10-492-835-8

Query Match 21.5%; Score 331.5; DB 6; Length 747;  
Best Local Similarity 37.8%; Pred. No. 8.7e-26;  
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS----FQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFL 121  
Db 293 KEKKRPMISQISGVKKLMHSSSLTNSCIDPFGVTEQEDVLAKE---LEDVKNKGLHVFR 349

Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDVMTLHRLVLMVQEDYHSQNPYHNAVHAAD 180  
Db 350 IAEI-SGNRPLVIMHTIFQERDLKTKPKIPVDLTILYLTMTLEDHYADVAVYNNIHAAD 408

Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMV 240  
Db 409 VVQSTHVLSTPALEAVFTDLEIAAIFASAIHDVHPGVSNQFLINTNSALAMYNDSS 468

Qy 241 VLENHHRSTIGMLRE 256  
Db 469 VLENHHLAVGFKLQRE 484

RESULT 4  
US-10-492-835-15  
; Sequence 15, Application US/10492835  
; Publication No. US20050289660A2  
; GENERAL INFORMATION:  
; APPLICANT: MEMORY PHARMACEUTICALS CORPORATION

```

; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS
; TITLE OF INVENTION: OF USE
; FILE REFERENCE: MEMORY 4 WO
; CURRENT APPLICATION NUMBER: US/10/492.835
; CURRENT FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 747
; TYPE: PRT
; ORGANISM: Murine sp.
US-10-492-835-15

Query Match      21.5%; Score 331.5; DB 6; Length 747;
Best Local Similarity 37.8%; Pred. No. 8.7e-26;
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS---FQRYFHASRLLRGIIPQAPLHLLDEVDYLGQARHMLSKVGMWDFDIFL 121
Db 293 KKKRPMISQGVKMLMHSSSLTNSCIPRGVKTQEDVLAKL---LEDVKNWGLHVR 349

Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHFHFKLDMVTLHRFLVMQVEDYHSQNPYHNAVHAAD 180
Db 350 IAEI-SGNRPLTVIMHTIFQERDLTKTKIPVDVTILTYLMTLEDHYHADVAYHNNIHAAD 408

Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPLIKTNHHLANLYQNS 240
Db 409 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDPGVNQPLINTNSLALMYNDSS 468

Qy 241 VLENHHRSTIGMLRE 256
Db 469 VLENHHLAVGFKLQ 484

RESULT 5
US-10-492-835-27
; Sequence 27, Application US/10492835
; Publication No. US20050289660A2
; GENERAL INFORMATION:
; APPLICANT: MEMORY PHARMACEUTICALS CORPORATION
; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS
; TITLE OF INVENTION: OF USE
; FILE REFERENCE: MEMORY 4 WO
; CURRENT APPLICATION NUMBER: US/10/492.835
; CURRENT FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 27
; LENGTH: 747
; TYPE: PRT
; ORGANISM: Rattus sp.
US-10-492-835-27

Query Match      21.5%; Score 331.5; DB 6; Length 747;
Best Local Similarity 37.8%; Pred. No. 8.7e-26;
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS---FQRYFHASRLLRGIIPQAPLHLLDEVDYLGQARHMLSKVGMWDFDIFL 121
Db 293 KKKRPMISQGVKMLMHSSSLTNSCIPRGVKTQEDVLAKL---LEDVKNWGLHVR 349

Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHFHFKLDMVTLHRFLVMQVEDYHSQNPYHNAVHAAD 180
Db 350 IAEI-SGNRPLTVIMHTIFQERDLTKTKIPVDVTILTYLMTLEDHYHADVAYHNNIHAAD 408

Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPLIKTNHHLANLYQNS 240
Db 409 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDPGVNQPLINTNSLALMYNDSS 468

Qy 241 VLENHHRSTIGMLRE 256
Db 469 VLENHHLAVGFKLQ 484

; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS
; TITLE OF INVENTION: OF USE
; FILE REFERENCE: MEMORY 4 WO
; CURRENT APPLICATION NUMBER: US/10/492.835
; CURRENT FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 10
; LENGTH: 507
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-091-018-10

Query Match      21.5%; Score 330.5; DB 7; Length 507;
Best Local Similarity 37.8%; Pred. No. 6.6e-26;
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS---FQRYFHASRLLRGIIPQAPLHLLDEVDYLGQARHMLSKVGMWDFDIFL 121
Db 52 KKKRPMISQGVKMLMHSSSLTNSCIPRGVKTQEDVLAKL---LEDVKNWGLHVR 108

Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHFHFKLDMVTLHRFLVMQVEDYHSQNPYHNAVHAAD 180
Db 109 IAEI-SGNRPLTVIMHTIFQERDLTKTKIPVDVTILTYLMTLEDHYHADVAYHNNIHAAD 167

Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPLIKTNHHLANLYQNS 240
Db 168 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDPGVNQPLINTNSLALMYNDSS 227

Qy 241 VLENHHRSTIGMLRE 256
Db 228 VLENHHLAVGFKLQ 243

RESULT 7
US-11-091-018-9
; Sequence 9, Application US/11091018
; Publication No. US20050287551A1
; GENERAL INFORMATION:
; APPLICANT: Gretaardottir, Solveig
; APPLICANT: Thorleifsson, Gudmar
; APPLICANT: Gulcher, Jeffrey R.
; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR HUMAN STROKE;
; TITLE OF INVENTION: METHODS OF TREATMENT
; FILE REFERENCE: 2345.2010-016
; CURRENT APPLICATION NUMBER: US/11/091.018
; CURRENT FILING DATE: 2005-03-25
; PRIOR APPLICATION NUMBER: PCT/US03/29906
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 10/255,120
; PRIOR FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: 09/811,352
; PRIOR FILING DATE: 2001-03-19
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 507
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-091-018-10
```

;; PRIOR FILING DATE: 2003-04-18  
;; PRIOR APPLICATION NUMBER: 10/650,120  
;; PRIOR FILING DATE: 2003-08-27  
;; PRIOR APPLICATION NUMBER: 10/067,514  
;; PRIOR FILING DATE: 2002-02-04  
;; PRIOR APPLICATION NUMBER: 09/811,352  
;; PRIOR FILING DATE: 2001-03-19  
;; NUMBER OF SEQ ID NOS: 102  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 9  
;; LENGTH: 585  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens  
US-11-091-018-9

Query Match 21.5%; Score 330.5; DB 7; Length 585;  
Best Local Similarity 37.8%; Pred. No. 8e-26;  
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS----FQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121  
Db 130 KKKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNKGLHVR 186  
Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHFKLDMTLHRFLVMQEDYHSQNPYHNAHAAD 180  
Db 187 IAEI-SGNRPLTVIMHTIFQERDLLKTKIPVDTLITYLMTLEDHYHADVAYHNNIHAAD 245  
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPLIKTNHHLANLYQNS 240  
Db 246 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDPGVSNQFLINTNSLALMYNDSS 305  
Qy 241 VLENHHWRSITIGMLRE 256  
Db 306 VLENHHLAVGFKLLQE 321

RESULT 8  
US-11-091-018-6  
;; Sequence 6, Application US/11091018  
;; Publication No. US20050287551A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Gretaarsdottir, Solveig  
;; APPLICANT: Thorleifsson, Gudmar  
;; APPLICANT: Gulcher, Jeffrey R.  
;; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR HUMAN STROKE;  
;; FILE REFERENCE: 2345.2010-016  
;; CURRENT APPLICATION NUMBER: US/11/091,018  
;; PRIOR FILING DATE: 2005-03-25  
;; PRIOR APPLICATION NUMBER: PCT/US03/29906  
;; PRIOR FILING DATE: 2003-09-25  
;; PRIOR APPLICATION NUMBER: 10/255,120  
;; PRIOR FILING DATE: 2002-09-25  
;; PRIOR APPLICATION NUMBER: 10/419,723  
;; PRIOR FILING DATE: 2003-04-18  
;; PRIOR APPLICATION NUMBER: 10/650,120  
;; PRIOR FILING DATE: 2003-08-27  
;; PRIOR APPLICATION NUMBER: 10/067,514  
;; PRIOR FILING DATE: 2002-02-04  
;; PRIOR APPLICATION NUMBER: 09/811,352  
;; PRIOR FILING DATE: 2001-03-19  
;; NUMBER OF SEQ ID NOS: 102  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 6  
;; LENGTH: 673  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens  
US-11-091-018-6

Query Match 21.5%; Score 330.5; DB 7; Length 673;  
Best Local Similarity 37.8%; Pred. No. 9.6e-26;  
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS----FQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121  
Db 218 KKKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNKGLHVR 274  
Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHFKLDMTLHRFLVMQEDYHSQNPYHNAHAAD 180  
Db 275 IAEI-SGNRPLTVIMHTIFQERDLLKTKIPVDTLITYLMTLEDHYHADVAYHNNIHAAD 333  
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPLIKTNHHLANLYQNS 240  
Db 334 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDPGVSNQFLINTNSLALMYNDSS 393  
Qy 241 VLENHHWRSITIGMLRE 256  
Db 394 VLENHHLAVGFKLLQE 409

RESULT 9  
US-11-091-018-8  
;; Sequence 8, Application US/11091018  
;; Publication No. US20050287551A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Gretaarsdottir, Solveig  
;; APPLICANT: Thorleifsson, Gudmar  
;; APPLICANT: Gulcher, Jeffrey R.  
;; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR HUMAN STROKE;  
;; FILE REFERENCE: 2345.2010-016  
;; CURRENT APPLICATION NUMBER: US/11/091,018  
;; PRIOR FILING DATE: 2005-03-25  
;; PRIOR APPLICATION NUMBER: PCT/US03/29906  
;; PRIOR FILING DATE: 2003-09-25  
;; PRIOR APPLICATION NUMBER: 10/255,120  
;; PRIOR FILING DATE: 2002-09-25  
;; PRIOR APPLICATION NUMBER: 10/419,723  
;; PRIOR FILING DATE: 2003-04-18  
;; PRIOR APPLICATION NUMBER: 10/650,120  
;; PRIOR FILING DATE: 2003-08-27  
;; PRIOR APPLICATION NUMBER: 10/067,514  
;; PRIOR FILING DATE: 2002-02-04  
;; PRIOR APPLICATION NUMBER: 09/811,352  
;; PRIOR FILING DATE: 2001-03-19  
;; NUMBER OF SEQ ID NOS: 102  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 8  
;; LENGTH: 687  
;; TYPE: PRT  
;; ORGANISM: Homo sapiens  
US-11-091-018-8

Query Match 21.5%; Score 330.5; DB 7; Length 687;  
Best Local Similarity 37.8%; Pred. No. 9.9e-26;  
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy 66 KKKVKRLLS----FQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121  
Db 232 KKKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNKGLHVR 288  
Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHFKLDMTLHRFLVMQEDYHSQNPYHNAHAAD 180  
Db 289 IAEI-SGNRPLTVIMHTIFQERDLLKTKIPVDTLITYLMTLEDHYHADVAYHNNIHAAD 347  
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPLIKTNHHLANLYQNS 240  
Db 348 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDPGVSNQFLINTNSLALMYNDSS 407  
Qy 241 VLENHHWRSITIGMLRE 256  
Db 408 VLENHHLAVGFKLLQE 423

RESULT 10  
US-11-091-018-4

```
; Sequence 4, Application US/11091018
; Publication No. US20050287551A1
; GENERAL INFORMATION:
; APPLICANT: Gretaarsdottir, Solveig
; APPLICANT: Thorleifsson, Gudmar
; APPLICANT: Guicher, Jeffrey R.
; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR HUMAN STROKE;
; TITLE OF INVENTION: METHODS OF TREATMENT
; FILE REFERENCE: 2345.2010-016
; CURRENT APPLICATION NUMBER: US/11/091.018
; PRIOR FILING DATE: 2005-03-25
; PRIOR APPLICATION NUMBER: PCT/US03/29906
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 10/255,120
; PRIOR FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: 10/419,723
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 10/650,120
; PRIOR FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: 10/067,514
; PRIOR FILING DATE: 2002-02-04
; PRIOR APPLICATION NUMBER: 09/811,352
; PRIOR FILING DATE: 2001-03-19
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 745
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-091-018-4

Query Match      21.5%; Score 330.5; DB 7; Length 745;
Best Local Similarity 37.8%; Pred. No. 1.1e-25;
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy      66 KKKVKRLS-----FQRYFHASRLRLGIIPOAPLHLLDEYLGQARHMLSKVGWDFDIFL 121
Db      290 KKKKRPMSQISGVKKMLHSSSLTNSIPRFGVKTQEDVLAKE---LEDVKNWGLHVR 346

Qy      122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDVMTLHRLFLVMVOEDYHSQNPYHNAHAAD 180
Db      347 IAEI-SGNRPLTVIMHTIFQERDLLKTKFKIPVDTLITYLMTLEDHYHADYAYHNNIHAAD 405

Qy      181 VTQAMCYLKEPKLASFLTPDLMGLLAAAHADVHPGVNQPLIKTNHHLANLYONMS 240
Db      406 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSALMYNDSS 465

Qy      241 VLENHHRSTIGMLRE 256
Db      466 VLENHHLAVGFKLLQE 481

RESULT 11
US-10-492-835-12
; Sequence 12, Application US/10492835
; Publication No. US20050289660A2
; GENERAL INFORMATION:
; APPLICANT: MEMORY PHARMACEUTICALS CORPORATION
; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS
; FILE REFERENCE: MEMORY 4 WO
; CURRENT APPLICATION NUMBER: US/10/492,835
; CURRENT FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 748
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-492-835-12

Query Match      21.5%; Score 330.5; DB 6; Length 748;
Best Local Similarity 37.8%; Pred. No. 1.1e-25;
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy      66 KKKVKRLS-----FQRYFHASRLRLGIIPOAPLHLLDEYLGQARHMLSKVGWDFDIFL 121
Db      293 KKKKRPMSQISGVKKMLHSSSLTNSIPRFGVKTQEDVLAKE---LEDVKNWGLHVR 349

Qy      122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDVMTLHRLFLVMVOEDYHSQNPYHNAHAAD 180
Db      350 IAEI-SGNRPLTVIMHTIFQERDLLKTKFKIPVDTLITYLMTLEDHYHADYAYHNNIHAAD 408

Qy      181 VTQAMCYLKEPKLASFLTPDLMGLLAAAHADVHPGVNQPLIKTNHHLANLYONMS 240
Db      409 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSALMYNDSS 468

Qy      241 VLENHHRSTIGMLRE 256
Db      469 VLENHHLAVGFKLLQE 484

RESULT 12
US-10-492-835-28
; Sequence 28, Application US/10492835
; Publication No. US20050289660A2
; GENERAL INFORMATION:
; APPLICANT: MEMORY PHARMACEUTICALS CORPORATION
; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS
; FILE REFERENCE: MEMORY 4 WO
; CURRENT APPLICATION NUMBER: US/10/492,835
; CURRENT FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 28
; LENGTH: 748
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-492-835-28

Query Match      21.5%; Score 330.5; DB 6; Length 748;
Best Local Similarity 37.8%; Pred. No. 1.1e-25;
Matches 74; Conservative 35; Mismatches 78; Indels 9; Gaps 4;

Qy      66 KKKVKRLS-----FQRYFHASRLRLGIIPOAPLHLLDEYLGQARHMLSKVGWDFDIFL 121
Db      293 KKKKRPMSQISGVKKMLHSSSLTNSIPRFGVKTQEDVLAKE---LEDVKNWGLHVR 349

Qy      122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDVMTLHRLFLVMVOEDYHSQNPYHNAHAAD 180
Db      350 IAEI-SGNRPLTVIMHTIFQERDLLKTKFKIPVDTLITYLMTLEDHYHADYAYHNNIHAAD 408

Qy      181 VTQAMCYLKEPKLASFLTPDLMGLLAAAHADVHPGVNQPLIKTNHHLANLYONMS 240
Db      409 VQSTHVLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSALMYNDSS 468

Qy      241 VLENHHRSTIGMLRE 256
Db      469 VLENHHLAVGFKLLQE 484

RESULT 13
US-11-091-018-2
; Sequence 2, Application US/11091018
; Publication No. US20050287551A1
; GENERAL INFORMATION:
; APPLICANT: Gretaarsdottir, Solveig
; APPLICANT: Thorleifsson, Gudmar
; APPLICANT: Guicher, Jeffrey R.
; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR HUMAN STROKE;
; TITLE OF INVENTION: METHODS OF TREATMENT
; FILE REFERENCE: 2345.2010-016
; CURRENT APPLICATION NUMBER: US/11/091.018
; PRIOR FILING DATE: 2005-03-25
; PRIOR APPLICATION NUMBER: PCT/US03/29906
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 10/255,120
; PRIOR FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: 10/419,723
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 10/650,120
; PRIOR FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: 10/067,514
; PRIOR FILING DATE: 2002-02-04
; PRIOR APPLICATION NUMBER: 09/811,352
; PRIOR FILING DATE: 2001-03-19
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 745
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-492-835-12

Query Match      21.5%; Score 330.5; DB 6; Length 748;
Best Local Similarity 37.8%; Pred. No. 1.1e-25;
```





GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 19:52:00 ; Search time 166.463 Seconds  
(without alignments)  
1187.771 Million cell updates/sec

Title: US-10-781-181-5  
Perfect score: 2408  
Sequence: 1 MSCLMVERCGEILFENPDQN.....PDHAGQGTSEBQGDSP 450

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_21.\*

- 1: Geneseq1980s.\*
- 2: Geneseq1990s.\*
- 3: Geneseq2000s.\*
- 4: Geneseq2001s.\*
- 5: Geneseq2002s.\*
- 6: Geneseq2003as.\*
- 7: Geneseq2003bs.\*
- 8: Geneseq2004s.\*
- 9: Geneseq2005s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2408	100.0	450	3	AA93569 Amino aci
2	2408	100.0	450	4	AAU08675 Human pho
3	2408	100.0	450	4	AAU08675 Human typ
4	2401	99.7	450	8	ADP78549 Human pho
5	2258	93.8	502	5	ABO9005 Human pho
6	2258	93.8	502	8	ADJ58904 Human cyc
7	2234	92.8	502	4	AAAB36503 Human lon
8	2219.5	92.2	451	3	AA93575 Amino aci
9	2192	91.0	446	3	AA93567 Amino aci
10	2166	90.0	446	3	AA93574 Amino aci
11	2165.5	89.9	445	3	AA93573 Amino aci
12	2121	88.1	437	3	AA93572 Amino aci
13	1990.5	82.7	413	3	AA93571 Amino aci
14	1865	77.5	391	4	AAU08676 Human pho
15	1801	74.8	335	9	ADY50214 Human PDE
16	1801	74.8	335	9	ADZ46770 Human PDE
17	1430	59.4	268	3	AA93593 Amino aci
18	1430	59.4	288	3	AA93568 Amino aci
19	1425.5	59.2	456	5	AAE24530 Mouse PDE
20	1419.5	58.9	482	5	AAE24531 Human PDE
21	1419.5	58.9	482	8	ADQ40842 Human pho
22	1419.5	58.9	482	8	ADR46207 Human pho
23	1419.5	58.9	482	9	ADY18092 PRO poly
24	1419.5	58.9	498	2	AAW00094 CAMP phos

25	1419.5	58.9	498	2	AA93569	AA93569 standard; protein; 450 AA.
26	1419.5	58.9	498	3	AA93569	AA93569
27	1419.5	58.9	498	8	ADR66097	ADR66097 Human pro
28	1419.5	58.9	498	8	ADR66439	ADR66439 Human pro
29	1418.5	58.9	456	8	ADO21910	ADO21910 Human CAM
30	1418.5	58.9	456	9	ADY18172	ADY18172 PRO poly
31	1410.5	58.6	426	5	AAE24528	AAE24528 Mouse PDE
32	1403.5	58.3	426	5	AAE24527	AAE24527 Human PDE
33	1403.5	58.3	446	5	AAE24532	AAE24532 Human PDE
34	1402.5	58.2	468	8	ABM83120	ABM83120 Human dia
35	1397.5	58.0	426	5	AAE24529	AAE24529 Rat PDE7a
36	1397.5	58.0	426	5	AAE24533	AAE24533 Rat PDE7a
37	1297	53.9	441	8	ABM83121	ABM83121 Human dia
38	1287	53.4	424	5	AAU79727	AAU79727 Human cyc
39	1286	53.4	432	4	AAU16967	AAU16967 Human nov
40	1280	53.2	320	4	AAAB36504	AAAB36504 Human sho
41	1280	53.2	320	8	ADJ58906	ADJ58906 Human cyc
42	1277	53.0	425	8	ABM83119	ABM83119 Human dia
43	1261	52.4	437	8	ABM83118	ABM83118 Human dia
44	1240.5	51.5	359	8	ADR46209	ADR46209 Human pho
45	1239.5	51.5	354	8	ADR46211	ADR46211 Human pho

#### ALIGNMENTS

RESULT 1  
AA93569  
XX ID AA93569 standard; protein; 450 AA.  
XX AC AA93569;  
XX DT 25-SEP-2000 (first entry)  
XX DE Amino acid sequence of a human phosphodiesterase enzyme.  
XX KW Phosphodiesterase; PDE-XIV; human; enzyme.  
XX OS Homo sapiens.  
XX PN EP1018559-A1.  
XX PD 12-JUL-2000.  
XX PF 09-NOV-1999; 99EP-00308902.  
XX PR 23-DEC-1998; 98GB-00028603.  
XX PR 17-SEP-1999; 99GB-00022123.  
XX (PFIZ ) PFIZER LTD.  
XX (PFIZ ) PFIZER INC.  
XX Fidoack M;  
XX WPI; 2000-433274/38.  
XX DR N-PSDB; AAA46651.  
XX PT Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,  
XX useful for preventing diagnosing and treating diseases associated with  
XX inappropriate PDE-XIV expression and/or activity.  
XX Disclosure; Page 45-47; 104pp; English.  
XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The  
XX phosphodiesterase polynucleotide and polypeptide may be used in the  
XX prevention, treatment and diagnosis of diseases associated with  
XX inappropriate PDE-XIV expression. For example, the polynucleotide be  
XX administered to treat diseases by rectifying mutations or deletions in a  
XX patient's genome that affect the activity of PDE-XIV. They may also be  
XX used to study the expression and function of PDE-XIV polypeptides and  
XX their role in metabolism. The PDE-XIV polypeptides may be used as  
XX antigens in the production of antibodies against PDE-XIV and in assays to  
XX identify modulators (agonists and antagonists) of PDE-XIV expression and

CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
 CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
 CC gene and/or expression product may be used in the preparation of a  
 CC composition for the treatment of a disorder associated with inappropriate  
 CC PDE-XIV expression and/or activity and to screen for agents that can  
 CC modulate PDE-XIV expression and/or activity. The anti-PDE-XIV antibodies  
 CC may also be used as diagnostic agents for detecting the presence of PDE-  
 CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbent assay  
 CC (ELISA))  
 CC  
 XX  
 SQ Sequence 450 AA;

Query Match 100.0%; Score 2408; DB 3; Length 450;  
 Best Local Similarity 100.0%; Pred. No. 1.6e-226;  
 Matches 450; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVRARRGSGYPFIDFRLNLTYS 60  
 Db 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVRARRGSGYPFIDFRLNLTYS 60

Qy 61 GEIGTKKKVKRLLSFQRYFHASRLLRGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIF 120  
 Db 61 GEIGTKKKVKRLLSFQRYFHASRLLRGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIF 120

Qy 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180  
 Db 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180

Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDPHGVPVGNQPLIKTNHHLANLYQMS 240  
 Db 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDPHGVPVGNQPLIKTNHHLANLYQMS 240

Qy 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLILATDINRQNEFLTRKKAHLN 300  
 Db 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLILATDINRQNEFLTRKKAHLN 300

Qy 301 KDLRLDAQDRHFMQLKALCADICNPCRIMWMSKOWSERVCEEFYRQGELEKFELEIS 360  
 Db 301 KDLRLDAQDRHFMQLKALCADICNPCRIMWMSKOWSERVCEEFYRQGELEKFELEIS 360

Qy 361 PLCNQKQDSIPSIQIGFMSYIPEPLFREWAFHTGNSLTSENMLGHLAHNAQWKSLLPRQ 420  
 Db 361 PLCNQKQDSIPSIQIGFMSYIPEPLFREWAFHTGNSLTSENMLGHLAHNAQWKSLLPRQ 420

Qy 421 HRSRSGSGGPDHHDHAGQGTSEBEQGDSP 450  
 Db 421 HRSRSGSGGPDHHDHAGQGTSEBEQGDSP 450

RESULT 2  
 AAU08675  
 ID AAU08675 standard; protein; 450 AA.  
 XX AAU08675;  
 AC  
 XX  
 XX 18-DEC-2001 (first entry)  
 DE Human phosphodiesterase type 7B #1.  
 XX  
 XX Human; phosphodiesterase type 7B; cardiovascular disease; asthma;  
 KW allergy; inflammatory disease; immune-related disorder; cardiovascular;  
 KW antiaesthetic; antiallergic; immunosuppressive; antiinflammatory.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200162940-A2.  
 XX  
 XX 30-AUG-2001.  
 XX  
 XX 20-FEB-2001; 2001WO-EP001858.  
 XX  
 XX 21-FEB-2000; 2000EP-00103655.  
 PR  
 XX

(MERE ) MERCK PATENT GMBH.

Kluxen F, Hentech B;

WFI; 2001-570636/64.

N-PSDB; AAS13248.

Phosphodiesterase 7B proteins and nucleic acids, useful for preventing,  
 diagnosing and treating, e.g. asthma, inflammation and allergies.

Claim 1; Page 36-37; 40pp; English.

XX The invention relates to a novel human Phosphodiesterase type 7B  
 CC polypeptide and the nucleic acid that encodes it. The protein and nucleic  
 CC acid may be used in the prevention, diagnosis and treatment of diseases  
 CC associated with inappropriate phosphodiesterase 7B (P7B) expression. For  
 CC example, The protein and nucleic acid may be used to treat disorders  
 CC associated with decreased expression by rectifying mutations or deletions  
 CC in a patient's genome that affect the activity of P7B by expressing  
 CC inactive proteins or to supplement the patients own production of P7B.  
 CC The nucleic acids may be used to produce P7B polypeptides, by inserting  
 CC the nucleic acids into a host cell and culturing the cell to express the  
 CC protein. The nucleic acid and its complements may also be used as DNA  
 CC probes in diagnostic assays to detect and quantitate the presence of  
 CC similar nucleic acids in samples, and therefore which patients may be in  
 CC need of restorative therapy. The P7B polypeptides may also be used as  
 CC antigens in the production of antibodies against P7B and in assays to  
 CC identify modulators of its expression and activity. The anti-P7B  
 CC antibodies and antagonists may also be used to down regulate expression  
 CC and activity. The anti-P7B antibodies may also be used as diagnostic  
 CC agents for detecting the presence of P7B in samples (e.g. by enzyme  
 CC linked immunosorbent assay (ELISA)). Disorders that may be prevented,  
 CC diagnosed and/or treated by the above methods include, for example  
 CC cardiovascular disease, asthma, allergy, inflammation, and immune-related  
 CC disorders. The present sequence represents a human phosphodiesterase 7B  
 XX

SQ Sequence 450 AA;

Query Match 100.0%; Score 2408; DB 4; Length 450;  
 Best Local Similarity 100.0%; Pred. No. 1.6e-226;  
 Matches 450; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVRARRGSGYPFIDFRLNLTYS 60  
 Db 1 MSCLMVERCGEILFENPDQNAKVCMLGDIRLQGTGVRARRGSGYPFIDFRLNLTYS 60

Qy 61 GEIGTKKKVKRLLSFQRYFHASRLLRGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIF 120  
 Db 61 GEIGTKKKVKRLLSFQRYFHASRLLRGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIF 120

Qy 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180  
 Db 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAAD 180

Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDPHGVPVGNQPLIKTNHHLANLYQMS 240  
 Db 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDPHGVPVGNQPLIKTNHHLANLYQMS 240

Qy 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLILATDINRQNEFLTRKKAHLN 300  
 Db 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLILATDINRQNEFLTRKKAHLN 300

Qy 301 KDLRLDAQDRHFMQLKALCADICNPCRIMWMSKOWSERVCEEFYRQGELEKFELEIS 360  
 Db 301 KDLRLDAQDRHFMQLKALCADICNPCRIMWMSKOWSERVCEEFYRQGELEKFELEIS 360

Qy 361 PLCNQKQDSIPSIQIGFMSYIPEPLFREWAFHTGNSLTSENMLGHLAHNAQWKSLLPRQ 420  
 Db 361 PLCNQKQDSIPSIQIGFMSYIPEPLFREWAFHTGNSLTSENMLGHLAHNAQWKSLLPRQ 420

Qy 421 HRSRSGSGGPDHHDHAGQGTSEBEQGDSP 450  
 Db 421 HRSRSGSGGPDHHDHAGQGTSEBEQGDSP 450

RESULT 3  
AAG78915  
ID AAG78915 standard; protein; 450 AA.  
AC AAG78915;  
XX  
DT 19-DEC-2001 (first entry)  
XX  
DE Human type 7B phosphodiesterase, PDE7B.  
XX  
KW Human; type 7B phosphodiesterase; PDE7B; enzyme.  
XX  
OS Homo sapiens.  
XX  
FN JP2001238680-A.  
XX  
XX  
PD 04-SEP-2001.  
XX  
XX 03-MAR-2000; 2000JP-00058159.  
XX  
XX 03-MAR-2000; 2000JP-00058159.  
XX  
XX (TANA ) TANABE SEIYAKU CO.  
XX  
XX WPI; 2001-610057/70.  
XX  
XX N-PSDB; AAI70009.  
XX  
XX New phosphodiesterase for use in the development of inhibitors of high  
PT selectivity and drugs of low side effect.  
XX  
XX Claim 2; Page 12-14; 18pp; Japanese.  
XX  
XX The present sequence is the protein sequence for human type 7B  
CC phosphodiesterase (PDE7B). The enzyme PDE7B can be used in the  
CC development of inhibitors of high selectivity and drugs of low side  
CC effects  
XX  
SQ Sequence 450 AA;  
Query Match 100.0%; Score 2408; DB 4; Length 450;  
Best Local Similarity 100.0%; Pred. No. 1.6e-226;  
Matches 450; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MSCLMVERCCEILLFENPDONAKVCMLGDIIRLQGTGVRAERRSYFPIDPRLNSTTYS 60  
Db 1 MSCLMVERCCEILLFENPDONAKVCMLGDIIRLQGTGVRAERRSYFPIDPRLNSTTYS 60  
Qy 61 GEIGTKKKVKLLSFQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSKVGWMDIF 120  
Db 61 GEIGTKKKVKLLSFQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSKVGWMDIF 120  
Qy 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVAAD 180  
Db 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVAAD 180  
Qy 181 VTQAMHCYLPKPKLASFLTPDIDMLGLLAAAHVDHGVNQPLIKTNHHLANLYQMS 240  
Db 181 VTQAMHCYLPKPKLASFLTPDIDMLGLLAAAHVDHGVNQPLIKTNHHLANLYQMS 240  
Qy 241 VLENHWRSTIGMLRESLLAHLKEMTDIEQQLSILATDINRQNEFTRLKAHLN 300  
Db 241 VLENHWRSTIGMLRESLLAHLKEMTDIEQQLSILATDINRQNEFTRLKAHLN 300  
Qy 301 KDLRLDAQDRHFMQLKALCADICNPRIWEMSKQSERVCBFFYRQGELEQKFELEIS 360  
Db 301 KDLRLDAQDRHFMQLKALCADICNPRIWEMSKQSERVCBFFYRQGELEQKFELEIS 360  
Qy 361 PLCNQOKDSIPSIOIGFMSYIPEPLFREWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQ 420  
Db 361 PLCNQOKDSIPSIOIGFMSYIPEPLFREWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQ 420

421 HRSRSGSGPDHHDHAGQGTESEBEQGDSP 450  
421 HRSRSGSGPDHHDHAGQGTESEBEQGDSP 450  
RESULT 4  
ADP79549  
ID ADP79549 standard; protein; 450 AA.  
XX  
AC ADP79549;  
XX  
DT 04-NOV-2004 (first entry)  
XX  
DE Human phosphodiesterase 7B nucleotide sequence.  
XX  
KW Human; phosphodiesterase 7B; PDE7b; cardiovascular-gen.; CNS-Gen.;  
XX gynaecological; haemostatic; respiratory-Gen.; cytostatic; gene therapy;  
XX enzyme.  
XX  
OS Homo sapiens.  
XX  
XX WO2004044196-A1.  
XX  
XX 27-MAY-2004.  
XX  
XX 05-NOV-2003; 2003WO-EP012342.  
XX  
XX 13-NOV-2002; 2002EP-00025502.  
XX  
XX (PARB ) BAYER HEALTHCARE AG.  
XX  
XX Golz S, Brueggemeier U, Summer H;  
XX  
XX WPI; 2004-440631/41.  
XX  
XX N-PSDB; ADP79548.  
XX  
XX Screening for therapeutic agents, useful in treating cardiovascular,  
PT reproduction, urological, hematological, respiratory system or cancer  
PT diseases, comprises contacting a test compound with a phosphodiesterase  
PT 7b.  
XX  
XX Disclosure; SEQ ID NO 2; 128pp; English.  
XX  
XX The present sequence is that of human phosphodiesterase 7b (PDE7b), an  
CC enzyme regulating intracellular levels of cAMP and cGMP. The invention  
CC relates to novel disease associations of PDE7b polynucleotides and  
CC polypeptides. It also relates to novel methods of screening for  
CC therapeutic agents for the treatment of cardiovascular diseases,  
CC disorders of the peripheral and central nervous system, reproduction  
CC diseases, urological diseases, hematological diseases, disorders of the  
CC respiratory system and cancer. PDE7b polynucleotides, polypeptides and  
CC regulators or modulators of PDE7b activity (e.g. an RNA molecule,  
CC antisense oligonucleotide, polypeptide, antibody or ribozyme) can be used  
CC in the treatment or diagnosis of these diseases and disorders.  
XX  
SQ Sequence 450 AA;  
Query Match 99.7%; Score 2401; DB 8; Length 450;  
Best Local Similarity 99.8%; Pred. No. 7.6e-226;  
Matches 449; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1 MSCLMVERCCEILLFENPDONAKVCMLGDIIRLQGTGVRAERRSYFPIDPRLNSTTYS 60  
Db 1 MSCLMVERCCEILLFENPDONAKVCMLGDIIRLQGTGVRAERRSYFPIDPRLNSTTYS 60  
Qy 61 GEIGTKKKVKLLSFQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSKVGWMDIF 120  
Db 61 GEIGTKKKVKLLSFQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSKVGWMDIF 120  
Qy 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVAAD 180  
Db 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVAAD 180

Qy 181 VTQAMHCYLKEPKLASFLTPDLIMLGLLAAAHVDHPGVNQPFLLIKTNHHLANLYQNMS 240  
 Db 181 VTQAMHCYLKEPKLASFLTPDLIMLGLLAAAHVDHPGVNQPFLLIKTNHHLANLYQNMS 240  
 Qy 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLIATDINRQNEFLTRKAHLHN 300  
 Db 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLIATDINRQNEFLTRKAHLHN 300  
 Qy 301 KDLRLDAQDRHFMQLTALKACADICNCRLEWMSKQSERVCEEFYRQGELEOKFELEIS 360  
 Db 301 KDLRLDAQDRHFMQLTALKACADICNCRLEWMSKQSERVCEEFYRQGELEOKFELEIS 360  
 Qy 361 PLCNQKQKDSIPSIQIGFMSYIVPELFWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQ 420  
 Db 361 PLCNQKQKDSIPSIQIGFMSYIVPELFWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQ 420  
 Qy 421 HRSRSGSGGPDHAGQGTESEBQEGDSP 450  
 Db 421 HRSRSGSGGPDHAGQGTESEBQEGDSP 450

## RESULT 5

ABB09005  
 ID ABB09005 standard; protein; 502 AA.

XX AC ABB09005;

XX DT 23-MAY-2002 (first entry)

XX DE Human phosphodiesterase-1.

XX KW HPDE; human phosphodiesterase; cyclic nucleotide phosphodiesterase;  
 antiinflammatory; neuroprotective; cytostatic; antianaemic;  
 immunosuppressive; HIV; cardiovascular disorder; mental disorder;  
 gene therapy; transgene; enzyme.

XX OS Homo sapiens.

XX PN WO2001198471-A2.

XX PD 27-DEC-2001.

XX PF 21-JUN-2001; 2001WO-US020140.

XX PR 22-JUN-2000; 2000US-0213741P.

XX PR 14-JUL-2000; 2000US-0218234P.

XX PR 16-OCT-2000; 2000US-0241100P.

XX PA (INCY-) INCYTE GENOMICS INC.

XX PI Thornton M, Ding L, Patterson C, Yao MG, Tribouley CM, Lal P;

XX PI Hafalia AJA, Baughn MR, Ramkumar J, Lu Y, Walia NK;

XX DR WPI; 2002-147799/19.

XX DR N-PSDB; ABA99136.

XX PT Novel human phosphodiesterase polypeptides and polynucleotides for  
 diagnosing, preventing and treating eye, neurological, cardiovascular,  
 cell proliferative and autoimmune/inflammatory disorders.

XX PS Claim 1; Page 97-98; 105pp; English.

XX CC This invention relates to isolated human phosphodiesterase polypeptides  
 (HPDE 1-4), which are antiinflammatory, neuroprotective, cytostatic,  
 antianaemic, immunosuppressive and anti-HIV in their action. The  
 polypeptides are useful for screening a compound for effectiveness as an  
 agonist or antagonist of the protein. The identified agonist, antagonist  
 and protein are useful for treating a disease or condition associated  
 with decreased or overexpression of functional HPDE in a patient. The  
 proteins are useful in preparing polyclonal or monoclonal antibodies by  
 hybridoma technology. They are also useful in the treatment and  
 prevention of eye, neurological, cardiovascular, cell proliferative and  
 autoimmune and inflammatory disorders, metabolic disorders and mental

CC disorders. The polynucleotides are useful for creating humanised animals  
 or transgenic animals to model human disease and to detect and quantify  
 gene expression in biopsied tissues in which expression of HPDE is  
 correlated with disease. HPDE, its fragments and antibodies specific for  
 HPDE are useful as elements on a microarray which is useful to monitor or  
 measure protein-protein interactions, drug-target interactions and gene  
 expression profiles. This sequence represents HPDE-1

XX SQ Sequence 502 AA;

Query Match 93.8%; Score 2258; DB 5; Length 502;  
 Best Local Similarity 100.0%; Pred. No. 9e-212;  
 Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDRLRGQGTGVRARERGSYPFDIFRLNSTTYSGEIGTKKKVRLLSFQRYFHASRLRG 87  
 Db 80 GDRLRGQGTGVRARERGSYPFDIFRLNSTTYSGEIGTKKKVRLLSFQRYFHASRLRG 139  
 Qy 88 IIPQAPLHLLDELYLQGARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147  
 Db 140 IIPQAPLHLLDELYLQGARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199  
 Qy 148 FKLDVMTLHRLVMQEDYHSQNPYHNAVAADVTOAMHCYLKEPKLASFLTPDLIMLGL 207  
 Db 200 FKLDVMTLHRLVMQEDYHSQNPYHNAVAADVTOAMHCYLKEPKLASFLTPDLIMLGL 259  
 Qy 208 LAAAHADVDPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 267  
 Db 260 LAAAHADVDPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 319  
 Qy 268 TDIEQQLGSLIATDINRQNEFLTRKAHLHNKDLREDAQDRHFMQLTALKACADICNP 327  
 Db 320 TDIEQQLGSLIATDINRQNEFLTRKAHLHNKDLREDAQDRHFMQLTALKACADICNP 379  
 Qy 328 CRIWMSKQSERVCEEFYRQGELEOKFELEISPLCNQKQKDSIPSIQIGFMSYIVPELFR 387  
 Db 380 CRIWMSKQSERVCEEFYRQGELEOKFELEISPLCNQKQKDSIPSIQIGFMSYIVPELFR 439  
 Qy 388 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPROHRSRSGSGGPDHAGQGTESEBQEG 447  
 Db 440 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPROHRSRSGSGGPDHAGQGTESEBQEG 499  
 Qy 448 DSP 450  
 Db 500 DSP 502

## RESULT 6

ADJ58904

ID ADJ58904 standard; protein; 502 AA.

XX AC ADJ58904;

XX DT 06-MAY-2004 (first entry)

XX DE Human cyclic nucleotide phosphodiesterase protein #1.

XX KW 27875; 22025; 27420; 17906; 16319; 55092; 10218; cancer;

XX KW cellular proliferation; cellular differentiation; immune disorder;

XX KW cardiovascular disorder; endothelial cell disorder;

XX KW haematopoietic disorder; blood vessel disorder; brain disorder; pain;

XX KW metabolic disorder; liver disorder; platelet disorder; gene therapy;

XX KW human; cyclic; enzyme.

XX OS Homo sapiens.

XX PN US2004006016-A1.

XX PD 08-JAN-2004.

XX PF 11-MAR-2003; 2003US-00386414.

XX PR 11-JUN-1999; 99US-00330970.

```
PR 25-OCT-1999; 99US-00426282.
PR 16-MAY-2000; 2000US-00571589.
PR 22-SEP-2000; 2000US-00668266.
PR 28-NOV-2000; 2000US-00724599.
PR 07-DEC-2000; 2000US-0254037P.
PR 10-APR-2001; 2001US-00833082.
PR 16-MAY-2001; 2001US-00860193.
PR 31-OCT-2001; 2001US-0335044P.
PR 08-DEC-2001; 2001US-00010943.
PR 29-OCT-2002; 2002US-00283023.
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX
XX Kapeller-Libermann R, White D, Robison KE, Macbeth KJ, Carroll JM;
PI Cook WJ, Meyers RE, Chun M, Williamson MJ;
XX
XX WPI; 2004-081738/08.
XX N-PSDB; ADJ58903.
XX
XX New isolated 27875, 22025, 27420, 17906, 16319, 55092, or 10218 nucleic
PT acid molecules, useful for diagnosing or treating cancer, pain, or
PT immune, endothelial cell, hematopoietic, blood vessel, brain, metabolic
PT and liver disorders.
XX
XX Claim 4; SEQ ID NO 4; 245pp; English.
XX
XX The present invention relates to an isolated 27875, 22025, 27420, 17906,
CC 16319, 55092, or 10218 nucleic acid molecule. The invention is useful for
CC diagnosing or treating cancer or aberrant cellular proliferation and/or
CC differentiation, immune disorders, heart disorders, cardiovascular
CC disorders including endothelial cell disorders, hematopoietic disorders,
CC blood vessel disorders, brain disorders, pain and metabolic disorders,
CC liver disorders and platelet disorders. The invention is also useful in
CC gene therapy. The present sequence is human cyclic nucleotide
CC phosphodiesterase.
XX
XX Sequence 502 AA;
SQ
Query Match 93.8%; Score 2258; DB 8; Length 502;
Best Local Similarity 100.0%; Pred. No. 9e-212;
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 28 GDIRLGGTGVRAERGSYPFDRLNLSNYYSGEIGTKKKVRLLSFQRYFHASRLRG 87
DB 80 GDIRLGGTGVRAERGSYPFDRLNLSNYYSGEIGTKKKVRLLSFQRYFHASRLRG 139
QY 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147
DB 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199
QY 148 FKLDWVTLHRLFLVMQEDYHSQNPYHNAVHAADVTOAMHCYLKEPKLASFLTPDLMGL 207
DB 200 FKLDWVTLHRLFLVMQEDYHSQNPYHNAVHAADVTOAMHCYLKEPKLASFLTPDLMGL 259
QY 208 LAAAHVDVHPGVNQPLIKTNHHLANLYQMSVLENHNRSTIGMLRESRLLAHLPKEM 267
DB 260 LAAAHVDVHPGVNQPLIKTNHHLANLYQMSVLENHNRSTIGMLRESRLLAHLPKEM 319
QY 268 TDIEQOGLSLIATDINRQNEFLTRKAHLNKOILFLEDAQDRHFMLOIALKACDINP 327
DB 320 TDIEQOGLSLIATDINRQNEFLTRKAHLNKOILFLEDAQDRHFMLOIALKACDINP 379
QY 328 CRIWENSKQNSRVECFYRQGELEQKFELEISPLCNQKQKDSIPSQIGFMSVIVBPLFR 387
DB 380 CRIWENSKQNSRVECFYRQGELEQKFELEISPLCNQKQKDSIPSQIGFMSVIVBPLFR 439
QY 388 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPROHRSRGSGSGPDHHDHAGQGTSEBEQG 447
DB 440 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPROHRSRGSGSGPDHHDHAGQGTSEBEQG 499
QY 448 DSP 450
DB 500 DSP 502
```

## RESULT 7

AAB36503  
ID AAB36503 standard; protein; 502 AA.

XX AAB36503;

XX 06-MAR-2001 (first entry)

XX Human long phosphodiesterase protein SEQ ID NO:1.

XX Human; long phosphodiesterase; short phosphodiesterase; diagnosis;  
KW cyclic nucleotide phosphodiesterase; nootropic; cardiac; hypotensive;  
KW nephrotropic; antidepressant; antiinflammatory; immunosuppressive;  
KW antiinfertility; antiaesthetic; vasotropic; gene therapy; dementia;  
KW amnesia; congestive heart failure; thrombosis; pulmonary hypertension;  
KW glomerulonephritis; bipolar depression; bronchial asthma; salt retention;  
KW atopic disease; autoimmune encephalomyelitis; organ transplantation;  
KW nephrotic syndrome; erectile dysfunction.

XX Homo sapiens.

XX US6146876-A.

XX 14-NOV-2000.

XX 11-JUN-1999; 99US-00330970.

XX 26-MAR-1999; 99US-00277423.

XX (MILL-) MILLENNIUM PHARM INC.

XX Kapeller-Libermann R, White D, Robison KE;

XX WPI; 2001-0233577/03.

XX N-PSDB; AAC87948.

XX Polynucleotide encoding novel cyclic nucleotide phosphodiesterase useful  
PT for treating disorders related with to protein e.g. dementia,  
PT hypertension, glomerulonephritis, and organ transplantation.

XX Claim 3; Fig 1; 42pp; English.

XX The present sequence represents the human long phosphodiesterase which is  
CC a cyclic nucleotide phosphodiesterase (I). (I) can have nootropic,  
CC cardiac, hypotensive, nephrotropic, antidepressant, antiinflammatory,  
CC immunosuppressive, antiinfertility, antiaesthetic and vasotropic  
CC activities, and can be used in gene therapy. (I) can be used for treating  
CC various disorders associated or mediated by (I), such as dementia,  
CC amnesia, congestive heart failure, thrombosis, pulmonary hypertension,  
CC glomerulonephritis, bipolar depression, bronchial asthma, atopic  
CC diseases, autoimmune encephalomyelitis, organ transplantation, salt  
CC retention in nephrotic syndrome and erectile dysfunction

XX Sequence 502 AA;

Query Match 92.8%; Score 2234; DB 4; Length 502;

Best Local Similarity 99.1%; Pred. No. 2e-209;

Matches 419; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 28 GDIRLGGTGVRAERGSYPFDRLNLSNYYSGEIGTKKKVRLLSFQRYFHASRLRG 87

DB 80 GDIRLGGTGVRAERGSYPFDRLNLSNYYSGEIGTKKKVRLLSFQRYFHASRLRG 139

QY 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147

DB 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199

QY 148 FKLDWVTLHRLFLVMQEDYHSQNPYHNAVHAADVTOAMHCYLKEPKLASFLTPDLMGL 207

DB 200 FKLDWVTLHRLFLVMQEDYHSQNPYHNAVHAADVTOAMHCYLKEPKLASFLTPDLMGL 259

```
Qy 208 LAAAHVDVHGVNQPFILKTNHHLANLYQNMVLENNHWRSTTIGMLRESRLLAHLPKEM 267
Db 260 LAAAHVDVHGVNQPFILKTNHHLGALYQNMVLENNHWRSTTIGMLRESRLLAHLPKEM 319
Qy 268 TQDIEQQLGSLILATDINRQNEFLTRLKAHLHNKDLRLDAQDRHFMQLQALKADICNP 327
Db 320 TQDIEQQLGSLILATDINRQNEFLTRLKAHLHNKDLRLDAQDRHFMQLQALKADICNP 379
Qy 328 CRIWEMSKQSERVCEBFYRGELEQKFELEISPLCNQKXDSIPSIQIGFMSYIVPELFR 387
Db 380 CRIWEMSKQSERVCEBFYRGELEQKFELEISPLCNQKXDSIPSIQIGFMSYIVPELFR 439
Qy 388 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPLQHRHRSRSGSGSDPDHAGOGTSEBQEG 447
Db 440 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPLQHRHRSRSGSGSDPDHAGOGTSEBQEG 499
Qy 448 DSP 450
Db 500 DSP 502

RESULT 8
AA93575
ID AA93575 standard; protein; 451 AA.
XX
AC AA93575;
XX
DT 25-SEP-2000 (first entry)
XX
DE Amino acid sequence of a phosphodiesterase enzyme.
XX
KW Phosphodiesterase; PDE-XIV; enzyme.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 12
FT Misc-difference 16 /label= Val, Ile
FT Misc-difference 16 /label= Ser, Asn
FT Misc-difference 18 /label= Glu, Asp
FT Misc-difference 20 /label= Ser, Val, Asn, Ala
FT Misc-difference 21 /label= Ser, Val, Asn, Ala
FT Misc-difference 30 /label= Val, Ile
FT Misc-difference 39 /label= Pro, Arg
FT Misc-difference 56 /label= Asn, Ser
FT Misc-difference 59 /label= His, Tyr
FT Misc-difference 114 /label= Thr, Met
FT Misc-difference 141 /label= Ser, Thr
FT Misc-difference 168 /label= Gly, His, Ser, Gln
FT Misc-difference 169 /label= Gly, His, Ser, Gln
FT Misc-difference 307 /label= Asp, Ala, Asn, Val
FT Misc-difference 308 /label= Asp, Ala, Asn, Val
FT Misc-difference 350 /label= Glu, Asp
FT Misc-difference 379 /label= Ser, Thr
FT Misc-difference 391 /label= His, Arg
FT Misc-difference 404
```

```
FT Misc-difference 418 /label= Gly, Ser
FT Misc-difference 419 /label= Pro, Arg, Ser, Asn
FT Misc-difference 423 /label= Pro, Arg, Ser, Asn
FT Misc-difference 435 /label= Ser, Arg
FT Misc-difference 438 /label= His, Leu
FT Misc-difference 440 /note= "these residues are either Gln-Gly-Pro or Pro-Ala-Pro"
FT Misc-difference 442 /note= "these residues are either Ser-Glu or Thr-Leu"
FT Misc-difference 446 /note= "optionally absent"
FT Misc-difference 449 /note= "these residues are either Asp-Ser or Ala-Thr"
XX EP1018559-A1.
XX 12-JUL-2000.
XX 09-NOV-1999; 99BP-00308902.
XX 23-DEC-1998; 98GB-00028603.
XX 17-SEP-1999; 99GB-00022123.
XX (PFIZ ) PFIZER LTD.
XX (PFIZ ) PFIZER INC.
XX Fidoack M;
XX WPI; 2000-433274/38.
XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes, useful for preventing diagnosing and treating diseases associated with inappropriate PDE-XIV expression and/or activity.
XX Disclosure; Page 75-78; 104pp; English.
XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The enzyme sequence is derived from a formula of the invention. The phosphodiesterase polynucleotide and polypeptide may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate PDE-XIV expression. For example, the polynucleotide be administered to treat diseases by rectifying mutations or deletions in a patient's genome that affect the activity of PDE-XIV. They may also be used to study the expression and function of PDE-XIV polypeptides and their role in metabolism. The PDE-XIV polypeptides may be used as antigens in the production of antibodies against PDE-XIV and in assays to identify modulators (agonists and antagonists) of PDE-XIV expression and activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV gene and/or expression product may be used in the preparation of a composition for the treatment of a disorder associated with inappropriate PDE-XIV expression and/or activity and to screen for agents that can modulate PDE-XIV expression and/or activity. The anti-PDE-XIV antibodies may also be used as diagnostic agents for detecting the presence of PDE-XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay (ELISA))
XX Sequence 451 AA;
SQ
```

```
Query Match 92.2%; Score 2219.5; DB 3; Length 451;
Best Local Similarity 93.1%; Pred. No. 4.6e-208;
Matches 420; Conservative 0; Mismatches 30; Indels 1; Gaps 1;
Qy 1 MSCLMVRCGEITLFPENPDONAKVCVCMIGDIRLGRGQTVGAERGSYPFFIDFRLNNTTYS 60
Db 1 MSCLMVRCGEITLFPENPDONAKVCVCMIGDIRLGRGQTVGAERGSYPFFIDFRLNNTTYS 60
Qy 61 GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPLHLLDELYLQOARHMLSKVGMWDFDIF 120
```

61 GEIGTKKKVRLLSFQRYFHASRLLRGIIPQAPLHLLDELYLQARHMLSKVGWDFDIF 120  
 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAHAAD 180  
 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAHAAD 180  
 181 VTOAMHCYLKPEKPLASFLTPDLMGLLAAAHVDHHPGVNQPFLIKTNHHLANLYQNS 240  
 181 VTOAMHCYLKPEKPLASFLTPDLMGLLAAAHVDHHPGVNQPFLIKTNHHLANLYQNS 240  
 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLILATDINRQNEFLTRKLAHLN 300  
 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLILATDINRQNEFLTRKLAHLN 300  
 301 KDLRLDAQDRHFLMQLKALCADI CNPCRIWEMSKQMSERVCBEFYRQGELEKFELEIS 360  
 301 KDLRLDAQDRHFLMQLKALCADI CNPCRIWEMSKQMSERVCBEFYRQGELEKFELEIS 360  
 361 PLCNQKQDSIPSIQIGFMSYIVPELFRWAHFTGNSTLSENMLGHLAHNKAQWKSLLPRQ 420  
 361 PLCNQKQDSIPSIQIGFMSYIVPELFRWAHFTGNSTLSENMLGHLAHNKAQWKSLLXXQ 420  
 421 HRSRSGSGGPDHHDHAGQGTSEBQ-EGDSP 450  
 421 HRSRSGSGGPDHHDHAGQGTSEBQ-EGDSP 451

## RESULT 9

AAY93567  
 ID AAY93567 standard; protein; 446 AA.  
 AC AAY93567;

25-SEP-2000 (first entry)  
 DE Amino acid sequence of a murine phosphodiesterase enzyme.

XX Phosphodiesterase; PDE-XIV; murine; enzyme.  
 XX Mus sp.

XX EPI018559-A1.  
 XX 12-JUL-2000.

XX 09-NOV-1999; 99EP-00308902.  
 XX 23-DEC-1998; 98GB-00028603.

XX 17-SEP-1999; 99GB-00022123.  
 XX (PFIZ ) PFIZER LTD.

XX (PFIZ ) PFIZER INC.  
 XX Fido M;

XX WPI; 2000-433274/38.  
 XX N-PSDB; AAA46649.

XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,  
 XX useful for preventing diagnosing and treating diseases associated with  
 XX inappropriate PDE-XIV expression and/or activity.

XX Disclosure; Page 39-41; 104pp; English.

CC The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The  
 CC phosphodiesterase polynucleotide and polypeptide may be used in the  
 CC prevention, treatment and diagnosis of diseases associated with  
 CC inappropriate PDE-XIV expression. For example, the polynucleotide be  
 CC administered to treat diseases by rectifying mutations or deletions in a  
 CC patient's genome that affect the activity of PDE-XIV. They may also be  
 CC used to study the expression and function of PDE-XIV polypeptides and  
 CC their role in metabolism. The PDE-XIV polypeptides may be used as

CC antigens in the production of antibodies against PDE-XIV and in assays to  
 CC identify modulators (agonists and antagonists) of PDE-XIV expression and  
 CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
 CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
 CC gene and/or expression product may be used in the preparation of a  
 CC composition for the treatment of a disorder associated with inappropriate  
 CC PDE-XIV expression and/or activity and to screen for agents that can  
 CC modulate PDE-XIV expression and or activity. The anti-PDE-XIV antibodies  
 CC may also be used as diagnostic agents for detecting the presence of PDE-  
 CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay  
 CC (ELISA))  
 XX  
 SQ Sequence 446 AA;

Query Match 91.0%; Score 2192; DB 3; Length 446;  
 Best Local Similarity 91.6%; Pred. No. 2.2e-205;

Matches 413; Conservative 13; Mismatches 19; Indels 6; Gaps 2;

QY 1 MSCLMVERCCEILFENPDQNAKVCVCMGLDRLRGQTGVRAERRGSYPFIDPRLNLTYS 60  
 DB 1 MSCLMVERCCEVLFESPEQSVCVCMGLDRLRGQTGVPAERRGSYPFIDPRLNLTYS 60  
 QY 61 GEIGTKKKVRLLSFQRYFHASRLLRGIIPQAPLHLLDELYLQARHMLSKVGWDFDIF 120  
 DB 61 GEIGTKKKVRLLSFQRYFHASRLLRGIIPQAPLHLLDELYLQARHMLSKVGWDFDIF 120  
 QY 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAHAAD 180  
 DB 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAHAAD 180  
 QY 181 VTOAMHCYLKPEKPLASFLTPDLMGLLAAAHVDHHPGVNQPFLIKTNHHLANLYQNS 240  
 DB 181 VTOAMHCYLKPEKPLASFLTPDLMGLLAAAHVDHHPGVNQPFLIKTNHHLANLYQNS 240  
 QY 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLILATDINRQNEFLTRKLAHLN 300  
 DB 241 VLENHWRSTIGMLRESRLLAHLPKEMTDIEQQLGSLILATDINRQNEFLTRKLAHLN 300  
 QY 301 KDLRLDAQDRHFLMQLKALCADI CNPCRIWEMSKQMSERVCBEFYRQGELEKFELEIS 360  
 DB 301 KDLRLDAQDRHFLMQLKALCADI CNPCRIWEMSKQMSERVCBEFYRQGELEKFELEIS 360  
 QY 361 PLCNQKQDSIPSIQIGFMSYIVPELFRWAHFTGNSTLSENMLGHLAHNKAQWKSLLPRQ 420  
 DB 361 PLCNQKQDSIPSIQIGFMSYIVPELFRWAHFTGNSTLSENMLGHLAHNKAQWKSLLSNQ 420  
 QY 421 HRSRSGSGGPDHHDHAGQGTSEBQ-EGDSP 450  
 DB 421 HRSRSGSGGPDHHDHAGQGTSEBQ-EGDSP 451

## RESULT 10

AAY93574  
 ID AAY93574 standard; protein; 446 AA.  
 AC AAY93574;

25-SEP-2000 (first entry)  
 DE Amino acid sequence of a phosphodiesterase enzyme.

XX Phosphodiesterase; PDE-XIV; enzyme.  
 XX Synthetic.

XX Key : Location/Qualifiers  
 FT Misc-difference 12 /label= Val, Ile  
 FT Misc-difference 16 /label= Ser, Asn  
 FT Misc-difference 18 /label= Glu, Asp  
 FT Misc-difference 20

FT /label= Ser, Val, Asn, Ala  
 FT Misc-difference 21  
 FT /label= Ser, Val, Asn, Ala  
 FT Misc-difference 30  
 FT /label= Val, Ile  
 FT Misc-difference 39  
 FT /label= Pro, Arg  
 FT Misc-difference 56  
 FT /label= Asn, Ser  
 FT Misc-difference 59  
 FT /label= His, Tyr  
 FT Misc-difference 114  
 FT /label= Thr, Met  
 FT Misc-difference 141  
 FT /label= Ser, Thr  
 FT Misc-difference 168  
 FT /label= Gly, His, Ser, Gln  
 FT Misc-difference 169  
 FT /label= Gly, His, Ser, Gln  
 FT Misc-difference 307  
 FT /label= Asp, Ala, Asn, Val  
 FT Misc-difference 308  
 FT /label= Asp, Ala, Asn, Val  
 FT Misc-difference 350  
 FT /label= Glu, Asp  
 FT Misc-difference 379  
 FT /label= Ser, Thr  
 FT Misc-difference 391  
 FT /label= His, Arg  
 FT Misc-difference 404  
 FT /label= Gly, Ser  
 FT Misc-difference 418  
 FT /label= Pro, Arg, Ser, Asn  
 FT Misc-difference 419  
 FT /label= Pro, Arg, Ser, Asn  
 FT Misc-difference 423  
 FT /label= Ser, Arg  
 FT Misc-difference 430  
 FT /label= His, Leu  
 FT Misc-difference 433  
 FT /label= Gln, Gly, Thr, Pro, Ala  
 FT Misc-difference 434  
 FT /label= Gln, Gly, Thr, Pro, Ala  
 FT Misc-difference 435  
 FT /label= Gln, Gly, Thr, Pro, Ala  
 FT Misc-difference 437  
 FT /label= Ser, Glu, Thr, Leu  
 FT Misc-difference 438  
 FT /label= Ser, Glu, Thr, Leu  
 FT Misc-difference 441  
 FT /note= "optionally absent"  
 FT Misc-difference 444  
 FT /label= Asp, Ser, Ala, Thr  
 FT Misc-difference 445  
 FT /label= Asp, Ser, Ala, Thr  
 XX EP1018559-A1.  
 XX  
 XX 12-JUL-2000.  
 XX  
 XX 09-NOV-1999; 99EP-00308902.  
 XX  
 XX 23-DEC-1998; 98GB-00028603.  
 XX 17-SEP-1999; 99GB-00022123.  
 XX  
 XX (PFIZ ) PFIZER LTD.  
 XX (PFIZ ) PFIZER INC.  
 XX  
 XX Fidock M;  
 XX  
 XX WPI; 2000-433274/38.  
 XX  
 XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,

PT useful for preventing diagnosing and treating diseases associated with  
 PT inappropriate PDE-XIV expression and/or activity.  
 XX  
 PS Disclosure; Page 70-72; 104pp; English.  
 XX  
 CC The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The  
 CC enzyme sequence is derived from a formula of the invention. The  
 CC phosphodiesterase polynucleotide and polypeptide may be used in the  
 CC prevention, treatment and diagnosis of diseases associated with  
 CC inappropriate PDE-XIV expression. For example, the polynucleotide be  
 CC administered to treat diseases by rectifying mutations or deletions in a  
 CC patient's genome that affect the activity of PDE-XIV. They may also be  
 CC used to study the expression and function of PDE-XIV polypeptides and  
 CC their role in metabolism. The PDE-XIV polypeptides may be used as  
 CC antigens in the production of antibodies against PDE-XIV and in assays to  
 CC identify modulators (agonists and antagonists) of PDE-XIV expression and  
 CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
 CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
 CC gene and/or expression product may be used in the preparation of a  
 CC composition for the treatment of a disorder associated with inappropriate  
 CC PDE-XIV expression and/or activity and to screen for agents that can  
 CC modulate PDE-XIV expression and/or activity. The anti-PDE-XIV antibodies  
 CC may also be used as diagnostic agents for detecting the presence of PDE-  
 CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay  
 CC (ELISA)).  
 XX  
 SQ Sequence 446 AA;  
 Query Match 90.0%; Score 2166; DB 3; Length 446;  
 Best Local Similarity 91.6%; Pred. No. 7.8e-203;  
 Matches 413; Conservative 0; Mismatches 32; Indels 6; Gaps 2;  
 QY 1 MSCLMVRCGEILFENPDQNAKVCVCMGLDIRLGRGTGVRAERGSYPFTDFRLNNTYS 60  
 DB 1 MSCLMVRCGEXLFLFXPXQXXKVCVCMGLGDXRLRGQTGVRAERGSYPFTDFRLNNTXS 60  
 QY 61 GEIGTKKKVKRLLSFORYPHASRLRLGIIPOAPLHLLDEDDYLGQARHMLS KVGWDFDIF 120  
 DB 61 GEIGTKKKVKRLLSFORYPHASRLRLGIIPOAPLHLLDEDDYLGQARHMLS KVGWDFDIF 120  
 QY 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMVTLHRLVMOVEDYHSQNPYHNAVHAAD 180  
 DB 121 LFDRLTNGNSLVTLCHLNFTHGLIHHFKLDVMVTLHRLVMOVEDYHSQNPYHNAVHAAD 180  
 QY 181 VTQAMHCYLKEPKLASFLTPDLIMLGLAAAHVDHDPGVNQPFLIKTNHHLANLYQNMS 240  
 DB 181 VTQAMHCYLKEPKLASFLTPDLIMLGLAAAHVDHDPGVNQPFLIKTNHHLANLYQNMS 240  
 QY 241 VLENHHWRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRKALHN 300  
 DB 241 VLENHHWRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRKALHN 300  
 QY 301 KDLRLLEDAQDRHFMQLKADICNPICRIMESKOWSERVCEEFYRQGELEOKFELEIS 360  
 DB 301 KDLRLLEXQDRHFMQLKADICNPICRIMESKOWSERVCEEFYRQGELEOKFELEIS 360  
 QY 361 PLCNQOKDSIPSIQIGFMSYIYVEPLFREWAHFTGNSLTSENMLGHLAHNAQWKSLLPRQ 420  
 DB 361 PLCNQOKDSIPSIQIGFMSYIYVEPLFREWAHFTGNSLTSENMLGHLAHNAQWKSLLPRQ 420  
 QY 421 HRSRSGSGSDPDHAGQCTESEEQ-EGDSP 450  
 DB 421 HXRSGS-----QDXAGXXXEXXEQTEGXPP 446  
 RESULT 11  
 ID AAY93573  
 XX AAY93573 standard; protein; 445 AA.  
 AC AAY93573;  
 XX  
 DT 25-SEP-2000 (first entry)  
 XX



DE XX Amino acid sequence of a phosphodiesterase enzyme.  
KW XX Phosphodiesterase; PDE-XIV; enzyme.  
OS XX Synthetic.  
XX XX  
XX XX Key Location/Qualifiers  
XX XX Misc-difference 12 /label= Val, Ile  
FT FT Misc-difference 16 /label= Ser, Asn  
FT FT Misc-difference 18 /label= Glu, Asp  
FT FT Misc-difference 20..21  
FT FT /label= Ser, Val, Asn, Ala  
FT FT /note= "these residues are a peptide comprising at least  
FT FT two or more of the above residues"  
FT FT Misc-difference 30  
FT FT /label= Val, Ile  
FT FT Misc-difference 39  
FT FT /label= Pro, Arg  
FT FT Misc-difference 56  
FT FT /label= Asn, Ser  
FT FT Misc-difference 59 /label= His, Tyr  
FT FT Misc-difference 114 /label= Thr, Met  
FT FT Misc-difference 141 /label= Ser, Thr  
FT FT Misc-difference 168..169  
FT FT /label= Gly, His, Ser, Gln  
FT FT /note= "these residues are a peptide comprising at least  
FT FT two or more of the above residues"  
FT FT Misc-difference 307..308  
FT FT /label= Asp, Ala, Asn, Val  
FT FT /note= "these residues are a peptide comprising at least  
FT FT two or more of the above residues"  
FT FT Misc-difference 350  
FT FT /label= Glu, Asp  
FT FT Misc-difference 379 /label= Ser, Thr  
FT FT Misc-difference 391 /label= His, Arg  
FT FT Misc-difference 404 /label= Gly, Ser  
FT FT Misc-difference 418..419  
FT FT /label= Pro, Arg, Ser, Asn  
FT FT /note= "these residues are a peptide comprising at least  
FT FT two or more of the above residues"  
FT FT Misc-difference 423 /label= Ser, Arg  
FT FT Misc-difference 423  
FT FT Misc-difference 427..428  
FT FT /label= Ser, Gly, Pro, Asp, His, Gln  
FT FT /note= "these residues are a peptide comprising at least  
FT FT two or more of the above residues"  
FT FT Misc-difference 430 /label= His, Leu  
FT FT Misc-difference 433..434  
FT FT /label= Gln, Gly, Thr, Pro, Ala  
FT FT /note= "these residues are a peptide comprising at least  
FT FT two or more of the above residues"  
FT FT Misc-difference 436..437  
FT FT /label= Ser, Glu, Thr, Leu  
FT FT /note= "these residues are a peptide comprising at least  
FT FT two or more of the above residues"  
FT FT Misc-difference 440 /note= "optionally absent"  
FT FT Misc-difference 443..444  
FT FT /label= Asp, Ser, Ala, Thr  
FT FT /note= "these residues are a peptide comprising at least  
FT FT two or more of the above residues"  
XX XX

PN EPI018559-A1.  
XX 12-JUL-2000.  
PD XX  
XX 09-NOV-1999; 99EP-00308902.  
XX 23-DEC-1998; 98GB-00028603.  
XX 17-SEP-1999; 99GB-00022123.  
XX (PFIZ ) PFIZER LTD.  
XX (PFIZ ) PFIZER INC.  
XX Fido M;  
XX WPI; 2000-433274/38.  
XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,  
XX useful for preventing diagnosing and treating diseases associated with  
XX inappropriate PDE-XIV expression and/or activity.  
XX Disclosure; Page 64-66; 104pp; English.  
XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The  
XX enzyme sequence is derived from a formula of the invention. The  
XX phosphodiesterase polynucleotide and polypeptide may be used in the  
XX prevention, treatment and diagnosis of diseases associated with  
XX inappropriate PDE-XIV expression. For example, the polynucleotide be  
XX administered to treat diseases by rectifying mutations or deletions in a  
XX patient's genome that affect the activity of PDE-XIV. They may also be  
XX used to study the expression and function of PDE-XIV polypeptides and  
XX their role in metabolism. The PDE-XIV polypeptides may be used as  
XX antigens in the production of antibodies against PDE-XIV and in assays to  
XX identify modulators (agonists and antagonists) of PDE-XIV expression and  
XX activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
XX used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
XX gene and/or expression product may be used in the preparation of a  
XX composition for the treatment of a disorder associated with inappropriate  
XX PDE-XIV expression and/or activity and to screen for agents that can  
XX modulate PDE-XIV expression and or activity. The anti-PDE-XIV antibodies  
XX may also be used as diagnostic agents for detecting the presence of PDE-  
XX XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay  
XX (ELISA))  
XX Sequence 445 AA;  
SQ

Query Match 89.9%; Score 2165.5; DB 3; Length 445;  
Best Local Similarity 91.3%; Pred. No. 8.7e-203;  
Matches 411; Conservative 1; Mismatches 33; Indels 5; Gaps 1;  
Qy 1 MSCLMVERCGEILFENPDQNAKVCVCMGLDTRLRGQTGVRAERGRSGYFIDFRLINSTYS 60  
Db 1 MSCLMVERCGEXLFEXPXQXXKVCVCMGLDGLXRLRGQTGVAXAERGRSGYFIDFRLINXTYS 60  
Qy 61 GEIGTKKKVKRLLSFORYPHASRLRGIIIPQAPLHLLDEYLGQARHMLSKVGWMDFDIF 120  
Db 61 GEIGTKKKVKRLLSFORYPHASRLRGIIIPQAPLHLLDEYLGQARHMLSKVGWMDFDIF 120  
Qy 121 LFDRLTNGNSLVTLCHLFNTHGLIHFHFKLDWTLHRFLVMVQEDYHSQNPYHNAHAAD 180  
Db 121 LFDRLTNGNSLVTLCHLFNTHGLIHFHFKLDWTLHRFLVMVQEDYHSQNPYHNAHAAD 180  
Qy 181 VTQAMHCYLKEPKLASPLTDLIMGLLAAAADVDHPGVNQPLIKTNHHLANLYQNS 240  
Db 181 VTQAMHCYLKEPKLASPLTDLIMGLLAAAADVDHPGVNQPLIKTNHHLANLYQNS 240  
Qy 241 VLENHHRSTIGMLRSRLLAHPKEMTDIIEQOLGSLIATDINRQNEFLTRKALHNLN 300  
Db 241 VLENHHRSTIGMLRSRLLAHPKEMTDIIEQOLGSLIATDINRQNEFLTRKALHNLN 300  
Qy 301 KDLRLDAQDRHFMLOIALKACADICNPCRISWMSKQWSEVCEFYRQGLEQKFELEIS 360  
Db 301 KDLRLDAQDRHFMLOIALKACADICNPCRISWMSKQWSEVCEFYRQGLEQKFELEIS 360

```
Qy 361 PLCNQKDSIPSIQIGMYSVIVEPLFREWAFHTGNSTLSENMLGHLAHNAQWKSLLPRQ 420
Db 361 PLCNQKDSIPSIQIGPMXYVIVEPLFREWAXFTGNSTLSENMLXHLAHNAQWKSLLXQ 420
Qy 421 HRSRGSGSGPDHPDHACQGTSEBOEGDSP 450
Db 421 HRXRGX-----XDXAGXEXXEQTEGXXP 445

RESULT 12
AA933572
ID AA933572 standard; protein; 437 AA.
XX AC
XX AAY933572;
XX 25-SEP-2000 (first entry)
XX DE
XX Amino acid sequence of a phosphodiesterase enzyme.
XX KW Phosphodiesterase; PDE-XIV; enzyme.
XX OS
XX Synthetic.
XX FH Key Location/Qualifiers
FT Misc-difference 12
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 16
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 18
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 20
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 29
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 38
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 55
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 58
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 113
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 140
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 167
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 305
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 347
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 376
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 388
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 401
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 415
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 419
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 423
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 425
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 428
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 430
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 433
FT /note= "any suitable peptide sequence or amino acid"
FT Misc-difference 436
FT /note= "any suitable peptide sequence or amino acid"
XX
```

```
PN EP1018559-A1.
XX 12-JUL-2000.
XX 09-NOV-1999; 99EP-00308902.
XX 23-DEC-1998; 98GB-00028603.
PR 17-SEP-1999; 99GB-00022123.
XX (PFIZ ) PFIZER LTD.
PA (PFIZ ) PFIZER INC.
XX Fidoack M;
XX WPI; 2000-433274/38.
XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,
FT useful for preventing diagnosing and treating diseases associated with
FT inappropriate PDE-XIV expression and/or activity.
XX Disclosure; Page 58-60; 104pp; English.
XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The
CC enzyme sequence is derived from a formula of the invention. The
CC phosphodiesterase polynucleotide and polypeptide may be used in the
CC prevention, treatment and diagnosis of diseases associated with
CC inappropriate PDE-XIV expression. For example, the polynucleotide be
CC administered to treat diseases by rectifying mutations or deletions in a
CC patient's genome that affect the activity of PDE-XIV. They may also be
CC used to study the expression and function of PDE-XIV polypeptides and
CC their role in metabolism. The PDE-XIV polypeptides may be used as
CC antigens in the production of antibodies against PDE-XIV and in assays to
CC identify modulators (agonists and antagonists) of PDE-XIV expression and
CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be
CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV
CC gene and/or expression product may be used in the preparation of a
CC composition for the treatment of a disorder associated with inappropriate
CC PDE-XIV expression and/or activity and to screen for agents that can
CC modulate PDE-XIV expression and or activity. The anti-PDE-XIV antibodies
CC may also be used as diagnostic agents for detecting the presence of PDE-
CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay
XX (ELISA))
XX SQ Sequence 437 AA;
```

```
Query Match 88.1%; Score 2121; DB 3; Length 437;
Best Local Similarity 91.9%; Pred. No. 1.9e-198;
Matches 411; Conservative 1; Mismatches 23; Indels 12; Gaps 6;
QY 1 MSCLMVERGCEILFENPDQNAKCVCMGDIRLGRGOTGVRAERGSYPFFIDFRLNNTTYS 60
Db 1 MSCLMVERGCEILFEXPAQ-XKCVCMGDXRLRGOTGVRAERGSYPFFIDFRLNNTTYS 59
QY 61 GEIGTKKKVKRLLSFQRYPHASRLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIF 120
Db 60 GEIGTKKKVKRLLSFQRYPHASRLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIF 119
QY 121 LFDRLTNGNSLVTLCHLNFTHGLIHFHFKLDMVTLHRLFLVMVQEDYHSQNPVHNAHAAD 180
Db 120 LFDRLTNGNSLVTLCHLNFHFKLDMVTLHRLFLVMVQEDYH-XNPVHNAHAAD 178
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAADVDHVGWNPQFPLIKTNHHLANLYQNMS 240
Db 179 VTQAMHCYLKEPKLASFLTPDLMGLLAAAADVDHVGWNPQFPLIKTNHHLANLYQNMS 238
QY 241 VLENHHWSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLRLKAHLN 300
Db 239 VLENHHWSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLRLKAHLN 298
QY 301 KDLRLDAQDRHFMLOIALKCADICNPCKRIWMSKQWSEVCEEFYRQGELEKQKFELEIS 360
Db 299 KDLRLLE-XODRHFMLQIALKCADICNPCKRIWMSKQWSEVCEEFYRQGELEKQKFELEIS 357
```

QY 361 PLCNQKDSIPSIQIGFMSYIVPLFREWAFHTGNTSLSENMLGHLAHNAQWKSLLPRO 420  
DB 358 PLCNQKDSIPSIQIGFMYIVPLFREWAFHTGNTSLSENMLGHLAHNAQWKSLL-XQ 416  
QY 421 HRSRSGSGPDHAGQGTSESEQE 447  
DB 417 HRXRGSK-----DXA--GXEXEQEG 435

RESULT 13  
ID AAY93571 standard; protein; 413 AA.  
AC AAY93571;  
XX 25-SEP-2000 (first entry)  
DT Amino acid sequence of a phosphodiesterase enzyme.  
DE Phosphodiesterase; PDE-XIV; enzyme.  
KW Synthetic.  
OS  
XX  
XX EPI018559-A1.  
XX 12-JUL-2000.  
XX 09-NOV-1999; 99EP-00308902.  
XX 23-DEC-1998; 98GB-00028603.  
PR 17-SEP-1999; 99GB-00022123.  
XX (PFIZ ) PFIZER LTD.  
PA (PFIZ ) PFIZER INC.  
XX  
XX Fidoack M;  
XX WPI; 2000-433274/38.  
XX  
XX Nucleic acids encoding recombinant phosphodiesterase (PDE)-XIV enzymes,  
PT useful for preventing diagnosing and treating diseases associated with  
PT inappropriate PDE-XIV expression and/or activity.  
XX  
XX Claim 2; Page 55-57; 104pp; English.  
XX  
XX The present sequence represents a phosphodiesterase (PDE)-XIV enzyme. The  
CC enzyme sequence is derived from a formula of the invention. The  
CC phosphodiesterase polynucleotide and polypeptide may be used in the  
CC prevention, treatment and diagnosis of diseases associated with  
CC inappropriate PDE-XIV expression. For example, the polynucleotide be  
CC administered to treat diseases by rectifying mutations or deletions in a  
CC patient's genome that affect the activity of PDE-XIV. They may also be  
CC used to study the expression and function of PDE-XIV polypeptides and  
CC their role in metabolism. The PDE-XIV polypeptides may be used as  
CC antigens in the production of antibodies against PDE-XIV and in assays to  
CC identify modulators (agonists and antagonists) of PDE-XIV expression and  
CC activity. The anti-PDE-XIV antibodies and PDE-XIV antagonists may also be  
CC used to down regulate PDE-XIV expression and activity (i.e. the PDE-XIV  
CC gene and/or expression product may be used in the preparation of a  
CC composition for the treatment of a disorder associated with inappropriate  
CC PDE-XIV expression and/or activity and to screen for agents that can  
CC modulate PDE-XIV expression and or activity. The anti-PDE-XIV antibodies  
CC may also be used as diagnostic agents for detecting the presence of PDE-  
CC XIV polypeptides in samples (e.g. by enzyme linked immunosorbant assay  
CC (ELISA))  
XX  
XX Sequence 413 AA;  
SQ

Query Match 82.7%; Score 1990.5; DB 3; Length 413;  
Best Local Similarity 90.8%; Pred. No. 1.1e-185;  
Matches 406; Conservative 1; Mismatches 5; Indels 35; Gaps 16;  
QY 1 MSCLMVERCCEILFENPDQNAKVCVLMGLDRLRGQTGVRAERRGSYFFIDRLINNTYS 60

DB 1 MSCLMVERCCE-LFE-----PQKCVMLGD-RLRGQTGV-AERRGSYFFIDRLINNT--S 51  
QY 61 GEIGTKKKVKRLLSFQRYPHASRLRGIIPOAPLHLLDELYLGOARHMLSKVGWDFDIF 120  
DB 52 GEIGTKKKVKRLLSFQRYPHASRLRGIIPOAPLHLLDELYLGOARHMLSKVG-WDFDIF 110  
QY 121 LFDRLTNGSLVTLTLLCHLNFTHGLIHHFKLDWVTLHRLVWQEDYHSONPYHNAVHAAD 180  
DB 111 LFDRLTNGSLVTLTLLCHLNF-HGLIHHFKLDWVTLHRLVWQEDYH--NPYHNAVHAAD 167  
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHADVHPGVNQPFLLIKTNHHLANLYQNMS 240  
DB 168 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHADVHPGVNQPFLLIKTNHHLANLYQNMS 227  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMTDIEQOLGSLILATDINRQNEFLTRLKAHLHN 300  
DB 228 VLENHHRSTIGMLRESRLLAHLPKEMTDIEQOLGSLILATDINRQNEFLTRLKAHLHN 287  
QY 301 KDLRLDAODRHEMLQIALKCADICNPCRITWMSKQWSEFVYRQGELEOKFELEIS 360  
DB 288 KDLRLD--QDRHEMLQIALKCADICNPCRITWMSKQWSEFVYRQGELEOKFELEIS 344  
QY 361 PLCNQKDSIPSIQIGFMSYIVPLFREWAFHTGNTSLSENMLGHLAHNAQWKSLLPRO 420  
DB 345 PLCNQKDSIPSIQIGFM-YIVPLFREWAFHTGNTSLSENMLGHLAHNAQWKSLL--Q 399  
QY 421 HRSRSGSGPDHAGQGTSESEQE 447  
DB 400 HR-RGSDA-----GSEQEG 412

RESULT 14  
AAU08676  
ID AAU08676 standard; protein; 391 AA.  
XX  
XX AAU08676;  
XX  
XX 18-DEC-2001 (first entry)  
DE Human phosphodiesterase type 7B #2.  
XX  
XX Human; phosphodiesterase type 7B; cardiovascular disease; asthma;  
KW allergy; inflammatory disease; immune-related disorder; cardiovascular;  
KW antiasthmatic; antiallergic; immunosuppressive; antiinflammatory.  
XX  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FT Misc-difference 188 /label= Unknown  
FT /note= "Encoded by CMC"  
FT Misc-difference 188 /note= "Encoded by GAR"  
FT Misc-difference 387 /label= Unknown  
FT /note= "Encoded by GNN"  
XX  
XX WC200162940-A2.  
XX  
XX 30-AUG-2001.  
XX  
XX 20-FEB-2001; 2001WO-EP001858.  
XX  
XX 21-FEB-2000; 2000EP-00103655.  
XX  
XX (MERE ) MERCK PATENT GMBH.  
XX  
XX Kluxen F., Hentsch B;  
XX  
XX WPI; 2001-570636/64.  
XX  
XX N-PSDB; AAS13249.  
XX

PT Phosphodiesterase 7B proteins and nucleic acids, useful for preventing,  
XX diagnosing and treating, e.g. asthma, inflammation and allergies.  
PS Claim 1; Page 39-40; 40pp; English.

XX The invention relates to a novel human Phosphodiesterase type 7B  
CC polypeptide and the nucleic acid that encodes it. The protein and nucleic  
CC acid may be used in the prevention, diagnosis and treatment of diseases  
CC associated with inappropriate phosphodiesterase 7B (P7B) expression. For  
CC example, the protein and nucleic acid may be used to treat disorders  
CC associated with decreased expression by rectifying mutations or deletions  
CC in a patient's genome that affect the activity of P7B by expressing  
CC inactive proteins or to supplement the patient's own production of P7B.  
CC The nucleic acids may be used to produce P7B polypeptides, by inserting  
CC the nucleic acids into a host cell and culturing the cell to express the  
CC protein. The nucleic acid and its complements may also be used as DNA  
CC probes in diagnostic assays to detect and quantitate the presence of  
CC similar nucleic acids in samples, and therefore which patients may be in  
CC need of restorative therapy. The P7B polypeptides may also be used as  
CC antigens in the production of antibodies against P7B and in assays to  
CC identify modulators of its expression and activity. The anti-P7B  
CC antibodies and antagonists may also be used to down regulate expression  
CC and activity. The anti-P7B antibodies may also be used as diagnostic  
CC agents for detecting the presence of P7B in samples (e.g. by enzyme  
CC linked immunosorbent assay (ELISA)). Disorders that may be prevented,  
CC diagnosed and/or treated by the above methods include, for example  
CC cardiovascular disease, asthma, allergy, inflammation, and immune-related  
CC disorders. The present sequence represents a human phosphodiesterase 7B  
XX Sequence 391 AA;

Query Match 77.5%; Score 1865; DB 4; Length 391;  
Best Local Similarity 92.7%; Pred. No. 2e-173;  
Matches 354; Conservative 2; Mismatches 26; Indels 0; Gaps 0;

QY 52 RLNNSTTSGEIGTKKKVRLLSFQRYFHASRLLRGIIPQAPLHLLDDEYLGQARHMLSK 111  
DB 10 RLNNSTTSGEIGTKKKVRLLSFQRYFHASRLLRGIIPQAPLHLLDDEYLGQARHMLSK 69  
QY 112 VGMWDFDIFLDRLTNGNSLVTLCHLNFTHGLIHHFKLDMVTLHRPLVMVQEDYHSQNP 171  
DB 70 VGMWDFDIFLDRLTNGNSLVTLCHLNFTHGLIHHFKLDMVTLHRPLVMVQEDYHSQNP 129  
QY 172 YHNAVHAADVTQAMHCYKPKLASFLTPDIDMLGLLAAAHDVDHPGVNQPELIKTNIH 231  
DB 130 YHNAVHAADVTQAMHCYKPKLASFLTPDIDMLGLLAAAHDVDHPGVNQPELIKTNIH 189  
QY 232 LANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKMTQDIEQQLGSLILATDINRQNEFL 291  
DB 190 LANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKMTQDIEQQLGSLILATDINRQNEFL 249  
QY 292 TRLKAHLHNKDLLEDAQDRHFMLOALKCADICNCRIEWMSKQNSRVCSEFYQOGL 351  
DB 250 TRLKAHLHNKDLLEDAQDRHFMLOALKCADICNCRIEWMSKQNSRVCSEFYQOGL 309  
QY 352 EQKFELEISPLCNQKQDSIPSIQIGPWSYIVPELFWAHTGNSTLSENMLGHLAHNKA 411  
DB 310 EQKFELEISPLCNQKQDSIPSIQIGPWSYIVPELFWAHTGNSTLSENMLGHLAHNKA 369  
QY 412 QWKSLLPQHRSRGSGSGDPH 433  
DB 370 QWKSLLPSPSDEAGALAXGLDH 391

RESULT 15  
ADY50214  
ID ADY50214 standard; protein; 335 AA.

XX ADY50214;  
AC ADY50214;  
XX 19-MAY-2005 (first entry)  
XX Human PDE7B phosphodiesterase domain SEQ ID NO:23.

XX phosphodiesterase 7B; PDE5A; X-ray crystallography; enzyme.  
KW Homo sapiens.  
OS US2005048573-A1.  
XX 03-MAR-2005.  
XX 03-FEB-2004; 2004US-00771833.  
XX 03-FEB-2003; 2003US-0444734P.  
PR 07-JUL-2003; 2003US-0485627P.  
XX (PLEX-) PLEXIKON INC.  
XX Artis DR, Bollag G, Card G, Martin F, Milburn MV, Zhang K;  
PI; 2005-202088/21.  
XX Development of ligands binding to phosphodiesterase-5A (PDE5A) comprises  
PT identifying PDE5A binding compounds, determining orientation of molecular  
PT scaffold, identifying chemical structures of molecular scaffolds and  
PT synthesizing ligand.  
XX Disclosure; SEQ ID NO 23; 111pp; English.  
XX The invention relates to a novel method for development of ligands  
CC binding to phosphodiesterase-5A (PDE5A). The method comprises identifying  
CC one or more compounds as molecular scaffolds that bind to a binding site  
CC of PDE5A, determining the orientation of at least one molecular scaffold  
CC in co-crystals with PDE5A, identifying chemical structures of the  
CC molecular scaffolds, and synthesizing a ligand with altered binding  
CC affinity and/or binding specificity. The method to identify the potential  
CC PDE5A binding compounds comprises either removing a computer  
CC representation of a compound complexed with PDE5A or modifying a computer  
CC addition of one or more chemical groups; fitting a computer  
CC representation of a compound from a computer database with a computer  
CC representation of the active site of PDE5A; and identifying compounds  
CC derived from the molecular scaffold that best fit the active site based  
CC on favorable geometric fit and energetically favorable complementary  
CC interactions as potential binding compounds; and further comprises  
CC searching a database for compounds having structural similarity to the  
CC molecular scaffold or derivative compound using a compound searching  
CC computer program or replacing portions of the compound with similar  
CC chemical structures using a compound construction computer program. The  
CC compound complexed with PDE5A is non-hydrolyzable cyclic guanosine  
CC monophosphate (cGMP) analog. The fitting comprises determining whether  
CC the compounds will interact with one or more of conserved PDE5A active  
CC site residues. The attachment component is a linker (a traceless linker)  
CC for attachment to a solid phase medium and comprises a label comprising a  
CC fluorophore. The attachment method further comprises attaching the  
CC compound or derivative to a solid phase medium through a linker attached  
CC at the energetically allowed site. The phosphodiesterase comprises  
CC conserved residues matching at least one conserved PDE5A active site  
CC residues. The phosphodiesterase binding compound or derivative is  
CC synthesized on the linker attached to the solid phase medium. The  
CC plurality of the compounds or derivatives is synthesized in combinatorial  
CC synthesis. The attachment of the compounds to the solid phase medium  
CC provides an affinity medium. The present sequence represents the  
CC phosphodiesterase domain of human phosphodiesterase 7B.  
XX Sequence 335 AA;

Query Match 74.8%; Score 1801; DB 9; Length 335;  
Best Local Similarity 100.0%; Pred. No. 2.9e-167;  
Matches 335; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 87 GIIPQAPLHLLDEDYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLNFTHGLTH 146  
DB 1 GIIPQAPLHLLDEDYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLNFTHGLTH 60

Qy 147 HFKLDWVTLHREFLVMVOEDYHSQNPYHNVAHADVTQAMHCYLKEPKLASFLTPLDIMLG 206  
Db 61 HFKLDWVTLHREFLVMVOEDYHSQNPYHNVAHADVTQAMHCYLKEPKLASFLTPLDIMLG 120  
Qy 207 LLA AAAHDVDHPGVNQPFLLKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLIAHLPK 266  
Db 121 LLA AAAHDVDHPGVNQPFLLKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLIAHLPK 180  
Qy 267 MTQDIEQQLGSLILATDINRQNEFLTRLKAHLHNKDLRLBDAQDRHPMLQIALKCADICN 326  
Db 181 MTQDIEQQLGSLILATDINRQNEFLTRLKAHLHNKDLRLBDAQDRHPMLQIALKCADICN 240  
Qy 327 PCRIWENSKOMSERVCBEFYRQGELEKFELEISPLCNQOKDSIPSIQIGFMSYIVEPLP 386  
Db 241 PCRIWENSKOMSERVCBEFYRQGELEKFELEISPLCNQOKDSIPSIQIGFMSYIVEPLP 300  
Qy 387 REWAHFTGNSTLSENMLGHLAHNKAQWKSLLPROH 421  
Db 301 REWAHFTGNSTLSENMLGHLAHNKAQWKSLLPROH 335

Search completed: March 10, 2006, 19:56:52  
Job time : 167.463 secs

**This Page Blank (uspio)**

GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 19:57:15 ; Search time 31.0976 Seconds  
(without alignments)  
1392.313 Million cell updates/sec

Title: US-10-781-181-5  
Perfect score: 2408  
Sequence: 1 MSCLMVERGCEILFENPDQN.....PDHAGQGTSESEBQGDSP 450

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 80.\*  
1: pir1.\*  
2: pir2.\*  
3: pir3.\*  
4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2408	100.0	450	JC7266	3',5'-cyclic-nucle
2	1419.5	58.9	498	A47286	3',5'-cyclic-AMP p
3	604.5	25.1	673	B13358	3',5'-cyclic-nucle
4	603.5	25.1	584	B53109	3',5'-cyclic-nucle
5	603.5	25.1	672	I61259	3',5'-cyclic-nucle
6	580.5	24.1	562	I59143	CAMP phosphodiesterase
7	580.5	24.1	564	A40949	cyclic-AMP phospho.
8	567.5	23.6	564	JC1519	3',5'-cyclic-nucle
9	567.5	23.6	736	I61354	phosphodiesterase
10	565	23.5	886	AS4442	3',5'-cyclic-nucle
11	559.5	23.2	610	I67946	3',5'-cyclic-nucle
12	559.5	23.2	844	I53865	phosphodiesterase
13	553	23.0	712	S71626	3',5'-cyclic-nucle
14	529.5	22.0	536	I67945	3',5'-cyclic-nucle
15	517	21.5	549	T16769	hypothetical prote
16	493	20.5	777	S65543	3',5'-cyclic-nucle
17	477.5	19.8	323	S55348	3',5'-cyclic-nucle
18	468	19.4	267	B33904	CAMP phosphodiesterase
19	468	19.4	535	A46378	3',5'-cyclic-nucle
20	467	19.4	534	A4162	3',5'-cyclic-nucle
21	466	19.4	519	T14783	hypothetical prote
22	466	19.4	535	A44161	3',5'-cyclic-nucle
23	461	19.1	664	T24459	hypothetical prote
24	454.5	18.9	530	A45334	3',5'-cyclic-nucle
25	452.5	18.8	768	T10796	3',5'-cyclic-nucle
26	449	18.6	536	JC6129	3',5'-cyclic-nucle
27	445.5	18.5	713	JW0088	3',5'-cyclic-nucle
28	441	18.3	659	JB0293	3',5'-cyclic-nucle
29	441	18.3	885	JC7898	3',5'-cyclic-nucle

30	409	17.0	491	2	A40283	3',5'-cyclic-nucle
31	381	15.8	875	1	JW0106	3',5'-cyclic-GMP p
32	377	15.7	875	1	A48719	3',5'-cyclic-GMP p
33	370	15.4	1054	2	T30901	cyclic nucleotide
34	368.5	15.3	1112	2	S70522	cyclic nucleotide
35	357.5	14.8	1108	2	A48508	CGMP-inhibited CAM
36	346	14.4	1141	2	A44093	3',5'-cyclic-GMP p
37	302.5	12.6	858	2	JC4520	3',5'-cyclic-GMP p
38	300	12.5	855	2	A34810	3',5'-cyclic-GMP p
39	299	12.4	928	1	JC3486	3',5'-cyclic-nucle
40	296	12.3	921	1	A40981	3',5'-cyclic-GMP p
41	283	11.8	853	2	A36617	3',5'-cyclic-GMP p
42	279	11.6	856	1	A47451	3',5'-cyclic-GMP p
43	278	11.5	856	2	S30762	3',5'-cyclic-GMP p
44	277.5	11.5	854	2	A42828	3',5'-cyclic-GMP p
45	269.5	11.2	862	2	I50186	3',5'-cyclic-GMP p

ALIGNMENTS

RESULT 1

JC7266  
3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17) 7B - human  
N:Alternate names: CAMP-specific phosphodiesterase 7B  
C:Species: Homo sapiens (man)  
C:Date: 18-Aug-2000 #sequence\_revision 18-Aug-2000 #text\_change 09-Jul-2004  
C:Accession: JC7266  
R:Sasaki, T.; Kotera, J.; Yuasa, K.; Omori, K.  
Biochem. Biophys. Res. Commun. 271, 575-583, 2000  
A:Title: Identification of human PDE7B, a CAMP-specific phosphodiesterase.  
A:Reference number: JC7266  
A:Accession: JC7266  
A:Molecule type: mRNA  
A:Residues: 1-450 <SAS>  
A:Cross-references: UNIPROT:Q9NP56; UNIPARC:UPI00000339FF; DDBJ:AB038040  
A:Experimental source: caudate nucleus  
C:Genetics:  
A:Gene: pde7B  
A:Map position: 6q23-24  
C:Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'-  
C:Keywords: phosphoric diester hydrolase

Query Match	100.0%	Score	2408	DB	2	Length	450
Best Local Similarity	100.0%	Pred. No.	5.4e-182				
Matches	450	Conservative	0	Mismatches	0	Indels	0
Gaps	0						
QY	1	MSCLMVERGCEILFENPDQNACVCMGLDIRLGOTGVRAERGSYPFIDFRLINSTYS	60				
DB	1	MSCLMVERGCEILFENPDQNACVCMGLDIRLGOTGVRAERGSYPFIDFRLINSTYS	60				
QY	61	GEIGTKKKVKRLLSFORYPHARSLRLLGIIPQAPLHLLDDEYLQARHMLSKVGMWDFDIF	120				
DB	61	GEIGTKKKVKRLLSFORYPHARSLRLLGIIPQAPLHLLDDEYLQARHMLSKVGMWDFDIF	120				
QY	121	LFDRLTNGNSLVTLCHLFNTHGLIHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVHAAD	180				
DB	121	LFDRLTNGNSLVTLCHLFNTHGLIHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVHAAD	180				
QY	181	VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHVGPNQFPFLIKTHHLANLQNMS	240				
DB	181	VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDHVGPNQFPFLIKTHHLANLQNMS	240				
QY	241	VLENHHRSTIGMLRESRLLAHLPKEMTODIEQQLGSLILATDINRQNEFLTKLKAHLHN	300				
DB	241	VLENHHRSTIGMLRESRLLAHLPKEMTODIEQQLGSLILATDINRQNEFLTKLKAHLHN	300				
QY	301	KDLRLLEDAQDRHFMFLQIALKACADINCPICRWMSQKWSERVCEEFYRQGELEBQKFELEIS	360				
DB	301	KDLRLLEDAQDRHFMFLQIALKACADINCPICRWMSQKWSERVCEEFYRQGELEBQKFELEIS	360				
QY	361	PLCNQOKSDIPSIOIGFMSYIIEPLFREWAHTTGSTLSENMLHLAHNAKQWKSLLPRQ	420				





A:Reference number: A34414; MUID:90046763; PMID:2554303

A:Accession: A34414

A:Molecule type: mRNA

A:Residues: 1-584 <SWI>

A:Cross-references: UNIPARC:UPI000002A6E1; GB:U09455; GB:M25349; NID:g517501; PIDN:AAA20

R:Swinnen, J.V.; Joseph, D.R.; Conti, M.

Proc. Natl. Acad. Sci. U.S.A. 86, 5325-5329, 1989

A:Title: Molecular cloning of rat homologues of the Drosophila melanogaster duncce CAMP P

A:Reference number: A33904; MUID:89315790; PMID:2546153

A:Accession: C33904

A:Molecule type: mRNA

A:Residues: 214-480 <SW2>

A:Cross-references: UNIPARC:UPI00001759B1; GB:M25349

R:Boiger, G.B.; Rodgers, L.K.; Riggs, M.

Gene 149, 237-244, 1994

A:Title: Differential CNS expression of alternative mRNA isoforms of the mammalian genes

A:Reference number: I53865; MUID:95047482; PMID:7958996

A:Accession: I67944

A:Molecule type: mRNA

A:Residues: 34-421, 'E', 423-584 <RES>

A:Cross-references: UNIPARC:UPI00001759B2; GB:L27060; NID:g436009; PID:g436010

C:Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'

C:Keywords: alternative initiators; alternative splicing; CAMP binding; phosphoric diest

F:237-465/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 25.1%; Score 603.5; DB 2; Length 584;

Best Local Similarity 33.3%; Pred. No. 1.2e-39;

Matches 135; Conservative 85; Mismatches 152; Indels 33; Gaps 9;

66 KKKVKRLLS-----FQRYFHASRLRGIIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121

130 KKKKRPMSQISGVKKLHSSSLTNSCIPRGVKTQEVDLAK-----LEDVKNKGLHVR 186

122 FDLNGSLVTLCH-LFNTHGLIHFKLDMVTLHRLVMVQEDVHSONPYHNAHAAD 180

187 IAEI-SGNRPLTVIMHTIPOERDLKTKFKIPVDLTITLMTLEDHYADVAHNNHAAD 245

181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHDPGVNQPFLTKTHHLANLYQNM 240

246 VVQSTHVLSTALEAVFTDLLELAIPASAIHVDHDPGVSNQFLINTSELALMYNDSS 305

241 VLENHHRSTIGMLRES--LLAHLPKEMTDIEQGLSLIATDINRQNEFLTRKAHL 298

306 VLENHHLAVGFKLLQENCDFQNLTKQKQSLRKAIDIVLATDMSKHNLLADLKTWV 365

299 HNKD-----LRLEDAQDRHFLQIALKCADICNPCRIMWMSKQSERVCEBYPYRQGELE 352

366 ETKKVTSSGVLDDNYSRIQVLMVHCHADLSNPTKPLQLYRQWTDRIEVEFFRQGDRE 425

353 QKFELEISPLCNOOKDIPSIQIGFMSYIVPLFREWHAFTGNSTLSENMLGHLAHNAK 412

426 RERGHEISPMCDKHNASVEKSVQGFIDYIVHPLWETWADLVHPD--AQDILTLEDNREW 483

413 WKSLLPRQHRSGSGSGDPDHAGQGTSE-----EQEGDS 449

484 YQSTIPIQ-----SPSPAPDDQEDGRQGTQKFEFELTLEEDGES 522

RESULT 5

161259

3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17) 4D, CAMP-specific, splice form E

N:Alternate names: cyclic-AMP phosphodiesterase

N:Contains: 3',5'-cyclic-nucleotide phosphodiesterase

C:Species: Rattus norvegicus (Norway rat)

C:Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 17-Nov-2000

C:Accession: I61259; I67943

R:Sette, C.; Vicini, E.; Conti, M.

J. Biol. Chem. 269, 18271-18274, 1994

A:Title: The ratPDE3/IVD phosphodiesterase gene codes for multiple proteins differential

A:Reference number: A53678; MUID:94308045; PMID:8034568

A:Accession: I61259

A:Status: translated from GB/EMBL/DBDJ

A:Molecule type: mRNA

A:Residues: 1-672 <RES>

A:Cross-references: UNIPARC:UPI00001759B7; EMBL:U09457; NID:g517418; PID:g517419

A:Accession: A53678

A:Status: translated from GB/EMBL/DBDJ

A:Molecule type: mRNA

A:Residues: 167-672 <RE2>

A:Cross-references: UNIPARC:UPI00001707C8; EMBL:U09456; NID:g517416; PIDN:AAA20393.1; PI

R:Boiger, G.B.; Rodgers, L.K.; Riggs, M.

Gene 149, 237-244, 1994

A:Title: Differential CNS expression of alternative mRNA isoforms of the mammalian genes

A:Reference number: I53865; MUID:95047482; PMID:7958996

A:Accession: I67943

A:Status: translated from GB/EMBL/DBDJ

A:Molecule type: mRNA

A:Residues: 'N', 96-625, 'Y', 627-672 <RE3>

A:Cross-references: UNIPARC:UPI0000170BF4; GB:L27059; NID:g436007; PIDN:AAA56857.1; PID:

C:Genetics:

A:Gene: PDE3/IVD gene

C:Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'

C:Keywords: CAMP binding; phosphoric diester hydrolase

F:325-553/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 25.1%; Score 603.5; DB 2; Length 672;

Best Local Similarity 33.3%; Pred. No. 1.5e-39;

Matches 135; Conservative 85; Mismatches 152; Indels 33; Gaps 9;

66 KKKVKRLLS-----FQRYFHASRLRGIIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121

218 KKKKRPMSQISGVKKLHSSSLTNSCIPRGVKTQEVDLAK-----LEDVKNKGLHVR 274

122 FDLNGSLVTLCH-LFNTHGLIHFKLDMVTLHRLVMVQEDVHSONPYHNAHAAD 180

275 IAEI-SGNRPLTVIMHTIPOERDLKTKFKIPVDLTITLMTLEDHYADVAHNNHAAD 333

181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHDPGVNQPFLTKTHHLANLYQNM 240

334 VVQSTHVLSTALEAVFTDLLELAIPASAIHVDHDPGVSNQFLINTSELALMYNDSS 393

241 VLENHHRSTIGMLRES--LLAHLPKEMTDIEQGLSLIATDINRQNEFLTRKAHL 298

394 VLENHHLAVGFKLLQENCDFQNLTKQKQSLRKAIDIVLATDMSKHNLLADLKTWV 453

299 HNKD-----LRLEDAQDRHFLQIALKCADICNPCRIMWMSKQSERVCEBYPYRQGELE 352

454 ETKKVTSSGVLDDNYSRIQVLMVHCHADLSNPTKPLQLYRQWTDRIEVEFFRQGDRE 513

353 QKFELEISPLCNOOKDIPSIQIGFMSYIVPLFREWHAFTGNSTLSENMLGHLAHNAK 412

514 RERGHEISPMCDKHNASVEKSVQGFIDYIVHPLWETWADLVHPD--AQDILTLEDNREW 571

413 WKSLLPRQHRSGSGSGDPDHAGQGTSE-----EQEGDS 449

572 YQSTIPIQ-----SPSPAPDDQEDGRQGTQKFEFELTLEEDGES 610

RESULT 6

159143

CAMP phosphodiesterase - rat (fragment)

C:Species: Rattus norvegicus (Norway rat)

C:Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 09-Jul-2004

C:Accession: I59143

R:Colicelli, J.; Birchmeier, C.; Michaeli, T.; O'Neill, K.; Riggs, M.; Wigler, M.

Proc. Natl. Acad. Sci. U.S.A. 86, 3599-3603, 1989

A:Title: Isolation and characterization of a mammalian gene encoding a high-affinity cAMP

A:Reference number: I59143; MUID:189264471; PMID:2542941

A:Accession: I59143

A:Status: preliminary; translated from GB/EMBL/DBDJ

A:Molecule type: mRNA

A:Residues: 1-562 <RES>

A:Cross-references: UNIPROT:P14646; UNIPARC:UPI00001440E1; GB:J04563; NID:g203967; PIDN:

C:Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'



A:Accession: I61359  
A:Status: preliminary; nucleic acid sequence not shown; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-564 <RES>  
A:Cross-references: UNIPARC:UPI000014CSAB; GB:L20971; NID:G347131; PIDN:AAA03593.1; PID:  
C:Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'-  
C:Keywords: phosphoric diester hydrolase  
F:233-461/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 23.6%; Score 567.5; DB 2; Length 564;  
Best Local Similarity 31.3%; Pred. No. 8.1e-37;  
Matches 129; Conservative 93; Mismatches 149; Indels 41; Gaps 8;

QY 66 KKKVKLLS-----FQRYFHASRLRGIIIPQAPLHLLDEYLGQARHMLSKVGWDFDIFL 121  
DB 126 KKKKQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELDLNK---WGLNIFN 182  
QY 122 FDLRTNGNSLVTLCHLNFTHGLIHFHFKLDVMTLHFLVMQVDYHSQNPYHNAHAADV 181  
DB 183 VAGYSHNRPLCTMYAIFQERDLTKFRISSTDTPIYMTLEDHYHSDVAYHNSLHAADV 242  
QY 182 TQAMHCYLKEPKLASFLTPDLIDMLGLLAAAHDVDPGVNQPLIKTNHHLNLYQNMSV 241  
DB 243 AQSTHLLSTPALDAVFTDLEILAAIFAAAHVDHDPGVSNQFLINTNSLALMYNDES 302  
QY 242 LENHWRSTIGMLRES--LLAHLPKMTQDIEQQLGSLILATDINRQNEFLTRLKAHLH 299  
DB 303 LENHHLAVGFKLQEBCHDFMNLTKKQRTLRKQVDMVLATDMSKHSLADLTKTWE 362  
QY 300 NKD-----LRLEDAQDRHFMLOIALKCADICNPRCIWEMSKOWSERVCEEFVQGELEQ 353  
DB 363 TKKVTSSGVLNLDNYTDRIQVLNVMHVCADLSNPTKSLRYQMTDRIMEEFPQQDKER 422  
QY 354 KFEELISPLCNQOKDIPSIQIGFMSYIIEPLFREWHAFTGNTLSSENMLGHLAHNAQW 413  
DB 423 ERGMEISPCDKHTASVEKSVQGFIDYIVHPLWETWADLVQPD--AQDILTLEDNRNMY 480  
QY 414 KSLPLQHRSGSSGGP-----DHDHAG-----QGTSEEBEGD 448  
DB 481 QSMIPQ-----SPSPPLDEQNRDQGLMEKFQFELTDEEDSEGEKEGE 525

RESULT 9  
I61354  
phosphodiesterase - human  
C:Species: Homo sapiens (man)  
C:Date: 06-Sep-1996 #sequence\_revision 06-Sep-1996 #text\_change 09-Jul-2004  
C:Accession: I61354  
R:Bolger, G.; Michaeli, T.; Martins, T.; St. John, T.; Steiner, B.; Rodgers, L.; Riggs,  
Mol. Cell. Biol. 13, 6558-6571, 1993  
A:Title: A family of human phosphodiesterases homologous to the dunce learning and mem  
A:Reference number: A54442; MUID:94019330; PMID:8413254  
A:Accession: I61354  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-736 <RES>  
A:Cross-references: UNIPROT:Q07343; UNIPARC:UPI0000127BF6; GB:L20966; NID:G347121; PIDN:  
C:Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'-  
F:405-633/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 23.6%; Score 567.5; DB 2; Length 736;  
Best Local Similarity 31.3%; Pred. No. 1.2e-36;  
Matches 129; Conservative 93; Mismatches 149; Indels 41; Gaps 8;

QY 66 KKKVKLLS-----FQRYFHASRLRGIIIPQAPLHLLDEYLGQARHMLSKVGWDFDIFL 121  
DB 298 KKKKQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELDLNK---WGLNIFN 354  
QY 122 FDLRTNGNSLVTLCHLNFTHGLIHFHFKLDVMTLHFLVMQVDYHSQNPYHNAHAADV 181  
DB 355 VAGYSHNRPLCTMYAIFQERDLTKFRISSTDTPIYMTLEDHYHSDVAYHNSLHAADV 414  
QY 182 TQAMHCYLKEPKLASFLTPDLIDMLGLLAAAHDVDPGVNQPLIKTNHHLNLYQNMSV 241

DB 415 AQSTHLLSTPALDAVFTDLEILAAIFAAAHVDHDPGVSNQFLINTNSLALMYNDES 474  
QY 242 LENHWRSTIGMLRES--LLAHLPKMTQDIEQQLGSLILATDINRQNEFLTRLKAHLH 299  
DB 475 LENHHLAVGFKLQEBCHDFMNLTKKQRTLRKQVDMVLATDMSKHSLADLTKTWE 534  
QY 300 NKD-----LRLEDAQDRHFMLOIALKCADICNPRCIWEMSKOWSERVCEEFVQGELEQ 353  
DB 535 TKKVTSSGVLNLDNYTDRIQVLNVMHVCADLSNPTKSLRYQMTDRIMEEFPQQDKER 594  
QY 354 KFEELISPLCNQOKDIPSIQIGFMSYIIEPLFREWHAFTGNTLSSENMLGHLAHNAQW 413  
DB 595 ERGMEISPCDKHTASVEKSVQGFIDYIVHPLWETWADLVQPD--AQDILTLEDNRNMY 652  
QY 414 KSLPLQHRSGSSGGP-----DHDHAG-----QGTSEEBEGD 448  
DB 653 QSMIPQ-----SPSPPLDEQNRDQGLMEKFQFELTDEEDSEGEKEGE 697

RESULT 10  
A54442  
3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17) 4A, CAMP-specific, long splice f  
N:Contains: 3',5'-cyclic AMP phosphodiesterase HPDE4A6 splice form  
C:Species: Homo sapiens (man)  
C:Date: 26-Jul-1996 #sequence\_revision 26-Jul-1996 #text\_change 09-Jul-2004  
C:Accession: A54442; S55788; A36317; S55787  
R:Bolger, G.; Michaeli, T.; Martins, T.; St. John, T.; Steiner, B.; Rodgers, L.; Riggs,  
Mol. Cell. Biol. 13, 6558-6571, 1993  
A:Title: A family of human phosphodiesterases homologous to the dunce learning and mem  
A:Reference number: A54442; MUID:94019330; PMID:8413254  
A:Accession: A54442  
A:Status: translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-886 <RES>  
A:Cross-references: UNIPROT:P27815; UNIPARC:UPI0000047003; GB:L20965; NID:G347119; PIDN:  
R:Sullivan, M.; Egerton, M.; Shakur, Y.; Marquardsen, A.; Houslay, M.D.  
Cell. Signal. 6, 793-812, 1994  
A:Title: Molecular cloning and expression, in both COS-1 cells and S. cerevisiae, of a h  
A:Reference number: S55788; MUID:95194817; PMID:7888306  
A:Accession: S55788  
A:Molecule type: mRNA  
A:Residues: 'MCPFPVTV', 210-735 'E', 737-886 <SUL>  
A:Cross-references: UNIPARC:UPI000002A6CE; EMBL:U18087; NID:G604374; PIDN:AAC50458.1; PI  
R:Livi, G.P.; Kmetz, P.; McHale, M.M.; Cieslinski, L.B.; Sathe, G.M.; Taylor, D.P.; Davi  
Mol. Cell. Biol. 10, 2678-2686, 1990  
A:Title: Cloning and expression of cDNA for a human low-K-m, rolipram-sensitive cyclic A  
A:Reference number: A36317; MUID:90258854; PMID:2160582  
A:Accession: A36317  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 'MCPFPVTV', 210-516 'Y', 518-722 'R', 724-726 'R', 728-735 'E', 737-788 'E', 790-  
A:Cross-references: UNIPARC:UPI000017C062; GB:M37744  
C:Genetics:  
A:Gene: GDB:PDE4A; DPDE2  
A:Cross-references: GDB:138776; OMIM:600126  
A:Map position: 19p13.1-19q12  
C:Keywords: alternative splicing; cAMP binding; phosphoric diester hydrolase  
F:432-660/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 23.5%; Score 565; DB 2; Length 886;  
Best Local Similarity 32.1%; Pred. No. 2.4e-36;  
Matches 126; Conservative 82; Mismatches 165; Indels 20; Gaps 6;

QY 69 VKELLSFQRYFHASRLRGIIIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLDRITNG 128  
DB 332 MSQITGLKMLHNSLNNSNIPRFGVTKTQDELLAQELENLNK---WGLNIFCVSYAGG 388  
QY 129 NSLVTLLCHLNFTHGLIHFHFKLDVMTLHFLVMQVDYHSQNPYHNAHAADVQAMHCY 188  
DB 389 RSLTCIMYMIQERDLKKFRIPDVTMTYMTLEDHYHADVAYHNSLHAADVLSQTHVL 448



QY 395 NSTLSNMLGHLAHNAQWKSLLPROHRSRGSSGSP-DHDHAGQG-----TE 441  
Db 649 PD--AQDILDTLSDNR-DW-----YHSATRQSPSPLEEEPGGLHPSLPDKFQFELTL 699  
QY 442 SEEQEGDS 449  
Db 700 EEEEDS 707

RESULT 13  
S71626  
3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17), cAMP-specific - human  
N;Alternate names: 3',5'-cyclic AMP phosphodiesterase  
C;Species: Homo sapiens (man)  
C;Date: 27-Nov-1997 #sequence\_revision 12-Dec-1997 #text\_change 09-Jul-2004  
C;Accession: S71626; I61356  
R;Engels, P.; Sullivan, M.; Mueller, T.; Luebbert, H.  
FEBS Lett. 350, 305-310, 1995  
A;Title: Molecular cloning and functional expression in yeast of a human cAMP-specific P  
A;Reference number: S71626; MUID:95145731; PMID:7843419  
A;Accession: S71626  
A;Molecule type: DNA  
A;Residues: 1-712 <ENG>  
A;Cross-references: UNIPROT:Q08493; UNIPARC:UPI0000163B31; EMBL:Z46632; NID:g727222; PID  
A;Experimental source: substantia nigra  
R;Bolger, G.; Michaeli, T.; Martins, T.; St. John, T.; Steiner, B.; Rodgers, L.; Riggs,  
Mol. Cell. Biol. 13, 6558-6574, 1993  
A;Title: A family of human phosphodiesterases homologous to the duncle learning and memora  
A;Reference number: A54442; MUID:94019330; PMID:8413254  
A;Accession: I61356  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: mRNA  
A;Residues: 462-712 <RES>  
A;Cross-references: UNIPARC:UPI000016AE86; GB:L20968; NID:g347125; PIDN:AAA03591.1; PID:  
C;Genetics:  
A;Gene: HSPB4C1  
C;Function:  
A;Description: cAMP hydrolysis; converts cAMP to non-cyclic AMP  
A;Pathway: cyclic nucleotide metabolism  
A;Note: expressed in various tissues but not in cells of the immune system  
C;Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'  
C;Keywords: phosphoric diester hydrolase  
F;387-615/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 23.0%; Score 553; DB 2; Length 712;  
Best Local Similarity 27.8%; Pred. No. 1.6e-35;  
Matches 135; Conservative 94; Mismatches 198; Indels 58; Gaps 10;

QY 11 EILFENPDQNAKVCVMGLDIRLRGQTGVRAERRGSYPFDIFRLN-----STTVSG-- 61  
Db 204 KLAETLDELWDCLDQLETLTQTRHSGVEMASNFKF-----RILNRELTHLSRSGNQ 257  
QY 62 -----EIGTKK-----KVKRLLSQRYPHASRLRGLRGIIPQAPLHLD 99  
Db 258 VSYIISRTFLDQQTVELPKVTABEAPQMSRISGLHGLCHSASLSATVPFRGVQTDQE 317  
QY 100 DYLGQARHMLSKVGMDFDIFLDRLTNGNSLVTLCHLNTGHLIHHFKLDMVTLLHREL 159  
Db 318 EQLAKE---LEDTNKGWLDVFKVADVSGNRPPLTAIFSIQERDLTKTFOIPADTLATYL 374  
QY 160 VMVQEDYHSQNPYHNAVAADVTQAMHCYLKEPKLASFLTPDIMGLLAAAHADVDPHG 219  
Db 375 LMLEGHYHANVAVHNSLHAADVQSTHVLATPALEAVFTDLLEALFASATHVDHPG 434  
QY 220 VNQPELTKTNHNLANYONNSVLNHHWRSTIGMLRESR---LLAHLPKEMTDIEQQLGS 277  
Db 435 VSNQFLINTNSDALMYNDASVLNHHHLAVGFKLLQAEQNCIDFQNLISAKORLSLRWID 494  
QY 278 LILATDINRQNEFLTRKLAHLHND-----LRLEDAQDRHFMQLKALCADI CNPCRIW 331  
Db 495 MVLATDMSKHMNLADLKTWVETKVTSLGLVLLDYSRDIQVQLNVHVCADLSNTKPL 554  
QY 332 EMSKQMSRVCBFFYRQGELEQKFELEISPLCNQKQKDSIPSIQIGFMSYIPELFWAH 591

Db 555 PLYRQWTDRIAMAEFFQGRERESGLDISPMCDKHTASVEKSOVGFDIYIAHLWETWAD 614  
QY 392 FTGNSTLSNMLGHLAHNAQWKSLLPROHRS-RGSSGSGPDH-----DHAGQGTSE 443  
Db 615 LVHPD--AQDILDTLSDNRWYQSKIPSPSDLTNPDRGDPDRFQFELTLEAEDEDEE 672  
QY 444 EQEGD 448  
Db 673 EEEGE 677

RESULT 14  
I67945  
3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17) - rat (fragment)  
N;Alternate names: cAMP phosphodiesterase 1  
C;Species: Rattus norvegicus (Norway rat)  
C;Date: 29-May-1998 #sequence\_revision 29-May-1998 #text\_change 09-Jul-2004  
C;Accession: I67945; A33904  
R;Bolger, G.B.; Rodgers, L.K.; Riggs, M.  
Gene 149, 237-244, 1994  
A;Title: Differential CNS expression of alternative mRNA isoforms of the mammalian genes  
A;Reference number: I53865; MUID:95047482; PMID:7958996  
A;Accession: I67945  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: mRNA  
A;Residues: 1-536 <RES>  
A;Cross-references: UNIPROT:P14644; UNIPARC:UPI0000127BF9; GB:L27061; NID:g436011; PIDN:  
R;Swinnen, J.V.; Joseph, D.R.; Conti, M.  
Proc. Natl. Acad. Sci. U.S.A. 86, 5325-5329, 1989  
A;Title: Molecular cloning of rat homologues of the Drosophila melanogaster duncle cAMP p  
A;Reference number: A33904; MUID:89315790; PMID:2546153  
A;Accession: A33904  
A;Status: preliminary  
A;Molecule type: mRNA  
A;Residues: 230-496 <SWI>  
A;Cross-references: UNIPARC:UPI00001759B4; GB:M25347; GB:M28410  
C;Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'  
C;Keywords: alternative splicing; cAMP binding; phosphoric diester hydrolase  
F;253-481/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>

Query Match 22.0%; Score 529.5; DB 2; Length 536;  
Best Local Similarity 30.8%; Pred. No. 7.5e-34;  
Matches 120; Conservative 79; Mismatches 169; Indels 21; Gaps 7;

QY 71 RLLSFQRYPHASRLRGLRGIIPQAPLHLDDEDYLGQARHMLSKVGMDFDIFLDRLTNGNS 130  
Db 156 QITGLRKSCHTS-LPTAAIPRFGVQTDQEQLAKE---LEDTNKGWLDVFKVAELSGNRP 211  
QY 131 LVTLLCHLNTGHLIHHFKLDMVTLLHRLFLVMQVEDYHSQNPYHNAVAADVTQAMHCYLK 190  
Db 212 LTAVIPRVQLERDLTKTFOIPADTLRLYLLTLEGHYHNVAVHNSIHAADVQSAHVLLG 271  
QY 191 EPKLASFLTPDIMGLLAAAHADVDPGVQNPPELTKTNHNLANYONNSVLNHHWRST 250  
Db 272 TPALEAVFTDLLEALFASATHVDHPGVSNQFLINTNSLALMYNDSSVLNHHHLAVG 331  
QY 251 IGMRESR---LLAHLPKEMTDIEQQLGLIATDINRQNEFLTRKLAHLHND----- 302  
Db 332 FKLLQAEQNCIDFQNLISAKORLSLRWIDVATDMSKHMNLADLKTWVETKVTSLGV 391  
QY 303 LRLEDAQDRHFMQLKALCADI CNPCRIWMSKQMSRVCBFFYRQGELEQKFELEISPL 362  
Db 392 LLLDYSRDIQVQLNVHVCADLSNPAKPLPLVRQWTERIMAEFFQGRERESGLDISPM 451  
QY 363 CNQKQKDSIPSIQIGFMSYIPELFWAHFTGNSTLSNMLGHLAHNAQWKSLLPROHR 422  
Db 452 CDKHTASVEKSOVGFDIYIAHLWETWADLVHPD---AQELDTLEDNRWYQSRVP---- 505  
QY 423 SRGSSGSGPDH---DHAGQGTSEEOEGD 448  
Db 506 CSPHPAIGDRPKFELTLEETEEDDE 534

RESULT 15  
T16769  
hypothetical protein R153.1 - Caenorhabditis elegans  
C:Species: Caenorhabditis elegans  
C:Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004  
C:Accession: T16769  
R:Kirsten, J.  
submitted to the EMBL Data Library, June 1995  
A:Description: The sequence of C. elegans cosmid R153.  
A:Reference number: Z18573  
A:Accession: T16769  
A:Status: preliminary; translated from GB/EMBL/DDBJ  
A:Molecule type: DNA  
A:Residues: 1-549 <KIR>  
A:Cross-references: UNIPROT:Q22000; UNIPARC:UPI000013C0D8; EMBL:U28729; NID:G861238; PID  
A:Experimental source: strain Bristol N2  
C:Genetics:  
A:Gene: CESP:R153.1  
A:Introns: 25/2; 56/3; 91/1; 116/3; 163/3; 304/3; 338/1; 389/3; 430/3; 491/3  
C:Superfamily: 3',5'-cyclic-nucleotide phosphodiesterase 1B, calmodulin-dependent; 3',5'  
F:281-509/Domain: 3',5'-cyclic-nucleotide phosphodiesterase homology <CNP>  
  
Query Match 21.5%; Score 517; DB 2; Length 549;  
Best Local Similarity 32.6%; Pred. NO. 7.5e-33;  
Matches 114; Conservative 72; Mismatches 140; Indels 24; Gaps 6;  
  
QY 105 ARHMLSKVGWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRFLVMVOE 164  
DB 216 AVHM-QRLDDWGDPVEFKIDELSKNHSLTVTFTSLLQRNLFKTFEIHQSTLVTLNLSH 274  
  
QY 165 DYHSQNPYHNAHAAVTOAMHCYLKEPKLAGFLTPLDIMLGLAAAHVDVHPGVNQPF 224  
DB 275 HYRN-NHYNFHFAADVAQSMVLLMSPVLTFTDLEVLAAIFAGAVHDVHPGETNOY 333  
  
QY 225 LIKTNHHLANLYONMSVLENHHRSTIGMLRESR--LLAHLPKEMTQDIEQQLGSLILAT 282  
DB 334 LINSNNELAIMYNDSEVLQHLAVAFKLLQDSNCDFLANLSRKQRLQPKIVIDWVLAT 393  
  
QY 283 DINRQNEFLRLKAHLH-----NKDLRLDAQDRHFMLOIALKCADICNPCRIMEMSKQ 336  
DB 394 DMSKMSLLADLKTMYEAKKVAGNNVIVLDKYNDKIQLQSMIHLADLSNPTKPIELYQQ 453  
  
QY 337 WSERVCEEYFROGELEQKPELEISPLCNOQKDSIPSIGFMSYIPEPLFREWAHFTGNS 396  
DB 454 WQRIWEEYWRQDKEKEGLGISPMCDRGNTIEKSVQGFIDYIVHPLYETWADLVYPD 513  
  
QY 397 TISENMLGHLAHNAQWKSLLPQHRSGSGSGSPDHDHAGQGTSEEOE 446  
DB 514 --AQNILDQLEENREWYQSRIPE-----EPDTARTVTEDDEHK 549

Search completed: March 10, 2006, 20:03:03  
Job time : 32.0976 secs

GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 19:52:25 ; Search time 187.805 Seconds  
(without alignments)  
1690.519 Million cell updates/sec

Title: US-10-781-181-5  
Perfect score: 2408  
Sequence: 1 MSLWVERGCEILFNPQDN.....PDHDHAGQCTESEBQGDSP 450

Scoring table:  
BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Uniprot 05.80.\*  
1: uniprot\_sprot.\*  
2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	2408	100.0	450	1 PDE7B_HUMAN	Q9np56 homo sapien
2	2408	100.0	450	2 Q5VWY9_HUMAN	Q5vwy9 homo sapien
3	2258	93.8	586	2 Q4L8B1_HUMAN	Q4l8b1 homo sapien
4	2192	91.0	446	1 PDE7B_MOUSE	Q9gqx1 mus musculus
5	2178	90.4	446	2 Q8VIE4_RAT	Q8vie4 rattus norv
6	2178	90.4	446	2 Q8CEB2_MOUSE	Q8ceb2 mus musculus
7	2161.5	89.8	459	2 Q8VIE2_RAT	Q8vie2 rattus norv
8	1764	73.3	359	2 Q8VIE3_RAT	Q8vie3 rattus norv
9	1510.5	62.7	456	2 Q4RR95_TETNG	Q4rr95 tetraodon n
10	1425.5	59.2	456	1 PDE7A_MOUSE	P70453 mus musculus
11	1424.5	59.2	482	2 Q6P5G2_MOUSE	Q6p5g2 mus musculus
12	1419.5	58.9	482	1 PDE7A_HUMAN	Q13946 homo sapien
13	1418.5	58.9	456	2 Q5R5B5_PONPY	Q5r5b5 pongo pygma
14	1397.5	58.0	426	1 PDE7A_RAT	Q08593 rattus norv
15	1287	53.4	424	2 Q96T72_HUMAN	Q96t72 homo sapien
16	1267.5	52.6	381	2 Q50SM0_XENILA	Q50sm0 xenopus lae
17	1107.5	46.0	324	2 Q4R6T4_MACFA	Q4r6t4 macaca fasc
18	872	36.2	305	2 Q7PNP5_ANOGA	Q7pnp5 anophelles g
19	711	29.5	199	2 Q4VXJ0_HUMAN	Q4vxj0 homo sapien
20	604.5	25.1	809	1 PDE4D_HUMAN	Q08499 homo sapien
21	603.5	25.1	803	1 PDE4D_RAT	P14270 rattus norv
22	600.5	24.9	747	1 PDE4D_MOUSE	Q01063 mus musculus
23	580.5	24.1	659	2 Q8VD81_RAT	Q8vd81 rattus norv
24	580.5	24.1	721	1 PDE4B_RAT	P14846 rattus norv
25	580.5	24.1	722	2 Q5RKL0_RAT	Q5rkl0 rattus norv
26	580.5	24.1	736	2 Q8VD82_RAT	Q8vd82 rattus norv
27	579.5	24.1	691	2 Q4R3J0_TETNG	Q4r3j0 tetraodon n
28	579	24.0	563	2 Q5ZXR6_CHICK	Q5zxr6 gallus gall
29	574.5	23.9	721	2 Q9QX17_MOUSE	Q9qxi7 mus musculus
30	573.5	23.8	503	2 Q61QY6_MOUSE	Q61qy6 mus musculus
31	573.5	23.8	542	2 Q91VY2_MOUSE	Q91vy2 mus musculus

32	573.5	23.8	682	2 Q5XGT5_XENILA	Q5xgt5 xenopus lae
33	573.5	23.8	721	2 Q8VBU5_MOUSE	Q8vbu5 mus musculus
34	572	23.8	683	2 Q4SBL4_TETNG	Q4sbl4 tetraodon n
35	568	23.6	867	2 Q4RL51_TETNG	Q4rl51 tetraodon n
36	567.5	23.6	564	2 Q5T3Z8_HUMAN	Q5t3z8 homo sapien
37	567.5	23.6	606	2 Q13945_HUMAN	Q13945 homo sapien
38	567.5	23.6	721	2 Q5VTH5_HUMAN	Q5vth5 homo sapien
39	567.5	23.6	726	2 Q59GM8_HUMAN	Q59gm8 homo sapien
40	567.5	23.6	736	1 PDE4B_HUMAN	Q07343 homo sapien
41	567.5	23.6	736	2 Q5VTH7_HUMAN	Q5vth7 homo sapien
42	565	23.5	647	2 Q8IVA7_HUMAN	Q8iva7 homo sapien
43	565	23.5	825	2 Q9H3H2_HUMAN	Q9h3h2 homo sapien
44	565	23.5	860	2 Q5DM53_HUMAN	Q5dm53 homo sapien
45	565	23.5	864	2 Q6PMT2_HUMAN	Q6pmt2 homo sapien

## ALIGNMENTS

## RESULT 1

ID	PDE7B_HUMAN	STANDARD;	PRT;	450 AA.
AC	Q9NP56;			
DT	16-OCT-2001 (Rel. 40, Created)			
DT	16-OCT-2001 (Rel. 40, Last sequence update)			
DT	10-MAY-2005 (Rel. 47, Last annotation update)			
DE	CAMP-specific 3',5'-cyclic phosphodiesterase 7B (EC 3.1.4.17).			
GN	Name=PDE7B;			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;			
OC	Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;			
OC	Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE.			
RC	TISSUE=Brain;			
RX	MEDLINE=20275458; PubMed=10814504; DOI=10.1006/bbrc.2000.2661;			
RA	Sasaki T., Kotera J., Yuasa K., Omori K.;			
RT	"Identification of human PDE7B, a CAMP-specific phosphodiesterase.";			
RL	Biochem. Biophys. Res. Commun. 271:575-583(2000).			
RN	[2]			
RP	NUCLEOTIDE SEQUENCE.			
RC	TISSUE=Fetal brain;			
RX	MEDLINE=20329226; PubMed=10872825; DOI=10.1006/bbrc.2000.2743;			
RA	Gardner C.E., Robas N.M., Cawkill D., Fidock M.D.;			
RT	"Cloning and characterization of the human and mouse PDE7B, a novel			
RL	CAMP-specific nucleotide phosphodiesterase.";			
RL	Biochem. Biophys. Res. Commun. 272:186-192(2000).			
RN	[3]			
RP	NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].			
RC	TISSUE=Brain;			
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;			
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,			
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,			
RA	Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,			
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,			
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,			
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,			
RA	Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,			
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Gunaratne P.H.,			
RA	Bosak S.A., McWan P.J., McKernan K.J., Malek J.A., Guntatne P.H.,			
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,			
RA	Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			
RA	Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,			
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,			
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E.,			
RA	Schmerch A., Schein J.E., Jones S.J.M., Marra M.A.;			
RT	"Generation and initial analysis of more than 15,000 full-length human			
RL	and mouse cDNA sequences.";			
CC	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).			
	-!- FUNCTION: May be involved in the control of cAMP-mediated neural			

activity and cAMP metabolism in the brain.  
-|- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O =  
adenosine 5'-phosphate.  
-|- COFACTOR: Divalent cations (By similarity).  
-|- ENZYME REGULATION: Inhibited by dipyradimole, IBMX and SCH51866.  
-|- INSENSITIVE TO zaprinast, rolipram, and milrinone.  
-|- PATHWAY: Cyclic nucleotide metabolism.  
-|- TISSUE SPECIFICITY: Highly expressed in brain. Also expressed in  
heart, liver, skeletal muscle and pancreas.  
-|- DOMAIN: Composed of a C-terminal catalytic domain containing two  
putative divalent metal sites and an N-terminal regulatory domain.  
-|- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase  
family.  
-----  
This Swiss-Prot entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use as long as its content is in no way modified and this statement is not  
removed.  
-----  
EMBL; AB038040; BAA96537.1; -; mRNA.  
EMBL; AJ251860; CAB92441.1; -; mRNA.  
EMBL; BC075082; AAH75082.1; -; mRNA.  
EMBL; BC075083; AAH75083.1; -; mRNA.  
PIR; JC7266; JC7266.  
PDB; 1LXW; Model; A=104-433.  
Ensembl; ENSG00000171408; Homo sapiens.  
HGNC; HGNC:8792; PDE7B.  
MIM; 604645; -;  
GO; GO:0004115; F:cAMP-specific phosphodiesterase activity; TAS.  
GO; GO:0007165; P:signal transduction; TAS.  
GO; GO:0007268; P:synaptic transmission; TAS.  
InterPro; IPR002073; PDEase.  
Pfam; PF00233; PDEase\_I; 1.  
PRINTS; PR00387; PDIESTERASE1.  
PROSITE; PS00126; PDEASE\_I; 1.  
3D-structure; CAMP; Hydrolase.  
FT REGION 172 410 Catalytic (By similarity).  
SQ SEQUENCE 450 AA; 51835 MW; EC142BF3E28D0028 CRC64;  
Query Match 100.0%; Score 2408; DB 1; Length 450;  
Best Local Similarity 100.0%; Pred. No. 3.3e-178;  
Matches 450; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MSCLWVERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERRGSPYFIDFRLNLTSTYS 60  
DB 1 MSCLWVERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERRGSPYFIDFRLNLTSTYS 60  
QY 61 GEIGTKKKVKRLLSQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIF 120  
DB 61 GEIGTKKKVKRLLSQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIF 120  
QY 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRLVMVQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRLVMVQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPFLIKTNHHLANLYQNS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPFLIKTNHHLANLYQNS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLN 300  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLN 300  
QY 301 KDLRLDAQDRHFMQLKACADINPCRIMWSKQSERVCEEPYRQGELEQKPELIS 360  
DB 301 KDLRLDAQDRHFMQLKACADINPCRIMWSKQSERVCEEPYRQGELEQKPELIS 360  
QY 361 PLCNQKDSISIQIGFMSYIVPELFWAHPGTGNTSENMLGHLAHNKQWKSLLPRQ 420  
DB 361 PLCNQKDSISIQIGFMSYIVPELFWAHPGTGNTSENMLGHLAHNKQWKSLLPRQ 420  
QY 421 HRSRSGSGDPDHAGOGTSESEQEGDSP 450

||||| 421 HRSRSGSGDPDHAGOGTSESEQEGDSP 450  
RESULT 2  
QSVVY9 HUMAN  
ID QSVVY9 HUMAN PRELIMINARY; PRT; 450 AA.  
AC QSVVY9;  
DT 01-FEB-2005 (TREMBLrel. 29, Created)  
DT 01-FEB-2005 (TREMBLrel. 29, Last sequence update)  
DT 13-SEP-2005 (TREMBLrel. 31, Last annotation update)  
DE OTTHUMP00000017267.  
GN Name=PDE7B; ORFNames=RP11-472B5.2-001;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RA Thomas D.;  
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP NUCLEOTIDE SEQUENCE.  
RA Williams S.;  
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RA Cobley V.;  
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AL360178; CAH73075.1; -; Genomic DNA.  
DR EMBL; AL138828; CAI95287.1; -; Genomic DNA.  
DR EMBL; AL133319; CAH73332.1; -; Genomic DNA.  
DR EMBL; AL133319; CAH73075.1; JOINED; Genomic DNA.  
DR EMBL; AL138828; CAH73075.1; JOINED; Genomic DNA.  
DR EMBL; AL138828; CAH73332.1; JOINED; Genomic DNA.  
DR EMBL; AL133319; CAI95287.1; JOINED; Genomic DNA.  
DR EMBL; AL133319; CAH73332.1; JOINED; Genomic DNA.  
DR EMBL; AL360178; CAH73332.1; JOINED; Genomic DNA.  
DR EMBL; AL360178; CAI95287.1; JOINED; Genomic DNA.  
DR Ensembl; ENSG00000171408; Homo sapiens.  
DR GO; GO:0004114; F:3',5'-cyclic nucleotide phosphodiesterase a. . .; IEA.  
DR GO; GO:0003824; P:catalytic activity; IEA.  
DR GO; GO:0007165; P:signal transduction; IEA.  
DR InterPro; IPR003607; Met\_phos\_hydro.  
DR InterPro; IPR002073; PDEase.  
DR PRINTS; PR00387; PDIESTERASE1.  
DR SMART; SM00471; HDC; 1.  
DR PROSITE; PS00126; PDEASE\_I; 1.  
SQ SEQUENCE 450 AA; 51835 MW; EC142BF3E28D0028 CRC64;  
Query Match 100.0%; Score 2408; DB 2; Length 450;  
Best Local Similarity 100.0%; Pred. No. 3.3e-178;  
Matches 450; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MSCLWVERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERRGSPYFIDFRLNLTSTYS 60  
DB 1 MSCLWVERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERRGSPYFIDFRLNLTSTYS 60  
QY 61 GEIGTKKKVKRLLSQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIF 120  
DB 61 GEIGTKKKVKRLLSQRYFHASRLRGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIF 120  
QY 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRLVMVQEDYHSQNPYHNAVHAAD 180  
DB 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDWVTLHRLVMVQEDYHSQNPYHNAVHAAD 180  
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPFLIKTNHHLANLYQNS 240  
DB 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHPGVNQPFLIKTNHHLANLYQNS 240  
QY 241 VLENHHRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLN 300  
DB 241 VLENHHRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLN 300



Db 241 VLENHWRSTIGMLRESLLAHLPKEMTQDIEQQLSLILATDINRQNEFLTRLKAHLN 300  
Qy 301 KDLRLDAQDRHFMQLKALCADICNPRIWMSKQWSEVCEFYRQGELEQKFELEIS 360  
Db 301 KDLRLDAQDRHFMQLKALCADICNPRIWMSKQWSEVCEFYRQGELEQKFELEIS 360  
Qy 361 PLCNQKQDSISIOIGFMSYIVELPFRWAHFTGNSTSENMLGHLAHNAKQWLSLPRQ 420  
Db 361 PLCNQKQDSISIOIGFMSYIVELPFRWAHFTGNSTSENMLGHLAHNAKQWLSLPRQ 420  
Qy 421 HRSRSGSGPDHHDAGQGTSEEGDSP 450  
Db 421 HRSRSGSGPDHHDAGQGTSEEGDSP 450

RESULT 3  
Q4LE81 HUMAN  
ID Q4LE81 HUMAN PRELIMINARY; PRT; 586 AA.  
AC Q4LE81,  
DT 13-SEP-2005 (TrEMBLrel. 31, Created)  
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)  
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)  
DE PDE7B variant protein (fragment).  
GN Name=PDE7B variant protein;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN NUCLEOTIDE SEQUENCE.  
RP TISSUE=Brain;  
RA Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,  
RA Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;  
RT "Preparation of a set of expression-ready clones of mammalian long  
RT cDNAs encoding large proteins by the ORF trap cloning method."  
RL Submitted (MAR-2005) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AB209990; BAE06072.1; -; mRNA.  
FT NON TER 1  
SQ SEQUENCE 586 AA; 66230 MW; F96F4F0549A9FE8D CRC64;

Query Match 93.8%; Score 2258; DB 2; Length 586;  
Best Local Similarity 100.0%; Pred. No. 2e-166;  
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDRLRGOTGVAERGSYPIDFRLNSTYTSIGETGKVKVRLLSQRYFHASRLRG 87  
Db 164 GDRLRGOTGVAERGSYPIDFRLNSTYTSIGETGKVKVRLLSQRYFHASRLRG 223  
Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFDLRTNGNSLVTLCHLFTNTHGLIHH 147  
Db 224 IIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFDLRTNGNSLVTLCHLFTNTHGLIHH 283  
Qy 148 PKLDVTLHRLFMVQEDYHSQNPYHNAHADVTQAMHCYKPKLASFLTPDLMGL 207  
Db 284 PKLDVTLHRLFMVQEDYHSQNPYHNAHADVTQAMHCYKPKLASFLTPDLMGL 343  
Qy 208 LAAAHVDVHPGVNQPFLIKTNHNLANYQNMSVLENHHRSTIGMLRESLLAHLPKEM 267  
Db 344 LAAAHVDVHPGVNQPFLIKTNHNLANYQNMSVLENHHRSTIGMLRESLLAHLPKEM 403  
Qy 268 TDIEQQQLSLILATDINRQNEFLTRLKAHLNKLRLDAQDRHFMQLKALCADICNP 327  
Db 404 TDIEQQQLSLILATDINRQNEFLTRLKAHLNKLRLDAQDRHFMQLKALCADICNP 463  
Qy 328 CRIMWSKQWSEVCEFYRQGELEQKFELEISPLCNQKQDSISIOIGFMSYIVELPFR 387  
Db 464 CRIMWSKQWSEVCEFYRQGELEQKFELEISPLCNQKQDSISIOIGFMSYIVELPFR 523  
Qy 388 EWAHFTGNSTSENMLGHLAHNAKQWLSLPRQHSRSGSGPDHHDAGQGTSEEG 447  
Db 524 EWAHFTGNSTSENMLGHLAHNAKQWLSLPRQHSRSGSGPDHHDAGQGTSEEG 583

Qy 448 DSP 450  
Db 584 DSP 586

RESULT 4  
PDE7B MOUSE  
ID PDE7B\_MOUSE STANDARD; PRT; 446 AA.  
AC Q9OXQ1;  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 10-MAY-2005 (Rel. 47, Last annotation update)  
DE CAMP-specific 3', 5'-cyclic phosphodiesterase 7B (BC 3.1.4.17).  
GN Name=Pde7b;  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridea; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN NUCLEOTIDE SEQUENCE.  
RP MEDLINE=20087273; PubMed=10618442; DOI=10.1073/pnas.97.1.472;  
RA Hetman J.M., Soderling S.H., Glavas N.A., Beavo J.A.;  
RT "Cloning and characterization of PDE7B, a CAMP-specific  
RT phosphodiesterase".  
RL Proc. Natl. Acad. Sci. U.S.A. 97:472-476(2000).  
RN NUCLEOTIDE SEQUENCE.  
RC STRAIN=C57BL/6J;  
RX MEDLINE=20329226; PubMed=10872825; DOI=10.1006/bbrc.2000.2743;  
RA Gardner C.E., Robas N.M., Cawkill D., Fildock M.D.;  
RT "Cloning and characterization of the human and mouse PDE7B, a novel  
RT CAMP-specific nucleotide phosphodiesterase".  
RL Biochem. Biophys. Res. Commun. 272:186-192(2000).  
CC -1- FUNCTION: May be involved in the control of cAMP-mediated neural  
CC activity and cAMP metabolism in the brain.  
CC -1- CATALYTIC ACTIVITY: Adenosine 3', 5'-cyclic phosphate + H(2)O =  
CC adenosine 5'-phosphate.  
CC -1- COFACTOR: Divalent cations (By similarity).  
CC -1- ENZYME REGULATION: Inhibited by diprydamole, IBMX and SCH51866.  
CC Insensitive to zaprinast, rolipram, and milrinone.  
CC -1- PATHWAY: Cyclic nucleotide metabolism.  
CC -1- TISSUE SPECIFICITY: Highly expressed in brain.  
CC -1- DOMAIN: Composed of a C-terminal catalytic domain containing two  
CC putative divalent metal sites and an N-terminal regulatory domain.  
CC -1- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase  
CC family.  
CC  
CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use as long as its content is in no way modified and this statement is not  
CC removed.  
CC  
CC EMBL; AF190639; AAP25195.1; -; mRNA.  
CC EMBL; AJ251859; CAB92530.1; -; mRNA.  
CC HSSP; Q08499; 10YN.  
CC Ensembl; ENSMUSG00000019990; Mus musculus.  
CC MGI; MGI:1352752; Pde7b.  
CC GO; GO:0004115; F:cAMP-specific phosphodiesterase activity; IDA.  
CC InterPro; IPR002073; PDEase.  
CC Pfam; PF00233; PDEase\_1; 1.  
CC PRINTS; PR00387; PDIESTERASE1.  
CC PROSITE; PS00126; PDEASE\_1; 1.  
KW CAMP; Hydrolase.  
.. FT REGION 172 410 Catalytic (By similarity).  
SQ SEQUENCE 446 AA; 51337 MW; 7C052664B693A5A8 CRC64;

Query Match 91.0%; Score 2192; DB 1; Length 446;  
Best Local Similarity 91.6%; Pred. No. 1.9e-161;  
Matches 413; Conservative 13; Mismatches 19; Indels 6; Gaps 2;

Qy 1 MSLMVERCGEILPENPDQNAKVCMLGDIRLQGTGVAERRGSYPIDFRLNSTYTS 60



Db 61 GEIGTKKKVKRLLSFPORYFHASRLLRGGIIPQAPLHLLDDEYLGQARHMLSKVGTWDFDIF 120  
 QY 121 LFDRLTNGNSLVTLTCLHLENTHGLIHHFKLDVMVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180  
 Db 121 LFDRLTNGNSLVTLTCLHFNHSHGLIHHFKLDVMVTLHRFLVMVQEDYHGHNPYHNAVHAAD 180  
 QY 181 VTQAMHCYILKEPKLASFLTPDLMGLGLLAAAHDVDHPGVNQPFLLKTNHHLANLQNMS 240  
 Db 181 VTQAMHCYILKEPKLASFLTPDLMGLGLLAAAHDVDHPGVNQPFLLKTNHHLANLQNMS 240  
 QY 241 VLENHHWRSTIGMWRRESRLLAHLPEKMTQDIEQOLGSLLIATDINRQNEFLTRLKAHLN 300  
 Db 241 VLENHHWRSTIGMWRRESRLLAHLPEKMTQDIEQOLGSLLIATDINRQNEFLTRLKAHLN 300  
 QY 301 KDLRLDADQRHFMQLQIALKCADICNPCRIMWMSKQMSERVCEEFYRQGELEQKFELEIS 360  
 Db 301 KDLRLNVQDRHFMQLQIALKCADICNPCRIMWMSKQMSERVCEEFYRQGELEQKFELEIS 360  
 QY 361 PLCNQOKDSIPSIQIGFMFYIIEPLPREWAHFTGNTLSNMLGLAHNAKQWKSLLPRQ 420  
 Db 361 PLCNQOKDSIPSIQIGFMFYIIEPLPREWAFRTGNTLSNMLSHLNAKQWKSLLSNQ 420  
 QY 421 HRRSGSGSGPDHHDHAGQGTSEEQ-EGDSP 450  
 Db 421 HRRSGS-----QDLAGPAPETLEQTEGATP 446

RESULT 7  
 Q8VIE2\_RAT PRELIMINARY; PRT; 459 AA.  
 AC Q8VIE2;  
 DT 01-MAR-2002 (TrEMBLrel. 20, Created)  
 DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE Cyclic nucleotide phosphodiesterase 7B4 (EC 3.1.4.17).  
 GN Name=Pde7b; Synonyms=RNPDE7B;  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 CC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
 CC Muridae; Murinae; Rattus.  
 OC NCBI\_TaxID=101116;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE.  
 RC TISSUS=Skeletal muscle;  
 RA Sasaki T., Kotera J., Omori K.;  
 RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.  
 DR ENBL; AB057411; BAB79639.1; -, mRNA.  
 DR HSP; Q08499; IOYN.  
 DR Ensembl; ENSRNOG0000013436; Rattus norvegicus.  
 DR RGD; 621016; Pde7b.  
 DR GO; GO:0044114; F.3.3', 5'-cyclic-nucleotide phosphodiesterase a. . . ; IEA.  
 DR GO; GO:0016787; P:hydrolase activity; IEA.  
 DR GO; GO:0007165; P:signal transduction; IEA.  
 DR InterPro; IPR003607; Met\_phos\_hydro.  
 DR InterPro; IPR002073; PDEase.  
 DR Pfam; PF00233; PDEase I; 1.  
 DR PRINTS; PR00387; PDIESTERASE1.  
 DR SMART; SM00471; Hdc; 1.  
 DR PROSITE; PS00126; PDEASE\_I; UNKNOWN\_1.  
 KW Hydrolase.  
 SQ SEQUENCE. 459 AA; 52680 MW; A3F26B95C7FC00A5 CRC64;

Query Match 89.8%; Score 2161.5; DB 2; Length 459;  
 Best Local Similarity 88.1%; Pred. No. 4.5e-159;  
 Matches 409; Conservative 16; Mismatches 20; Indels 19; Gaps 3;

QY 1 MSCLMYRCEGILFENPDQNAKVCVCL-----GBIRLQGTGVRAERGSYP 47  
 Db 1 MSCLMYRCEGVLFENPEQNVCVCLAA5SPPLPMAGQGDVRLRGQGVPAERGSYP 60  
 QY 48 FDFRLLNNTTYSGETGKTKVKRLLSFPORYFHASRLLRGGIIPQAPLHLLDDEYLGQARH 107  
 Db 61 FDFRLLNNTTYSGETGSKKVKRLLSFPORYFHASRLLRGGIIPQAPLHLLDDEYLGQARH 120

```
QY 108 MLSKVGWDFDI FLDRLTNGNSLVTLCHLFNTHGLIHHFKLDMTLHRLFLVMVDYH 167
Db 121 MLSKVGWDFDI FLDRLTNGNSLVTLCHLFNTHGLIHHFKLDMTLHRLFLVMVDYH 180
QY 168 SQNPYHNAHAADVQAMHCYLKEPKLASFLTPDLIMGLLAAAHDVDPGVNQPFLLK 227
Db 181 GHPYHNAHAADVQAMHCYLKEPKLASFLTPDLIMGLLAAAHDVDPGVNQPFLLK 240
QY 228 TNHHLANLYQNMVLENHHWRSTIGMLRESRLAHLPKEMTDI EQLGLSLIATDINRQ 287
Db 241 TNHHLANLYQNMVLENHHWRSTIGMLRESRLAHLPKEMTDI EQLGLSLIATDINRQ 300
QY 288 NEFLTRLKAHLHNKDLRLDAQDRHFMLOIALKADICNPCR TWEMSKWSEVCEEFYR 347
Db 301 NEFLTRLKAHLHNKDLRLDAQDRHFMLOIALKADICNPCR TWEMSKWSEVCEEFYR 360
QY 348 QGELEQKFELEISPLCNQKXDSIPSIQIGFMSYIVPEPLFREWAFHTGNSLTSENMLGHLA 407
Db 361 QGDLEQKFELEISPLCNQKXDSIPSIQIGFMTYIVPEPLFREWAFHTGNSLTSENMLNHLA 420
QY 408 HNKAAQWKSLLPRQHRSGSGSPDHDHAGQGTESEEQ-EGDSP 450
Db 421 HNKAAQWKSLLSNQHRRGSG-----QDPAGTAPETLEQTEGATP 459

RESULT 8
Q8VIE3_RAT PRELIMINARY; PRT; 359 AA.
AC Q8VIE3;
DT 01-MAR-2002 (T-EMBLrel. 20, Created)
DT 01-MAR-2002 (T-EMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (T-EMBLrel. 26, Last annotation update)
DE Cyclic nucleotide phosphodiesterase 7B3 (SC 3.1.4.17).
GN Names-Pde7b; Synonyms-RNPDE7B;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Testis;
RA Sasaki T., Kotera J., Omori K.;
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB057410; BAB79638.1; -, mRNA.
DR HSSP; Q08499; 10YN.
DR RGD; 621016; Pde7b.
DR GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase a. . .; IEA.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR GO; GO:0007165; P:signal transduction; IEA.
DR InterPro; IPR003607; Met_phos_hydro.
DR InterPro; IPR002073; PDEase.
DR Pfam; PF00233; PDEase I; 1.
DR PRINTS; PR00387; PDIESTERASE1.
DR SMART; SM00471; HDC; 1.
DR PROSITE; PS00126; PDEASE_I; UNKNOWN_1.
KW Hydrolase.
SQ SEQUENCE 359 AA; 41456 MW; 0FF72792737CE48A CRC64;

Query Match 73.3%; Score 1764; DB 2; Length 359;
Best Local Similarity 92.0%; Pred. No. 2.3e-128;
Matches 333; Conservative 7; Mismatches 16; Indels 6; Gaps 2;

QY 90 PQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHHFK 149
Db 3 PQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHHFK 62
QY 150 LDMVTLHRLFLVMVQEDYHSONPVHNAHADVTQAMHCYLKEPKLASFLTPDLIMGLLA 209
Db 63 LDMVTLHRLFLVMVQEDYHGNPVHNAHADVTQAMHCYLKEPKLASFLTPDLIMGLLA 122
QY 210 AAAHDVDHPGVNQPFLLKTNHHLANLYQNMVLENHHWRSTIGMLRESRLAHLPKEMTQ 269
```

```
Db 123 AAAHDVDHPGVNQPFLLKTNHHLANLYQNMVLENHHWRSTIGMLRESRLAHLPKEMTQ 182
QY 270 DIEQQLGSLIATDINRQNEFLTRLKAHLHNKDLRLDAQDRHFMLOIALKADICNPCR 329
Db 183 DIEQQLGSLIATDINRQNEFLTRLKAHLHNKDLRLDAQDRHFMLOIALKADICNPCR 242
QY 330 IWEMSKWSEVCEEFYRQGELEQKFELEISPLCNQKXDSIPSIQIGFMSYIVPEPLFREW 389
Db 243 IWEMSKWSEVCEEFYRQGELEQKFELEISPLCNQKXDSIPSIQIGFMTYIVPEPLFREW 302
QY 390 AHFTGNSLTSENMLGHLAHLNKAAQWKSLLPRQHRSGSGSPDHDHAGQGTESEEQ-EGD 448
Db 303 ARFTGNSLTSENMLNHLAHLNKAAQWKSLLSNQHRRGSG-----QDPAGTAPETLEQTEGA 357
QY 449 SP 450
Db 358 TP 359

RESULT 9
Q4RR95_TETNG PRELIMINARY; PRT; 456 AA.
AC Q4RR95;
DT 13-SEP-2005 (T-EMBLrel. 31, Created)
DT 13-SEP-2005 (T-EMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (T-EMBLrel. 31, Last annotation update)
DE Chromosome 14 SCAF15003, whole genome shotgun sequence.
DE (fragment).
GN ORFNames=GSTENG00030267001;
OS Tetraodon nigroviridis (Green puffer).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
OC Tetraodontidae; Tetraodontidae; Tetraodon.
OX NCBI_TaxID=99883;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Jaillon O., Aury J.M., Brunet F., Petit J.L., Stange-Thomann N.,
RA Mauceli E., Bouneau L., Fischer C., Orouf-Costaz C., Bernot A.,
RA Nicaud S., Jaife D., Fisher S., Lutfalla G., Dossat C., Segurens B.,
RA Dasilva C., Salanoubat M., Levy M., Boudet N., Castellano S.,
RA Anthouard V., Jubin C., Castellani V., Katinka M., Vacherie B.,
RA Biemont C., Skalli Z., Cattolico L., Poullain J., De Berardinis V.,
RA Cruaud C., Duprat S., Brottier P., Coutanceau J.P., Gouzy J.,
RA Parra G., Lardier G., Chapple C., McKernan K.J., McEwan P., Bosak S.,
RA Kellis M., Volff J.N., Guigo R., Zody M.C., Mesirov J.,
RA Lindblad-Toh K., Birren B., Nusbaum C., Kahn D., Robinson-Rechavi M.,
RA Laudet V., Schachter V., Quetier F., Saurin W., Scarpelli C.,
RA Wincker P., Lander E.S., Weissbach J., Roest Crollius H.;
RT "Genome duplication in the teleost fish Tetraodon nigroviridis reveals
RT the early vertebrate proto-karyotype.";
RL Nature 431:946-957(2004).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RG Genoscope; Whitehead Institute Centre for Genome Research;
RL Submitted (FEB-2004) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; CAAB01015003; CAG09087.1; -, Genomic_DNA.
FT NON_TER 1 1
FT NON_TER 456 456
SQ SEQUENCE 456 AA; 52118 MW; 60B4805381D70669 CRC64;

Query Match 62.7%; Score 1510.5; DB 2; Length 456;
Best Local Similarity 64.5%; Pred. No. 1.4e-108;
Matches 294; Conservative 52; Mismatches 63; Indels 47; Gaps 8;

QY 7 ERGCEILFENPDQNAKVCVML-----GDRL-RGQTGV-RAERGSYP 47
Db 1 QRCGAVTLTSPQNAVQVRMLDRHVDRNRPKHLPAASIAECKLSTGHAGVLLVERGSYP 60
```

QY 48 FIDRLINSTYSGEI--GTTKKVKRLSSQRYPHASRLRLGIIPOAP--LHLLDEYLG 103  
 Db 61 LIDLQVLKSSSQOGEVAGSRRKVRQQLSPQRYCHASRLRLGIVPHAPLSLHLLDDGYLG 120  
 QY 104 QARHMLSKVGMWDFDIFLFDRLNGSLVTLCHLNFTHGLIHHFKLDWVTLHRLFLVMVQ 163  
 Db 121 QAAHMLSKVGTWDFDIFLFDRLNGSLVTLCHLNFTHGLIHHFKLDWVTLHRLFLVMVQ 180  
 QY 164 EDYHSQNPYNVNAHAADVTQAMCYLKEPKLASFLTPDLMGLLAAAHDVDPHGVNQ 223  
 Db 181 EDYHSQNPYNVNAHAADVTQAMCYLKEPKLASFLTPDLMGLLAAAHDVDPHGVNQ 240  
 QY 224 FLIKTHHLLANLY-----QNMVLENHHRSTIGMLRESRLAHLPKEMTODIEQOLGS 277  
 Db 241 FLIKTHHLLANLY-----QNMVLENHHRSTIGMLRESRLAHLPKEMTODIEQOLGS 300  
 QY 278 LILATDINRQNEFLTRKLAHLHNKDLRLDAQDRHFMV-----QIALK 320  
 Db 301 LILATDINRQNEFLTRKLAHLHNKDLRLDAQDRHFMV-----QIALK 360  
 QY 321 CADICNPCRIMWMSKQWSEVCEEFYRQGELEQKFELEISPLCNQKQSDIPSIGFMSY 380  
 Db 361 CADVNCPCRVWALSQWSEVCEEFYRQGELEQKFELEISPLCNQKQSDIPSIGFMSY 419  
 QY 381 IVEPLFREWAFHFGNSTLSENMLGHLAHLNAQWKS 416  
 Db 420 IVEPLFDEWHFRTEPSPSLRTMGHLHQNKAWSRL 455

RESULT 10  
 PDE7A\_MOUSE STANDARD; PRT; 456 AA.  
 AC P70453; Q9ERB3;  
 DT 15-JUL-1998 (Rel. 36, Created)  
 DT 15-JUL-1998 (Rel. 36, Last sequence update)  
 DT 10-MAY-2005 (Rel. 47, Last annotation update)  
 DE High-affinity CAMP-specific 3',5'-cyclic phosphodiesterase 7A  
 DE (SC 3.1.4.17) (P2A).  
 GN Names=Pde7a;  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutharia; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
 OC Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE (ISOFORM 1).  
 RC TISSUE=Skeletal muscle;  
 RX MEDLINE=97098542; PubMed=8943082; DOI=10.1073/pnas.93.24.14188;  
 RA Bloom T.J., Beavo J.A.;  
 RT "Identification and tissue-specific expression of PDE7  
 RT phosphodiesterase splice variants."  
 RL Proc. Natl. Acad. Sci. U.S.A. 93:14188-14192 (1996).  
 RN [2]  
 RP NUCLEOTIDE SEQUENCE (ISOFORM 2).  
 RC TISSUE=Brain, and Testis;  
 RX MEDLINE=20483661; PubMed=11072622; DOI=10.1006/bbr.2000.3613;  
 RA Wang P., Wu P., Egan R.W., Billah M.M.;  
 RT "Cloning, characterization, and tissue distribution of mouse  
 RT phosphodiesterase 7A1."  
 RL Biochem. Biophys. Res. Commun. 276:1271-1277 (2000).  
 CC -1- FUNCTION: Plays a role in signal transduction by regulating the  
 CC intracellular concentration of cyclic nucleotides. This  
 CC phosphodiesterase is highly specific for cAMP and may have a role  
 CC in muscle signal transduction.  
 CC -1- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O =  
 CC adenosine 5'-phosphate.  
 CC -1- COFACTOR: Divalent cations.  
 CC -1- ENZYME REGULATION: Insensitive to all selective PDE inhibitors.  
 CC -1- PATHWAY: Cyclic nucleotide metabolism.  
 CC -1- ALTERNATIVE PRODUCTS:  
 CC Event-Alternative splicing; Named isoforms=2;  
 CC Comment=Additional isoforms seem to exist;  
 CC Name=1; Synonyms=PDE7A2;

CC IsoId=P70453-1; Sequence=Displayed;  
 CC Name=2; Synonyms=PDE7A1;  
 CC IsoId=P70453-2; Sequence=VSP\_004594;  
 CC -1- TISSUE SPECIFICITY: Widely expressed with highest levels in the  
 CC skeletal muscle.  
 CC -1- DOMAIN: Composed of a C-terminal catalytic domain containing two  
 CC putative divalent metal sites and an N-terminal regulatory domain.  
 CC -1- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase  
 CC family.  
 CC This Swiss-Prot entry is copyrighted. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use as long as its content is in no way modified and this statement is not  
 CC removed.  
 CC -----  
 CC EMBL; U68171; AAB08479.1; -; mRNA.  
 CC EMBL; AY007702; AAG16295.1; -; mRNA.  
 CC HSSP; Q08499; LOYN.  
 CC Ensemble; ENSMUSG0000019990; Mus musculus.  
 CC MGI; MGI:1202402; Pde7a.  
 CC GO; GO:0005615; C:extracellular space; TAS.  
 CC InterPro; IPR002073; PDBase.  
 CC Pfam; PF00233; PDEase\_I.1.  
 CC PRINTS; PR00387; PD1ESTERASE1.  
 CC PROSITE; PS00126; PDEASE\_I.1.  
 CC Alternative splicing; CAMP; Hydrolase.  
 CC FT REGION 161 425  
 CC FT VARSPLIC 1 20  
 CC QHVLSSRRGAISFSSSSALFGCPHRLSQ (in isoform  
 CC 2).  
 CC /FTId=VSP\_004594.  
 CC FT CONFLICT 407 407  
 CC FT SEQUENCE 456 AA; 52443 MW; 0B826B96490D9F6E CRC64;  
 SQ  
 Query Match 59.2%; Score 1425.5; DB 1; Length 456;  
 Best Local Similarity 62.2%; Pred. No. 5.7e-102;  
 Matches 263; Conservative 71; Mismatches 88; Indels 1; Gaps 1;  
 QY 7 ERCEGLFENPDQNAKCVMLGDIRLQGTGVRAERRGSPYFDLRLNLTYSGRIGTK 66  
 Db 20 KRGAISYSSDOTALYIRMLGDVVRVRAGPETERGSHPIYDFRIFHSQSDIASVSA 79  
 QY 67 KVKRLLSFQRYPHASRLRLGIIPOAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLT 126  
 Db 80 RNIRLLSFQRYLRSRVRFGATVCSLLDLDYNGQAKCMLEKVGNNWDFLFLDRLT 139  
 QY 127 NGNSLVTLCHLNFTHGLIHHFKLDWVTLHRLFLVMVQEDYHSQNPYNVNAHAADVTQAMH 186  
 Db 140 NGNSLVSLTFHLFSLHGLIEYFHLDMVKLRRLPLVMTQEDYHSQNPYNVNAHAADVTQAMH 199  
 QY 187 CYLKEPKLASFLTPDLMGLLAAAHDVDPHGVNQPFLLIKTNHLLANLYQNMSVLENHH 246  
 Db 200 CYLKEPKLASVTPWDILSLAATHDLDPGVNQPFLLIKTNHLLANLYQNMSVLENHH 259  
 QY 247 WRSTIGMLRESRLAHLPKEMTQDIEQOLGSLLATDINRQNEFLTRKLAHLHNKDLRL 306  
 Db 260 WRSAVGLLRESGLFSLPLESRQMEAQIGALILATDISRQNEYLESLFRSHLDKGLDHL 319  
 QY 307 DAQDRHFMVQIALKCADICNPCRIMWMSKQWSEVCEEFYRQGELEQKFELEISPLCNQ 366  
 Db 320 DGRHRLVQLMALKCADICNPCRIMWMSKQWSEVCEEFYRQGELEQKFELEISPLCDRQ 379  
 QY 367 KDSIPSIQGFMSYIVEPLFREWAFHFGNSTLSENMLGHLAHLNAQWKSLLPRQHSRGS 426  
 Db 380 TESIANIQGFMTYLVLEPLFTEWAFSA-TRLSQTMGLHVGINKASWKGLORQPPSSDA 438  
 QY 427 SGS 429  
 Db 439 NAA 441

RESULT 11







AC O08593;  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 10-MAY-2005 (Rel. 47, Last annotation update)  
DE High-affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A  
DE (EC 3.1.4.17) (Rolipram-insensitive cyclic phosphodiesterase type 7)  
DE (Fragment).  
GN Name=Pde7a;  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;  
OC Muridae; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Brain;  
RX MEDLINE=98176136; PubMed=9515162;  
RA Hoffmann R., Abdel'Al S., Engels P.;  
RT "Differential distribution of rat PDE-7 mRNA in embryonic and adult  
rat brain.";  
RL Cell Biochem. Biophys. 28:103-113(1998).  
CC -!- FUNCTION: Plays a role in signal transduction by regulating the  
CC intracellular concentration of cyclic nucleotides. This  
CC phosphodiesterase is highly specific for cAMP and may have a role  
CC in muscle signal transduction (By similarity).  
CC -!- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O =  
CC adenosine 5'-phosphate.  
CC -!- COFACTOR: Divalent cations (By similarity).  
CC -!- ENZYME REGULATION: Insensitive to all selective PDE inhibitors (By  
CC similarity).  
CC -!- PATHWAY: Cyclic nucleotide metabolism.  
CC -!- DOMAIN: Composed of a C-terminal catalytic domain containing two  
CC putative divalent metal sites and an N-terminal regulatory domain.  
CC -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase  
CC family.  
CC  
CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use as long as its content is in no way modified and this statement is not  
CC removed.  
CC  
CC EMBL; U77880; AAB51234.1; -; mRNA.  
DR HSSP; Q08499; 1MKD.  
DR RGD; 68391; Pde7a.  
DR InterPro; IPR003607; Met\_phos\_hydro.  
DR Pfam; PF00233; PDEase\_I; 1.  
DR PRINTS; PR00387; PDIESTERASE1.  
DR SMART; SM00471; HDC; 1.  
DR PROSITE; PS00126; PDEASE\_I; 1.  
KW CAMP; Hydrolase.  
FT REGION 131 395 Catalytic (By similarity).  
FT NON\_TER 1  
SQ SEQUENCE 426 AA; 49274 MW; 129BDC01C9351D26 CRC64;  
  
Query Match 58.0%; Score 1397.5; DB 1; Length 426;  
Best Local Similarity 62.4%; Pred. No. 7.7e-100;  
Matches 257; Conservative 68; Mismatches 86; Indels 1; Gaps 1;  
  
QY 18 DQNAKVCMLGDIRLQGTGVRAERGSYPFFDRLNSTTYSGEITGKKVKRLISFOR 77  
Db 1 DQALYIRMLGDVVRSRAGFERRGSHPYIDPRIFHAQSEIASVSARNIRLLISFOR 60  
QY 78 YFASRLRGITPQAPLHLLDEYDYGQARHMLSKVGMWDFDPLFRLTNGNSLVTLCH 137  
Db 61 YLRSSRRFRGATVCRSLNLDYDNGQAKCMLEKVGNNWDFDPLFRLTNGNSLVSLTPH 120  
QY 138 LFNTHGLIHHPKLDVMTLHRLFVMOQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASF 197  
Db 121 LFSLHGLIEYFHLDDVVKLRFVMOQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLAS 180  
QY 198 LTPFLDMLGLAAAAHDVDHPGVNPPFLIKTNHHLANLYQNMSVLENHHWRSTIGMLRES 257

Db 181 VTPWDILLSIAAATHDLDPGVNPPFLIKTNHYLATLYKNTSVLENHHWRSAVGLRES 240  
QY 258 RLLAHLPKEMTODIEQQLGSLILATDINRQNEFLTELKALHNLKOLRLLEDAQDRHFWLQI 317  
Db 241 GLFSLPLRESRHEMAQIGALILATDISRQNEFLSLFRSHLDKGLDHLDDGRRHHLVLQM 300  
QY 318 ALKCADICNPCRIMESKQWSEVCEPVRQCELEKQKPELEISPLCNCQKDSIPSIQIGF 377  
Db 301 ALKCADICNPCRINWELSKQWSEKVTPEFFHQGDIEKKYHLGVSPICDRQTESIANIQIGF 360  
QY 378 MSYIYVEIPREFWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQHSRSGSGS 429  
Db 361 MTYLQEPLEFTEWARFS-DTRLSTQTLGHVGLNKASKWGLQRQOPSSSEDASAA 411  
  
RESULT 15  
Q96T72 HUMAN  
ID Q96T72 HUMAN PRELIMINARY; PRT; 424 AA.  
AC Q96T72;  
DT 01-DEC-2001 (TREMBLrel. 19, Created)  
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)  
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)  
DE CAMP-specific cyclic nucleotide phosphodiesterase PDE7A3.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RX MEDLINE=21265467; PubMed=11371644; DOI=10.1073/pnas.101131098;  
RA Glavas N.A., Ostenson C., Schaefer J.B., Vasta V., Beavo J.A.;  
RT "T cell activation up-regulates cyclic nucleotide phosphodiesterases  
RT 8A1 and 7A3.";  
RL Proc. Natl. Acad. Sci. U.S.A. 98:6319-6324 (2001).  
DR EMBL; AF332652; AAK57640.1; -; mRNA.  
DR HSSP; Q08499; 1OYN.  
DR Ensembl; ENSG00000171408; Homo sapiens.  
DR GO; GO:004114; F:3',5'-cyclic-nucleotide phosphodiesterase a. . .; IEA.  
DR GO; GO:001678; F:hydrolase activity; IEA.  
DR GO; GO:0007165; F:signal transduction; IEA.  
DR InterPro; IPR003607; Met\_phos\_hydro.  
DR InterPro; IPR002073; PDEase.  
DR Pfam; PF00233; PDEase\_I; 1.  
DR PRINTS; PR00387; PDIESTERASE1.  
DR SMART; SM00471; HDC; 1.  
DR PROSITE; PS00126; PDEASE\_I; UNKNOWN 1.  
DR PROSITE; PS00126; PDEASE\_I; 48827 MW; A7DBF40D08A7B561 CRC64;  
SQ SEQUENCE 424 AA; 48827 MW; A7DBF40D08A7B561 CRC64;  
  
Query Match 53.4%; Score 1287; DB 2; Length 424;  
Best Local Similarity 62.7%; Pred. No. 2.9e-91;  
Matches 235; Conservative 64; Mismatches 76; Indels 0; Gaps 0;  
  
QY 7 ERCGEILFENPDQNAKVCMLGDIRLQGTGVRAERGSYPFFDRLNSTTYSGEITGK 66  
Db 46 QRRGAISYDSDQATLYIRMLGDVVRSRAGFERRGSHPYIDPRIFHSQSEIEVSVA 105  
QY 67 KKVKRLLSQRYFHASRLRGITPQAPLHLLDEYDYGQARHMLSKVGMWDFDPLFDRLT 126  
Db 106 RNIRELLSFQRYLRSRFRFGTAVSNSNLDDYNGQAKCMLEKVGNNWDFDPLFDRLT 165  
QY 127 NGNSLVTLCHLFNTHGLIHHPKLDVMTLHRLFVMOQEDYHSQNPYHNAVHAADVTQAMH 186  
Db 166 NGNSLVSTLTFHLSLHGLIEYFHLDDVVKLRFVMOQEDYHSQNPYHNAVHAADVTQAMH 225  
QY 187 CYLKEPKLASFLTPDLMGLAAAAHDVDHPGVNPPFLIKTNHHLANLYQNMSVLENHH 246  
Db 226 CYLKEPKLASVTPWDILLSIAAATHDLDPGVNPPFLIKTNHYLATLYKNTSVLENHH 285  
QY 247 WRSTIGMLRESLHLPKEMTODIEQQLGSLILATDINRQNEFLTELKALHNLKOLRLLE 306  
Db 286 WRSAYGLLRESGLFSLHPLRESRQMQMETQIGALILATDISRQNEFLSLFRSHLDKGLD 345



Search completed: March 10, 2006, 20:02:08  
Job time : 189.805 secs

**This Page Blank (uspto)**

GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 20:02:25 ; Search time 40.8537 Seconds  
(without alignments)  
910.666 Million cell updates/sec

Title: US-10-781-181-5  
Perfect score: 2408  
Sequence: 1 MSLMVERCGEILLFENPDQN.....PDHAGQGTSEBQGDSP 450

Scoring table:  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/ptodata/1/iaa/5 COMB.pap:\*  
2: /cgn2\_6/ptodata/1/iaa/6 COMB.pap:\*  
3: /cgn2\_6/ptodata/1/iaa/H COMB.pap:\*  
4: /cgn2\_6/ptodata/1/iaa/PCTUS COMB.pap:\*  
5: /cgn2\_6/ptodata/1/iaa/RE COMB.pap:\*  
6: /cgn2\_6/ptodata/1/iaa/backfiles1.pap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2258	93.8	502	2	US-09-330-970-1
2	2051	85.2	390	2	US-09-949-016-10020
3	1419.5	58.9	498	1	US-07-688-352C-20
4	1419.5	58.9	498	1	US-08-474-379C-20
5	1419.5	58.9	498	2	US-09-146-249A-20
6	1419.5	58.9	498	2	US-08-206-188B-20
7	1280	53.2	320	2	US-09-330-970-3
8	604.5	25.1	518	2	US-09-602-735B-2
9	604.5	25.1	673	1	US-08-474-379C-63
10	604.5	25.1	673	2	US-09-146-249A-63
11	604.5	25.1	673	2	US-08-206-188B-63
12	603.5	25.1	517	2	US-09-602-735B-4
13	599.5	24.9	673	1	US-08-577-492-35
14	599.5	24.9	673	2	US-09-079-630-35
15	580.5	24.1	562	1	US-07-688-352C-4
16	580.5	24.1	562	1	US-08-942-521B-8
17	580.5	24.1	562	1	US-08-474-379C-4
18	580.5	24.1	562	2	US-09-146-249A-4
19	580.5	24.1	562	2	US-08-206-188B-4
20	580.5	24.1	562	4	PCT-US91-02714-4
21	574.5	23.9	721	2	US-09-983-754-2
22	567.5	23.6	564	1	US-08-577-492-34
23	567.5	23.6	564	1	US-08-942-521B-2
24	567.5	23.6	564	1	US-08-474-379C-59
25	567.5	23.6	564	2	US-08-146-249A-59
26	567.5	23.6	564	2	US-08-206-188B-59
27	567.5	23.6	564	2	US-09-192-702-2

28	567.5	23.6	564	2	US-09-079-630-34	Sequence 34, Appl
29	567.5	23.6	564	2	US-08-445-474-2	Sequence 2, Appl
30	567.5	23.6	564	2	US-09-983-754-4	Sequence 4, Appl
31	567.5	23.6	564	4	PCT-US94-02612-2	Sequence 2, Appl
32	567.5	23.6	736	1	US-07-688-352C-24	Sequence 24, Appl
33	567.5	23.6	736	1	US-08-474-379C-24	Sequence 24, Appl
34	567.5	23.6	736	2	US-09-146-249A-24	Sequence 24, Appl
35	567.5	23.6	736	2	US-08-206-188B-24	Sequence 24, Appl
36	567.5	23.6	736	4	PCT-US91-02714-23	Sequence 23, Appl
37	565	23.5	885	1	US-08-577-492-33	Sequence 33, Appl
38	565	23.5	885	2	US-09-079-630-33	Sequence 33, Appl
39	565	23.5	886	1	US-08-474-379C-65	Sequence 65, Appl
40	565	23.5	886	2	US-09-146-249A-65	Sequence 65, Appl
41	565	23.5	886	2	US-08-206-188B-65	Sequence 65, Appl
42	565	23.5	901	2	US-09-917-254-93	Sequence 93, Appl
43	563	23.4	686	1	US-08-942-521B-9	Sequence 9, Appl
44	562	23.3	606	1	US-08-577-492-32	Sequence 32, Appl
45	562	23.3	606	2	US-09-079-630-32	Sequence 32, Appl

ALIGNMENTS

RESULT 1  
US-09-330-970-1  
; Sequence 1, Application US/09330970  
; Patent No. 6146876  
; GENERAL INFORMATION:  
; APPLICANT: Robison, Keith E.  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: White, David  
; TITLE OF INVENTION: A No. 6146876el Human Cyclic Nucleotide  
; FILE OF INVENTION: Phosphodiesterase  
; FILE REFERENCE: 5800-28  
; CURRENT APPLICATION NUMBER: US/09/330,970  
; CURRENT FILING DATE: 1999-06-11  
; EARLIER APPLICATION NUMBER: 09/277,423  
; EARLIER FILING DATE: 1999-03-26  
; NUMBER OF SEQ ID NOS: 40  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 1  
; LENGTH: 502  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-330-970-1

Query Match	93.8%	Score 2258;	DB 2;	Length 502;
Best Local Similarity	100.0%	Pred. No. 1.2e-229;	Mismatches 0;	Indels 0;
Matches 423;	Conservative 0;	0;	0;	Gaps 0;
Qy	28	GDRLRGQTGVRAERGSYPFIDFRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG	87	
Db	80	GDRLRGQTGVRAERGSYPFIDFRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG	139	
Qy	88	IIQAPLHLLDEYLGQARHLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFTNTHGLIHH	147	
Db	140	IIQAPLHLLDEYLGQARHLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFTNTHGLIHH	199	
Qy	148	FKLDVTLHRLFLVWQEDVHSQNPYHNAVHAADVTQAMHCYKLPKSLASFLTPLDMLGL	207	
Db	200	FKLDVTLHRLFLVWQEDVHSQNPYHNAVHAADVTQAMHCYKLPKSLASFLTPLDMLGL	259	
Qy	208	LAAAAHDVHPGVNQPFILKTNHHLNLYQNMVLENHNRSTIGMLRESLLAHLPKEM	267	
Db	260	LAAAAHDVHPGVNQPFILKTNHHLNLYQNMVLENHNRSTIGMLRESLLAHLPKEM	319	
Qy	268	TQDIEQGLSLIATDINRQNEFLTRLKAHLNKLRLLEDAQDRHFMQLTALKCADICNP	327	
Db	320	TQDIEQGLSLIATDINRQNEFLTRLKAHLNKLRLLEDAQDRHFMQLTALKCADICNP	379	
Qy	328	CRIEWMSQWSEVCEFEYRQGELEKFELEISPLCNQCKDSIPSIQIGFMSVIVEPLFR	387	
Db	380	CRIEWMSQWSEVCEFEYRQGELEKFELEISPLCNQCKDSIPSIQIGFMSVIVEPLFR	439	

QY	388	EWAHFTGNSTLS	ENMLGHLAHNKAQWKSL	LPQHRSRGSSGSPDHDHAGQGTSEEQEG	447
Db	440	EWAHFTGNSTLS <th>ENMLGHLAHNKAQWKSL</th> <th>LPQHRSRGSSGSPDHDHAGQGTSEEQEG</th> <td>499</td>	ENMLGHLAHNKAQWKSL	LPQHRSRGSSGSPDHDHAGQGTSEEQEG	499
QY	448	DSP	450		
Db	500	DSP	502		
RESULT 2					
US-09-949-016-10020					
; Sequence 10020, Application US/09949016					
; Patent No. 6812339					
; GENERAL INFORMATION:					
; APPLICANT: VENTER, J. Craig et al.					
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED					
; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF					
; FILE REFERENCE: CL001307					
; CURRENT APPLICATION NUMBER: US/09/949,016					
; CURRENT FILING DATE: 2000-04-14					
; PRIOR APPLICATION NUMBER: 60/241,755					
; PRIOR FILING DATE: 2000-10-20					
; PRIOR APPLICATION NUMBER: 60/237,768					
; PRIOR FILING DATE: 2000-10-03					
; PRIOR APPLICATION NUMBER: 60/231,498					
; PRIOR FILING DATE: 2000-09-08					
; NUMBER OF SEQ ID NOS: 207012					
; SOFTWARE: FastSeq for Windows Version 4.0					
; SEQ ID NO 10020					
; LENGTH: 390					
; TYPE: PRT					
; ORGANISM: Human					
US-09-949-016-10020					
Query Match 85.2%; Score 2051; DB 2; Length 390;					
Best Local Similarity 92.4%; Pred. No. 6.1e-208;					
Matches 390; Conservative 0; Mismatches 0; Indels 32; Gaps 1;					
QY	29	DIRLRGQTGVRA	RRGSPVFFD	FRLLNSTTYSGE	IGTKKKVKRLLSFORYPHASLLRGI 88
Db	1	DIRLRGQTGVRA	RRGSPVFFD	FRLLNSTTYSGE	IGTKKKVKRLLSFORYPHASLLRGI 60
QY	89	IPQAPLHLLDE	DYLGQARHMLSKVGMWDF	IFLDFRLTNGNSLV	TLLCHLFNTHGLIHHF 148
Db	61	IPQAPLHLLDE	DYLGQARHMLSKVGMWDF	IFLDFRLTN-----	----- 99
QY	149	KLDVMTLHR	FLVMQVEDYHSQNPYHNA	VHAADVTOAMHCYL	KEPKLASFLPLDMLGLL 208
Db	100	-----	VMVQEDYHSQNPYHNA	VHAADVTOAMHCYL	KEPKLASFLPLDMLGLL 148
QY	209	AAAAHVDHP	GVNQPFLIKTNHHLANLYQNMS	VLENHHWRSTIGMLRES	RLLAHLUPKEMT 268
Db	149	AAAAHVDHP	GVNQPFLIKTNHHLANLYQNMS	VLENHHWRSTIGMLRES	RLLAHLUPKEMT 208
QY	269	QDIEQQGLS	LILATDINRQNEFLTRLKAHLN	KDLRLLEDAADRHFMLQ	IALKCADICNPC 328
Db	209	QDIEQQGLS	LILATDINRQNEFLTRLKAHLN	KDLRLLEDAQDRHFMLQ	IALKCADICNPC 268
QY	329	RIWEMSKQ	SERVCEEFYRQGELEISPL	CNQOKDIPSIQIGFMS	YIIVEPLPRE 388
Db	269	RIWEMSKQ	SERVCEEFYRQGELEISPL	CNQOKDIPSIQIGFMS	YIIVEPLPRE 328
QY	389	WAHFTGNSTLS	ENMLGHLAHNKAQWKSL	LPQHRSRGSSGSPDHDHAGQGTSEEQEGD	448
Db	329	WAHFTGNSTLS	ENMLGHLAHNKAQWKSL	LPQHRSRGSSGSPDHDHAGQGTSEEQEGD	388
QY	449	SP	450		
Db	389	SP	390		

```

US-07-688-352C-20
; Sequence 20, Application US/07688352C
; Patent No. 5527896
; GENERAL INFORMATION:
; APPLICANT: Wigler, Michael H.
; APPLICANT: Colicelli, John J.
; TITLE OF INVENTION: Cloning by Complementation and Related
; TITLE OF INVENTION: Processes
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Bicknell
; STREET: Two First National Plaza, 20 South Clark
; STREET: Street
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READING FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/07/688,352C
; APPLICATION NUMBER: US/07/688,352C
; FILING DATE: 19910419
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/511,715
; FILING DATE: 20-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Borun, Michael F.
; REGISTRATION NUMBER: 25447
; REFERENCE/DOCKET NUMBER: 27805/30197
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 346-5750
; TELEFAX: (312) 984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 498 amino acids
; TYPE: AMINO ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-07-688-352C-20

Query Match          58.9%; Score 1419.5; DB 1; Length 498
Best Local Similarity 61.7%; Pred. No. 5.2e-141;
Matches 261; Conservative 70; Mismatches 91; Indels

Qy      7  ERGCEILFENPDQAKVCVCMGLDIRLQGTGVRAERRGSYPFIDFRLNLS
Db      62  QRGKALSYDSDQATLYRMJGDUVRVSRAGFSEKRGSHPYIDFRLFHSC

Qy      67  KKYKRLLSFORYPHASRLRGIIPQAPLHLLDDYLGQARHMLSKVGMWDF
Db      122  RNIRRLLSFQYRLSRFRFGTAVSNLSNILDYDNGQAKCMLEKVKGNWNR

Qy      127  NGNSLVTLCHLPNTHGLIHFFKDMVTYHRFLVMQVEDYHSQNPYINAVH
Db      182  NGNSLVSLTHPLFSLHGLIEYFPHLDMKRLRFLVMIQEDYHSQNPYINAVH

Qy      187  CYLKEPKLASFLTPDLMGLMLGAAAHADVDPGVNQPFLLKTNHLLANLYK
Db      242  CYLKEPKLANSVTPDWLILSLIAAAATHLDHPGVNQPFLLKTNHLYLATLYK

Qy      247  WRSTIGMLRESRLLAHLPEKMTQDIEQQLGSLILATDINRQNEFLRLKAK
Db      302  WRSVAGLLRESGLFSLHPLESRQOMETQIGALILATDISRQNEVYLSLFRSH

Qy      307  DAQDRHFMQLIAUKCADICNPICRIWEMSKWSQSERVCEEFYRQGELEOKFPEI
Db      362  DTRHRLVLMQALKCADICNPCTRWELSKWSQSEKVTPEEPHQGDIEKKYHL

```

Qy 367 KDSIPSTOIGFMSYIVBPLFEWAHFTGNSLTSENMLGHLAHHKAQWKSLLPROHRSRG 426  
Db 422 TESTIANIQIGFMTYLVBEPLFEWAHFTGNSLTSENMLGHLAHHKAQWKSLLPROHRSRG 480  
Qy 427 SGS 429  
Db 481 DAA 483

## RESULT 4

US-08-474-379C-20  
; Sequence 20, Application US/08474379C  
; Patent No. 597305  
; GENERAL INFORMATION:  
; APPLICANT: Wigler, Michael H.  
; APPLICANT: Colicelli, John J.  
; TITLE OF INVENTION: CLONING BY COMPLEMENTATION AND RELATED  
; TITLE OF INVENTION: PROCESSES  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 233 South Wacker Drive/6300 Sears Tower  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/474,379C  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/511,715  
; FILING DATE: 20-APR-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/206,188  
; FILING DATE: 01-MAR-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/688,352  
; FILING DATE: 19-APR-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clough, David W.  
; REGISTRATION NUMBER: 36,107  
; REFERENCE/DOCKET NUMBER: 27866/32771  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; INFORMATION FOR SEQ ID NO: 20:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 498 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-474-379C-20

Query Match 58.9%; Score 1419.5; DB 1; Length 498;  
Best Local Similarity 61.7%; Pred. No. 5.2e-141;  
Matches 261; Conservative 70; Mismatches 91; Indels 1; Gaps 1;  
Qy 7 ERCCGILPENDDAKVCMLGDLRLRGQTGVRAERGSYPIDFRILNSTYSGEIGTK 66  
Db 62 QRRGAISTDSDQALYIRMGDVVRVRAGFERRSGSHYIDFRIFHSSEIEVSVA 121  
Qy 67 KKVRLLSFQRYFHASRLRGIPOAPLHLLDEDLGQAREMLSKVGMWDFDIFDLRL 126  
Db 122 RNIRLLSFQRYLSSRRFRGTAVNSNLILDDYNGQAKCMLEKVGWNNDFDIFDLRL 181  
Qy 127 NGNSLVTLCHLFNTHGLIHFKLDVTLHRLFLVMVQEDYHSQNPYHNAVHAADVTQAMH 186

Db 182 NGNSLVSLTTHLSLHGLIEYFHLDMWKLRFVLMIQEDYHSQNPYHNAVHAADVTQAMH 241  
Qy 187 CYLKEPKLASFPLDPLMGLLAAAHVDVHPGVNQPFLLKTNHHLANLTONKMSVLENHH 246  
Db 242 CYLKEPKLANSVTPWDILLSLIAAATHDLDPGVNQPFLLKTNHHLATLYKNTSVLENHH 301  
Qy 247 WRSTIGMLRESRLLAHLPKEMTODIEOOLGSLILATDINRQNEFLTRLKAHLHNDLRL 306  
Db 302 WRSAGLLRESGLFSLPLFLESROOMETQIGALILATDISRQNEYSLSFRSHLDRGDLCL 361  
Qy 307 DAQRHFMLOIALKADICNCPRIWMSKOWSERVCEEFYRQGELEQKFELEISPLCNQ 366  
Db 362 DTRRHVLQWALKAADICNCPRTWELSKOWSEKVTSEFFHQGDIEKKYHLGVSPCLDRH 421  
Qy 367 KDSIPSTOIGFMSYIVBPLFEWAHFTGNSLTSENMLGHLAHHKAQWKSLLPROHRSRG 426  
Db 422 TESTIANIQIGFMTYLVBEPLFEWAHFTGNSLTSENMLGHLAHHKAQWKSLLPROHRSRG 480  
Qy 427 SGS 429  
Db 481 DAA 483

## RESULT 5

US-09-146-249A-20  
; Sequence 20, Application US/09146249A  
; Patent No. 6069240  
; GENERAL INFORMATION:  
; APPLICANT: Wigler, Michael H.  
; APPLICANT: Colicelli, John J.  
; TITLE OF INVENTION: Cloning by Complementation and Related  
; TITLE OF INVENTION: PROCESSES  
; NUMBER OF SEQUENCES: 85  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/146,249A  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/511,715  
; FILING DATE: 20-APR-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clough, David W.  
; REGISTRATION NUMBER: 36,107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 312/474-6300  
; TELEFAX: 312-474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 20:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 498 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-146-249A-20

Query Match 58.9%; Score 1419.5; DB 2; Length 498;  
Best Local Similarity 61.7%; Pred. No. 5.2e-141;  
Matches 261; Conservative 91; Mismatches 91; Indels 1; Gaps 1;

QY 7 ERCEILFENPDONAKVCVCMGDIRLQGTGVAERRGSPYDFIRLLNSTTYSGEIGTK 66  
Db 62 QRRGAIYSDDQATYALYRMLGDRVRVRAGFESERRGSHPIYDFIRFHSQSIEVSVA 121  
QY 67 KKVRLLSFQRYPHASRLRGIIPOAPLHLLDEDYLGQARHMLSKVGMWDFDIFLDRLT 126  
Db 122 RNIRRLLSFQRYLRSRRFRGTAVNSNLIDDDYNGQAKMELKVGNNWDFDIFLDRLT 181  
QY 127 NGNSLVTLCHLNFTHGLIHHFKLDMVTLHRFLVMQEDYHSQNPYHNAHAADVTOAMH 186  
Db 182 NGNSLVSLTFPLSLHGLIEYFHLDMKLRFLVMIQEDYHSQNPYHNAHAADVTOAMH 241  
QY 187 CYLKEPKLASFLTPDLMLGLLAAAHDVDPGVNQPFLIKTNHHLANLYQNMVLENHH 246  
Db 242 CYLKEPKLANSVTPDWILLSLAAATHDLDPGVNQPFLIKTNHLYLATLYKNTSVLENHH 301  
QY 247 WRSTIGMLRESRLAHLPKEMTQDIEQOLGSLILATDINRQNEFLRLKAHLHNDLRL 306  
Db 302 WRSVAGLLRESGLFSLHPLSRQMETQIGALLIATDISRQNEFLSLFRSHLDRGDLCLE 361  
QY 307 DAOHRHFMQLTALKACADICNPRIWEMSKOWSERVCEEFYRQGELEKFELEISPLCNOQ 366  
Db 362 DTRHRHLVLQWALKACADICNPCTRWELSKOWSEKVTSEFFHQGDIEKKYHLGVSPLCDRH 421  
QY 367 KDSIPSIQIGFMSYIVPEPLPREWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQHSRGS 426  
Db 422 TESTANIQIGFMTYLVPELFTWARFS-NTRLSQTMGLGHVGLNKAWSKGLQREQSSEDT 480  
QY 427 SGS 429  
Db 481 DAA 483

## RESULT 6

US-08-206-188B-20  
; Sequence 20, Application US/08206188B  
; Patent No. 6100025  
; GENERAL INFORMATION:  
; APPLICANT: Wigler, Michael H.  
; APPLICANT: Colicelli, John J.  
; TITLE OF INVENTION: Cloning by Complementation and Related  
; TITLE OF INVENTION: Processes  
; NUMBER OF SEQUENCES: 84  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/206,188B  
; FILING DATE: 01-MAR-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/511,715  
; FILING DATE: 20-APR-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clough, David W.  
; REGISTRATION NUMBER: 36107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 312/474-6300  
; TELEFAX: 312-474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 20:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 498 amino acids  
; TYPE: amino acid

; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-206-188B-20

Query Match 58.9%; Score 1419.5; DB 2; Length 498;  
Best Local Similarity 61.7%; Pred. No. 5.2e-141;

Matches 261; Conservative 70; Mismatches 91; Indels 1; Gaps 1;

QY 7 ERCEILFENPDONAKVCVCMGDIRLQGTGVAERRGSPYDFIRLLNSTTYSGEIGTK 66  
Db 62 QRRGAIYSDDQATYALYRMLGDRVRVRAGFESERRGSHPIYDFIRFHSQSIEVSVA 121

QY 67 KKVRLLSFQRYPHASRLRGIIPOAPLHLLDEDYLGQARHMLSKVGMWDFDIFLDRLT 126  
Db 122 RNIRRLLSFQRYLRSRRFRGTAVNSNLIDDDYNGQAKMELKVGNNWDFDIFLDRLT 181

QY 127 NGNSLVTLCHLNFTHGLIHHFKLDMVTLHRFLVMQEDYHSQNPYHNAHAADVTOAMH 186  
Db 182 NGNSLVSLTFPLSLHGLIEYFHLDMKLRFLVMIQEDYHSQNPYHNAHAADVTOAMH 241

QY 187 CYLKEPKLASFLTPDLMLGLLAAAHDVDPGVNQPFLIKTNHHLANLYQNMVLENHH 246  
Db 242 CYLKEPKLANSVTPDWILLSLAAATHDLDPGVNQPFLIKTNHLYLATLYKNTSVLENHH 301

QY 247 WRSTIGMLRESRLAHLPKEMTQDIEQOLGSLILATDINRQNEFLRLKAHLHNDLRL 306  
Db 302 WRSVAGLLRESGLFSLHPLSRQMETQIGALLIATDISRQNEFLSLFRSHLDRGDLCLE 361

QY 307 DAOHRHFMQLTALKACADICNPRIWEMSKOWSERVCEEFYRQGELEKFELEISPLCNOQ 366  
Db 362 DTRHRHLVLQWALKACADICNPCTRWELSKOWSEKVTSEFFHQGDIEKKYHLGVSPLCDRH 421

QY 367 KDSIPSIQIGFMSYIVPEPLPREWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQHSRGS 426  
Db 422 TESTANIQIGFMTYLVPELFTWARFS-NTRLSQTMGLGHVGLNKAWSKGLQREQSSEDT 480

QY 427 SGS 429

Db 481 DAA 483

## RESULT 7

US-09-330-970-3  
; Sequence 3, Application US/09330970  
; Patent No. 6146876  
; GENERAL INFORMATION:  
; APPLICANT: Robison, Keith E.  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: White, David  
; TITLE OF INVENTION: A No. 6146876el Human Cyclic Nucleotide  
; TITLE OF INVENTION: Phosphodiesterase  
; FILE REFERENCE: 5800-28  
; CURRENT APPLICATION NUMBER: US/09/330,970  
; CURRENT FILING DATE: 1999-06-11  
; EARLIER APPLICATION NUMBER: 09/277,423  
; EARLIER FILING DATE: 1999-03-26  
; NUMBER OF SEQ ID NOS: 40  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 3  
; LENGTH: 320  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-330-970-3

Query Match 53.2%; Score 1280; DB 2; Length 320;  
Best Local Similarity 100.0%; Pred. No. 1.4e-126;

Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 GDRLRGQTGVAERRGSPYDFIRLLNSTTYSGEIGTKKKKVKRLLSFORYPHASRLRG 87

Db 80 GDRLRGQTGVAERRGSPYDFIRLLNSTTYSGEIGTKKKKVKRLLSFORYPHASRLRG 139

QY 88 IIPQAPLHLLDDEYLGQARHMLSKVGMWDFDIPLFDRLTNGNSLVTLTLLCHLNFTHGLIHH 147  
Db 140 IIPQAPLHLLDDEYLGQARHMLSKVGMWDFDIPLFDRLTNGNSLVTLTLLCHLNFTHGLIHH 199  
QY 148 FKLDVTLHRLVNVQEDYHSQNPYHNAADVTQAMHCYLKEPKLASFLTPDIDIMGL 207  
Db 200 FKLDVTLHRLVNVQEDYHSQNPYHNAADVTQAMHCYLKEPKLASFLTPDIDIMGL 259  
QY 208 LAAAHVDHVGVPNPFLIKTNHHLANLYQMSVLENNHWRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAHVDHVGVPNPFLIKTNHHLANLYQMSVLENNHWRSTIGMLRESRLLAHLPKEM 319  
QY 268 T 268  
Db 320 T 320

RESULT 8  
US-09-602-735B-2  
; Sequence 2, Application US/09602735B  
; Patent No. 6656717  
; GENERAL INFORMATION:  
; APPLICANT: Xin, Xiaonan  
; APPLICANT: Unterbeck, Axel  
; APPLICANT: Hu, Yinghe  
; TITLE OF INVENTION: Cyclic AMP Phosphodiesterase Isoforms and Methods of  
; TITLE OF INVENTION: Use  
; FILE REFERENCE: 453260-55  
; CURRENT APPLICATION NUMBER: US/09/602,735B  
; CURRENT FILING DATE: 2000-06-23  
; PRIOR APPLICATION NUMBER: U.S. 60/141,196  
; PRIOR FILING DATE: 1999-06-25  
; NUMBER OF SEQ ID NOS: 21  
; SOFTWARE: Patent In Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 518  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-602-735B-2

Query Match 25.1%; Score 604.5; DB 2; Length 518;  
Best Local Similarity 33.3%; Pred. No. 8e-55;  
Matches 135; Conservative 86; Mismatches 151; Indels 33; Gaps 9;

QY 66 KKKVKRLLS----PQRYFHASRLLRGIIPQAPLHLLDDEYLGQARHMLSKVGMWDFDIPL 121  
Db 63 KKKVKRLLS----PQRYFHASRLLRGIIPQAPLHLLDDEYLGQARHMLSKVGMWDFDIPL 119  
QY 122 FDRLTNGNSLVTLTLLCH-LFNTHGLIHHFKLDVTLHRLVNVQEDYHSQNPYHNAAD 180  
Db 120 IAEI-SGNRPLVTIMHTIFQERDLTKFKIPVDLTILYMTLEDHYHADVAYHNNIHAAD 178  
QY 181 VTQAMHCYLKEPKLASFLTPDIDIMGLAAAHVDHVGVPNPFLIKTNHHLANLYQMS 240  
Db 179 VVOSTHVLLSTPALEAVFTDLEILAFASAIHDVDPGVNSQFLINTSELALMYNDSS 238  
QY 241 VLENHWRSTIGMLRESR--LLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRKAHL 298  
Db 239 VLENHHLAVGFKLQEQNCDFQNLTKKQSLRKWIDIVLATDMSKNNLLADLKTW 298  
QY 299 HNKD-----LRLDAQDRHFMLOIALKCADICNPICRIMSKWSKSERVCEEFVROGELE 352  
Db 299 ETKKVTSSGVLDDNYSDRIQVLQNMVHCADLSNFTKPLQLYRQWTDRIIMEEFPQGDRE 358  
QY 353 QKPLEISPLCNQOKDSIPSIQIGFMSYIYVLEPREWHAFTGNSTLSENMLGLAHNAKQ 412  
Db 359 RERGMETSPMCDKGNASVEKSVQGFIDYIYVHPLMETWADLVHPD--AQDILDTLEDNREW 416  
QY 413 WKSLLPRQHRGRSGSGOPDHAGQGTSE-----EOEGDS 449  
Db 417 YQSTIPI-----SPSPAPDDPEEGROGQTEKFOFELTLEDGES 455

RESULT 9  
US-08-474-379C-63  
; Sequence 63, Application US/08474379C  
; Patent No. 5977305  
; GENERAL INFORMATION:  
; APPLICANT: Wigler, Michael H.  
; APPLICANT: Colicelli, John J.  
; TITLE OF INVENTION: CLONING BY COMPLEMENTATION AND RELATED  
; TITLE OF INVENTION: PROCESSES  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 233 South Wacker Drive/6300 Sears Tower  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/474,379C  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/511,715  
; FILING DATE: 20-APR-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/206,188  
; FILING DATE: 01-MAR-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/688,352  
; FILING DATE: 19-APR-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clough, David W.  
; REGISTRATION NUMBER: 36,107  
; REFERENCE/DOCKET NUMBER: 27866/32771  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 474-6300  
; TELEFAX: (312) 474-0448  
; INFORMATION FOR SEQ ID NO: 63:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 673 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-474-379C-63

Query Match 25.1%; Score 604.5; DB 1; Length 673;  
Best Local Similarity 33.3%; Pred. No. 1.2e-54;  
Matches 135; Conservative 86; Mismatches 151; Indels 33; Gaps 9;

QY 66 KKKVKRLLS----PQRYFHASRLLRGIIPQAPLHLLDDEYLGQARHMLSKVGMWDFDIPL 121  
Db 218 KKKVKRLLS----PQRYFHASRLLRGIIPQAPLHLLDDEYLGQARHMLSKVGMWDFDIPL 274  
QY 122 FDRLTNGNSLVTLTLLCH-LFNTHGLIHHFKLDVTLHRLVNVQEDYHSQNPYHNAAD 180  
Db 275 IAEI-SGNRPLVTIMHTIFQERDLTKFKIPVDLTILYMTLEDHYHADVAYHNNIHAAD 333  
QY 181 VTQAMHCYLKEPKLASFLTPDIDIMGLAAAHVDHVGVPNPFLIKTNHHLANLYQMS 240  
Db 334 VVOSTHVLLSTPALEAVFTDLEILAFASAIHDVDPGVNSQFLINTSELALMYNDSS 393  
QY 241 VLENHWRSTIGMLRESR--LLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRKAHL 298  
Db 394 VLENHHLAVGFKLQEQNCDFQNLTKKQSLRKWIDIVLATDMSKNNLLADLKTW 453  
QY 299 HNKD-----LRLDAQDRHFMLOIALKCADICNPICRIMSKWSKSERVCEEFVROGELE 352  
Db 454 ETKKVTSSGVLDDNYSDRIQVLQNMVHCADLSNFTKPLQLYRQWTDRIIMEEFPQGDRE 513

QY 353 QKFEISPLCNOQKDSIPSQIGFMSYIVPEPLREWAHFTGNSTLSENMLGHLAHNAK 412  
DB 514 RERGMEISPMCDKHNASVEKSGVGFIDYIVHPLWETWADLVHPD--AQDILTLEDNREW 571

QY 413 WKSLLPQHRSGSGSGPDHAGQGTSE-----EQGDS 449  
DB 572 YQSTIPQ-----SPSPAPDDPEGRGQGTKEKFQFELTLEDGES 610

RESULT 10  
US-09-146-249A-63  
; Sequence 63, Application US/09146249A  
; Patent No. 6069240  
; GENERAL INFORMATION:  
; APPLICANT: Wigler, Michael H.  
; APPLICANT: Colicelli, John J.  
; TITLE OF INVENTION: Cloning by Complementation and Related  
; TITLE OF INVENTION: Processes  
; NUMBER OF SEQUENCES: 85  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/146,249A  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/511,715  
; FILING DATE: 20-APR-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clough, David W.  
; REGISTRATION NUMBER: 36,107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 312/474-6300  
; TELEFAX: 312-474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 63:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 673 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-09-146-249A-63

Query Match 25.1%; Score 604.5; DB 2; Length 673;  
Best Local Similarity 33.3%; Pred. No. 1.2e-54;  
Matches 135; Conservative 86; Mismatches 151; Indels 33; Gaps 9;

QY 66 KKKVKRLLS----FQRYFHASRLRLGIIPOAPLHLLDDEYLGQARHMLSKVGMWDFDIFL 121  
DB 218 KKKKRPMSQISGVKKLHMSSSLTNSIPRFGVKTEQEDVLAKL---LEDVKNKGLHVR 274

QY 122 FDLRTNGNSLVTLCH-LFNTHGLIHFKLDWVTLRFLVMVQEDYHSQNPYHNAVHAAD 180  
DB 275 IAEI-SGNRPLTVIMHTIFQERDLTKFKIPVDTLITYLMTLEDHYHADYVYHNNIHAAD 333

QY 181 VTQAMHCYKPKLASFLTPDLMGLLAAAHDVDPGVNQPFLIKTNHHLANLYQNM 240  
DB 334 VVQSTHLLSTPALEAVFTDLEILAAIPASAIHDVDPGVNQPFLINTNSALMYNDSS 393

QY 241 VLENHHRSTIGMLRSR--LLAHLPKMTQDTEQOLGSLIATDINRQNEFTRLKAHL 298  
DB 394 VLENHHLAVGFKLQENCDIFQNLTKQORSLRKRVIVDIVLATDMSKMNLIADLKTWV 453

QY 299 HNKD-----LRLEDAQDRHFMLOIAKCADICNPCRIMWSKOWSRVCEEFYQGELE 352  
DB 454 ETKKVTSSGVLLDNTSDRIQVQWVWCHADLSNPKPLQYQWTDRIWEEFFRQGDRE 513

QY 353 QKFEISPLCNOQKDSIPSQIGFMSYIVPEPLREWAHFTGNSTLSENMLGHLAHNAK 412  
DB 514 RERGMEISPMCDKHNASVEKSGVGFIDYIVHPLWETWADLVHPD--AQDILTLEDNREW 571

QY 413 WKSLLPQHRSGSGSGPDHAGQGTSE-----EQGDS 449  
DB 572 YQSTIPQ-----SPSPAPDDPEGRGQGTKEKFQFELTLEDGES 610

## RESULT 11

US-08-206-188B-63  
; Sequence 63, Application US/08206188B  
; Patent No. 6100025  
; GENERAL INFORMATION:  
; APPLICANT: Wigler, Michael H.  
; APPLICANT: Colicelli, John J.  
; TITLE OF INVENTION: Cloning by Complementation and Related  
; TITLE OF INVENTION: Processes  
; NUMBER OF SEQUENCES: 84  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/206,188B  
; FILING DATE: 01-MAR-1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/511,715  
; FILING DATE: 20-APR-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clough, David W.  
; REGISTRATION NUMBER: 36107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 312/474-6300  
; TELEFAX: 312-474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 63:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 673 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-206-188B-63

Query Match 25.1%; Score 604.5; DB 2; Length 673;  
Best Local Similarity 33.3%; Pred. No. 1.2e-54;  
Matches 135; Conservative 86; Mismatches 151; Indels 33; Gaps 9;

QY 66 KKKVKRLLS----FQRYFHASRLRLGIIPOAPLHLLDDEYLGQARHMLSKVGMWDFDIFL 121  
DB 218 KKKKRPMSQISGVKKLHMSSSLTNSIPRFGVKTEQEDVLAKL---LEDVKNKGLHVR 274

QY 122 FDLRTNGNSLVTLCH-LFNTHGLIHFKLDWVTLRFLVMVQEDYHSQNPYHNAVHAAD 180  
DB 275 IAEI-SGNRPLTVIMHTIFQERDLTKFKIPVDTLITYLMTLEDHYHADYVYHNNIHAAD 333

QY 181 VTQAMHCYKPKLASFLTPDLMGLLAAAHDVDPGVNQPFLIKTNHHLANLYQNM 240  
DB 334 VVQSTHLLSTPALEAVFTDLEILAAIPASAIHDVDPGVNQPFLINTNSALMYNDSS 393







```

Qy 182 TOAMHCYLKEPKLASFLTPLDIMGLLAAAHVDHFGVNOFPFLIKTNHHLANLYQNMV 241
Db 241 AQSTHVLSTPALDAVFTDLEILAAIFAAAIHVDHFGVSNQFLINTNSELALMYNDES 300
Qy 242 LENHHRSTIGMLRESR--LLAHLPKEMTQDIEOQLGSLIILATDINRQNEFLTELKAHL 299
Db 301 LENHHLAVGFKLQBEHCDFQNLTKKQRTLRKQVDMVLATDMSKMSLLADLKTWE 360
Qy 300 NKD-----LLEDAQDRHFMLQIALKCADICNPCIWMSKQWSEVCEFYRQGELEQ 353
Db 361 TKKVTSSGVLLLDNYTDRIQVLRNMVHCADLSNPTKSILEYRQWTDRIWEEFFQGDKE 420
Qy 354 KFELEISPLCNQOQKDSIPSIQIGFMSYIVEPLFREWAHFTGNSTLSENMLGHLAHNKAQW 413
Db 421 ERGMEISPMCDKHTASVEKSVQGVFDYIVHPLWETWADLVQPD--AQDILDLEDNRN 478
Qy 414 KSLLEPR-----QHRSSGSSGSPDHDH----ACQGTSESEQEGDSP 450
Db 479 QSMIPQSPPLDERSRDCQGLMEKFOFELTLEEDSEGEKEGEGP 525

```

Search completed: March 10, 2006, 20:04:14  
Job time : 41.8537 secs

ims Page Blank (uspio)

GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 10, 2006, 20:18:07 ; Search time 135.976 Seconds  
(without alignments)  
1382.771 Million cell updates/sec

Title: US-10-781-181-5  
Perfect score: 2408  
Sequence: 1 MSCLWVRCGEILFENPDQN.....PDHAGQGTSEBQGDSP 450

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA Main.\*  
1: /cgm2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pdb.\*  
2: /cgm2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pdb.\*  
3: /cgm2\_6/ptodata/1/pubpaa/US09\_PUBCOMB.pdb.\*  
4: /cgm2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pdb.\*  
5: /cgm2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pdb.\*  
6: /cgm2\_6/ptodata/1/pubpaa/US11\_PUBCOMB.pdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2408	100.0	450	4	US-10-781-181-5
2	2408	100.0	450	5	US-10-204-268A-2
3	2258	93.8	502	4	US-10-273-517-1
4	2258	93.8	502	4	US-10-386-414-4
5	2258	93.8	502	4	US-10-311-104-1
6	2258	93.8	502	6	US-11-048-744-1
7	2258	93.8	502	6	US-11-048-068-1
8	2192	91.0	446	4	US-10-781-181-1
9	1865	77.5	391	5	US-10-204-268A-4
10	1801	74.8	335	5	US-10-771-833-23
11	1801	74.8	335	5	US-10-886-949-23
12	1430	59.4	288	4	US-10-781-181-3
13	1410.5	58.6	426	3	US-09-966-781A-2
14	1403.5	58.3	426	3	US-09-966-781A-1
15	1397.5	58.0	426	3	US-09-966-781A-3
16	1287	53.4	424	5	US-10-380-437-6
17	1287	53.4	424	5	US-10-380-437-53
18	1286	53.4	432	3	US-09-764-898-208
19	1280	53.2	320	4	US-10-386-414-6
20	1234.5	51.3	334	5	US-10-771-833-22
21	1234.5	51.3	334	5	US-10-886-949-22
22	1194.5	49.6	336	4	US-10-258-746-2
23	771	32.0	211	3	US-09-764-898-280
24	771	32.0	211	3	US-09-989-442-120
25	604.5	25.1	507	4	US-10-076-597-49
26	604.5	25.1	507	4	US-10-067-514-10
27	604.5	25.1	507	4	US-10-419-723-10

28	604.5	25.1	507	4	US-10-255-120-10	Sequence 10, Appl
29	604.5	25.1	507	4	US-10-755-889-304	Sequence 304, App
30	604.5	25.1	507	5	US-10-868-397-10	Sequence 10, Appl
31	604.5	25.1	518	4	US-10-882-722-2	Sequence 2, Appl
32	604.5	25.1	585	4	US-10-067-514-9	Sequence 9, Appl
33	604.5	25.1	585	4	US-10-419-723-9	Sequence 9, Appl
34	604.5	25.1	585	4	US-10-255-120-9	Sequence 9, Appl
35	604.5	25.1	585	5	US-10-868-397-9	Sequence 9, Appl
36	604.5	25.1	684	5	US-10-735-973-2	Sequence 2, Appl
37	604.5	25.1	673	4	US-10-076-597-51	Sequence 51, Appl
38	604.5	25.1	673	4	US-10-067-514-6	Sequence 6, Appl
39	604.5	25.1	673	4	US-10-419-723-6	Sequence 6, Appl
40	604.5	25.1	673	4	US-10-255-120-6	Sequence 4, Appl
41	604.5	25.1	673	4	US-10-329-439-4	Sequence 4, Appl
42	604.5	25.1	673	5	US-10-884-206-36	Sequence 36, Appl
43	604.5	25.1	673	5	US-10-735-973-1	Sequence 1, Appl
44	604.5	25.1	679	5	US-10-735-973-6	Sequence 6, Appl
45	604.5	25.1	687	4	US-10-067-514-8	Sequence 8, Appl

## ALIGNMENTS

## RESULT 1

US-10-781-181-5  
; Sequence 5, Application US/10781181  
; Publication No. US20040137508A1  
; GENERAL INFORMATION:  
; APPLICANT: Pfizer Inc.  
; APPLICANT: Fiddock, Mark David  
; TITLE OF INVENTION: Enzyme PDE xiv  
; FILE REFERENCE: PC10315B  
; CURRENT APPLICATION NUMBER: US/10/781,181  
; CURRENT FILING DATE: 2004-02-18  
; PRIOR APPLICATION NUMBER: GB 9828603.2  
; PRIOR FILING DATE: 1998-12-23  
; PRIOR APPLICATION NUMBER: US 09/471,459  
; PRIOR FILING DATE: 1999-12-22  
; PRIOR APPLICATION NUMBER: GB 9922123.6  
; PRIOR FILING DATE: 1999-09-17  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 5  
; LENGTH: 450  
; TYPE: PRT  
; ORGANISM: Human  
US-10-781-181-5

Query Match	100.0%;	Score 2408;	DB 4;	Length 450;
Best Local Similarity	100.0%;	Pred. No. 9.2e-226;	Mismatches 0;	Indels 0;
Matches 450;	Conservative 0;			
QY	1	MSCLWVRCGEILFENPDQNAKVCMLGDIRLRGQGTGVAERRGSYFFIDFRLINSTTYS	60	
DB	1	MSCLWVRCGEILFENPDQNAKVCMLGDIRLRGQGTGVAERRGSYFFIDFRLINSTTYS	60	
QY	61	GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPLHLLDELDYLQGAHMLSKVGMWDFDIF	120	
DB	61	GEIGTKKKVKRLLSFQRYFHASRLRGIIIPQAPLHLLDELDYLQGAHMLSKVGMWDFDIF	120	
QY	121	LPRLTNGSLVTLCHLFNTHGLIHFFKLDWTLHRLFLVMQVEDYHSQPNYHNAVHAAD	180	
DB	121	LPRLTNGSLVTLCHLFNTHGLIHFFKLDWTLHRLFLVMQVEDYHSQPNYHNAVHAAD	180	
QY	181	VTQAMHCYLKPKLASPLTFLDLMGLAAAHDVHPGVNPPILIKTNHHLANLYQNS	240	
DB	181	VTQAMHCYLKPKLASPLTFLDLMGLAAAHDVHPGVNPPILIKTNHHLANLYQNS	240	
QY	241	VLENHHRWSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLN	300	
DB	241	VLENHHRWSTIGMLRESRLLAHLPKEMTQDIEQQLGSLILATDINRQNEFLTRLKAHLN	300	
QY	301	KDLRLDAQDRHFMQLKALKAIDICNPCRIMWMSKQWSERVCEFYRQGLEQKFELEIS	360	

```
Db 301 KDLRLDAQDRHFMQLKALCADICNPCRIMWMSKQSERVCEFYRQGLEQKFELEIS 360
Qy 361 PLCNQKQKDSIPSIQIGFMSYIVELPFWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQ 420
Db 361 PLCNQKQKDSIPSIQIGFMSYIVELPFWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQ 420
Qy 421 HRSRSGSGGPDHHDHAGQGTSEBEQGDSP 450
Db 421 HRSRSGSGGPDHHDHAGQGTSEBEQGDSP 450

RESULT 2
US-10-204-268A-2
; Sequence 2, Application US/10204268A
; Publication No. US20050058647A1
; GENERAL INFORMATION:
; APPLICANT: KLUEN, FRANZ-WERNER
; APPLICANT: HENTSCH, BERND
; TITLE OF INVENTION: NEW PHOSPHODIESTERASE TYPE 7B
; FILE REFERENCE: MERCK-2484
; CURRENT APPLICATION NUMBER: US/10/204,268A
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: PCT/EP01/01858
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: EP 00103655.7
; PRIOR FILING DATE: 2000-02-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: Patent in ver. 2.1
; SEQ ID NO 2
; TYPE: PRT
; LENGTH: 450
; ORGANISM: Homo sapiens
US-10-204-268A-2

Query Match 100.0%; Score 2408; DB 5; Length 450;
Best Local Similarity 100.0%; Pred. No. 9,2e-226;
Matches 450; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERCCEIIFENPDQNAKVCMLGDIRLGQGTGVAERGSYPFIDFRLNSTTYS 60
Db 1 MSCLMVERCCEIIFENPDQNAKVCMLGDIRLGQGTGVAERGSYPFIDFRLNSTTYS 60
Qy 61 GEIGTKKVKRLLSFOFYFHASRLLRGIIIPQAPLHLLDEYLGQARHMLSKVGWDFDIF 120
Db 61 GEIGTKKVKRLLSFOFYFHASRLLRGIIIPQAPLHLLDEYLGQARHMLSKVGWDFDIF 120
Qy 121 LPDRLTNGNSLVTLCHLFNTHGLIHFKLDWVTLHRFLVMQEDYHSQNPYHNAHAAD 180
Db 121 LPDRLTNGNSLVTLCHLFNTHGLIHFKLDWVTLHRFLVMQEDYHSQNPYHNAHAAD 180
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDPGVNQPFLLKTNHHLANLYQNS 240
Db 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVDPGVNQPFLLKTNHHLANLYQNS 240
Qy 241 VLENHWRSTIGMLRESRLLAHLPKEMTQDIEQOLGSLILATDINRQNEFLTRKKAHLN 300
Db 241 VLENHWRSTIGMLRESRLLAHLPKEMTQDIEQOLGSLILATDINRQNEFLTRKKAHLN 300
Qy 301 KDLRLDAQDRHFMQLKALCADICNPCRIMWMSKQSERVCEFYRQGLEQKFELEIS 360
Db 301 KDLRLDAQDRHFMQLKALCADICNPCRIMWMSKQSERVCEFYRQGLEQKFELEIS 360
Qy 361 PLCNQKQKDSIPSIQIGFMSYIVELPFWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQ 420
Db 361 PLCNQKQKDSIPSIQIGFMSYIVELPFWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQ 420
Qy 421 HRSRSGSGGPDHHDHAGQGTSEBEQGDSP 450
Db 421 HRSRSGSGGPDHHDHAGQGTSEBEQGDSP 450
```

RESULT 3

```
US-10-273-517-1
; Sequence 1, Application US/10273517
; Publication No. US20030143588A1
; GENERAL INFORMATION:
; APPLICANT: THORNTON, Michael B.; DING, Li
; APPLICANT: ARVIZU, Chandra S.; YAO, Monique G.
; APPLICANT: TRIBOULEY, Catherine M.; LAL, Preeti G.
; APPLICANT: HAPALIA, April J. A.; BAUGHN, Mariah R.
; APPLICANT: RAMKUMAR, Jayalaxmi; LU, Yan
; APPLICANT: CHAWLA, Narinder K.
; TITLE OF INVENTION: PHOSPHODIESTERASES
; FILE REFERENCE: PI-0136 USA
; CURRENT APPLICATION NUMBER: US/10/273,517
; CURRENT FILING DATE: 2002-10-18
; PRIOR APPLICATION NUMBER: 60/241,100
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/218,234
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US01/20140
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: 60/213,741
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PERL Program
; SEQ ID NO 1
; LENGTH: 502
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No. US20030143588A1 7476201CD1
US-10-273-517-1
```

```
Query Match 93.8%; Score 2258; DB 4; Length 502;
Best Local Similarity 100.0%; Pred. No. 4,7e-211;
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDRLRGQGTGVAERGSYPFIDFRLNSTTYSGEIGTKKVKRLLSFOFYFHASRLRG 87
Db 80 GDRLRGQGTGVAERGSYPFIDFRLNSTTYSGEIGTKKVKRLLSFOFYFHASRLRG 139
Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199
Qy 148 FKLDWVTLHRFLVMQEDYHSQNPYHNAHAADVTQAMHCYLKEPKLASFLTPDLMGL 207
Db 200 FKLDWVTLHRFLVMQEDYHSQNPYHNAHAADVTQAMHCYLKEPKLASFLTPDLMGL 259
Qy 208 LAAAADVDHPGVNQPFLLKTNHHLANLYQNSVLENHWRSTIGMLRESRLLAHLPKEM 267
Db 260 LAAAADVDHPGVNQPFLLKTNHHLANLYQNSVLENHWRSTIGMLRESRLLAHLPKEM 319
Qy 268 TQDIEQOLGSLILATDINRQNEFLTRKKAHLNKLRLDAQDRHFMQLKALCADICNP 327
Db 320 TQDIEQOLGSLILATDINRQNEFLTRKKAHLNKLRLDAQDRHFMQLKALCADICNP 379
Qy 328 CRIMWMSKQSERVCEFYRQGLEQKFELEISPLCNQKQKDSIPSIQIGFMSYIVELPFR 387
Db 380 CRIMWMSKQSERVCEFYRQGLEQKFELEISPLCNQKQKDSIPSIQIGFMSYIVELPFR 439
Qy 388 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPQHRSGSGGPDHHDHAGQGTSEBEQEG 447
Db 440 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPQHRSGSGGPDHHDHAGQGTSEBEQEG 499
Qy 448 DSP 450
Db 500 DSP 502

RESULT 4
US-10-386-414-4
; Sequence 4, Application US/10386414
```

```
Publication No. US20040006016A1
GENERAL INFORMATION:
APPLICANT: Kapeller-libermann, Rosana
APPLICANT: Robison, Keith E.
APPLICANT: White, David
APPLICANT: Williamson, Mark W.
APPLICANT: Cook, William James
APPLICANT: Meyers, Rachel E.
APPLICANT: Macbeth, Kyle J.
APPLICANT: Carroll, Joseph M.
APPLICANT: Chun, Miyoung
TITLE OF INVENTION: NOVEL 27875, 22025, 27420, 17906, 16319,
55052 AND 10218 MOLECULES AND USES THEREFOR
FILE REFERENCE: MF103-0210WIM
CURRENT APPLICATION NUMBER: US/10/386,414
CURRENT FILING DATE: 2003-03-11
PRIORITY APPLICATION NUMBER: 09/426,282
PRIORITY FILING DATE: 1999-10-25
PRIORITY APPLICATION NUMBER: 09/668,266
PRIORITY FILING DATE: 2000-09-22
PRIORITY APPLICATION NUMBER: 09/330,970
PRIORITY FILING DATE: 1999-06-11
PRIORITY APPLICATION NUMBER: 09/724,599
PRIORITY FILING DATE: 2000-11-28
PRIORITY APPLICATION NUMBER: 09/860,193
PRIORITY FILING DATE: 2001-05-16
PRIORITY APPLICATION NUMBER: 10/283,023
PRIORITY FILING DATE: 2002-10-29
PRIORITY APPLICATION NUMBER: 60/335,044
PRIORITY FILING DATE: 2001-10-31
PRIORITY APPLICATION NUMBER: 10/010,943
PRIORITY FILING DATE: 2001-12-06
PRIORITY APPLICATION NUMBER: 60/254,037
PRIORITY FILING DATE: 2000-12-07
PRIORITY APPLICATION NUMBER: 09/833,082
PRIORITY FILING DATE: 2001-04-10
NUMBER OF SEQ ID NOS: 19
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 4
LENGTH: 502
TYPE: PRT
ORGANISM: Homo Sapien
US-10-386-414-4

Query Match 93.8%; Score 2258; DB 4; Length 502;
Best Local Similarity 100.0%; Pred. No. 4.7e-211;
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDIRLRGQTGVARRRGSPYFIDPRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87
Db 80 GDIRLRGQTGVARRRGSPYFIDPRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139
Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGWMDFIPLFDRLTNGNSLVTLCHLFNTHGLIHH 147
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGWMDFIPLFDRLTNGNSLVTLCHLFNTHGLIHH 199
Qy 148 FKLDMTVTLHRLFLVMVQEDYHSQNPYHNAVAADVTQAMHCYKLPKSLASFLTPDLMGL 207
Db 200 FKLDMTVTLHRLFLVMVQEDYHSQNPYHNAVAADVTQAMHCYKLPKSLASFLTPDLMGL 259
Qy 208 LAAAAHDVDPGVNQPFLLKTNHHLANLYQNMVLENHNRSTIGMLRESRLLAHLKPEM 267
Db 260 LAAAAHDVDPGVNQPFLLKTNHHLANLYQNMVLENHNRSTIGMLRESRLLAHLKPEM 319
Qy 268 TDIEQGLSILATDINRQNEFLTRLKAHLNKLRLLEDAQDRHFMQLKALCADICNP 327
Db 320 TDIEQGLSILATDINRQNEFLTRLKAHLNKLRLLEDAQDRHFMQLKALCADICNP 379
Qy 328 CRIWEMSKQSERVCEFFYRQGELEQKFELEISPLCNQKDSIPSIQIGFMSYIVEPLFR 387
Db 380 CRIWEMSKQSERVCEFFYRQGELEQKFELEISPLCNQKDSIPSIQIGFMSYIVEPLFR 439
Qy 388 EWAHFTGNSTLSENMLGHLAHNAQWKSLLPROHRSRGSGSPDHDHAGGTSEBQEG 447

RESULT 5
US-10-311-104-1
Sequence 1, Application US/10311104
Publication No. US20040054138A1
GENERAL INFORMATION:
APPLICANT: INCYTE GENOMICS, INC.
APPLICANT: THORNTON, Michael
APPLICANT: DING, Li
APPLICANT: ARIVU Chandra S.
APPLICANT: YAO, Monique G.
APPLICANT: TRIBOULEY, Catherine M.
APPLICANT: LAL, Preeti G.
APPLICANT: HAPALIA, April J. A.
APPLICANT: BAUGHN, Mariah R.
APPLICANT: RAMKUMAR, Jayalaxmi
APPLICANT: LU, Yan
APPLICANT: Chawla, Narinder K.
TITLE OF INVENTION: PHOSPHODIESTERASES
FILE REFERENCE: FI-0136 PCT
CURRENT APPLICATION NUMBER: US/10/311,104
CURRENT FILING DATE: 2002-12-12
PRIORITY APPLICATION NUMBER: PCT/US01/20140
PRIORITY FILING DATE: 2001-06-21
PRIORITY APPLICATION NUMBER: 60/213,741
PRIORITY FILING DATE: 2000-06-22
PRIORITY APPLICATION NUMBER: 60/218,234
PRIORITY FILING DATE: 2000-07-14
PRIORITY APPLICATION NUMBER: 60/241,100
PRIORITY FILING DATE: 2000-10-16
NUMBER OF SEQ ID NOS: 8
SOFTWARE: PERL Program
SEQ ID NO 1
LENGTH: 502
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Incyte ID No. US20040054138A1 7476201CD1
US-10-311-104-1

Query Match 93.8%; Score 2258; DB 4; Length 502;
Best Local Similarity 100.0%; Pred. No. 4.7e-211;
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDIRLRGQTGVARRRGSPYFIDPRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87
Db 80 GDIRLRGQTGVARRRGSPYFIDPRLNLTSTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139
Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGWMDFIPLFDRLTNGNSLVTLCHLFNTHGLIHH 147
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGWMDFIPLFDRLTNGNSLVTLCHLFNTHGLIHH 199
Qy 148 FKLDMTVTLHRLFLVMVQEDYHSQNPYHNAVAADVTQAMHCYKLPKSLASFLTPDLMGL 207
Db 200 FKLDMTVTLHRLFLVMVQEDYHSQNPYHNAVAADVTQAMHCYKLPKSLASFLTPDLMGL 259
Qy 208 LAAAAHDVDPGVNQPFLLKTNHHLANLYQNMVLENHNRSTIGMLRESRLLAHLKPEM 267
Db 260 LAAAAHDVDPGVNQPFLLKTNHHLANLYQNMVLENHNRSTIGMLRESRLLAHLKPEM 319
Qy 268 TDIEQGLSILATDINRQNEFLTRLKAHLNKLRLLEDAQDRHFMQLKALCADICNP 327
Db 320 TDIEQGLSILATDINRQNEFLTRLKAHLNKLRLLEDAQDRHFMQLKALCADICNP 379
Qy 328 CRIWEMSKQSERVCEFFYRQGELEQKFELEISPLCNQKDSIPSIQIGFMSYIVEPLFR 387
```

Db 380 CRIWMSKQWSEVCEEFYRQGELEQKFELEISPLCNQKDSIPSIQIGFMSYIVBPLFR 439  
Qy 388 EWAHFTGNSTLSNMLGHLAHNKAQWKSLLPROHRSRGSSGSPDHDHAGCGTSEBQEG 447  
Db 440 EWAHFTGNSTLSNMLGHLAHNKAQWKSLLPROHRSRGSSGSPDHDHAGCGTSEBQEG 499  
Qy 448 DSP 450  
Db 500 DSP 502

## RESULT 6

US-11-048-744-1  
; Sequence 1, Application US/11048744  
; Publication No. US20050164275A1  
; GENERAL INFORMATION:  
; APPLICANT: THORNTON, Michael B.; DING, Li  
; APPLICANT: ARVIZU, Chandra S.; YAO, Monique G.  
; APPLICANT: TRIBOULEY, Catherine M.; LAL, Preeti G.  
; APPLICANT: HAFALIA, April J. A.; BAUGHN, Mariah R.  
; APPLICANT: RAMKUMAR, Jayalaxmi; LU, Yan  
; APPLICANT: CHAWLA, Narinder K.  
; TITLE OF INVENTION: PHOSPHODIESTERASES  
; FILE REFERENCE: PI-0136 USA  
; CURRENT FILING DATE: 2005-02-03  
; PRIOR APPLICATION NUMBER: US/11/048,744  
; PRIOR FILING DATE: 2002-10-18  
; PRIOR APPLICATION NUMBER: 60/241,100  
; PRIOR FILING DATE: 2000-10-16  
; PRIOR APPLICATION NUMBER: 60/218,234  
; PRIOR FILING DATE: 2000-07-14  
; PRIOR APPLICATION NUMBER: US01/20140  
; PRIOR FILING DATE: 2001-06-21  
; PRIOR APPLICATION NUMBER: 60/213,741  
; PRIOR FILING DATE: 2000-06-22  
; NUMBER OF SEQ ID NOS: 8  
; SOFTWARE: PERL Program  
; SEQ ID NO 1  
; LENGTH: 502  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc feature  
; OTHER INFORMATION: Incyte ID No: 7476201CDI  
US-11-048-744-1

Query Match 93.8%; Score 2258; DB 6; Length 502;  
Best Local Similarity 100.0%; Pred. No. 4.7e-211;  
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 28 GDRLRGQTGVRAERGSYPFIDRLNLSNTTYSGEIGTKKKVKRLLSFORYPHASRLLRG 87  
Db 80 GDRLRGQTGVRAERGSYPFIDRLNLSNTTYSGEIGTKKKVKRLLSFORYPHASRLLRG 139  
Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199  
Qy 148 FKLDWMTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 207  
Db 200 FKLDWMTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 259  
Qy 208 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 319  
Qy 268 TDIEQOLGSLILATDINRQNEFLTRKKAHLNKKDLREDAQDRHFMQLTALKCADICNP 327  
Db 320 TDIEQOLGSLILATDINRQNEFLTRKKAHLNKKDLREDAQDRHFMQLTALKCADICNP 379  
Qy 328 CRIWMSKQWSEVCEEFYRQGELEQKFELEISPLCNQKDSIPSIQIGFMSYIVBPLFR 387

Db 380 CRIWMSKQWSEVCEEFYRQGELEQKFELEISPLCNQKDSIPSIQIGFMSYIVBPLFR 439  
Qy 388 EWAHFTGNSTLSNMLGHLAHNKAQWKSLLPROHRSRGSSGSPDHDHAGCGTSEBQEG 447  
Db 440 EWAHFTGNSTLSNMLGHLAHNKAQWKSLLPROHRSRGSSGSPDHDHAGCGTSEBQEG 499  
Qy 448 DSP 450  
Db 500 DSP 502

## RESULT 7

US-11-048-068-1  
; Sequence 1, Application US/11048068  
; Publication No. US20050202478A1  
; GENERAL INFORMATION:  
; APPLICANT: INCYTE GENOMICS, INC.  
; APPLICANT: THORNTON, Michael  
; APPLICANT: DING, Li  
; APPLICANT: PATTERSON, Chandra  
; APPLICANT: YAO, Monique G.  
; APPLICANT: TRIBOULEY, Catherine M.  
; APPLICANT: LAL, Preeti  
; APPLICANT: HAFALIA, April J. A.  
; APPLICANT: BAUGHN, Mariah R.  
; APPLICANT: RAMKUMAR, Jayalaxmi  
; APPLICANT: LU, Yan  
; APPLICANT: WALIA, Narinder K.  
; TITLE OF INVENTION: PHOSPHODIESTERASES  
; FILE REFERENCE: PI-0136 PCT  
; CURRENT APPLICATION NUMBER: US/11/048,068  
; CURRENT FILING DATE: 2005-02-02  
; PRIOR APPLICATION NUMBER: 60/213,741  
; PRIOR FILING DATE: 2000-06-22  
; NUMBER OF SEQ ID NOS: 8  
; SOFTWARE: PERL Program  
; SEQ ID NO 1  
; LENGTH: 502  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc feature  
; OTHER INFORMATION: Incyte ID No: 7476201CDI  
US-11-048-068-1

Query Match 93.8%; Score 2258; DB 6; Length 502;  
Best Local Similarity 100.0%; Pred. No. 4.7e-211;  
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 28 GDRLRGQTGVRAERGSYPFIDRLNLSNTTYSGEIGTKKKVKRLLSFORYPHASRLLRG 87  
Db 80 GDRLRGQTGVRAERGSYPFIDRLNLSNTTYSGEIGTKKKVKRLLSFORYPHASRLLRG 139  
Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGWDFDIFLFDRLTNGNSLVTLCHLFNTHGLIHH 199  
Qy 148 FKLDWMTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 207  
Db 200 FKLDWMTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGL 259  
Qy 208 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAAHDVHPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEM 319  
Qy 268 TDIEQOLGSLILATDINRQNEFLTRKKAHLNKKDLREDAQDRHFMQLTALKCADICNP 327  
Db 320 TDIEQOLGSLILATDINRQNEFLTRKKAHLNKKDLREDAQDRHFMQLTALKCADICNP 379  
Qy 328 CRIWMSKQWSEVCEEFYRQGELEQKFELEISPLCNQKDSIPSIQIGFMSYIVBPLFR 387  
Db 380 CRIWMSKQWSEVCEEFYRQGELEQKFELEISPLCNQKDSIPSIQIGFMSYIVBPLFR 439



Qy 388 EWAHFTGNSTLSENMLGHLAHNAKQWKSLLPRQHRSGSGSGDPDHAGOGTSEBQEG 447  
Db 440 EWAHFTGNSTLSENMLGHLAHNAKQWKSLLPRQHRSGSGSGDPDHAGOGTSEBQEG 499  
Qy 448 DSP 450  
Db 500 DSP 502

## RESULT 8

US-10-781-181-1  
; Sequence 1, Application US/10781181  
; Publication No. US20040137508A1  
; GENERAL INFORMATION:  
; APPLICANT: Pfizer Inc.  
; APPLICANT: Fideock, Mark David  
; TITLE OF INVENTION: Enzyme PDE xiv  
; FILE REFERENCE: PCT/EP01/01858  
; CURRENT APPLICATION NUMBER: US/10781,181  
; CURRENT FILING DATE: 2004-02-18  
; PRIOR APPLICATION NUMBER: GB 9828603.2  
; PRIOR FILING DATE: 1998-12-23  
; PRIOR APPLICATION NUMBER: US 09/471,459  
; PRIOR FILING DATE: 1999-12-22  
; PRIOR APPLICATION NUMBER: GB 9922123.6  
; PRIOR FILING DATE: 1999-09-17  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1  
; LENGTH: 446  
; TYPE: PRT  
; ORGANISM: Mouse  
US-10-781-181-1

Query Match 91.0%; Score 2192; DB 4; Length 446;

Best Local Similarity 91.6%; Pred. No. 1.1e-204; Indels 6; Gaps 2;  
Matches 413; Conservative 13; Mismatches 19;

Qy 1 MSCLMVERCEGILFENPDQNAKVCMLGDIIRLQGTGVAERRSYFPIDFRLNSTYS 60  
Db 1 MSCLMVERCEGILFENPDQNAKVCMLGDIIRLQGTGVAERRSYFPIDFRLNSTYS 60  
Qy 61 GEIGTKKKVKLLSFQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSKVGMWDFDIF 120  
Db 61 GEIGTKKKVKLLSFQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSKVGMWDFDIF 120  
Qy 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVHAAD 180  
Db 121 LFDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNPYHNAVHAAD 180  
Qy 181 VTOAMHCYKPEKPLASFLTPDIDMLGLLAAAHVDHFGVNOPELITKNHHLANLYQNS 240  
Db 181 VTOAMHCYKPEKPLASFLTPDIDMLGLLAAAHVDHFGVNOPELITKNHHLANLYQNS 240  
Qy 241 VLENHWRSTIGMLRESRLLAHLKEMTDIEQQLGSLILATDINRQNEFLTRKLAHLN 300  
Db 241 VLENHWRSTIGMLRESRLLAHLKEMTDIEQQLGSLILATDINRQNEFLTRKLAHLN 300  
Qy 301 KDLRLDAQDRHFMQLKADICNPCRIMWMSKQWSEVCEEFYRQGLEOKFELEIS 360  
Db 301 KDLRLDAQDRHFMQLKADICNPCRIMWMSKQWSEVCEEFYRQGLEOKFELEIS 360  
Qy 361 PLCNQKQKDSIPSIQIGFMSYIVLPEFREWHAFTGNSTLSENMLGHLAHNAKQWKSLLPRQ 420  
Db 361 PLCNQKQKDSIPSIQIGFMSYIVLPEFREWHAFTGNSTLSENMLGHLAHNAKQWKSLLPRQ 420  
Qy 421 HRSRSGSGSGDPDHAGOGTSEBQEGDSP 450  
Db 421 HRSRSGSGSGDPDHAGOGTSEBQEGDSP 450  
Qy 448 DSP 450  
Db 500 DSP 502

## RESULT 9

US-10-204-268A-4  
; Sequence 4, Application US/10204268A  
; Publication No. US20050058647A1  
; GENERAL INFORMATION:  
; APPLICANT: KLUXEN, FRANZ-WERNER  
; APPLICANT: HENTSCH, BERND  
; TITLE OF INVENTION: NEW PHOSPHODIESTERASE TYPE 7B  
; FILE REFERENCE: MERCK-2484  
; CURRENT APPLICATION NUMBER: US/10204,268A  
; CURRENT FILING DATE: 2002-08-20  
; PRIOR APPLICATION NUMBER: PCT/EP01/01858  
; PRIOR FILING DATE: 2002-02-20  
; PRIOR APPLICATION NUMBER: EP 00103655.7  
; PRIOR FILING DATE: 2000-02-21  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 391  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: MOD RES  
; LOCATION: (188)  
; OTHER INFORMATION: Pro or His  
; FEATURE:  
; NAME/KEY: MOD RES  
; LOCATION: (387)  
; OTHER INFORMATION: Val, Ala, Asp, Glu or Gly  
US-10-204-268A-4

Query Match 77.5%; Score 1865; DB 5; Length 391;

Best Local Similarity 92.7%; Pred. No. 7.4e-173; Indels 0; Gaps 0;  
Matches 354; Conservative 2; Mismatches 26;

Qy 52 RLNSTTYSGEIGTKKKVKLLSFQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSK 111  
Db 10 RLNSTTYSGEIGTKKKVKLLSFQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSK 69  
Qy 112 VGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNP 171  
Db 70 VGMWDFDIFLDRLTNGNSLVTLCHLFNTHGLIHHFKLDMVTLHRLFLVMVQEDYHSQNP 129  
Qy 172 YHNAVHAADVTOAMHCYKPEKPLASFLTPDIDMLGLLAAAHVDHFGVNOPELITKNH 231  
Db 130 YHNAVHAADVTOAMHCYKPEKPLASFLTPDIDMLGLLAAAHVDHFGVNOPELITKNH 189  
Qy 232 LANLYQNSVLENHWRSTIGMLRESRLLAHLKEMTDIEQQLGSLILATDINRQNEFL 291  
Db 190 LANLYQNSVLENHWRSTIGMLRESRLLAHLKEMTDIEQQLGSLILATDINRQNEFL 249  
Qy 292 TRKLAHLHNDRLDAQDRHFMQLKADICNPCRIMWMSKQWSEVCEEFYRQGLE 351  
Db 250 TRKLAHLHNDRLDAQDRHFMQLKADICNPCRIMWMSKQWSEVCEEFYRQGLE 309  
Qy 352 EQKFELEISPLCNOQKQKDSIPSIQIGFMSYIVLPEFREWHAFTGNSTLSENMLGHLAHNA 411  
Db 310 EQKFELEISPLCNOQKQKDSIPSIQIGFMSYIVLPEFREWHAFTGNSTLSENMLGHLAHNA 369  
Qy 412 QWKSLLPRQHRSGSGSGDPD 433  
Db 370 QWKSLLPSSTEAGAAALXGLDH 391

## RESULT 10

US-10-771-833-23  
; Sequence 23, Application US/10771833  
; Publication No. US20050048573A1  
; GENERAL INFORMATION:  
; APPLICANT: MILBURN, MICHAEL V.  
; TITLE OF INVENTION: PDE5A CRYSTAL STRUCTURE AND USES  
; FILE REFERENCE: 039363-1106  
; CURRENT APPLICATION NUMBER: US/10771,833  
; CURRENT FILING DATE: 2004-02-03

```
; PRIOR APPLICATION NUMBER: 60/485,627
; PRIOR FILING DATE: 2003-07-07
; PRIOR APPLICATION NUMBER: 60/444,734
; PRIOR FILING DATE: 2003-02-03
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: Patentin Ver. 3.2
; SEQ ID NO 23
; LENGTH: 335
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-833-23

Query Match      74.8%; Score 1801; DB 5; Length 335;
Best Local Similarity 100.0%; Pred. No. 1e-166;
Matches 335; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 87 GIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLNFTHGLIH 146
Db 1 GIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLNFTHGLIH 60

Qy 147 HFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLIMLG 206
Db 61 HFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLIMLG 120

Qy 207 LLA AAAHVDVHPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRTIGMLRESRLLAHLPK 266
Db 121 LLA AAAHVDVHPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRTIGMLRESRLLAHLPK 180

Qy 267 MTODIEQQLGSLILATDINRQNEFLTRLKAHLNKKDLRLLEDAQDRHFMQLQIALKCADICN 326
Db 181 MTODIEQQLGSLILATDINRQNEFLTRLKAHLNKKDLRLLEDAQDRHFMQLQIALKCADICN 240

Qy 327 PCRIWMSKQWSRVCEEFYRQGELEQKFELEISPLCNQOKDSIPSTQIGFMSYIIVEPLF 386
Db 241 PCRIWMSKQWSRVCEEFYRQGELEQKFELEISPLCNQOKDSIPSTQIGFMSYIIVEPLF 300

Qy 387 REWAHFTGNSTLSENMLGHLAHNKAQWKSLLPROH 421
Db 301 REWAHFTGNSTLSENMLGHLAHNKAQWKSLLPROH 335

RESULT 11
US-10-886-949-23
; Sequence 23, Application US/10886949
; Publication No. US20050079548A1
; GENERAL INFORMATION:
; APPLICANT: DEAN R. ARTIS
; APPLICANT: BOLLAG, GIDSON
; APPLICANT: CARD, GRAHAM
; APPLICANT: MARTIN, FERNANDO
; APPLICANT: MILBURN, MICHAEL V.
; APPLICANT: ZHANG, KAM
; TITLE OF INVENTION: PDEA CRYSTAL STRUCTURE AND USES
; FILE REFERENCE: 039363-1108
; CURRENT APPLICATION NUMBER: US/10/886,949
; CURRENT FILING DATE: 2004-07-07
; PRIOR APPLICATION NUMBER: 60/485,627
; PRIOR FILING DATE: 2003-07-07
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: Patentin Ver. 3.2
; SEQ ID NO 23
; LENGTH: 335
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-886-949-23

Query Match      74.8%; Score 1801; DB 5; Length 335;
Best Local Similarity 100.0%; Pred. No. 1e-166;
Matches 335; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 87 GIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLNFTHGLIH 146
Db 1 GIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCHLNFTHGLIH 60

Qy 147 HFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLIMLG 206
Db 61 HFKLDWVTLHRFLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLIMLG 120

Qy 207 LLA AAAHVDVHPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRTIGMLRESRLLAHLPK 266
Db 121 LLA AAAHVDVHPGVNQPFLLIKTNHHLANLYQNMSVLENHHWRTIGMLRESRLLAHLPK 180

Qy 267 MTODIEQQLGSLILATDINRQNEFLTRLKAHLNKKDLRLLEDAQDRHFMQLQIALKCADICN 326
Db 181 MTODIEQQLGSLILATDINRQNEFLTRLKAHLNKKDLRLLEDAQDRHFMQLQIALKCADICN 240

Qy 327 PCRIWMSKQWSRVCEEFYRQGELEQKFELEISPLCNQOKDSIPSTQIGFMSYIIVEPLF 386
Db 241 PCRIWMSKQWSRVCEEFYRQGELEQKFELEISPLCNQOKDSIPSTQIGFMSYIIVEPLF 300

Qy 387 REWAHFTGNSTLSENMLGHLAHNKAQWKSLLPROH 421
Db 301 REWAHFTGNSTLSENMLGHLAHNKAQWKSLLPROH 335

RESULT 12
US-10-781-181-3
; Sequence 3, Application US/10781181
; Publication No. US20040137508A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: FIDOCK, MARK DAVID
; TITLE OF INVENTION: Enzyme PDE xiv
; FILE REFERENCE: PC10315B
; CURRENT APPLICATION NUMBER: US/10/781,181
; CURRENT FILING DATE: 2004-02-18
; PRIOR APPLICATION NUMBER: GB 9828603.2
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: US 09/471,459
; PRIOR FILING DATE: 1999-12-22
; PRIOR APPLICATION NUMBER: GB 9922123.6
; PRIOR FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 3
; LENGTH: 288
; TYPE: PRT
; ORGANISM: Human
US-10-781-181-3

Query Match      59.4%; Score 1430; DB 4; Length 288;
Best Local Similarity 100.0%; Pred. No. 1.3e-130;
Matches 268; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MSCLMVERGCEILFENPDQNAKVCVCMGLDIRLGQTGVRAERGSYPFIDFRLNSTTYS 60
Db 1 MSCLMVERGCEILFENPDQNAKVCVCMGLDIRLGQTGVRAERGSYPFIDFRLNSTTYS 60

Qy 61 GIGITKKVKRLLSFOFYPHASRLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIF 120
Db 61 GIGITKKVKRLLSFOFYPHASRLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIF 120

Qy 121 LFDRLTNGNSLVTLCHLNFTHGLIHFKDLDMVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180
Db 121 LFDRLTNGNSLVTLCHLNFTHGLIHFKDLDMVTLHRFLVMVQEDYHSQNPYHNAVHAAD 180

Qy 181 VTQAMHCYLKEPKLASFLTPDLIMGLLAAAADVDHPGVNQPFLLIKTNHHLANLYQNMS 240
Db 181 VTQAMHCYLKEPKLASFLTPDLIMGLLAAAADVDHPGVNQPFLLIKTNHHLANLYQNMS 240

Qy 241 VLENHHWRTIGMLRESRLLAHLPKEMT 268
Db 241 VLENHHWRTIGMLRESRLLAHLPKEMT 268

RESULT 13
```

```
US-09-966-781A-2
; Sequence 2, Application US/09966781A
; Publication No. US20030036184A1
; GENERAL INFORMATION:
; APPLICANT: SOULARD, PATRICIA
; TITLE OF INVENTION: POLYPEPTIDES EXHIBITING PDE7 ACTIVITY AND THEIR USE FOR
; FILE REFERENCE: A000281US
; CURRENT APPLICATION NUMBER: US/09/966, 781A
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: EP004026837
; PRIOR FILING DATE: 2000-09-28
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 426
; TYPE: PRT
; ORGANISM: Mus sp.
US-09-966-781A-2

Query Match      58.6%; Score 1410.5; DB 3; Length 426;
Best Local Similarity 63.1%; Pred. No. 1.9e-128;
Matches 260; Conservative 67; Mismatches 84; Indels 1; Gaps 1;

QY 18 DONAKVCMLGDIIRLQGTGVRARRGSGYPFIDRLLNSTTYSGEIGTKKKVKRLLSFOR 77
Db 1 DOTALYIRMLGDIIVRSRAGFETERRGSHPYIDFRIFHSQSDEIASVSARNIRRLLSFOR 60
QY 78 YFHASRLRLGIIPOAPLHLDEDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCH 137
Db 61 YLRSSFRFGATVCSNLDLDEYNGQAKMELKVGWGNFDFLDRLTNGNSLVSLTFH 120
QY 138 LFNTGHLIHFKLDVMTLHRLVMOVQEDYHSQNPYHNAHAAVDTQAMHCYKPEKPLASF 197
Db 121 LFSLHGLIEYFHLDMVKLRRLFYMIQEDYHSQNPYHNAHAAVDTQAMHCYKPEKPLANS 180
QY 198 LTPDLIMLGLLAAAHDVDPGVNQPFLIKTNHHLANLYQNMVLENHNRSTIGMLRES 257
Db 181 VTPWDILSLIAAATHDLDHPGVNQPFLIKTNHLYLATLYKNTSVLENHNRSAVGLLRES 240
QY 258 RLLAHLPKEMTQDIEQOLGSLIATDINRQNEFLTRKAHLHNKDLRLLEDAQDRHFMLOI 317
Db 241 GLFSHLPLESRQMEQIGALILATDISRQNEVLSLFRSHLDGRDLCLEDRHRLVLQM 300
QY 318 ALKADICNCPRIWEMSKQWSEVCEFYRQGELEISPLCNOQKDSIPSIOIGF 377
Db 301 ALKADICNCPRIWEMSKQWSEVCEFYRQGELEISPLCNOQKDSIPSIOIGF 360
QY 378 MSYIVLPLFEWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQHRSGSGS 429
Db 361 MTYLVEPLFEWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQHRSGSGS 411

RESULT 15
US-09-966-781A-3
; Sequence 3, Application US/09966781A
; Publication No. US20030036184A1
; GENERAL INFORMATION:
; APPLICANT: SOULARD, PATRICIA
; TITLE OF INVENTION: POLYPEPTIDES EXHIBITING PDE7 ACTIVITY AND THEIR USE FOR
; FILE REFERENCE: A000281US
; CURRENT APPLICATION NUMBER: US/09/966, 781A
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: EP004026837
; PRIOR FILING DATE: 2000-09-28
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 426
; TYPE: PRT
; ORGANISM: Rattus sp.
US-09-966-781A-3

Query Match      58.0%; Score 1397.5; DB 3; Length 426;
Best Local Similarity 62.4%; Pred. No. 3.5e-127;
Matches 257; Conservative 68; Mismatches 86; Indels 1; Gaps 1;

QY 18 DONAKVCMLGDIIRLQGTGVRARRGSGYPFIDRLLNSTTYSGEIGTKKKVKRLLSFOR 77
Db 1 DOTALYIRMLGDIIVRSRAGFETERRGSHPYIDFRIFHAQSEIASVSARNIRRLLSFOR 60
QY 78 YFHASRLRLGIIPOAPLHLDEDEYLGQARHMLSKVGMWDFDIFLDRLTNGNSLVTLCH 137
Db 61 YLRSSFRFGATVCSNLDLDEYNGQAKMELKVGWGNFDFLDRLTNGNSLVSLTFH 120
QY 138 LFNTGHLIHFKLDVMTLHRLVMOVQEDYHSQNPYHNAHAAVDTQAMHCYKPEKPLASF 197
Db 121 LFSLHGLIEYFHLDMVKLRRLFYMIQEDYHSQNPYHNAHAAVDTQAMHCYKPEKPLANS 180
QY 198 LTPDLIMLGLLAAAHDVDPGVNQPFLIKTNHHLANLYQNMVLENHNRSTIGMLRES 257
Db 181 VTPWDILSLIAAATHDLDHPGVNQPFLIKTNHLYLATLYKNTSVLENHNRSAVGLLRES 240
QY 258 RLLAHLPKEMTQDIEQOLGSLIATDINRQNEFLTRKAHLHNKDLRLLEDAQDRHFMLOI 317
Db 241 GLFSHLPLESRQMEQIGALILATDISRQNEVLSLFRSHLDGRDLCLEDRHRLVLQM 300
QY 318 ALKADICNCPRIWEMSKQWSEVCEFYRQGELEISPLCNOQKDSIPSIOIGF 377
Db 301 ALKADICNCPRIWEMSKQWSEVCEFYRQGELEISPLCNOQKDSIPSIOIGF 360
QY 378 MSYIVLPLFEWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQHRSGSGS 429
Db 361 MTYLVEPLFEWAHFTGNSTLSENMLGHLAHNAQWKSLLPRQHRSGSGS 411

RESULT 14
US-09-966-781A-1
; Sequence 1, Application US/09966781A
; Publication No. US20030036184A1
; GENERAL INFORMATION:
; APPLICANT: SOULARD, PATRICIA
; TITLE OF INVENTION: POLYPEPTIDES EXHIBITING PDE7 ACTIVITY AND THEIR USE FOR
; FILE REFERENCE: A000281US
; CURRENT APPLICATION NUMBER: US/09/966, 781A
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: EP004026837
; PRIOR FILING DATE: 2000-09-28
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 426
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-966-781A-1
```

Db	181	VTPWDILLSLIAAATHOLDHPGVNQPELIKTNHYLATLYKNTSVLENHHWRSVAGLLRES	240
Qy	258	RLLAHLPEKMTQDIEQQGLSLILATDINRQNEFLTRLKAHLHNKDLLEDAQDRHFMLQI	317
Db	241	GLFSHLPESRHEWEAQIGALILATDISRQNEYLSPFRSHLDKGDHLDDGRHRLVLQM	300
Qy	318	ALKCADICNPCRIMSKQWSEVCEEFYRQGELEQKFELEISPLCNQKQKDSIPSQIGF	377
Db	301	ALKCADICNPCRINWELSKQWSEKVTTEFFHQGDIEKKYHLGVSPCLCDRQTESIANIQIGF	360
Qy	378	MSYIVEPLPREWAHFTGNSTLSENMLGHLAHNKAQWKSLLPROHRSRGSSGS	429
Db	361	MTYLQEPFTTEWARFS-DTRLSTQMLGHVGLNKASWKGLQROQPSSEDASAA	411

Search completed: March 10, 2006, 20:22:34  
Job time : 136.976 secs

GenCore version 5.1.7  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

# OM protein - protein search, using sw model

Run on: March 10, 2006, 20:19:01 ; Search time 17.6829 Seconds  
(without alignments)  
708.350 Million cell updates/sec

Title: US-10-781-181-5  
Perfect score: 2408  
Sequence: 1 MSLMVERCEILLFENPDQN.....PDHAGQGTSESEQSDSP 450

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 161667 seqs, 27834885 residues

Total number of hits satisfying chosen parameters: 161667

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications AA New.\*  
1: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB.pep.\*  
2: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB.pep.\*  
3: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB.pep.\*  
4: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB.pep.\*  
5: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB.pep.\*  
6: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB.pep.\*  
7: /cgn2\_6/ptodata/2/pubpaa/US11\_NEW\_PUB.pep.\*  
8: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2258	93.8	502	7	US-11-226-701-4
2	1280	53.2	320	7	US-11-226-701-6
3	604.5	25.1	507	7	US-11-091-018-10
4	604.5	25.1	585	7	US-11-091-018-9
5	604.5	25.1	673	7	US-11-091-018-6
6	604.5	25.1	687	7	US-11-091-018-8
7	604.5	25.1	745	7	US-11-091-018-4
8	604.5	25.1	748	6	US-10-492-835-12
9	604.5	25.1	748	6	US-10-492-835-28
10	604.5	25.1	809	7	US-11-091-018-2
11	603.5	25.1	747	6	US-10-492-835-8
12	603.5	25.1	747	6	US-10-492-835-27
13	594.5	24.7	747	6	US-10-492-835-15
14	570.5	23.7	736	7	US-11-123-893-13
15	567.5	23.6	736	7	US-11-169-041-207
16	556.5	23.1	398	7	US-11-123-893-11
17	546.5	22.7	357	7	US-11-123-893-12
18	448.5	18.6	769	7	US-11-072-512-2646
19	298	12.4	941	6	US-10-501-035-343
20	277.5	11.5	854	6	US-10-511-657-4
21	191	7.9	786	7	US-11-072-512-2944
22	103	4.3	968	6	US-10-501-035-219
23	94.5	3.9	611	7	US-11-087-099-8358
24	91.5	3.8	635	7	US-11-096-568A-29628
25	91.5	3.8	710	7	US-11-096-568A-29627

26	90	3.7	1049	7	US-11-137-465-42	Sequence 42, Appli
27	86	3.6	418	7	US-11-109-156-2	Sequence 2, Appli
28	83.5	3.5	937	7	US-11-096-568A-31319	Sequence 31319, A
29	82.5	3.4	422	7	US-11-230-251-26	Sequence 26, Appli
30	82	3.4	366	7	US-11-096-568A-5564	Sequence 5564, Ap
31	82	3.4	372	7	US-11-096-568A-5563	Sequence 5563, Ap
32	82	3.4	643	7	US-11-096-568A-27797	Sequence 27797, A
33	82	3.4	1024	6	US-10-131-826A-198	Sequence 198, App
34	82	3.4	1024	6	US-10-973-115B-198	Sequence 198, App
35	81.5	3.4	808	7	US-11-072-512-2324	Sequence 2324, Ap
36	81	3.4	286	7	US-11-072-512-3361	Sequence 3361, Ap
37	81	3.4	418	7	US-11-099-691-1	Sequence 1, Appli
38	81	3.4	484	7	US-11-072-512-3381	Sequence 3381, Ap
39	81	3.4	678	7	US-11-072-512-3832	Sequence 3832, Ap
40	81	3.4	852	6	US-10-467-657-5004	Sequence 5004, Ap
41	81	3.4	926	7	US-11-232-405A-34	Sequence 34, Appli
42	81	3.4	6738	6	US-10-922-232B-56	Sequence 56, Appli
43	80.5	3.3	326	7	US-11-087-099-1590	Sequence 1590, Ap
44	80.5	3.3	376	7	US-11-098-686-10379	Sequence 10379, A
45	80.5	3.3	3487	7	US-11-087-099-10423	Sequence 10423, A

## ALIGNMENTS

RESULT 1  
US-11-226-701-4  
; Sequence 4, Application US/11226701  
; Publication No. US2006009632A1  
; GENERAL INFORMATION:  
; APPLICANT: Millennium Pharmaceuticals, Inc.  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: Robison, Keith E.  
; APPLICANT: White, David  
; APPLICANT: Williamson, Mark W.  
; APPLICANT: Cook, William James  
; APPLICANT: Meyers, Rachel E.  
; APPLICANT: MacBeth, Kyle J.  
; APPLICANT: Carroll, Joseph M.  
; APPLICANT: Chun, Miyoung  
; TITLE OF INVENTION: NOVEL 27875, 22025, 27420, 17906, 16319,  
; TITLE OF INVENTION: 55092 AND 10218 MOLECULES AND USES THEREFOR  
; FILE REFERENCE: MFI03-0210NMIM  
; CURRENT APPLICATION NUMBER: US/11/226,701  
; PRIOR FILING DATE: 2005-09-14  
; PRIOR APPLICATION NUMBER: US/10/386,414  
; PRIOR FILING DATE: 2003-03-11  
; PRIOR APPLICATION NUMBER: 09/426,282  
; PRIOR FILING DATE: 1999-10-25  
; PRIOR APPLICATION NUMBER: 09/668,266  
; PRIOR FILING DATE: 2000-09-22  
; PRIOR APPLICATION NUMBER: 09/330,970  
; PRIOR FILING DATE: 1999-06-11  
; PRIOR APPLICATION NUMBER: 09/724,599  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 09/860,193  
; PRIOR FILING DATE: 2001-05-16  
; PRIOR APPLICATION NUMBER: 09/571,689  
; PRIOR FILING DATE: 2000-05-16  
; PRIOR APPLICATION NUMBER: 10/283,023  
; PRIOR FILING DATE: 2002-10-29  
; PRIOR APPLICATION NUMBER: 60/335,044  
; PRIOR FILING DATE: 2001-10-31  
; PRIOR APPLICATION NUMBER: 10/010,943  
; PRIOR FILING DATE: 2001-12-06  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 502  
; TYPE: PRT  
; ORGANISM: Homo Sapiens  
US-11-226-701-4

Query Match 93.8%; Score 2258; DB 7; Length 502;  
Best Local Similarity 100.0%; Pred. No. 9.2e-201; Indels 0; Gaps 0;  
Matches 423; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDRLRGQTGVRAERRGSYPFIDFRLNSTTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87  
Db 80 GDRLRGQTGVRAERRGSYPFIDFRLNSTTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139

Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFLDRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFLDRLTNGNSLVTLCHLFNTHGLIHH 199

Qy 148 FKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIDMLGL 207  
Db 200 FKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIDMLGL 259

Qy 208 LAAAAHDVDPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAAHDVDPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 319

Qy 268 TDIEQOLGSLIATDINRQNEFLTRLKAHLHNKDLRLDAQDRHFMQLTALKCADICNP 327  
Db 320 TDIEQOLGSLIATDINRQNEFLTRLKAHLHNKDLRLDAQDRHFMQLTALKCADICNP 379

Qy 328 CRIWMSKQSERVCEFYRQGELEOKFELEISPLCNQKXDSIPSIQIGFMSYIVPELFR 387  
Db 380 CRIWMSKQSERVCEFYRQGELEOKFELEISPLCNQKXDSIPSIQIGFMSYIVPELFR 439

Qy 388 EWAHGTNSTLSENLGHLAHNAQWKSLLPRQHRSGSGSGGPDHDHAGQGTESEBEQEG 447  
Db 440 EWAHGTNSTLSENLGHLAHNAQWKSLLPRQHRSGSGSGGPDHDHAGQGTESEBEQEG 499

Qy 448 DSP 450  
Db 500 DSP 502

RESULT 2

US-11-226-701-6  
; Sequence 6, Application US/11226701  
; Publication No. US2006009632A1  
; GENERAL INFORMATION:  
; APPLICANT: Millennium Pharmaceuticals, Inc.  
; APPLICANT: Kapeller-Libermann, Rosana  
; APPLICANT: Robison, Keith E.  
; APPLICANT: White, David  
; APPLICANT: Williamson, Mark W.  
; APPLICANT: Cook, William James  
; APPLICANT: Meyers, Rachel E.  
; APPLICANT: MacBeth, Kyle J.  
; APPLICANT: Carroll, Joseph M.  
; APPLICANT: Chun, Mlyoung  
; TITLE OF INVENTION: NOVEL 27875, 22025, 27420, 17906, 16319,  
; TITLE OF INVENTION: 55092 AND 10218 MOLECULES AND USES THEREFOR  
; FILE REFERENCE: MPI03-0210WNIM  
; CURRENT APPLICATION NUMBER: US/11/226, 701  
; CURRENT FILING DATE: 2005-09-14  
; PRIOR APPLICATION NUMBER: US/10/386, 414  
; PRIOR FILING DATE: 2003-03-11  
; PRIOR APPLICATION NUMBER: 09/426, 282  
; PRIOR FILING DATE: 1999-10-25  
; PRIOR APPLICATION NUMBER: 09/668, 266  
; PRIOR FILING DATE: 2000-09-22  
; PRIOR APPLICATION NUMBER: 09/330, 970  
; PRIOR FILING DATE: 1999-06-11  
; PRIOR APPLICATION NUMBER: 09/724, 599  
; PRIOR FILING DATE: 2000-11-28  
; PRIOR APPLICATION NUMBER: 09/860, 193  
; PRIOR FILING DATE: 2001-05-16  
; PRIOR APPLICATION NUMBER: 09/571, 689  
; PRIOR FILING DATE: 2000-05-16  
; PRIOR APPLICATION NUMBER: 10/283, 023

Query Match 53.2%; Score 1280; DB 7; Length 320;  
Best Local Similarity 100.0%; Pred. No. 1.3e-110; Indels 0; Gaps 0;  
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 28 GDRLRGQTGVRAERRGSYPFIDFRLNSTTYSGEIGTKKKVKRLLSFQRYFHASRLRG 87  
Db 80 GDRLRGQTGVRAERRGSYPFIDFRLNSTTYSGEIGTKKKVKRLLSFQRYFHASRLRG 139

Qy 88 IIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFLDRLTNGNSLVTLCHLFNTHGLIHH 147  
Db 140 IIPQAPLHLLDEYLGQARHMLSKVGMWDFIDFLDRLTNGNSLVTLCHLFNTHGLIHH 199

Qy 148 FKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIDMLGL 207  
Db 200 FKLDVMTLHRLFLVMQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDIDMLGL 259

Qy 208 LAAAAHDVDPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 267  
Db 260 LAAAAHDVDPGVNQPFLLIKTNHHLANLYQNMVLENHHRSTIGMLRESRLLAHLPKEM 319

Qy 268 T 268  
Db 320 T 320

RESULT 3

US-11-091-018-10  
; Sequence 10, Application US/11091018  
; Publication No. US20050287551A1  
; GENERAL INFORMATION:  
; APPLICANT: Gretaardottir, Solveig  
; APPLICANT: Thorleifsson, Gudmar  
; APPLICANT: Guicher, Jeffrey R.  
; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR HUMAN STROKE;  
; TITLE OF INVENTION: METHODS OF TREATMENT  
; FILE REFERENCE: 2345.2010-016  
; CURRENT APPLICATION NUMBER: US/11/091, 018  
; CURRENT FILING DATE: 2005-03-25  
; PRIOR APPLICATION NUMBER: PCT/US03/29906  
; PRIOR FILING DATE: 2003-09-25  
; PRIOR APPLICATION NUMBER: 10/255, 120  
; PRIOR FILING DATE: 2002-09-25  
; PRIOR APPLICATION NUMBER: 10/419, 723  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: 10/650, 120  
; PRIOR FILING DATE: 2003-08-27  
; PRIOR APPLICATION NUMBER: 10/067, 514  
; PRIOR FILING DATE: 2002-02-04  
; PRIOR APPLICATION NUMBER: 09/811, 352  
; PRIOR FILING DATE: 2001-03-19  
; NUMBER OF SEQ ID NOS: 102  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 10  
; LENGTH: 507  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-091-018-10

Query Match 25.1%; Score 604.5; DB 7; Length 507;

```
Best Local Similarity 33.3%; Pred. No. 6.8e-48;
Matches 135; Conservative 86; Mismatches 151; Indels 33; Gaps 9;

Qy 66 KKKVKRLLS----FQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121
Db 52 KKKKRPMSQISGVKMLHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNWGLHVFR 108
Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDMVTLHRFLVMVOEDYHSQNPYHNAVHAAD 180
Db 109 IABL-SGNRPLTVIMHTIIFOERDLLTKFKIPVDTLITYLMTLEDHYHADVAYHNNIHAAD 167
Qy 181 VTQAMCHYLKEPKLASFLTPDLIMLGLAAAHVDHPGVNQPFLLIKTNHHLANLYONMS 240
Db 168 VVOSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVNSQFLINTNSSELALMYNDSS 227
Qy 241 VLENHHRSTIGMLRESR--LLAHLPEKMTQDIEQQGLSLATDINRQNEFLTRLKAHL 298
Db 228 VLENHHLAVGFKLQEBNCDFQNLTKQRQSLRKWVIDIVLATDMSKHNLLADLKTVM 287
Qy 299 HNKD-----LRLEDAQRHFMLOIALKCADICNPCRIMWMSKOWSERVCEEFYRQGELE 352
Db 288 ETRKVTSSGVLDDNYSRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIIMEEFPQGDRE 347
Qy 353 QKPELEISPLCNOQKQSIQISQIFGMSYIVEPLFRWAHFTGNSTSENMLGLAHNAKAQ 412
Db 348 RERGMEISPMCDKHNASVEKSVQGFIDYIVHPLWETWADLVHPD--AQDILDTLEDNREW 405
Qy 413 WKSLLPQHRSGSSGGPDHHDAGQGTSE-----EQEGDS 449
Db 406 YQSTIPQ-----SPSPAPDDPEGRQGTQKQFELTLEEDGES 444

RESULT 4
US-11-091-018-9
; Sequence 9, Application US/11091018
; Publication No. US20050287551A1
; GENERAL INFORMATION:
; APPLICANT: Gretaarsdottir, Solveig
; APPLICANT: Thorleifsson, Gudmar
; APPLICANT: Gulcher, Jeffrey R.
; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR HUMAN STROKE;
; TITLE OF INVENTION: METHODS OF TREATMENT
; FILE REFERENCE: 2345.2010-016
; CURRENT APPLICATION NUMBER: US/11/091.018
; PRIOR FILING DATE: 2005-03-25
; PRIOR APPLICATION NUMBER: 10/419,723
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 10/650,120
; PRIOR FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: 10/067,514
; PRIOR FILING DATE: 2002-02-04
; PRIOR APPLICATION NUMBER: 09/811,352
; PRIOR FILING DATE: 2001-03-19
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 585
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-091-018-9

Query Match 25.1%; Score 604.5; DB 7; Length 585;
Best Local Similarity 33.3%; Pred. No. 8.2e-48;
Matches 135; Conservative 86; Mismatches 151; Indels 33; Gaps 9;

Qy 66 KKKVKRLLS----FQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121
Db 130 KKKKRPMSQISGVKMLHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNWGLHVFR 186

Best Local Similarity 33.3%; Pred. No. 6.8e-48;
Matches 135; Conservative 86; Mismatches 151; Indels 33; Gaps 9;

Qy 66 KKKVKRLLS----FQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121
Db 218 KKKKRPMSQISGVKMLHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNWGLHVFR 274
Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDMVTLHRFLVMVOEDYHSQNPYHNAVHAAD 180
Db 275 IABL-SGNRPLTVIMHTIIFOERDLLTKFKIPVDTLITYLMTLEDHYHADVAYHNNIHAAD 333
Qy 181 VTQAMCHYLKEPKLASFLTPDLIMLGLAAAHVDHPGVNQPFLLIKTNHHLANLYONMS 240
Db 334 VVOSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVNSQFLINTNSSELALMYNDSS 393

Best Local Similarity 33.3%; Pred. No. 9.9e-48;
Matches 135; Conservative 86; Mismatches 151; Indels 33; Gaps 9;

Qy 66 KKKVKRLLS----FQRYFHASRLLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121
Db 218 KKKKRPMSQISGVKMLHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNWGLHVFR 274
Qy 122 FDLRTNGNSLVTLCH-LFNTHGLIHHFKLDMVTLHRFLVMVOEDYHSQNPYHNAVHAAD 180
Db 275 IABL-SGNRPLTVIMHTIIFOERDLLTKFKIPVDTLITYLMTLEDHYHADVAYHNNIHAAD 333
Qy 181 VTQAMCHYLKEPKLASFLTPDLIMLGLAAAHVDHPGVNQPFLLIKTNHHLANLYONMS 240
Db 334 VVOSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVNSQFLINTNSSELALMYNDSS 393
```







Db 354 KKKKRPMSQISGVKKLHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNKGLHVP 410  
Qy 122 FDLTNGNSLVTLCH-LFNTHGLIHFKLDMVTLHRFLVMQEDVHSQNPYHNAHAAD 180  
Db 411 IAEI-SGNRPLTVIMHTIFQERDLTKFKIPVDLTITLMTLEDHYHADVAYHNNHAAD 469  
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHDPGVNQPFLLKTNHHLANLYONMS 240  
Db 470 VVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDPGVSNQFLINTNSEALAMYNDSS 529  
Qy 241 VLENHHRSTIGMLRESR--LLAHLPKEMTDIEQOLGSLIATDINRQNEFTRLKAHL 298  
Db 530 VLENHHLAVGFKLQEBNCDFQNLTKKQSRKQWIDIVLATDMSKMNLLADLKTWV 589  
Qy 299 HNKD-----LRLEDAQDRHFMQLKADICNPCRIMWSKQWSEVCEEFYRQGELE 352  
Db 590 ETQKVTSSGVLLLDNYSRDIQVLQNMVHCADLSNPTKPLQLYRQWTDRIWEEFFRQGDRE 649  
Qy 353 QKPELEISPLCNOQKDSIPSIOIGFMSYIVEPLFRWAHFTGNSTLSENMLGLAHNAKQ 412  
Db 650 RERGMISPMCKHNASVEKSGVGFIDYIVHPLWETWADLVHPD--AQDILDTLEDNREW 707  
Qy 413 WKSLLPRQHRSGSGSPDHDHAGQGTSE-----EQEGDS 449  
Db 708 YQSTIPQ-----SPSPAPDDPEGQGTKEKFQFELTLEEDGES 746

## RESULT 11

US-10-492-835-8  
; Sequence 8, Application US/10492835  
; Publication No. US20050289660A2  
; GENERAL INFORMATION:  
; APPLICANT: MEMORY PHARMACEUTICALS CORPORATION  
; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS  
; FILE REFERENCE: MEMORY 4 WO  
; CURRENT APPLICATION NUMBER: US/10/492,835  
; CURRENT FILING DATE: 2004-04-15  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: Patentin Ver. 3.2  
; SEQ ID NO 8  
; TYPE: PRT  
; ORGANISM: Rattus sp.  
US-10-492-835-8

Query Match 25.1%; Score 603.5; DB 6; Length 747;  
Best Local Similarity 33.3%; Pred. No. 1.4e-47;  
Matches 135; Conservative 85; Mismatches 152; Indels 33; Gaps 9;

Qy 66 KKKVKLLS----FQRYFHASRLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121  
Db 293 KKKKRPMSQISGVKKLHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNKGLHVP 349  
Qy 122 FDLTNGNSLVTLCH-LFNTHGLIHFKLDMVTLHRFLVMQEDVHSQNPYHNAHAAD 180  
Db 350 IAEI-SGNRPLTVIMHTIFQERDLTKFKIPVDLTITLMTLEDHYHADVAYHNNHAAD 408  
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHDPGVNQPFLLKTNHHLANLYONMS 240  
Db 409 VVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDPGVSNQFLINTNSEALAMYNDSS 468  
Qy 241 VLENHHRSTIGMLRESR--LLAHLPKEMTDIEQOLGSLIATDINRQNEFTRLKAHL 298  
Db 469 VLENHHLAVGFKLQEBNCDFQNLTKKQSRKQWIDIVLATDMSKMNLLADLKTWV 528  
Qy 299 HNKD-----LRLEDAQDRHFMQLKADICNPCRIMWSKQWSEVCEEFYRQGELE 352  
Db 529 ETQKVTSSGVLLLDNYSRDIQVLQNMVHCADLSNPTKPLQLYRQWTDRIWEEFFRQGDRE 588  
Qy 353 QKPELEISPLCNOQKDSIPSIOIGFMSYIVEPLFRWAHFTGNSTLSENMLGLAHNAKQ 412

Db 589 RERGMISPMCKHNASVEKSGVGFIDYIVHPLWETWADLVHPD--AQDILDTLEDNREW 646  
Qy 413 WKSLLPRQHRSGSGSPDHDHAGQGTSE-----EQEGDS 449  
Db 647 YQSTIPQ-----SPSPAPDDPEGQGTKEKFQFELTLEEDGES 685

## RESULT 12

US-10-492-835-27  
; Sequence 27, Application US/10492835  
; Publication No. US20050289660A2  
; GENERAL INFORMATION:  
; APPLICANT: MEMORY PHARMACEUTICALS CORPORATION  
; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS  
; FILE REFERENCE: MEMORY 4 WO  
; CURRENT APPLICATION NUMBER: US/10/492,835  
; CURRENT FILING DATE: 2004-04-15  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: Patentin Ver. 3.2  
; SEQ ID NO 27  
; LENGTH: 747  
; TYPE: PRT  
; ORGANISM: Rattus sp.  
US-10-492-835-27

Query Match 25.1%; Score 603.5; DB 6; Length 747;  
Best Local Similarity 33.3%; Pred. No. 1.4e-47;  
Matches 135; Conservative 85; Mismatches 152; Indels 33; Gaps 9;

Qy 66 KKKVKLLS----FQRYFHASRLRGIIPQAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121  
Db 293 KKKKRPMSQISGVKKLHSSSLTNSSIPRFGVKTEQEDVLAKE---LEDVKNKGLHVP 349  
Qy 122 FDLTNGNSLVTLCH-LFNTHGLIHFKLDMVTLHRFLVMQEDVHSQNPYHNAHAAD 180  
Db 350 IAEI-SGNRPLTVIMHTIFQERDLTKFKIPVDLTITLMTLEDHYHADVAYHNNHAAD 408  
Qy 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHVDHDPGVNQPFLLKTNHHLANLYONMS 240  
Db 409 VVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDPGVSNQFLINTNSEALAMYNDSS 468  
Qy 241 VLENHHRSTIGMLRESR--LLAHLPKEMTDIEQOLGSLIATDINRQNEFTRLKAHL 298  
Db 469 VLENHHLAVGFKLQEBNCDFQNLTKKQSRKQWIDIVLATDMSKMNLLADLKTWV 528  
Qy 299 HNKD-----LRLEDAQDRHFMQLKADICNPCRIMWSKQWSEVCEEFYRQGELE 352  
Db 529 ETQKVTSSGVLLLDNYSRDIQVLQNMVHCADLSNPTKPLQLYRQWTDRIWEEFFRQGDRE 588  
Qy 353 QKPELEISPLCNOQKDSIPSIOIGFMSYIVEPLFRWAHFTGNSTLSENMLGLAHNAKQ 412  
Db 589 RERGMISPMCKHNASVEKSGVGFIDYIVHPLWETWADLVHPD--AQDILDTLEDNREW 646  
Qy 413 WKSLLPRQHRSGSGSPDHDHAGQGTSE-----EQEGDS 449  
Db 647 YQSTIPQ-----SPSPAPDDPEGQGTKEKFQFELTLEEDGES 685

## RESULT 13

US-10-492-835-15  
; Sequence 15, Application US/10492835  
; Publication No. US20050289660A2  
; GENERAL INFORMATION:  
; APPLICANT: MEMORY PHARMACEUTICALS CORPORATION  
; TITLE OF INVENTION: CYCLIC AMP PHOSPHODIESTERASE 4D7 ISOFORMS AND METHODS  
; FILE REFERENCE: MEMORY 4 WO  
; CURRENT APPLICATION NUMBER: US/10/492,835  
; CURRENT FILING DATE: 2004-04-15  
; NUMBER OF SEQ ID NOS: 28  
; SOFTWARE: Patentin Ver. 3.2  
; SEQ ID NO 15

```

; LENGTH: 747
; TYPE: PRT
; ORGANISM: Murine sp.
; US-10-492-835-15

Query Match
  24.7%; Score 594.5; DB 6; Length 747;
Best Local Similarity
  33.4%; Pred. No. 9.6e-47;
Matches 131; Conservative 84; Mismatches 152; Indels 25; Gaps 8;

QY 66 KKKVKRLLS-----FORYPHASRLLRGIPOAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121
DB 293 KEKKKPMQISGVKKLMHSSLSITNSCIPRFQVKTQEQDVLAXE---LEDVKNKGLHVR 349
QY 122 FDLRTNGSLVTLCH-LFNTHGLIHFKLDVMVTLHRLFLVMVQEDYHSQNPYHNAVHAAD 180
DB 350 IABL-SGNRPFLVIMHTIFQERDILLKTKFIPVDLTITVLTMTLEDHYADVAYHNNIHAAD 408
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVHGVNQPFLLKTNHHLANLYQNMS 240
DB 409 VQVSTHLLSTPALEAVFTDLLEILAAIFASAIHVDHVPFVNSQNFLLNTNSALMYNDSS 468
QY 241 VLENHHWRSTIGMLRESR--LLAHLPKEMTQDIEOQLGSLIATDINRONEFLRLKAHL 298
DB 469 VLENHHLAVGFKLLQENCDIFQNLTKQORSLRKXVDIVLATDMSKHMMLLADLKTVM 528
QY 299 HNKD-----LRLEDAQDRHFMQLAKCADICNPCRISWMSKQSERVCEEFYRQGELE 352
DB 529 ETQKVTSSGVLLLDNYSRIQVQLNMVHCADLSNPTKPLQYRQWTDRIIMEEPRQGDRE 588
QY 353 QKFELEISPLCNQKSDSPISQIGPMSYIVPELFWAHFTGNSTLSENMLGHLAHNAQ 412
DB 589 RRGEMISPMCDKHNAFVEKSVQGFIDYIVHPLWETWADLV--HPQAQDILDTLEDNREW 646
QY 413 KSLLPQHRHSRSGSGSGDPDHAGQGTESR 444
DB 647 YOSTIPQ-----SPSPAPDDPEGRQGTOK 672

RESULT 14
US-11-123-893-13
; Sequence 13, Application US/11123893
; Publication No. US20060041006A1
; GENERAL INFORMATION:
; APPLICANT: IBRAHIM, PRABHA
; APPLICANT: CHO, HANNA
; APPLICANT: ENGLAND, BRUCE
; APPLICANT: GILLETTE, SAM
; APPLICANT: ARTIS, DEAN RICHARD
; APPLICANT: ZUCKERMAN, REBECCA
; APPLICANT: ZHANG, CHAO
; TITLE OF INVENTION: PDB4B INHIBITORS AND USES THEREOF
; FILE REFERENCE: 039363-1109
; CURRENT APPLICATION NUMBER: US/11/123,893
; CURRENT FILING DATE: 2005-05-06
; PRIOR APPLICATION NUMBER: 60/569,435
; PRIOR FILING DATE: 2004-05-06
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: Patent In Ver. 3.3
; SEQ ID NO 13
; LENGTH: 349
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-123-893-13

Query Match
  23.7%; Score 570.5; DB 7; Length 349;
Best Local Similarity
  34.4%; Pred. No. 5.6e-45;
Matches 122; Conservative 77; Mismatches 135; Indels 21; Gaps 7;

QY 99 EDYLGOARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCH-LFNTHGLIHFKLDVMVTLHR 157
DB 4 EDVLAK-----LEDVKNKGLHVRFAEL-SGNRPFLVIMHTIFQERDILLKTKFIPVDLTIT 59
QY 158 FLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVH 217

; LENGTH: 747
; TYPE: PRT
; ORGANISM: Murine sp.
; US-10-492-835-15

Query Match
  24.7%; Score 594.5; DB 6; Length 747;
Best Local Similarity
  33.4%; Pred. No. 9.6e-47;
Matches 131; Conservative 84; Mismatches 152; Indels 25; Gaps 8;

QY 66 KKKVKRLLS-----FORYPHASRLLRGIPOAPLHLLDEYLGQARHMLSKVGMWDFDIFL 121
DB 293 KEKKKPMQISGVKKLMHSSLSITNSCIPRFQVKTQEQDVLAXE---LEDVKNKGLHVR 349
QY 122 FDLRTNGSLVTLCH-LFNTHGLIHFKLDVMVTLHRLFLVMVQEDYHSQNPYHNAVHAAD 180
DB 350 IABL-SGNRPFLVIMHTIFQERDILLKTKFIPVDLTITVLTMTLEDHYADVAYHNNIHAAD 408
QY 181 VTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVHGVNQPFLLKTNHHLANLYQNMS 240
DB 409 VQVSTHLLSTPALEAVFTDLLEILAAIFASAIHVDHVPFVNSQNFLLNTNSALMYNDSS 468
QY 241 VLENHHWRSTIGMLRESR--LLAHLPKEMTQDIEOQLGSLIATDINRONEFLRLKAHL 298
DB 469 VLENHHLAVGFKLLQENCDIFQNLTKQORSLRKXVDIVLATDMSKHMMLLADLKTVM 528
QY 299 HNKD-----LRLEDAQDRHFMQLAKCADICNPCRISWMSKQSERVCEEFYRQGELE 352
DB 529 ETQKVTSSGVLLLDNYSRIQVQLNMVHCADLSNPTKPLQYRQWTDRIIMEEPRQGDRE 588
QY 353 QKFELEISPLCNQKSDSPISQIGPMSYIVPELFWAHFTGNSTLSENMLGHLAHNAQ 412
DB 589 RRGEMISPMCDKHNAFVEKSVQGFIDYIVHPLWETWADLV--HPQAQDILDTLEDNREW 646
QY 413 KSLLPQHRHSRSGSGSGDPDHAGQGTESR 444
DB 647 YOSTIPQ-----SPSPAPDDPEGRQGTOK 672

RESULT 14
US-11-123-893-13
; Sequence 13, Application US/11123893
; Publication No. US20060041006A1
; GENERAL INFORMATION:
; APPLICANT: IBRAHIM, PRABHA
; APPLICANT: CHO, HANNA
; APPLICANT: ENGLAND, BRUCE
; APPLICANT: GILLETTE, SAM
; APPLICANT: ARTIS, DEAN RICHARD
; APPLICANT: ZUCKERMAN, REBECCA
; APPLICANT: ZHANG, CHAO
; TITLE OF INVENTION: PDB4B INHIBITORS AND USES THEREOF
; FILE REFERENCE: 039363-1109
; CURRENT APPLICATION NUMBER: US/11/123,893
; CURRENT FILING DATE: 2005-05-06
; PRIOR APPLICATION NUMBER: 60/569,435
; PRIOR FILING DATE: 2004-05-06
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: Patent In Ver. 3.3
; SEQ ID NO 13
; LENGTH: 349
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-123-893-13

Query Match
  23.7%; Score 570.5; DB 7; Length 349;
Best Local Similarity
  34.4%; Pred. No. 5.6e-45;
Matches 122; Conservative 77; Mismatches 135; Indels 21; Gaps 7;

QY 99 EDYLGOARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCH-LFNTHGLIHFKLDVMVTLHR 157
DB 4 EDVLAK-----LEDVKNKGLHVRFAEL-SGNRPFLVIMHTIFQERDILLKTKFIPVDLTIT 59
QY 158 FLVMVQEDYHSQNPYHNAVHAADVTQAMHCYLKEPKLASFLTPDLMGLLAAAHDVH 217

```

Db 653 QSMIPQ-----SPSPPLDEQNRCQGLMEKFOFELTLDDEEDSEGPEKEGE 697

Search completed: March 10, 2006, 20:23:10  
Job time : 18.6829 secs